

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

1

FOOD AND DRUG ADMINISTRATION (FDA)  
CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)

FEMALE SEXUAL DYSFUNCTION  
PATIENT-FOCUSED DRUG DEVELOPMENT  
PUBLIC MEETING

Monday, October 27, 2014

FDA White Oak Campus  
10903 New Hampshire Avenue  
Bldg. 31, The Great Room  
Silver Spring, Maryland 20993

Reported by: Michael Farkas  
Capital Reporting Company

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

2

1 M E E T I N G R O S T E R

2 FDA PANEL

3 Julie Beitz

4 Hylton Joffe

5 Audrey Gassman, M.D.

6 Christina Chang, M.D., M.P.H.

7 Marcea Whitaker

8 Theresa Mullin, Ph.D.

9 Ashley Slagle

10 Sandra Kweder, M.D.

11

12

13

14

15

16

17

18

19

20

21

22

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2014

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

3

1	T A B L E O F C O N T E N T S	
2	AGENDA ITEM	PAGE
3	Opening Remarks Audrey Gassman, M.D.	8
4	Overview of FDA's Patient-Focused Drug	
5	Development Initiative	
6	Theresa Mullin, Ph.D.	14
7	Background on Disease Area and Treatment	
8	Christina Chang, M.D., M.P.H.	20
9	Overview of Discussion Format	
9	Sara Eggers, Ph.D.	30
10	Panel #1 Comments: Topic 1	47
11	Large-Group Facilitated Discussion: Topic 1	66
12	Break	
13	Panel #2 Comments: Topic 2	124
14	Large-Group Facilitated Discussion: Topic 2	127
15	Open Public Comment	191
16	Closing Remarks	
17	Sandra Kweder, M.D.	221
18		
19		
20		
21		
22		

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

4

1 P R O C E E D I N G S

2 O P E N I N G R E M A R K S

3 DR. EGGERS: One minute to still say  
4 good morning and then it will be afternoon. We  
5 are going to get started in a minute. So if you  
6 want to take your seats. I see actually everyone  
7 is all prepared for this. This is the quickest  
8 we've ever gotten silent for one of these meetings  
9 before. So I think we'll begin.

10 Good afternoon. My name is Sara Eggers  
11 and I'm in CDER, the Center for Drug Evaluation  
12 and Research in the Office of Strategic Programs.

13 I'd like to welcome you to today's  
14 meeting on Female Sexual Dysfunction particularly  
15 related to interest and arousal as part of our  
16 agency's patient- focused drug development  
17 initiative.

18 [Applause.]

19 Thank you. We -- give me one second. I can do  
20 this on my own without any notes.

21 We have a very full day today and  
22 tomorrow. And we have a lot of work to do on all

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

5

1 of our parts. So I'm going to soon turn it over to  
2 Dr. Audrey Gassman who will give a proper welcome.  
3 But before we do I want to go over a few agenda  
4 items and other details.

5 Oh, they we go. Okay. We're going to  
6 start with FDA doing some talking first to set the  
7 context by giving an overview of our patient-  
8 focused drug development initiative, giving some  
9 background on female sexual dysfunction and its  
10 therapeutic options. And then I'll come back and  
11 give an overview of the discussion format. I will  
12 be serving as the facilitator today.

13 Our two primary topics are: number one  
14 the disease symptoms and daily impacts that matter  
15 most to patients. What is it about their condition  
16 that bothers them the most; that bothers you the  
17 most? And then topic two, what are your  
18 perspectives on current approaches to treating  
19 female sexual dysfunction particularly as it  
20 relates to interest and arousal.

21 Those are our two main discussion topics  
22 today. We will engage patients and patient

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

6

1 representatives in the audience participating here  
2 today and on the Web.

3           And then as we do for all of our  
4 patient- focused drug development meetings, we  
5 have a half hour for an open public comment at the  
6 end of the meeting which will give anyone a chance  
7 to make a comment even if it is not quite related  
8 to the topics at hand. I believe the registration  
9 for that has been -- we have filled to capacity  
10 for that open public comment and Pujita will be  
11 giving you more information then.

12           And then at the end we will wrap up and  
13 do closing remarks for today. And then tomorrow  
14 is our more scientific discussion on specific  
15 issues related to drug development and evaluation  
16 for FSD particularly interest and arousal.

17           There are a few housekeeping issues.  
18 The restrooms are located about as far away as you  
19 can go at the end of the hall that way. There is  
20 a Kiosk that has basic food and we encourage you  
21 to get up as you need. This is not a formal  
22 meeting setting. So if you need to get up to use

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

7

1 the restrooms, please do. Please silence your  
2 phones.

3           We will be recording the transcript of  
4 this meeting. We are also on the Webcast. So a  
5 shout out to those of you on the Webcast, we  
6 understand there is a very healthy participation  
7 registration for the Webcast. It is great to see  
8 so much interest in this meeting. So our Webcast  
9 will be live right now and it will also be  
10 archived on our Web site.

11           We also understand that there are media  
12 outlets present. You probably noticed them on  
13 your way in. And we are happy to see the level of  
14 excitement and interest in this meeting. We just  
15 want to make you aware that their presence is in  
16 no way affiliated with FDA. And your  
17 participation or your non-participation in any  
18 kind of -- if they ask you to participate in an  
19 interview, is completely at your discretion.  
20 Okay.

21           With that I'm going to turn it to Audrey  
22 who will give some welcome remarks.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

8

1 Thank you.

2 DR. GASSMAN: Thank you, Sara.

3 Good afternoon and welcome to today's  
4 meeting on Female Sexual Dysfunction Patient-  
5 Focused Drug Development. I'm Audrey Gassman,  
6 Deputy Director of the Division of Bone,  
7 Reproductive and Urologic Products, also known as  
8 DBRUP in the Office of New Drugs at the FDA.

9 This is an important meeting and we are  
10 looking forward to hearing from women who  
11 experience sexual dysfunction and what they look  
12 for in treatments for this condition. We're  
13 pleased to see so many patients and advocates in  
14 the audience. And I understand that there are  
15 many others joining remotely from the Web. Thank  
16 you again for being here and being part of this  
17 meeting.

18 Today's meeting is one in a series of  
19 what is called patient FDA's Patient-Focused Drug  
20 Development meetings. Theresa Mullin will  
21 describe this initiative in more detail in a few  
22 minutes.



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

9

1           Female sexual dysfunction is a complex  
2 and multi-faceted disorder that affects women  
3 across a wide spectrum of symptoms and severity.  
4 Our meeting over the next two days will focus on  
5 the most common form female sexual interest and  
6 arousal disorder also known as FSIAD.

7           Later Christina Chang, our lead medical  
8 team leader, will provide some brief background on  
9 FSIAD.

10           I just want to say that we recognize  
11 that this is a condition that can greatly impact  
12 the quality of life.

13           The FDA is committed to supporting the  
14 development of drug therapies for FSD. When we  
15 discuss drug development over the next two days we  
16 are referring to the process of identifying,  
17 developing and evaluating potential therapies that  
18 can help patients manage their FSD. FDA's mission  
19 is to protect and promote public health by  
20 evaluating the safety and efficacy of new drugs.

21           While we play a critical role in drug  
22 development, we are just one part of the process.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

10

1 We do not develop drugs or conduct clinical  
2 trials.

3 Drug companies often working with  
4 researchers or patient communities are the ones  
5 who will conduct the trials and submit  
6 applications for new drugs to the FDA. We work  
7 closely with the drug companies throughout the  
8 drug development process. We are therefore glad  
9 to see representation and tremendous interest in  
10 today's meeting from industry, academia and other  
11 government partners in the room and on the Web.

12 I want to spend a few minutes providing  
13 a bit of background on the FDA's important role in  
14 drug evaluation. For a drug to be approved for  
15 marketing FDA must determine that it is safe and  
16 effective for its intended use. Our regulatory  
17 decisions are based on science, medicine as well  
18 as legal and regulatory standards. First and  
19 foremost the drug must demonstrate substantial  
20 evidence of efficacy for its intended use. This  
21 is a requirement by law.

22 Although the meaning of safe is not

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

11

1 explicitly defined in the statutes or regulations,  
2 the safety of a drug is assessed by determining  
3 whether the benefits outweigh the risks. The FDA  
4 makes each determination for a new drug based on  
5 the totality of information provided by drug  
6 companies in their new drug application which is a  
7 request for marketing authorization in the U.S.

8           FDA's benefit risk assessment takes into  
9 account many factors including the presence of  
10 alternative therapies for the indication, the  
11 goals of the proposed therapy, the magnitude of  
12 the demonstrated benefit, and the nature of the  
13 risks associated with the new product.

14           We take our roles very seriously. We  
15 are aware of claims from external sources that the  
16 FDA favors therapies in regard to men when it  
17 comes to indications related to sexual dysfunction  
18 or sexual difficulties. As a representative of  
19 the Division and of the FDA I want to assure you  
20 that we are willing and ready to work with all  
21 sponsors and investigators to address these  
22 conditions whether they are in men, women, or

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

12

1 both.

2 We evaluate all applications  
3 individually based on submitted evidence and do  
4 not apply different standards or regulatory  
5 standards when making our decisions.

6 Drug development for a female sexual  
7 dysfunction is very complicated due to many  
8 factors such as the ability to diagnose the  
9 dysfunction, the presence of underlying medical  
10 conditions that may be responsible for the  
11 dysfunction, challenges identifying outcomes that  
12 are both meaningful to patients and are  
13 measurable, and challenges designing trials that  
14 can reliably assess drug efficacy and safety.

15 FDA wants to help facilitate this  
16 complicated process. For example, we advise all  
17 sponsors who intend to treat symptom related  
18 conditions including female sexual dysfunction to  
19 consider our 2009 guidance on development of  
20 patient- reported outcomes which provides  
21 recommendations for development.

22 There are still many scientific issues

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

13

1 that need to be resolved in this field. Tomorrow  
2 we will have a discussion that will be more  
3 technical in nature exploring important aspects of  
4 drug development process for FSD. We will cover  
5 topics that include diagnostic criteria, clinical  
6 trial design and outcome measures.

7           Today's meeting, however, is about  
8 listening to patients. We think very carefully  
9 about the kinds of things we should be measuring  
10 and evaluating for new drug for FSD and hearing  
11 your perspectives on this will be invaluable.  
12 Specifically we would like to hear from patients  
13 what symptoms matter most and how they affect  
14 daily life and sexual experiences. We are also  
15 interested in understanding what patients are  
16 currently doing to help themselves to treat this  
17 condition.

18           What we hear from you today can help us  
19 understand what patients would value in treatments  
20 for FSD. Your input can help us understand how to  
21 develop better end points to measure the aspects  
22 of FSD that are important to patients and to

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

14

1 develop better tools such as patient-reported  
2 outcomes or PROs.

3 Sara Eggers will explain our meeting  
4 format process which is designed to encourage a  
5 rich discussion today.

6 I want to reiterate one point. The  
7 important issues that I have mentioned are common  
8 to the development and evaluation for any drug to  
9 treat female sexual dysfunction. Therefore, our  
10 goal today and tomorrow for that matter is to  
11 explore these issues broadly and not focus  
12 attention on any one specific drug or therapy.

13 Thank you again for your participation  
14 and for being here today.

15 I'll now turn it over to Theresa Mullin  
16 who will provide some background on FDA's overall  
17 patient- focused drug development efforts.

18 DR. MULLIN: Hi. Theresa Mullin and I  
19 direct the Office of Strategic Programs in the  
20 Center for Drugs. And I just want to take a  
21 minute to give you the background on this meeting  
22 and it is one -- one way we look at this is one of

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

15

1 a series of meetings that we are I'll say piloting  
2 this approach to do a better job of more  
3 systematically trying to collect information from  
4 patients about their perspective on their  
5 condition and the treatments available as Andrea  
6 mentioned.

7           We understand that the patient's  
8 perspective is quite critical to our understanding  
9 and thus our ability to assess the benefits and  
10 risks of any new therapy. Patients are the ones  
11 who experience the disease; they are the ones who  
12 will get any benefit that can be gotten from a new  
13 drug; and also be the ones to experience the  
14 risks. And so their role is quite critical and  
15 unique in terms of informing our decision making.

16           And before this initiative began in 2012  
17 we didn't really have a way to systematically  
18 collect this kind of information. We had a  
19 patient representative program that allowed us to  
20 involve one or two patients in our process. And,  
21 of course, because they would be involved in the  
22 discussion of particular drugs we had to go

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

16

1 through a lot of conflict of interest screening.  
2 And we still have this program and it is very  
3 valuable. But as you can hear it limits our  
4 ability to get wider input. And we knew we really  
5 needed to hear from as diverse and broad a  
6 community as possible who is affected by any given  
7 disease.

8           So we designed this program and included  
9 it in our reauthorized prescription drug user fee  
10 commitments that we made in 2012 and so we have  
11 committed in that program to include at least 20  
12 meetings in different disease areas over the five  
13 years to sort of as I said pilot this approach and  
14 figure out how we can optimize it to get the most  
15 benefit both in the meeting and then in our follow  
16 up to these meetings. This helps us better  
17 understand and advise sponsors during the drug  
18 development process and also, of course, also give  
19 us more insight than we would have had in  
20 reviewing any particular application that gets  
21 submitted.

22           So -- just a minute, I need to find the



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

17

1 advance key. Ah. Okay. Did I already -- did I  
2 go twice? I'm sorry; my slides look so much alike  
3 that - - oh there we go.

4           So this process just quickly started in  
5 2012. We published a Federal Register Notice  
6 which is our usual way of communicating to the  
7 public with about 40 diseases in it. We asked for  
8 comment. We got about 4,500 comments on that  
9 list. And that helped us to sort of sort through.  
10 We came up with a list of 16 that we are focusing  
11 on in the first three years.

12           And then in this slide as you see there  
13 is a Federal Register Notice there on October the  
14 8th we published a list of diseases that we were  
15 offering as candidates for the final two years of  
16 the program, 2016 and '17 and we're hoping to  
17 receive public comment by I think December the 5th  
18 on what we will set up there.

19           And this slide shows you the diseases  
20 that we are covering in those first three years.  
21 The ones on the left for fiscal year '13 and '14  
22 are ones we've already done at this point. And we

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

18

1 are working our way through producing our reports  
2 and following up on those.

3           And today's meeting is on female sexual  
4 dysfunction. It is the first meeting we are  
5 having in 2015 for this fiscal year.

6           And so as Andrea said each of our  
7 meetings covers two essential areas which are:  
8 What are the patients' experiences with the  
9 disease? What are the most problematic aspects of  
10 it? What are they doing to treat it today? What  
11 are they -- there may not be any good treatments  
12 available but what are they doing to try to cope  
13 with the condition?

14           We start with those questions and we  
15 tailor it further. The review division may have  
16 other things they want to take advantage of having  
17 you here today to hear about other things as well.  
18 So for example we had a meeting on HIV Aids, we  
19 took that opportunity to talk to the patients  
20 about their perspective on cure research. Would  
21 they be willing to forego the treatments that were  
22 available to participate in a trial that involved

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

19

1 cure therapy? And so there are things we can talk  
2 to the patients or hear from them about that  
3 provide a unique opportunity. We try to put those  
4 into these meetings as well if we can.

5           And then we take what we learn here;  
6 what we have found is the more active  
7 participation, the more we get to hear from what  
8 you think and the more patients who are able to  
9 participate here in the room or on the Webcast or  
10 through the Docket, the more we benefit and the  
11 more of a rich source of information this gives  
12 us.

13           So we are very happy, gratified to have  
14 so many people here today.

15           And so the final slide I have here is  
16 the report that we produce at the end of this  
17 which is sort of our first deliverable, our first  
18 product of these meetings is called the voice of  
19 the patient. So following each of these meetings  
20 we try to take the transcript and the other  
21 information, our notes and write up the summary of  
22 what we heard and try to capture it in the words

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

20

1 that you used to tell us what you are experiencing  
2 because those are really the most authentic way we  
3 can record this and try to convey to the reviewers  
4 today or beyond this what we heard and what you're  
5 experiencing.

6 We take that report and use it as a way  
7 to communicate in the future to our staff, to have  
8 it as a reference document, and also to inform our  
9 subsequent efforts that we may try to segue from  
10 this into patient-reported outcome tools and other  
11 ways to follow up longer term to give the full  
12 benefit of this for future drug development in our  
13 decision making.

14 And with that I'll turn it over to the  
15 next speaker.

16 DR. CHANG: Thank you, Dr. Mullin. Good  
17 afternoon everyone. Welcome to the Patient-  
18 Focused Drug Development meeting on female sexual  
19 interest/arousal disorder here at FDA.

20 My name is Christina Chang. I am a  
21 clinical team leader in the Division of Bone,  
22 Reproductive and Urologic Products here in CDER.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

21

1 And my division reviews the drugs that intended to  
2 treat female sexual dysfunction or FSD for short.

3 My team is specifically responsible for  
4 reviewing any clinical data that are submitted in  
5 support of these applications.

6 We appreciate so many of you being here  
7 participating in this workshop here on campus.

8 And also for those who are joining us via the Web.

9 And we are very grateful to those patients who are  
10 willing to share the personal stories on a very,  
11 very sensitive topic. So again very welcome.

12 And given the limited time that we have  
13 and the complexity of the female sexual  
14 dysfunction overall we would like to focus today's  
15 workshop primarily on FSIAD or female sexual  
16 interest arousal disorder.

17 The reason for today's meeting is that  
18 although sexual dysfunction is not a life  
19 threatening condition we do realize and recognize  
20 that the dysfunction can significantly impact a  
21 woman's quality of life. And its affects can  
22 definitely result in major disturbances in family

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

22

1 life. Service studies have suggested that women  
2 more than men have complained about having sexual  
3 difficulties and that these problems appear to be  
4 very common in U.S. women. In this frequently  
5 cited 1995 study women between the ages of 18 and  
6 59 reported complaints to the investigators and  
7 these complaints include lack of sexual desire,  
8 difficulty in becoming aroused, inability to  
9 achieve orgasm, anxiety about sexual performance,  
10 reaching orgasm too rapidly, pain during sexual  
11 intercourse, or failure to derive pleasure from  
12 sex.

13           The 43 percent figure emerged from  
14 analysis of responses from more the 1700 women.  
15 Some critics have pointed out that the women in  
16 the study were not specifically asked about  
17 whether their complaints were severe enough to  
18 bother them. And subsequently a lot of  
19 discussions ensued on how we should define what  
20 exactly constitutes female sexual dysfunction.

21           But it is not possible to talk about  
22 dysfunction without first discussing normal sexual

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

23

1 function. Normal sexual response in women depends  
2 on a very complex web of interacting factors  
3 including physiological, emotional, relationship  
4 dynamics, and much, much more. Significant  
5 changes in any of these components can affect a  
6 woman's sexual desire, response and satisfaction.

7           Although the definition of sexual  
8 dysfunction in women has been the subject of some  
9 debate because it appears to be less quantifiable  
10 what has not been disputed is that for a woman to  
11 be diagnosed with a dysfunction her symptoms must  
12 be severe enough to be a source of personal  
13 distress. And as a 2008 study by Dr. Shifren (ph)  
14 shows that an estimated 12 percent of U.S. adult  
15 women may have sexual problems when their  
16 diagnosis takes into account the presence of  
17 personal distress.

18           So we went from 43 percent to 12 percent  
19 but this is obviously still a significant segment  
20 of the female population in this country.

21           I want to move on now to a brief  
22 overview of the female sexual dysfunction as

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

24

1 defined by the

2 American Psychiatric Association. FSD

3 is a term that covers a heterogeneous collection

4 of conditions and in the past FSD was classified

5 into four different conditions. The first:

6 Hypoactive sexual desire disorder characterized by

7 the absence or reduced interest in sexual activity

8 as well as not being receptive to a partner's

9 initiation of sexual activity. Second: Female

10 sexual arousal disorder characterized by the

11 inability to attain or maintain sexual excitement.

12 Third: Orgasmic disorder characterized by the

13 difficulty to attain orgasm despite sufficient

14 arousal. And the last being pain disorder where

15 women complain of pain during sexual intercourse.

16 In May of last year Hypoactive Sexual

17 Desire Disorder or HSDD and Female Sexual Arousal

18 Disorder or FSAD were combined into a single

19 diagnosis in the Fifth Edition of the Diagnostic

20 and Statistical Manual. The other disorders

21 remain relatively unchanged.

22 With FSIAD being a relatively new



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

25

1 diagnosis we know that there has been limited  
2 clinical experience and consequently we are hoping  
3 very much to hear your thoughts on this new  
4 diagnosis.

5           As outlined in the DSM5 here are the  
6 features that are used to arrive at a diagnosis of  
7 FSIAD. There are six symptoms that I have taken  
8 verbatim from the diagnostic manual and as you can  
9 see the first three as well as the fifth symptom  
10 relate to the absent or reduced sexual desire.  
11 The final three symptoms have to do with the  
12 absent or reduced arousal.

13           The manual specifies that to qualify for  
14 the diagnosis the patient must have had at least  
15 three of these symptoms for at least six months in  
16 duration. And specifically for two of the symptoms  
17 namely number four and number six the manual also  
18 mandates documenting the frequency when the  
19 patient would notice these symptoms. So the  
20 patients report these two symptoms, number four  
21 and number six, occurring in at least 75 percent  
22 of the sexual encounters.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

26

1           Furthermore the symptoms in the previous  
2 slide must cause significant distress to the  
3 patient.

4           However, what clinically significant  
5 distress means exactly is not really defined in  
6 the manual. And most importantly three other  
7 contributors to sexual dysfunction must be ruled  
8 out before making the diagnosis. First: the  
9 problem with having either low desire or low  
10 arousal cannot be explained by another psychiatric  
11 disorder such as depression or anxiety.

12           Second: any relationship factors should  
13 be considered before making a diagnosis. But here  
14 again the manual does not elaborate on what these  
15 relationship stressors may be or how severe they  
16 have to be. It seems that there are many other  
17 stressors besides partner violence such as kids,  
18 work, other relationship dynamics, et cetera. So  
19 we would like to hear your perspective. And  
20 finally the third factor that needs to be  
21 considered is: medical illnesses, medications or  
22 any other substance use. So FSIAD is really

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

27

1 almost a diagnosis of exclusion.

2           Additionally the manual outlines other  
3 ways to describe FSIAD such as using a severity  
4 grading, classified as mild, moderate, or severe.

5 Another way of categorizing the condition is  
6 whether the patient has always had the condition  
7 or it's something new in her sexual experience.

8 The third classification would be whether the  
9 condition is situational such that it only happens  
10 in specific environments with a particular partner  
11 or whether the conditions is generalized meaning  
12 that there are no identifiable triggers.

13           And as we all know there are no drugs  
14 approved by FDA to specifically treat FSIAD, HSDD,  
15 or FSAD. Some existing products have been studied  
16 for these conditions. But these products have had  
17 their own issues. For example Sildenafil or  
18 Viagra was studied for the treatment of female  
19 sexual arousal dysfunction or disorder but was not  
20 shown to be effective.

21           Other products such as hormonal  
22 therapies may have potential safety issues when

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

28

1 they are taken long term.

2 Non drug therapies include behavioral  
3 therapies or couples sex therapy. But we are not  
4 aware of any large scale studies to support these  
5 treatments.

6 So we are very interested in hearing  
7 from the patients as to what remedies you've been  
8 using to help with your sexual problems and  
9 whether you feel that they've helped or not.

10 I also want to point out that for pain  
11 associated with sex or the sexual pain disorder  
12 FDA has actually approved several products. In  
13 addition to several estrogen containing products,  
14 we've recently approves Ospemifene for the  
15 treatment of pain during intercourse that is  
16 associated with vulvar or vaginal changes due to  
17 menopause.

18 So part of the rationale for convening  
19 this meeting today is our recognition that we do  
20 not yet have drug therapies to help women with  
21 either low sexual desire or low arousal.

22 And as I mentioned already when it comes

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

29

1 to HSDD, FSAD, or FSIAD making the diagnosis  
2 correctly is complicated. Accordingly developing  
3 drugs to treat these conditions is also very  
4 complicated. And this workshop presents an  
5 opportunity that going forward the FDA industry  
6 and the larger community could be hopefully on the  
7 same page with respect to the terminologies  
8 relating to these conditions. And identifying the  
9 appropriate patients which really have dysfunction  
10 in desire or arousal can help us move forward in  
11 developing safe and effective drug therapies for  
12 those who can really benefit.

13           From the discussion today we'd also like  
14 to get a better sense from the patients on what  
15 are the most important symptoms we should measure  
16 in clinical trials to see if a drug can be a  
17 benefit. And how shall we measure these changes.  
18 These are very important parameters in assessing  
19 whether a drug works for its intended purpose.

20           In order to help identify meaningful end  
21 points for clinical trials the FDA is very  
22 interested in patient-reported outcomes. Patient-

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

30

1 reported outcomes or PROs can represent direct  
2 measures of treatment benefit in identifying how a  
3 patient feels or how a patient functions.

4           For conditions like FSIAD, HSDD, or FSAD  
5 where a diagnosis is based on a more qualitative  
6 than quantitative assessment input from the  
7 patients is really essential. And we very much  
8 would like to see well defined and reliable PRO  
9 instruments developed, validated, and evaluated in  
10 clinical trials for drug development.

11           I will just put in a plug for tomorrow's  
12 program. We are also having a scientific workshop  
13 tomorrow to discuss some of the very challenging  
14 issues in developing drug therapies for these  
15 conditions and we hope that many of you will be  
16 able to join us tomorrow.

17           Thank you all again for being here. And  
18 now let me turn it over to Dr. Sara Eggers.

19           DR. EGGERS: Thank you very much to all  
20 of the FDA colleagues for providing that  
21 background. We've got one more FDA speaker that  
22 stands in the way of the discussion with you, so

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

31

1 I'll try to make this as brief as possible.

2           This meeting today is quite different in  
3 format and style from other public meetings you  
4 may have attended. And as Audrey mentioned that  
5 is really the goal; that is our intent is to have  
6 a format that really encourages and enables  
7 dialogue with patients.

8           The two topics that we are covering  
9 we've mentioned this before but I'll go into a bit  
10 more detail. One the symptoms that matter most to  
11 you and in particular symptoms or aspects of your  
12 condition that have the most significant impact on  
13 your sexual experience, specifically and more  
14 broadly on your daily life. And how specifically  
15 do these symptoms affect your sexual experiences.  
16 And how, if at all, do they change over time?

17           And then after the break we'll come back  
18 and talk about the approaches to treating FSIAD.  
19 What are you currently doing to treat your  
20 condition and its symptoms? How well do they work  
21 for you? What are their biggest downsides? And  
22 importantly what would you look for in an ideal

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

32

1 treatment? What specific things would you like --  
2 aspects of your condition would you like to see  
3 addressed?

4           As far as our format for each of those  
5 two topics we're first going to ask a panel of  
6 patients to share their stories with us and  
7 provide a good foundation for a facilitated  
8 discussion that will follow.

9           And those of you who are on Topic 1 if  
10 you could please make your way to the front at  
11 this time. Bring your name tags. If you don't  
12 have tent card, I probably have it up here for  
13 you.

14           These panel members were identified from  
15 those when we put out the invitation in the  
16 Federal Register Notice we invited people to  
17 submit comments if they were interested in  
18 presenting comments to start our discussion and we  
19 identified women who experience a range of  
20 symptoms, a reflective range of perspectives to  
21 attend. So I thank you in advance for coming up  
22 here.



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

33

1           After they have their comments, there  
2 may be some clarifying questions. But then we are  
3 going to move out into the facilitated discussion,  
4 really follow up and build on what we heard from  
5 the panel discussants and ask more detailed  
6 questions for that.

7           And the purpose here is to build on what  
8 we heard from the panel and really get a sense of  
9 what is more in depth and what range of  
10 perspectives and experiences are out there.

11           So, we have staff floating around; you  
12 don't have to get up to any microphones. We have  
13 staff floating around who will bring the mic to  
14 you. So when I ask a question, just raise your  
15 hand and we're going to try to take everyone who  
16 wants to speak. I have some ground rules that we  
17 will go over in a minute.

18           We are going to ask that you please  
19 state your first name. We don't need your last  
20 name. Just your first name is fine before  
21 speaking. And for the sake of transparency we  
22 also request that at the time that you first speak

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

34

1 and that includes the panel discussants as well  
2 that you disclose if you are affiliated with an  
3 organization that has an interest in FSD or if  
4 your travel has been sponsored or if you have  
5 significant financial interest in FSD drug  
6 development. That is in the sake of transparency  
7 and we'll just ask everyone to disclose that at  
8 the first time that they speak.

9           And when we ask a question try to keep  
10 your responses focused on the specific question or  
11 topic at hand. You should have a chance to speak  
12 on any topics as they come up. So that will  
13 really help the conversation move forward. Please  
14 try to keep those responses limited to a minute or  
15 two.

16           I'm going to regularly ask through a  
17 show of hands if you in the audience and the  
18 Webcast can chime in as well, if you generally  
19 share a particular view that was just experiences  
20 so that we can really build on what one another is  
21 saying.

22           So we also have a strong Web

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

35

1 participation. And this is really important. We  
2 want to hear from the women on the Web today as  
3 well. Although we may not read or summarize all  
4 of your comments today they are being reviewed,  
5 they will be part of the public record and we are  
6 incorporating them into our final reports.

7           We are also going to occasionally go to  
8 the phones to give you on the Web another  
9 opportunity to contribute as time permits. All of  
10 you will have a chance to answer polling questions  
11 and I am going to ask for the polling questions,  
12 we will put them on the table please, there are  
13 little clickers, okay so there are going to be  
14 some clickers floating around and we are going to  
15 ask that just women who identify themselves as  
16 having FSD and particular interest in arousal to  
17 take the clicker and to answer the questions.

18           This is not at all a scientific survey.  
19 It is merely a discussion aid. It helps us  
20 understand who is in the room and what  
21 perspectives you might share and what your  
22 experiences might be. So please don't treat this

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

36

1 in any way as a scientific exercise.

2 But we do find that it really does  
3 enable a discussion. We can build on things that  
4 we hear from the polling.

5 We also importantly have a Public  
6 Docket. We know that there are many, many issues  
7 that you won't be able to talk about today and  
8 many things that you wish you could talk about in  
9 more detail and you all have the opportunity,  
10 anyone in the audience, anyone participating in  
11 the meeting whether you are a patient, patient  
12 representative or not to contribute a comment,  
13 follow up on what you have said at the meeting or  
14 a comment that just provides your full story. And  
15 if you have people who weren't able to attend the  
16 meeting today we encourage them as well to share  
17 their stories with us and your experiences.

18 On our Website you can see the  
19 information for the Public Docket. A Docket is an  
20 unfortunate word for a repository that you can --  
21 it is a vehicle for us to get comments from the  
22 public. So it is just a Website you are sending

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

37

1 your comment to. When you go to Regulations.gov  
2 if you follow our Web link you will get to a link  
3 and just click on the comment now button.

4           There are other resources for you so the  
5 FDA's office of Health and Constituent Affairs  
6 really focuses on providing patients with  
7 information that they need. And they are the ones  
8 as Theresa mentioned run the patient  
9 representative program. So if you have any  
10 questions or you would like to follow up with  
11 them, their information is here.

12           And also CDER now has a new Office of  
13 Professional Affairs and Stakeholder Engagement.  
14 And we have Ria Blakely (ph) is around; she is  
15 right there in the back, has her hand raised.  
16 Particularly if you are an organization or a  
17 health care provider or others who wants to engage  
18 with FDA you may feel free to reach out to Ria.

19           Our primary goal today is to enable a  
20 fair and open discussion. To insure that I'd like  
21 to go over a few participation ground rules. We  
22 are here first and foremost to listen to women who

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

38

1 experience female sexual dysfunction particularly  
2 as it relates to interest and arousal. So we  
3 encourage all participants with FSAID to  
4 contribute to the dialogue. Your partners and  
5 advocates are welcome, too, but we ask that you  
6 focus your participation on helping further  
7 understand women's experiences and perspectives  
8 with respect to the questions posed. We are going  
9 to try to accommodate everyone who wants to speak  
10 and again if we don't get your full comments,  
11 please go to the Docket.

12           For the advocate organizations and the  
13 many, many health care providers that have  
14 registered today we encourage you to listen to the  
15 dialogue today and submit a comment to the Docket  
16 that expresses your understanding as to the  
17 dialogue which the input that we hear today  
18 reflects your understanding of the women that you  
19 work with, reflects their perspective and  
20 experiences because we do want to make sure that  
21 we do reflect the broad range of experiences that  
22 are out there and perspectives that are out there.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

39

1           We are happy to see participants today  
2 who represent research, industry and other  
3 organizations. We do believe that this input is  
4 important for you as well and we just ask you to  
5 stay in listening mode today.

6           FDA staff is here to listen and to take  
7 notes and to help ask follow up questions as the  
8 day goes forward. We won't be able to address any  
9 questions from the audience today that might  
10 arise.

11           The purpose of tomorrow's meeting is to  
12 discuss these issues, regulatory and drug  
13 development issues in more depth. So if you have  
14 a question and you are able to participate  
15 tomorrow, I recommend that you hold it, see if it  
16 gets answered there and there is Q&A sessions and  
17 there are opportunities to ask those questions.  
18 And if at the end of that time you still haven't  
19 heard the answers that you are looking for, please  
20 the contact information for Ria and for the Office  
21 of Health and Constituent Affairs or there are  
22 evaluation forms at the end of today's meeting

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2014

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

40

1 that we are going to ask you to fill out, feel  
2 free to write your questions and we will try to  
3 address them in some way either directly or  
4 indirectly.

5           As we described today our discussion is  
6 focused on symptoms first and foremost and on  
7 experiences with treatment and approaches. We  
8 understand that there are other important issues,  
9 many other important issues to insure that the  
10 women with FSD get treatment and support that they  
11 need. Our narrow focus today reflects FDA's need  
12 for specific information as both Audrey and  
13 Christina mentioned.

14           There are a few things that our  
15 discussion will not focus on today. And that  
16 includes specific issues with any particular  
17 product or any particular drug under evaluation.

18           We are also not addressing the broader  
19 question about whether there is or is not a need  
20 for medical treatment for FSD. As Dr. Gassman  
21 stated FDA is committing to supporting the  
22 development of drug therapies for FSD. And our



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

41

1 discussion may touch upon specific treatments and  
2 this is appropriate. We do want to ask about  
3 treatments. However, the discussion of those  
4 treatments we hope is done in a way that helps us  
5 understand those broader issues. What symptoms  
6 are generally being addressed? How do you know  
7 that that treatment is working? We don't really  
8 necessarily care what treatment it is, what is  
9 useful to us is to say well, how does a woman know  
10 when a treatment is working? What specific things  
11 it is addressing? And how meaningful is that to  
12 you as patients?

13           The opinions expressed here today are  
14 personal opinions. This discussion is going to  
15 touch on very sensitive topics. I don't even need  
16 to say that. We all know that this is a very,  
17 very personal experience that all women are  
18 facing, sexual experience. Everyone faces these  
19 as very personal experiences. And we want the  
20 women up here to feel comfortable talking about  
21 their experiences and expressing their  
22 perspectives. Therefore, demonstrating respect is

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

42

1 of paramount importance. We expect everyone here  
2 to be on that same page in terms of respect.

3 Please wait to be acknowledged before  
4 speaking and then speak into the microphone. And  
5 please do not direct your comment to or about any  
6 specific individual and avoid negative language  
7 and please keep side conversations to a minimum.

8 Okay. Got that over with.

9 Now let's move on. We want your  
10 feedback to the meeting, we really do appreciate  
11 the evaluations that we get and we do review them  
12 carefully. We have another several meetings  
13 moving forward and what we learn from each of  
14 these meetings really helps us with the next.

15 Does everyone have a clicker who wants a  
16 clicker? We have a few of the polling questions  
17 and these just again give us a sense of who is in  
18 the room and who is on the Web at this point. So  
19 we start with an easy one. This will help you  
20 practice with the clickers as well.

21 So where do you live, where are you  
22 coming from; a) if you are inside the Washington,

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

43

1 D.C. metro area and b) if you are from outside?

2           As we expected this is an issue that has  
3 a very wide geographic representation here today  
4 so we thank you. We thank you all whether you  
5 traversed the beltway everyday and so this is  
6 something you routinely do or if this is one of  
7 the rare occasions when you have to do so.

8           Are you participating today because you  
9 personally are significantly bothered by: a)  
10 absent or reduced desire for interest in sexual  
11 activity or sexual fantasies; b) absent or reduced  
12 sexual excitement, sexual pleasure or sexual  
13 arousal during sexual activity; c) both; d)  
14 neither but you have some other symptom associated  
15 with FSD? And if none of these apply, just don't  
16 answer the question.

17           We'll give some time.

18           Okay. So a lot of you here are battling  
19 with both of these. We will delve into these, try  
20 to tease them apart a bit and for those of you  
21 that feel that only one or the other, we will try  
22 to get your experiences on how you experience the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

44

1 one but not the other and how those experiences  
2 are for you.

3           What is your age?

4           We have a range of ages represented  
5 here. It is really wonderful to see so many people  
6 who are younger than 30 here participating today  
7 as well as the entire range. This differing of  
8 the age range indicates that you might have  
9 experiences that are very different depending on  
10 whether you have or have not gone through  
11 menopause.

12           Can I back up a minute? I neglected to  
13 ask about the Web polling results for the previous  
14 question about what their interest is in this  
15 meeting.

16           MS. GIAMBONE: Yes, we have about 55  
17 percent of the people on line voted for absent or  
18 reduced desire or interest in sexual activity or  
19 sexual fantasies. And for question 3 we have for  
20 the age we have about one third of the people  
21 between the ages of 31 to 40 and about 30 percent  
22 of the people between 51 and 60.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

45

1 DR. EGGERS: Okay. Thank you.

2 Have you received a diagnosis of Female  
3 Sexual Interest or Arousal Disorder, FSIAD,  
4 Hypoactive Sexual Desire Disorder, HSDD, or Female  
5 Sexual Arousal Disorder, FSAD from a health care  
6 provider?

7 Okay. So it looks like we have a mix of  
8 both.

9 From here on I get tongue-tied very  
10 easily so I am going to just say FSD from now on  
11 and by that we mean FSD with particular focus on  
12 interest and arousal. But if I have to say either  
13 the acronyms out we could be here until tomorrow.

14 How long have you had symptoms of FSD?  
15 Less than five years, five to ten, ten to 20, more  
16 than 20, or you are not sure.

17 Okay. This is also a very nice mix of  
18 experiences that we have here. We are going to  
19 try to tease apart some of that a little bit as we  
20 go on.

21 And on the Web?

22 MS. GIAMBONE: 50 percent of the people

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

46

1 on the Web said that they have had symptoms from  
2 five to ten years.

3 DR. EGGERS: Okay. That is it for our  
4 polling questions for now. And we have a few more  
5 as the two discussion topics unfold. But thank  
6 you very much for answering those.

7 And now it is time to move into the  
8 Topic 1 discussion. And again this is on -- and  
9 everyone you have the agenda and the questions  
10 that we posed in our Federal Register Notice that  
11 were the focus of today's discussion are printed  
12 on the last page or the back of that agenda. This  
13 is very much just a summary of those to fit on one  
14 slide. But we've gone over what the main point of  
15 this discussion is.

16 A few other things we want to know is  
17 about if your symptoms wax and wane over time. We  
18 have a few questions about if you are asked to  
19 rate your symptoms. We have some considerations  
20 we'd like to get from you. And then finally we'll  
21 talk about what worries you about that distress  
22 portion as we get into the facilitated discussion.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

47

1           But to kick it off we are going to have  
2 each of the four of you go. I know you all by  
3 phone, by name, but I don't -- they should have  
4 printed your names on the other sides of the

5           VICTORIA: Do you want me to start?

6           DR. EGGERS: You can start. Oh and when  
7 you -- just push it once.

8           VICTORIA: Hello. Okay. My name is  
9 Viki and I have to say at first Veritas has taking  
10 care of my travel expenses through grants from  
11 Sprout Pharmaceuticals, Even the Score, and the  
12 Institute for Sexual Medicine.

13           So starting off I'm 39 years old. I'm  
14 here to tell my story about my experience living  
15 with HSDD. My symptoms became significantly  
16 noticeable about five years ago after the birth of  
17 my fourth child. A couple years before that I had  
18 experienced a slight decrease in desire and fewer  
19 sexual occurrences but I figure it was just  
20 because we were both busier in our lives.

21           I realized that there was something more  
22 going on with me when I started to just not want

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

48

1 to have sex at all. I stopped initiating sex and  
2 my desire became nonexistent. This was not normal  
3 for me. My husband and I had a very fulfilling  
4 and healthy sex life up until this point. Our  
5 friends would even make comments about how we  
6 couldn't keep our hands off each other.

7 I sought out answers from different  
8 specialists to find out what was happening to me  
9 and if there was something I could do. I had an  
10 array of tests done spanning from full panel blood  
11 work to hormone testing to even internal  
12 ultrasounds. No one had any answers for me when  
13 all of my tests came back normal. But I knew  
14 there had to be something else going on.

15 My mom told me I should go to San Diego  
16 to see Dr. Goldstein because she was a patient of  
17 his and he may have answers for me. I was  
18 reluctant at first because I had already spent so  
19 much money on testing and my insurance would not  
20 cover any test that had to do with hormones. My  
21 mom felt it was so important for me to see him  
22 that she flew me to San Diego and he diagnosed me



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

49

1 with HSDD.

2           My symptoms rapidly worsened over the  
3 last three years. I found myself avoiding any  
4 situations where a sexual experience may occur.  
5 For example going to bed after my husband fell  
6 asleep or jumping out of bed in the morning before  
7 -- sorry, before he got up just so he wouldn't try  
8 to initiate sex. I even found myself avoiding  
9 simple hugs and kisses.

10           The defining moment for me was when my  
11 husband and I took a vacation for a week to Mexico  
12 without kids. This was supposed to be a time for  
13 the two of us to relax and enjoy each other. In  
14 the past when we had taken vacations together we  
15 barely left the room. My mom always joked "don't  
16 get pregnant" when we left. But unfortunately my  
17 symptoms stayed the same. In a beautiful place  
18 with the man I love my body was like a shell with  
19 nothing inside. I just did not feel like I wanted  
20 to have sex. My desire was still gone. This was  
21 devastating to both of us and definitely put a  
22 strain on the trip.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

50

1           My sexual experiences recently are more  
2 out of obligation to keep my husband satisfied  
3 after all it is not his fault this is happening to  
4 me.

5           I feel it is important to say my husband  
6 and I talk very openly about HSDD. I know he  
7 loves me very much and tries hard to understand.  
8 He does not have any problems as far as his sexual  
9 function or desire. So it is difficult for him to  
10 relate.

11           I would like to note if he did have a  
12 problem with sexual dysfunction as a man he would  
13 have many options for treatment. But that being  
14 said it has put a big strain on our relationship  
15 and he has said to me that he feels stupid at  
16 times and he keeps getting shut down. I know he  
17 feels rejected.

18           This is the last thing I want the man I  
19 love to feel. It makes me feel so guilty and  
20 frustrated. I can't be the woman he married.

21           So I think to myself I'm only 39 years  
22 old am I just going to be like this forever. What

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

51

1 does it mean for my future and the future of my  
2 marriage? Is there no hope for me to get back the  
3 feelings I had before? Women like me who feel  
4 this way need a solution. We deserve to feel our  
5 sexual desire again.

6 Thank you.

7 DR. EGGERS: Thank you very much  
8 Victoria.

9 BEVERLY: Good afternoon. My name is  
10 Beverly. And Veritas arranged my travel here  
11 today. But I do have to tell you I would be here  
12 regardless; I'm quite passionate about the subject  
13 so I appreciate the opportunity that the FDA has  
14 given me to come here today and talk to you and  
15 tell you my story.

16 I'm hoping that hearing my personal  
17 story about how I've suffered with this medical  
18 condition will help you understand why women need  
19 help. I started out having this issue about four  
20 years ago. Initially I thought it was just going  
21 to be something that passed quickly.

22 It started because I had an allergic

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

52

1 reaction to a medication. Then my whole life  
2 changed. It basically turned upside down.

3 I saw over 30 doctors in a variety of  
4 specialties before I found treatment. I am about  
5 \$35,000 into this issue at this point. I started  
6 with my personal gynecologist, moved on to my  
7 general practitioner, my concierge doctor, saw  
8 specialists at major teaching and research  
9 hospitals, sought out the help of top  
10 urogynecologists, endocrinologists and other  
11 specialties. I wasn't getting any help. But I  
12 wasn't going to stop.

13 I endured pudendal nerve injections  
14 because they might work. I was given anti-  
15 depressants which ironically make it even more  
16 impossible for you to orgasm. Anybody who didn't  
17 know that? Muscle relaxers, pain killers, I've a  
18 drawer full. Then I had life threatening things  
19 like face swelling, rapid heartbeat, major weight  
20 loss. No one could find the root of my problem.  
21 But I kept getting prescriptions for things that  
22 didn't help.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

53

1           In case you are unfamiliar with the  
2 condition I'll share some of the things that I  
3 experienced as symptoms. They include, not  
4 limited to, but pain, depression, inability to  
5 maintain relationships, loss of interest, loss of  
6 ability to get aroused, low self-confidence,  
7 inability to achieve orgasm, inability to maintain  
8 relationships with your friends, your family. It  
9 really impacts your self esteem and you have to be  
10 an advocate for yourself because there is really  
11 no help out there.

12           I run a small business. I'm an  
13 entrepreneur. I have to get up every day and go  
14 out and interact with people at high levels in the  
15 community. I almost lost the ability to do that.

16           I adopted a daughter from Russia when  
17 she was nine years old. When this hit she was  
18 about 15 years old and needed me most. I lost at  
19 least three years with her. And I'll never regain  
20 that time.

21           I think the thing that makes me most  
22 angry and most disappointed is that if I went to

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

54

1 my doctor and I was a man and I said these things  
2 they would be able to write me a prescription  
3 within a couple of minutes for a drug that is  
4 insurance covered and FDA approved. I don't know  
5 how all their drugs got through approval but I'd  
6 like to know who is behind that.

7 I probably spent 50 hours in manual  
8 pelvic floor physical therapy thinking that might  
9 be the problem. And yes that is just as personal  
10 and intrusive as it sounds.

11 Fortunately for me I didn't believe all  
12 those other doctors and I didn't take all of those  
13 other drugs for any period of time particularly  
14 when they had life affecting threatening side  
15 affects like face swelling.

16 I found Dr. Goldstein and I received  
17 some treatment from him. He had the answers, he  
18 did different blood panels. He did some other  
19 testing. I even talked to a sex therapist in his  
20 practice who confirmed this was not in my head but  
21 a physiological issue and medical condition.

22 Prior to the onset of this I had a very

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

55

1 robust and fulfilling sex life.

2           Now that I'm being treated I don't have  
3 issues with arousal, interest, or orgasm. All of  
4 those things are possible. I have a great and  
5 supportive significant other. Unfortunately I  
6 lost a major relationship to this issue. And I  
7 never want to go back there.

8           The topic is never far from my mind.  
9 I'll never forget how it impacts my life. And I  
10 know it could come back at any time.

11           My significant other is very aware of  
12 how my symptoms wax and wane. He knows when my  
13 treatment is due. It is very evidence in how I  
14 initiate or how interested I am or how aroused I  
15 get. I can tell you for sure there is a direct  
16 correlation.

17           Recently I appealed to my insurance  
18 company who declined to pay for any of my  
19 treatments. We went to full third party medical  
20 appeal. Unfortunately they determined it was not  
21 medically necessary and told me that no future  
22 appeal will be possible. The biggest thing that

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

56

1 scares me is someday I might not be able to afford  
2 the treatments I get. And if I were a man every  
3 treatment I've gotten would be covered.

4           In closing I would just like to express  
5 that I was passionate about this and honestly  
6 quite angry about it as I started to prepare to  
7 come here to tell my story. After I was briefed  
8 by Sara from the FDA about my participation I  
9 honestly was dismayed and it became fairly  
10 profound. She was delightful to speak with when  
11 she told me about what to expect here today.  
12 Unfortunately when she told me not to set my  
13 expectations too high as nothing was likely to  
14 happen quickly you can understand that I was very  
15 surprised and more than disappointed.

16           I feel strongly that we need this to  
17 happen quickly. We need approval. We need  
18 doctors to get educated. We need people to  
19 understand this is a severe medical condition.  
20 And we need women to stop suffering in silence.

21           I know none of you want your mothers or  
22 sisters or daughters to go through this. It is an



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

57

1 unmet medical need. And no amount of talk therapy  
2 is going to fix it. We can't get better from a  
3 physiological need by talking about it. I would  
4 just be delighted if we had the same choices as  
5 men.

6 Thank you for the opportunity to tell my  
7 story.

8 DR. EGGERS: Thank you, Beverly.

9 And then Carol. Beverly if you could  
10 shut off your microphone.

11 CAROL: Good afternoon. I welcome the  
12 opportunity to participate in this meeting and  
13 tell my story. By sharing this experience I hope  
14 that it will assist and support women who are  
15 currently sexually dysfunctional as well as those  
16 who will experience it in the future.

17 I devoted a significant amount of time  
18 and energy on my quest for an answer, a solution,  
19 a treatment. I consulted numerous physicians and  
20 specialists and experimented with various pills,  
21 injections and topical medications.

22 My symptoms waxed and waned based on the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

58

1 type of medication, its delivery system, dosage  
2 and the period of time I was on it. I experienced  
3 brief honeymoon periods when I was sexually  
4 functioning 75 to 80 percent. However, once the  
5 affect of the drug began to wear off I was back to  
6 where I started.

7           In my case there was an active interplay  
8 between my physical symptoms and the psychological  
9 aspects of my condition. For clarity sake I would  
10 like to discuss these separately.

11           A first and most frustrating symptom was  
12 the loss of my skin sensitivity. The skin  
13 numbness felt like my entire body was encased in a  
14 rubber glove sealing off all physical sensation.  
15 Another analogy would be having my body injected  
16 with a physical numbing agent like Lidocaine or  
17 Novocain. The second and related symptom was that  
18 I could not have an orgasm. I could not become  
19 lubricated, aroused or sexually excited even after  
20 sexual stimulation. No matter how intensely I  
21 tried I attempted to talk myself into climaxing, I  
22 never succeeded. I never succeeded and had no

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

59

1 history with this type of condition and never  
2 experienced sexual dissatisfaction in the past. I  
3 became so frustrated that any attempt to have  
4 sexual intercourse would end up in me crying.

5           The onset of both of these symptoms  
6 began when I was in my early 50s. It was a very  
7 gradual process over a period of months and became  
8 progressively more pronounced. It began with  
9 small subtle physical changes. The ability to be  
10 stimulated by being touched slowly disappeared.  
11 Sexual arousal and response time kept taking  
12 longer and longer until it became nonexistent.

13           I had difficulty coping with my new  
14 reality. Come to terms with the discrepancy  
15 between who I was and who I became. I felt  
16 sexually unattractive, inadequate, dysfunctional,  
17 isolated and asexual. My primary concern was that  
18 I would never be able to experience sexual  
19 pleasure again.

20           After several years, a significant  
21 amount of determination, patience, trial and  
22 error, and the support of an excellent physician

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

60

1 and the correct dosage of medication my condition  
2 finally stabilized. I'm able to climax, however,  
3 my skin sensitivity has never been completely  
4 restored.

5 Part of getting older is learning to  
6 accept the things you cannot change, the courage  
7 to change the things you can and the wisdom to  
8 know the difference.

9 Thank you.

10 DR. EGGERS: Thank you very much Carol.

11 And finally we have Karen.

12 KAREN: In 1971 at the age of 23 I had  
13 to make a careful decision about the type of birth  
14 control I would use after the birth of my first  
15 and only child. My mother-in-law had had a stroke  
16 at age 45 and was paralyzed for the rest of her  
17 life. She was in the first wave to use the then  
18 revolutionary birth control pill of the 1960s. My  
19 doctor recommended the brand new Dalkon shield IUD  
20 which was being marketed as the Cadillac of  
21 contraception. The advertising brochure I  
22 received boasted that it was 100 percent safe with

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

61

1 no general effects on the body.

2           12 years later at the age of 35 my  
3 reproductive sexual life and sexual life were  
4 forever altered when I had to have a total  
5 hysterectomy including the removal of my ovaries.  
6 During my recovery I learned that the Dalkon  
7 shield caused the cumulative damage from the  
8 pelvic inflammatory disease that went undiagnosed  
9 and untreated for 12 years.

10           The Dalkon shield debacle went down into  
11 history for being the most egregious breach of  
12 medical misconduct. The doctor inventor made a  
13 number of ethical lapses in the reporting of his  
14 research results. Tens of thousands of women  
15 suffered a wide range of pelvic damages.

16           I was please when I came through the  
17 building today to see a display case out front  
18 with former defective products and for all you to  
19 see the Dalkon Shield IUD, it's out there. At the  
20 time the FDA did not approve devices and it was  
21 precisely because of this case that the FDA began  
22 to approve devices as well as drugs.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

62

1           My hysterectomy left me traumatized in  
2 shock, psychically devastated by the loss of my  
3 fertility and my precious highly erotic  
4 relationship with my husband. My bodily and  
5 psychic symptoms were severe for many years. I  
6 had a total loss of sexual desire and arousal.  
7 Orgasm was out of the question.

8           As I now know the loss of the sexual  
9 pelvic organs has a profound effect on sexual  
10 function. In the 1980s, however, doctors were  
11 still claiming that the only loss from a  
12 hysterectomy would be the ability to get pregnant.

13           My eventual recovery included retooling  
14 my career as a teacher to become a sexuality  
15 educator. I hope to educate other women about the  
16 sanctity of their sexual organs and how they could  
17 make more informed decisions than I did as a young  
18 woman.

19           Over time I was able to regenerate my  
20 sexual interest and capacity although I never  
21 fully recovered. At best I have been able over  
22 time to have what I call a feeble orgasm. I

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

63

1 incorporated what I had learned about positive  
2 sexuality and sensuality techniques to enhance my  
3 sexual experiences. However, there has always  
4 been an ebb and flow.

5           Life stressors presented challenges to  
6 my capacities. For me the loss of a good job, the  
7 illnesses and deaths of my parents, et cetera  
8 added to that ebb and flow in my sex life. Those  
9 stresses and the PTSD of the hysterectomy make my  
10 symptoms sometimes better and sometimes worse. At  
11 present I am dealing with the death of my dear  
12 husband. This loss has cause another major  
13 stressor to my sexuality a natural consequence of  
14 losing the love of my life.

15           The challenge of aging also presents an  
16 additional issue to my sexual functioning at this  
17 time. At the ripe old age of 67 I turned to my  
18 sexuality profession and became the cofounder of  
19 what is now the Sexuality and Aging Consortium.

20           Here is a warning, the boomers are  
21 coming.

22           [Laughter.]

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

64

1 Literally and figuratively and they, we, will  
2 demand sexual access in those long term care  
3 facilities that we may enter in a few years. Our  
4 society and health care community at large are ill  
5 equipped to deal with this phenomenon. So much  
6 ignorance pervades our stereotypes of old age.

7           For my part I accept the reality of my  
8 age and past challenges. I do not hold an  
9 unrealistic expectation associated with the  
10 cultural pressures to be forever young, beautiful  
11 and sexy. I, and many other women, young or old  
12 are not ever going to achieve the mind blowing  
13 nirvana of orgasmic ecstasy that saturates our  
14 popular culture. I am confident that one day I  
15 will return to a satisfying form of sexual  
16 expression whether it be self-love, wink wink,  
17 and/or partnered coupling. I don't think of  
18 myself as a cougar. I am more of a kitten. You  
19 won't hear me roar but if you listen carefully you  
20 might hear me purr.

21           Thank you.

22           DR. EGGERS: Thank you very much Karen.



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

65

1 I would like to extend a round of  
2 applause to all of the women up here.

3 [Applause.]

4 We know this is very personal to talk about and we  
5 very much appreciate that.

6 Unless my colleagues have any clarifying  
7 questions for any of the panelists, I'm going to  
8 grab a microphone and make my way to the front.

9 DR. KWEDER: Sara I do have a question.

10 DR. EGGERS: Yes, go ahead.

11 DR. KWEDER: Two of the panelists I  
12 think it was -- let's see it was Beverly and Carol  
13 both said they are currently being treated. I  
14 thought that is what you said. And so if you  
15 could say what the treatment is, if it is  
16 medication or some other form of therapy that  
17 would be helpful.

18 BEVERLY: Sure I am happy to share that.  
19 I am currently being treated with implanted  
20 testosterone pellets.

21 CAROL: I'm also taking testosterone but  
22 I am using a localized gel every day.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

66

1 DR. EGGERS: And we will be addressing  
2 those products a little bit more in Topic 2.

3 Any other -- Marcea, please?

4 MS. WHITTAKER: Yes. I have a question  
5 for Beverly. Thank you again for your story. You  
6 mentioned that your partner knows when you need  
7 treatment. Can you expound on that a little bit?

8 BEVERLY: Certainly. I am more than  
9 happy to expound on it. The issue with arousal  
10 and interest is really what is at question here.  
11 And we have a very robust sexual life. But when  
12 I'm not interested or I'm not initiating or I'm  
13 not interested in his advances it becomes very  
14 clear that the pellet that is inserted in me is  
15 wearing off. Because we don't have any other  
16 stressors in our relationship, there are no issues  
17 in our life. And so the only thing that really  
18 comes into play is that treatment needs to happen  
19 again.

20 DR. EGGERS: Okay. So I'm going to  
21 start off by asking for a show of hands how many  
22 of you heard your own experiences reflected in at

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

67

1 least one of the panel member's comments today so  
2 far?

3 Great. Thank you.

4 Anyone who said my experience is nothing  
5 like what any of the women are talking about up  
6 here?

7 Okay.

8 At the end if we haven't addressed your  
9 different situations we'll come back to you. But  
10 I think that is reassuring that the range of  
11 experiences, we did hear a range of experiences  
12 presented this afternoon and we are now going to  
13 build upon that in a little bit.

14 We do have a polling question. Before  
15 we get to that I want to ask a few questions on  
16 terminology. And I'm -- many of you said that you  
17 experienced both in one of the first polling  
18 questions that you had, both difficulties with  
19 interest and difficulties with arousal. And if  
20 someone would like to share what's the difference  
21 between those two, how do you conceptualize those  
22 differently? If you are interested in sharing

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

68

1 just raise your hand and we'll come to you with  
2 the microphone; if you could just state your name;  
3 and if you have any of those disclosures to make.

4 MS. GOLDSTEIN: Hi, I'm Sue Goldstein.  
5 I paid for my own travel and what else am I  
6 suppose to disclose?

7 DR. EGGERS: If you are affiliated with  
8 any organizations that have an interest.

9 MS. GOLDSTEIN: Okay. I am here as a  
10 patient. But I'm also here as a sexuality  
11 educator and author and I've interviewed a lot of  
12 patients. I'm a clinical researcher so I have  
13 talked to a lot of patients and I'm also on the  
14 Board of the International Society for the Study  
15 of Women's Sexual Health.

16 I think as a patient differentiating  
17 between desire and arousal if you are interested  
18 in having sex or if you are receptive to your  
19 partner approaching you that is desire. When you  
20 are getting wet, when you are getting tingly, when  
21 you are having those bodily changes in bed or as  
22 you are approaching the bed I think that -- it is

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

69

1 the wetness that is the arousal. So while you  
2 have the interest and your body may be starting to  
3 get turned on, that is desire. But once you start  
4 getting your body actually changing, it is the  
5 getting wet, it is the -- maybe it is your nipples  
6 getting erect, your clitoris getting engorged,  
7 enlarged. Those bodily changes are the arousal.  
8 So I think that one of the biggest problems is you  
9 may not have an arousal issue but if you have no  
10 desire your body isn't going to be aroused until  
11 perhaps your partner starts stimulating you and  
12 then you have bodily arousal and then maybe you  
13 may have more interest. But the arousal can't  
14 just occur standing there looking at your hot  
15 husband or maybe you don't have a hot husband. I  
16 am married 40 years and I still think my husband  
17 is hot. But they are two separate things. But  
18 there is -- certainly there is an interplay but  
19 that doesn't mean that they are the same thing.

20 MS. EGGERS: We will be exploring that I  
21 think throughout our conversation.

22 How many of you did that -- did Sue's

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

70

1 comment resonate with that is how you  
2 conceptualize it as well?

3 Okay.

4 Any completely different  
5 conceptualizations?

6 Do you want to -- right here.

7 LEONORE: I think that it is enormously  
8 diverse. I don't think that you know all the  
9 words sounded good but I think if we sat down had  
10 a more personal conversation differences would  
11 emerge.

12 DR. EGGERS: And I think we should take  
13 this point to heart for all of the -- what was  
14 your name?

15 LEONORE: Leonore. We should take  
16 Leonore's point to heart for all of our discussion  
17 about just how variable and personal these will be  
18 to everyone.

19 So a show of hands if you could, there  
20 were a couple of panelists or maybe all of you who  
21 indicated that you used to have one kind of normal  
22 regarding your sexual experiences and now you face

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

71

1 a distinctly different normal, your experiences  
2 have changed. How many of you and if you feel  
3 comfortable raising your hand experienced that  
4 same thing where you had a one type of sexual  
5 experience and normal about that and now it is  
6 completely different.

7 Okay.

8 Are there any show of hands where this  
9 has been your normal for as long as you can  
10 remember that for your sort of adult life you've  
11 always been living with this normal?

12 Okay.

13 So most of you this has sort of had an  
14 onset; but we do have a couple of you who have  
15 been dealing with this most of your lives. That  
16 is helpful to set the context.

17 I'd like to go to a polling question  
18 now. And these are just again to start a  
19 discussion.

20 We'd like to know for those of you who  
21 experience absence or reduced sexual interest  
22 which of the following affects do you consider to

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

72

1 have the most significant impact on your daily  
2 life. And you can choose two. It is just a  
3 discussion starter including other if there is  
4 something other. So a) no or reduced interest in  
5 sexual activity, b) no or reduced sexual or erotic  
6 thought or fantasies, c) no or reduced initiation  
7 of sexual activity, d) not being responsive to my  
8 partner's attempt to initiate sexual activity. Or  
9 again other. Pick two that are the most important  
10 to you.

11                   And on the Web we encourage you to  
12 answer the same question.

13                   Okay. Well you've made my job  
14 difficult. We are going to be exploring a lot of  
15 these issues. So about equal numbers of a), c),  
16 and d) with less for erotic or sexual thoughts or  
17 fantasies.

18                   So let's explore a few of these in a  
19 little bit more detail. And I'm going to start  
20 with the response to you partners initiation which  
21 is d) here. Any of you, you didn't just have to  
22 pick the polling choice for this. Any of you can



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

73

1 please comment on this. Are your sexual  
2 activities, this is maybe an easy question. Are  
3 your sexual activities typically initiated by you,  
4 your partner or both? You? Your partner? Both?  
5 Okay.

6 So it appears that the role of your  
7 partner's initiation is very important to your  
8 sexual experience.

9 How do you conceptualize when we talked  
10 about responsiveness to that initiation? When you  
11 saw this question what were you -- what was going  
12 through your minds when you said about being  
13 responsive? What happens? Can anyone describe  
14 anything that happens to you physically or  
15 mentally when your partner is initiating?

16 MS. PRICE: I'm Carla Price. The  
17 biggest thing that I feel is anxiety because I  
18 know that I'm not going to be able to respond  
19 back. So I just tense up, I'm anxious. And like  
20 one of the speakers said I definitely try to avoid  
21 it at all costs. So I'll stay up late. I get up  
22 early. Avoid any alone time. And my children are

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

74

1 married and out of the house so I don't have a lot  
2 of stresses other than this and it really shows.

3 DR. EGGERS: Thank you Carla.

4 Would anyone else like to comment? We  
5 had one over here. Anyone else? There in the  
6 back.

7 UNIDENTIFIED PERSON: I'll say hey, let  
8 me just finish doing the dishes or close my  
9 computer and make some space for this.

10 DR. EGGERS: And what is going through  
11 your head, if I can ask?

12 UNIDENTIFIED PERSON: Well, it hadn't  
13 occurred to me but it occurs to him so okay I'm  
14 open for that.

15 DR. EGGERS: Okay. Would anyone else  
16 like to share any kind of physical or mental  
17 responses? Yes, Beverly?

18 BEVERLY: It is interesting because what  
19 goes through my head is am I going to be able to  
20 orgasm during this and is that going to impact how  
21 he feels about our relationship because honestly  
22 that is a huge part of men's self worth if they

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

75

1 can get you there. And I've seen the wheels  
2 almost come off my relationship a number of times  
3 when that piece is lacking. So if I know my  
4 treatment is wearing off I tend to avoid sex  
5 because I know that that is going to create an  
6 issue.

7 DR. EGGERS: Thank you.

8 Let's talk about your own initiation.  
9 If it happens that you initiate sex, does your  
10 experience differ at those times than if your  
11 partner has initiated sexual experience  
12 physically, mentally or emotionally? Is it a  
13 different experience? Is it the same experience?  
14 Show of hands. Is it the same experience?

15 Okay. Go ahead.

16 BEVERLY: I would say it is a vastly  
17 different experience. If you are feeling aroused  
18 and you are feeling interested and you want to  
19 initiate sex the likelihood that you are going to  
20 have a successful exchange in bed or wherever you  
21 decide to have sex is much higher at least in my  
22 world. If I'm thinking about sex, if I'm

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

76

1 interested, if I'm aroused it is going to be a  
2 much more fulfilling experience that if I'm going  
3 along because I was doing the dishes and I can  
4 figure out how to make time for it.

5 DR. EGGERS: Okay.

6 BEVERLY: And so that just depends on  
7 how you are being impacted by the arousal issue  
8 and interest issue.

9 DR. EGGERS: Okay. Does anyone -- does  
10 Beverly's point resonate with you?

11 Okay.

12 Any final -- anyone want to build upon  
13 that?

14 Go ahead, yes.

15 LEONORE: I think that Beverly's  
16 experience is idiosyncratic to her, not unique,  
17 but I think other people expect that when they  
18 respond but don't initiate that there will be  
19 longer foreplay and that if that has been  
20 communicated with their partner the foreplay will  
21 be choreographed to fit the situation.

22 DR. EGGERS: Thank you. I think there

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

77

1 were a couple of hands over here.

2                   KATHERINE: Hi, I'm Katherine. I don't  
3 want to say this really because my husband is  
4 sitting right next to me but I can tell you that  
5 when he does initiate my response is kind of  
6 sigh] and that is both mentally and physically.  
7 My body really doesn't do anything and nothing  
8 happens to me mentally or emotionally either. And  
9 I actually don't ever initiate sexual activity  
10 since this happened so it is kind of hard for me  
11 to answer your follow-up question to that.

12                   DR. EGGERS: Is it hard for others to  
13 answer the follow up question, like Katherine  
14 said?

15                   Go ahead Victoria.

16                   VICTORIA: I have to say I 100 percent  
17 relate to what she just said and I felt the same  
18 way. When you asked that question I was kind of  
19 going I never initiate so I don't even know  
20 anymore.

21                   DR. EGGERS: This -- what makes the  
22 questions that we are asking difficult for you is

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

78

1 as much as we want to know what the answer to the  
2 question is. So please feel free if we are asking  
3 the questions in the wrong way you can alter them  
4 to fit your experience, so feel free.

5 We have a hand right here.

6 CARMON: Hi, my name is Carmon and my  
7 trip was funded by Veritas but like Beverly I  
8 would have flown here without that. I am really  
9 excited that you are doing this.

10 My husband and I have suffered for over  
11 30 years with my low libido and I did get  
12 treatment which has helped me tremendously. And  
13 for the first time in a long, long time I do  
14 initiate sex sometimes. And for my husband that  
15 is a wonderful blessing because he knows that it  
16 is not duty sex but that I actually want him. And  
17 he wants me to want him. And I think that most  
18 partners feel that way about their sexual  
19 relationships. So it does make a big difference  
20 that I'm able to do that now.

21 DR. EGGERS: Thank you.

22 Who else? Here.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

79

1           SUE: It is Sue again. I think one of  
2 the problems that I know occurs for me is that  
3 even if I'm willing when my husband initiates to  
4 have sex I can't stay in the moment necessarily  
5 and then your body stops responding. And even  
6 going into the bedroom is like am I going to stay  
7 focused today, am I going to have an orgasm today.  
8 It is like you feel sometimes like why waste your  
9 time having sex if nothing is going to happen but  
10 say okay I'm willing to try again, I love my  
11 husband. Essentially it starts out being duty sex  
12 and if you are lucky it turns into great sex. I'm  
13 in my 60s and sometimes sex is the best it has  
14 ever been in my life because like some of these  
15 other women my children are grown so I don't have  
16 those kinds of stressors. But sometimes my body  
17 just betrays me and it doesn't respond or it  
18 responds but then if I can't stay in the moment  
19 and I've taught myself to refocus back, sort of my  
20 own version of mindfulness. But it doesn't always  
21 work. And that is a really hard issue to deal  
22 with. And there are times that like Beverly when

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

80

1 my -- I have a testosterone pellet and when it is  
2 fresher and newer my body -- I am more interested  
3 and when it is getting later my husband can also  
4 tell. He goes, go get your blood test; it is  
5 probably time for a new pellet. And we never know  
6 when we can count on our minds and our bodies.

7 DR. EGGERS: Thank you Sue.

8 One more right here and then -- oh, we  
9 will do two more. One more right here and then  
10 one more in the back.

11 AMANDA: Hi, I'm Amanda and likewise I  
12 signed up to be part of this discussion before I  
13 found out that my travel could be funded by  
14 Veritas. But in response to the question I agree  
15 with what everybody said. Obligatory sex is a far  
16 cry from initiating and I think for years the  
17 burden of a healthy or a regular sexual  
18 relationship has fallen on the men particularly my  
19 husband. And I think that they've sort of got the  
20 bum rap and women have too. But unfortunately in  
21 the lack of desire that is what it falls down to.  
22 So in the short amount of time that I was treated



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

81

1 it made a dramatic difference for us as far as my  
2 initiating and I can tell that it definitely  
3 elevated our whole level of intimacy and the way  
4 we related to each other. Once I stopped it  
5 returned to normal and unfortunately the burden  
6 falls in his shoes. But I think it would be  
7 interesting one day if you guys could pull some  
8 men and get their thoughts on the process.

9 DR. EGGERS: All right. Thank you.

10 Okay. One more back there?

11 THEA: Hi, my name is Thea. I have no  
12 funding to be here. I know for myself and many of  
13 my friends growing up we sort of learned not to  
14 initiate sex because some of our boyfriends made  
15 fun of us or I know there is a stereotype that men  
16 are always wanting sex but that wasn't always my  
17 experience. And also it took us longer to orgasm  
18 and we found that embarrassing and wondered if we  
19 were normal because in porn, in culture, in  
20 Hollywood movies it seemed very easy for women.  
21 So there was a lot of shame around that.

22 DR. EGGERS: Thank you very much. Leah,

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

82

1 right? Thank you

2 Let's move on to the next question that focuses on

3 arousal. For those of you who experience absent

4 or reduced sexual arousal which of the following

5 affects do you consider to have the most

6 significant impact on your daily life? And here

7 again you can choose up to two. No or reduced

8 sexual excitement pleasure during sexual activity?

9 No or reduced sexual arousal in response to

10 written, verbal or visual cues? No or reduced

11 genital or non genital sensation during sexual

12 activity? Or other?

13 Okay. So the top two in terms of

14 frequency here no or reduced sexual excitement or

15 pleasure or no or reduced genital or non genital

16 sensation during sexual activity.

17 On the Web can we get a sense of what

18 the responses were?

19 MS. GIAMBONE: Sure. 50 percent of the

20 people on the Web said no or reduced sexual

21 excitement or pleasure during sexual activity. 40

22 percent said no or reduced sexual arousal in

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

83

1 response to written, verbal, or visual cues.

2 Followed by 30 percent with or reduced genital or  
3 non genital sensation. And then ten percent said  
4 other.

5 DR. EGGERS: Okay. If you are on the Web  
6 it sounds like a few more of you talked about  
7 arousal in response to written, verbal or visual  
8 cues. Send in - - type in a comment to that.

9 On the Web did I ask about what the  
10 responses -- did they look similar to that first  
11 question I asked?

12 MS. GIAMGONE: Yes, very much so.

13 DR. EGGERS: Very similar. Okay. So  
14 let's go into a little bit of these issues in a  
15 little bit more depth. How do you differentiate  
16 between the terms excitement, pleasure, sensation,  
17 arousal? Do you tend to use -- do they mean very  
18 similar things for you? Do you prefer one term?  
19 Does one term arousal or excitement or a different  
20 term resonate for you?

21 We will go with Karen first.

22 KAREN: I forgot to disclose that I have

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

84

1 not received any remuneration of any type to be  
2 here.

3 I think in my opinion that question is  
4 incredibly varied and everyone is going to be  
5 using a different word to describe what is either  
6 psychological or physical. Excitement, arousal I  
7 mean pick a, b, c or d.

8 DR. EGGERS: Then can I follow up. Does  
9 it make it difficult to answer these questions and  
10 identify which one of these would be most  
11 important to you given that they all use different  
12 terms?

13 Following up on what Karen said. I see  
14 some head nodding.

15 So if I ask about the sexual excitement  
16 and pleasure during sexual activity would someone  
17 be brave enough to explain what are you  
18 conceptualizing when you did respond to that one?  
19 Is it the sensations? Does it include orgasm? You  
20 know this is a very tough subject to address and  
21 so we do appreciate all of your thoughts and  
22 experiences.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

85

1 Well if you do want to comment on that  
2 and work it in somehow, feel free because we do  
3 know it is difficult as Karen was saying.

4 Sure go ahead.

5 LOUANNE: I'm Louanne and I am a patient  
6 and I am also a therapist. And my travel was paid  
7 for by Veritas.

8 The way I look at it from the therapist  
9 mindset sexual excitement is what you make out of  
10 what your body is feeling. But sensation is what  
11 you actually believe you are feeling and it is the  
12 transmission of the nervous impulses that you go,  
13 oh, I feel that, it is muted; it's less than I  
14 felt before but I feel that. And then I think a)  
15 is what you make of what you are feeling and how  
16 pleasurable you categorize it for yourself.

17 DR. EGGERS: Okay. Thank you. Anyone  
18 else want to comment?

19 Yeah, right here.

20 DR. PARISH: So my name is Dr. Sharon  
21 Parish. I'm President of the International  
22 Society for the Study of Women's Sexual Health and

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

86

1 my travel was supported by SPROUT.

2 I think looking at the distribution of  
3 responses here. I think it is very important to  
4 understand the age range of the women both in the  
5 teleconference and also in the room. And c) is  
6 going to be very different in a younger versus an  
7 older woman. And I think this differentiation in  
8 understanding these responses is very critical to  
9 understanding this diagnosis in patients here and  
10 in our offices.

11 DR. EGGERS: Do the FDA colleagues want  
12 to follow up on any aspects of what we've been  
13 talking about interest or arousal?

14 Yes, Christy.

15 DR. CHANG: I have a question on  
16 response b) actually. So even though it didn't  
17 get as many votes as either a) or c) I'm just  
18 wondering if any of the ladies could clarify for  
19 us what kind of written cues, verbal cues, visual  
20 cues or even tactile cues may help in helping to  
21 reduce the difficulty with arousal?

22 DR. EGGERS: Okay. We'll go with Karen.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

87

1           KAREN: Well as a sexuality educator I  
2 am very interested in finding ways to become the  
3 best lover you can become. And for some people  
4 that is looking at erotica. For some people in  
5 response to your question that is using sex toys  
6 of all kinds, either alone or with your partner.  
7 It is so again varied in the ways that you can  
8 besides just being anxious about it that you can  
9 learn to be a good lover and to accept the limits  
10 of what you are able to achieve or accomplish  
11 without feeling like a failure.

12           DR. EGGERS: Does anyone else have  
13 another follow up. We have one here.

14           NATALIE: Hi, my name is Natalie. I  
15 received a travel stipend to be here today as well  
16 from Veritas --

17           DR. EGGERS: Can you talk a little  
18 closer to the mic. Thank you.

19           NATALIE: I have a thought about arousal  
20 and desire that occurs to me. I used to have a  
21 normal sex life my whole life and then this  
22 happened. It was a year of going through hell but

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

88

1 I am now being successfully treated. And so the  
2 question about desire is basically before -- it is  
3 not a matter of how much foreplay we do or not.  
4 I'll be approached and we can spend forever trying  
5 to make something happen. And the difference is  
6 the desire within me. It is very obvious for men  
7 when it is working and not because they are able  
8 to have sex. I am able to grit through it which I  
9 often do in terms of like I do it for him but not  
10 for me. So the loss of the desire is what I think  
11 it is important to make that distinction. It used  
12 to be there. It is not anymore unless I keep  
13 getting treated every four to six months.

14 DR. EGGERS: Thank you very much.

15 Yes. Sandy.

16 DR. KWEDER: If it is okay can I probe  
17 one of the responses.

18 DR. EGGERS: Oh, of course.

19 DR. KWEDER: I can't see the woman who  
20 is the head of the society, there you are. Can  
21 you say a little bit -- can you expand a little  
22 bit on the comment that you made about some of the



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

89

1 differences you might expect or expectations for  
2 some of these responses based on age range. Can  
3 you comment on that a little bit?

4 DR. PARISH: Sure. Absolutely. So I  
5 was referring to item c) no or reduced genital or  
6 non genital sensation during sexual activity. You  
7 know both organic diseases that are sometimes co  
8 morbid with older women such as diabetes,  
9 hypertension and other neurologic conditions or  
10 genital symptoms of menopause related to vulvar  
11 and vestibular changes may result in changes in  
12 genital and non genital sensation during sexual  
13 activity. So I think looking at the spectrum of  
14 responses has to be in the context of  
15 understanding we have a distribution of ages of  
16 women in the room and it might be useful to  
17 separate that out.

18 DR. EGGERS: Yes, Marcea?

19 MS. WHITTAKER: I have a question and  
20 Sara actually asked it and I think it is important  
21 as we move forward. The question was when we  
22 think about excitement and pleasure and arousal

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

90

1 does that include orgasm. And so we can maybe  
2 just do a show or hands.

3 DR. EGGERS: Sure. So if in those set  
4 of terms you would include orgasm could you please  
5 raise your hand if you feel comfortable.

6 Okay.

7 If that term doesn't need to be there,  
8 is not included in that, I'll assume the rest of  
9 you? Raise your hand.

10 It does not need to be; is not a part of  
11 that? It can be but doesn't have to be; raise  
12 your hand please.

13 Okay. Seems like a majority. Thanks  
14 for clarifying.

15 I wonder if we can go back to this  
16 question here about the age range. Can I ask how  
17 many people who indicated c) about the sensation -  
18 - I have to do some math here -- how many of you  
19 are 40 and less? Let's take 51 and older? How  
20 many of you answered c)?

21 Okay. And younger than 51?

22 Okay. So we obviously don't have

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

91

1 exactly the spread but it does say that there is a  
2 difference. At the break we'll try to see what the  
3 clicker responses were and go back. We might mess  
4 up some technology here. We are kind of one  
5 direction.

6 DR. MODJOROS: Hello, my name is Melanie  
7 Modjoros. I'm a physician and a sex therapist in  
8 northern Virginia. I have no financial interest  
9 to disclose.

10 And I think this is a very interesting  
11 question. Every woman conceptualizes it a little  
12 bit differently. From my patients sexual  
13 excitement is often akin to the building of an  
14 orgasm but not necessarily the actual orgasm.  
15 Sexual pleasure is usually included in that  
16 building but, of course, the pinnacle is the  
17 orgasm and the climax that most men and women are  
18 looking for.

19 The sexual arousal in response to  
20 written, verbal, and visual cues can be in a solo  
21 setting or in a couple setting. And that is  
22 different because if a woman hears and I've heard

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

92

1 this from my patients, if a woman hears her  
2 husband say something sexy or naughty in her ear  
3 that may turn her on. That may result in arousal  
4 instantly or not instantly and that may change and  
5 that may cause distress.

6           So these answers are very heavy. They  
7 are very dense. And teasing it out even more I  
8 think would be helpful because every woman  
9 experiences it a little bit differently and every  
10 woman and couple conceptualizes it differently.

11           DR. EGGERS: Okay. We can take a couple  
12 more and then we will move on. But while we are  
13 getting the mics over there I'll encourage  
14 everyone, I think my colleagues would agree to  
15 write about this in the Docket. Write about how  
16 you make those distinctions and you can really  
17 expand upon it there. That would be very helpful.

18           We will take one more and then we will  
19 move on to other symptoms.

20           UNIDENTIFIED PERSON: When you asked the  
21 question about do we include orgasm in the concept  
22 of sexual pleasure, I think you got few answers

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

93

1 because we were confused by the question a little  
2 bit.

3 DR. EGGERS: Okay.

4 UNIDENTIFIED PERSON: And then someone  
5 added in well it doesn't have to always happen, it  
6 can be included and I think that is a very dense  
7 question that needs to be teased out to because it  
8 winds up that if a woman has never had an orgasm  
9 it is a bit like going to a movie and always  
10 leaving ten minutes before the movie ends. And  
11 after a while you stop wanting to go to the  
12 movies. And so for some people who know that  
13 orgasm is an option and it is an option that they  
14 can have relatively easily then it is not as  
15 crucial of a factor. But when it is never a  
16 factor then it is a very crucial one. So I think  
17 we kind of blended all of that together when we  
18 were raising our hands about that.

19 DR. EGGERS: Okay. Thank you. Thank you  
20 for the clarification.

21 Let's move on to other symptoms that are  
22 beyond arousal and interest. And then we are

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

94

1 going to be following up on sort of the sexual  
2 event. So we are going to be coming back to that.

3           There were some others in both of these  
4 categories. Actually let me -- I'm going to give  
5 a shout out to the folks on the Web. Before we  
6 get into other symptoms is there a brief summary  
7 we can have of comments on interest our arousal  
8 from the Web?

9           MS. GIAMBONE: We haven't heard too much  
10 on the symptoms. We've heard more impacts coming  
11 through.

12           DR. EGGERS: Okay. We'll wait for  
13 impacts at the end.

14           MS. GIAMBONE: Sure.

15           DR. EGGERS: Now let's talk about other  
16 symptoms. What was included in your other?  
17 Anyone willing to share that?

18           Okay. Just so we can tease out some of  
19 the other aspects of FSD that you might have, can  
20 I have a show of hands again for how many  
21 experience something other than -- you have  
22 interest and arousal challenges but you also have

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

95

1 one of the other aspects of FSD, pain or orgasm or  
2 headaches or something else?

3           Would you like to expand upon yours a  
4 little bit Carla?

5           MS. PRICE: I'm Carla Price and I failed  
6 to mention that I am funded through Veritas but I  
7 would have come otherwise.

8           My problem is coital headaches, so as my  
9 arousal builds often times I experience just an  
10 unbelievable migraine that is worse than any  
11 migraine I've ever experienced. So it doesn't  
12 happen all the time but more often than not, so  
13 some of my low libido might just be the fact that  
14 there is pain waiting at the end. So it is  
15 painful pleasure I guess you might say. So it's  
16 not real fun.

17           DR. EGGERS: And Carla if I might follow  
18 up a little bit then. If your headaches did not -  
19 - if there is ever a time when your headaches do  
20 not accompany your sexual experience, is your  
21 interest and arousal still affected? Does it  
22 return?

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

96

1 MS. PRICE: No. I actually have to say  
2 that I still have a decrease in arousal. The one  
3 thing that -- I have been treated a little bit and  
4 it has helped about 50 percent but again the  
5 arousal -- the desire seems to be an issue. Which  
6 I do want to add I like the comment I would love  
7 to look at the husbands and partners views. It  
8 has come to the point where my husband doesn't  
9 even want to initiate sex because he is afraid  
10 that he will hurt me because of my headaches. So  
11 he said what fun is it for me to cause you such  
12 pain. And so our marriage and relationship has  
13 been really rocky. And it is -- I mean it has  
14 affected his self-esteem and his manhood. So it  
15 is definitely a domino effect.

16 DR. EGGERS: Thank you, Carla.

17 So I think we have another opportunity  
18 for the Docket comments which is to ask your  
19 husbands to submit -- your partners to submit a  
20 comment, invite them to. We would like to hear  
21 from men as well on their perspectives on this.

22 Would anyone else like to talk about any



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

97

1 other symptoms particularly as they relate to or  
2 how they affect interest and arousal?

3 We have Beverly and then we'll go back  
4 there.

5 BEVERLY: I just want to say that I  
6 don't know if these are all physical things and so  
7 if I'm reading the question most significant  
8 impact on your daily life and I covered that a  
9 little bit when I was speaking because I think  
10 there is a whole myriad of other things that it  
11 affects. Most often it affects things like my  
12 self confidence and how I approach the world and  
13 how I feel about myself and what I project to  
14 other people. So I don't know if anybody is  
15 thinking about that because the multiple choice  
16 answers that you offered were really so specific  
17 to being aroused or to being interested or actual  
18 intercourse.

19 And I think that other category can take  
20 into account a whole lot of other things that I'm  
21 sure a lot of women in this room experience. But  
22 we are so focused on how it actually works with

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

98

1 actual sex act that it is not -- they are not  
2 bringing in this whole other area.

3 DR. EGGERS: Okay. So maybe I'll go a  
4 little bit astray on this and say if you knew that  
5 anxiety could have been one of your choices, how  
6 many of you would have put anxiety as it was  
7 described. Someone described anxiety here. How  
8 many of you would have put that in your top two?

9 Okay. Several. And we had -- we did  
10 hear about it earlier is your experience the same  
11 as what we heard about which is a physical anxiety  
12 that happens when you think about desire or when  
13 you think about arousal or when initiation  
14 happens?

15 BEVERLY: The problem with that too is  
16 when you take that to any physician and you tell  
17 them you have anxiety or you are depressed about  
18 it, they give you an anti-depressant which then  
19 inhibits your desire and inhibits your ability to  
20 orgasm. And so it ends up becoming a circle.

21 DR. EGGERS: Okay. Great.

22 I do want to go back there; there was a

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

99

1 comment back there.

2 JUDY: Hi. My name is Judy. And the  
3 Social Sciences and Humanities Research Council of  
4 Canada paid for my trip. I'm here as a  
5 researcher.

6 But my research is on language in  
7 particular, and in particular language relating to  
8 health, medical conditions and this one in  
9 particular which I've studied for a while. I  
10 find it interesting how central the language of  
11 symptoms is. And it is a word that you keep using.  
12 And I think that the idea that these are symptoms  
13 suggests that there is an underlying disease and  
14 that that is kind of the position that we are  
15 starting from even though we are talking about  
16 variety and experience and the DSM criteria are  
17 kind of more open than that in fact. And so I  
18 wonder what would happen if we stop using the  
19 language of symptoms to talk about everything  
20 we're experiencing.

21 DR. EGGERS: Would it be better for the  
22 purpose of discussion if we used the term aspects,

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

100

1 that should cover everything, so I'll try to use  
2 that term moving forward; can't promise it. But  
3 I'll if I think of it I'll try to use that term.  
4 It sounds like that is a more appropriate term.

5 Are there any other aspects of interest  
6 and arousal that FDA wants to follow up on?

7 MR. JOFFE: I had one question. I think  
8 it has come from a few people that treatment can  
9 kind of make some of the arousal and desire wax  
10 and wane. But I was wondering for those of you  
11 who maybe aren't on treatment or even those on  
12 treatment could separate it, trying to get a sense  
13 of what arousal and desire is doing in general.  
14 Is there a waxing and waning over time or do you  
15 feel it is kind of a steady state of where you are  
16 all the time with this condition?

17 DR. EGGERS: We will go with Vicki  
18 first.

19 VICTORIA: I had treatment when I first  
20 went to see Dr. Goldstein he did -- I got the  
21 testosterone pellet and it did work like some of  
22 these women are saying for a short period of time.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

101

1 But it wasn't in my budget to keep going back and  
2 flying back to see him and it wasn't offered where  
3 I live. So I am currently not on any treatment.  
4 And I -- when I was on the treatment it helped a  
5 little bit. And now I am just back where I  
6 started and my symptoms are pretty constant and  
7 they don't wax and wane. It is the same every  
8 day.

9 DR. EGGERS: Can I get a show of hands  
10 for how many people share the same experience as  
11 Victoria?

12 Okay.

13 Karen did you want to follow up on that?

14 KAREN: Well I guess it is again and my  
15 role as a sexuality educator that the way that can  
16 be dealt with these things is to enlarge your  
17 perspective beyond the -- as I call it in my  
18 classes, the stairway to heaven -- [Laughter]

19 KAREN: -- which is a lockstep way of  
20 going and getting to the ultimate orgasm. And  
21 there are from personal experience a lot of outer  
22 course sensuality based communications and

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

102

1 experiences with your partner that can reduce the  
2 anxiety and the pressure of having to go all the  
3 way to the top.

4 DR. EGGERS: Okay. Thank you.

5 We will be revisiting this in more depth  
6 in the next discussion about treatments in  
7 general.

8 I want to tee up the phone to see if  
9 there is anyone in particular on the phone who  
10 absent treatment you experience waxing and waning  
11 of symptoms; that would be useful to hear about.

12 Did anyone -- we asked about absence of  
13 treatment, no waxing and waning or a constant  
14 symptom, is there anyone who does experience a  
15 waxing and waning of -- sorry, aspects, of their  
16 condition over time. Okay. In the back there.

17 THEA: Sorry, I mean I think that it is  
18 fair to say that desire waxes and wanes as a  
19 normal state of human physiology and being. I'm  
20 also a sex researcher and that is what all of the  
21 evidence points to.

22 DR. EGGERS: Does anyone have an

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

103

1 experience they can use to illustrate that?

2           SUE: I think one of the confounding  
3 facts of that question is a lot of us are on  
4 therapies that are not constant. If you are  
5 taking a daily testosterone gel for instance it is  
6 relatively constant whereas if you are using a  
7 pellet it forces the waxing and waning. But I  
8 think in addition that for some of us who are  
9 older things change as well. I know I interviewed  
10 a lot of women for a book I wrote and one of the  
11 women said it was like a light switch turned off.  
12 She just lost all interest, all desire; and it  
13 didn't change whereas for me it was something that  
14 happened slowly over time and then for me with  
15 time for treatment I was better and now as I am  
16 getting older I have been on treatment for 13  
17 years, I was diagnosed 13 years ago and now I find  
18 that testosterone alone isn't enough. I have  
19 changed. But it is not a daily waxing and waning  
20 per se but it is a slow change so I think we  
21 really have two kinds of patients; those who just  
22 one day everything changed. I think Vicki said it

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

104

1 after her fourth child everything just totally  
2 changed whereas for some of us it is a slower  
3 progression.

4 DR. EGGERS: Thank you very much.  
5 Go ahead, right there?

6 MS. KINGSBERG: Will all due respect to  
7 the normalcy of desire -- I'm Sheryl Kingsberg;  
8 I'm a psychologist and professor in reproductive  
9 biology at Case Western Reserve. I think the  
10 premise of this whole meeting is about an unmet  
11 medical need and that we've all agreed that this  
12 is a condition that we are working to find  
13 treatments for. So I think symptom is appropriate  
14 and I think it does a disservice to the women who  
15 have come all this way to talk about their  
16 condition and their symptoms to be respectful of  
17 that. That this is really very distressing.

18 DR. EGGERS: Right here. Yeah, if you  
19 could state your name and indicate -- there was a  
20 hand right here. And make your disclosure please.

21 BEN: Yes, thank you. My name is Ben  
22 and I'm here with my wife. Veritas did pay for our



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

105

1 travel. This is an issue that is very important to  
2 us. A couple of people have mentioned the impact  
3 on the man in the relationship and I can speak  
4 from personal experience. And it does have a huge  
5 impact when your lover, your soul mate is no  
6 longer interested in having sex with you. We've  
7 experienced the waxing and waning but it  
8 definitely affects the man. Again I know it is  
9 primarily about the woman but it affects the man,  
10 it certainly affects your ego, how you feel about  
11 yourself and it affects the broader relationship.  
12 So it has broader implication than just the man  
13 and the woman. It actually affects the  
14 relationship in the entire family.

15 DR. EGGERS: Thank you.

16 All right. I have a question about  
17 symptoms or aspects and their changing over time.  
18 We heard mention -- I can't remember -- I don't  
19 believe any of you mentioned this but in the  
20 comments that were sent to us a few people  
21 mentioned keeping a log and a diary, a daily diary  
22 every day. Does anyone keep a diary of their

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

106

1 condition?

2 Here, yes, can you explain what you put  
3 in your diary?

4 MS. REED-HOFF: Oh, I use a topical.  
5 I'm Judith Reed-Hoff (ph) and Veritas handled our  
6 travel arrangements, thank you very much.

7 I use a topical EstroGel and Testim and  
8 so then I record every day what the volume is that  
9 I administer to myself and then when it gets -- I  
10 feel out of whack then usually I know it is time  
11 to have my blood test done because Dr. Goldstein  
12 is very emphatic about following up anywhere. I  
13 started off at three to four weeks and now six to  
14 eight weeks.

15 DR. EGGERS: So if you were asked to  
16 think about tracking your symptoms over time; does  
17 anyone track those over time just as a natural  
18 thing that you do?

19 You track symptoms, too?

20 JUDITH: Yes, I do, I track symptoms  
21 because I think it is important that I know  
22 because sometime we think we are feeling okay but

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

107

1 if you write it down it makes a lot more sense and  
2 you can look back and say okay this was not a good  
3 day or a good evening and then I'm able to know  
4 what to do from then on.

5 DR. EGGERS: Was there -- yes, Carol?

6 CAROL: When I was being treated at the  
7 beginning of this experiment I kept a diary  
8 religiously and I did symptoms every day and the  
9 reason I did that was when I went to see my  
10 physician we would look for patterns that the  
11 symptoms are a lot of times related to the amount,  
12 the dosage of medication that you are on. And  
13 when you are not on enough you are going to become  
14 symptomatic. And when you increase it a little bit  
15 it resolves the problem until you get to the next  
16 hurdle. So it was very useful for both me and the  
17 doctor that treated me.

18 DR. EGGERS: Okay. So I think what we  
19 are hearing is that the tracking of symptoms over  
20 time is in large part due to finding the right  
21 treatment or dose for you. But I imagine the same  
22 sort of aspects apply to the question that I'm

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

108

1 going to ask so I am going to ask first I'm going  
2 to ask this question.

3           Knowing that you would want to track  
4 your symptoms as accurately as possible, how often  
5 do you think you would need to report in order to  
6 remember those symptoms accurately?

7           Okay. We have very clearly -- well,  
8 we've made it clear that this is dependent on if  
9 you are on a treatment. But I'm going to ask you  
10 to when you answer the question just say whether  
11 you are on a treatment or not and answer the  
12 question -- anyone to answer the question about  
13 what time period do you need. Do you need to  
14 record them daily, weekly, monthly, et cetera?

15           We have one hand here and then we will  
16 go on to others.

17           AMANDA: I am not currently on a  
18 treatment. And I myself at times did keep track of  
19 symptoms but what I found unfortunately was daily  
20 was not important because to me as time went on it  
21 was the broader picture and the longer range and  
22 it actually became more depressing and distressing

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

109

1 to think about on a daily basis. It sort of  
2 became the new norm which really was not  
3 acceptable. So my goal was the long term affect  
4 and how it was affecting me.

5           So conversely you have really good  
6 sexual experience when I was being treated you  
7 don't also need to record that because you don't  
8 forget that and especially as few and far between  
9 as those occurrences were that was more critical  
10 and more important that I track than a daily  
11 occurrence because to me it became the new norm.

12           DR. EGGERS: Okay. How many people does  
13 it resonate for what Amanda said?

14           Okay. Any different experiences? We  
15 have a hand here in the back.

16           LEONORE: You know it's -- we're talking  
17 about treatment and we've only been talking about  
18 certain kinds of medical treatments. So let me  
19 just say that non-medical interventions: psycho-  
20 therapeutic intervention, psycho-educational  
21 interventions. These also involve a certain amount  
22 of paying attention to what is going on in the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

110

1 relationship and paying attention to what is going  
2 on in one's moods and in one's body. But it is  
3 done in a completely different way because  
4 attentional focus is really reframed in some sex  
5 therapy, sex therapy that I do as a problem so  
6 that you don't want to get obsessively  
7 preoccupied with self monitoring. So I'm finding  
8 this conversation a little difficult. If we could  
9 talk specifically about medical interventions and  
10 how you deal with reduce arousal and paying  
11 attention and this and that but it is done quite  
12 differently with psycho-therapeutic interventions  
13 even though one could pay attention to symptoms or  
14 aspects. But one tries to get away from  
15 obsessional self focus as the magnifying problem  
16 rather than a useful intervention.

17 DR. EGGERS: Okay. I think there was  
18 another hand up and I'll turn and see if there are  
19 any follow up questions to that. Thank you very  
20 much.

21 KATHERINE: I actually had never even  
22 thought of the idea of keeping a diary or a log of

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

111

1 my symptoms because as someone mentioned on the  
2 other side of the room I was one of the people  
3 that had the switch flip in my head. And I had it  
4 one day and the next day I didn't.

5           And when I just realized my feelings  
6 were kind of always that way I felt no need to  
7 write it down because they are the same every  
8 single day. There is nothing dynamic. There is no  
9 waxing or waning with me. And I'm not on any  
10 treatment. So --

11           DR. EGGERS: Thank you very much  
12 Katherine.

13           Are there any follow up questions?

14           OPERATOR: We have one question from  
15 Maria.

16           DR. EGGERS: Okay. Let's go to the  
17 phone.

18           Yes, operator. Yes, Maria, hi.

19           MARIA: Hi. How are you?

20           DR. EGGERS: Very good, thanks.

21           MARIA: Good. I have a question in  
22 reference to the treatment from a physician

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

112

1 standpoint. [Garbled.]

2 DR. EGGERS: Maria. Can I interrupt you  
3 for a second? Can you hold the phone further  
4 away. Let's see if we fix the sound quality.

5 MARIA: Okay. One moment. Is that  
6 better?

7 DR. EGGERS: That is better, yes. If  
8 you could just briefly recap what you were saying?

9 MARIA: One moment. I will take it.  
10 Can you hear me?

11 DR. EGGERS: Yes.

12 OPERATOR: Much better.

13 MARIA: Okay. Great. I was saying that  
14 when I was treated, I recently had BioTE which are  
15 the pellets done. And I had to actually change  
16 physicians because my OB Gynecologist, the doctor  
17 I had been going to for the last 50 years did not  
18 agree with the actual treatment due to the  
19 information that had been submitted to them of the  
20 year in terms of the danger and why wouldn't --  
21 and all of the information that comes across I  
22 think that our practitioners are well informed. I



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

113

1 gave my practitioner with information and I am  
2 just like looking over the Internet. How can I  
3 fix my problem? I am like when is in Vitro coming  
4 out? Why can't Flibanserin -- why can't those  
5 drugs be approved? What is the issue? I mean my  
6 depression --

7 DR. EGGERS: Hey, Maria, I am going to  
8 interrupt you at this point because we are going  
9 to be talking about those issues in our afternoon  
10 discussion. Did you have anything that you would  
11 like to contribute about the symptoms you feel  
12 particularly as they change over time?

13 MARIA: Yes.

14 DR. EGGERS: Okay. Thank you.

15 MARIA: My vaginal dryness is there. I  
16 didn't use to have that issue at all. In terms of  
17 anxiety building up with the thought of sex that  
18 has increased immensely which is a deterrent for  
19 me having sex and a deterrent for my husband  
20 fulfilling sex.

21 DR. EGGERS: Okay. Thank you very much.

22 MARIA: Okay.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

114

1 DR. EGGERS: Do we have one more person  
2 on the phone? No. No we don't. Okay.

3 We have a few more minutes. And let's  
4 first see if there is any Web comments that have  
5 come in particularly on the ideas that we've been  
6 talking about changing or not changing over time.

7 MS. GIAMBONE: So we have heard a few  
8 symptoms mentioned; disinterest, repulsion,  
9 intense pain that has brought tears. And then in  
10 terms of changing over time one participant  
11 commented that for her the challenges were in the  
12 beginning of her sexual experience and then  
13 sometimes the challenge would be reaching an  
14 orgasm so that it varies throughout the  
15 experience. And then other factors, we heard a  
16 few factors on feeling guilty and feeling as  
17 though their partner felt as a failure that they  
18 couldn't please -- satisfy.

19 DR. EGGERS: Thank you.

20 I want to ask a few questions about  
21 engaging in sexual activity. We've talked about  
22 that some. But I have a few directed questions

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

115

1 about that.

2           So if you were asked to rate whether  
3 your last sexual event was satisfactory or not  
4 satisfactory what would go into this  
5 determination? I realize this is a very hard  
6 question so you can change the question if you  
7 need to. But what we want to know is what goes  
8 into a determination of whether a particular  
9 sexual event, however -- you've determined that  
10 you've had sex of some sort. How do you determine  
11 whether that is satisfactory or not to you? What  
12 factors into that?

13           Okay. Karen, please.

14           KAREN: Well it depends on what your  
15 expectations are for the outcome.

16           MS. EGGERS: So your expectations. Have  
17 you expectations -- show of hands if your  
18 expectations now on what you would consider a  
19 satisfactory sexual event has changed than when  
20 before this happened?

21           Show of hands? Okay. So within this  
22 new set of expectations is it easy to tell whether

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

116

1 a sexual event was satisfactory or not?

2 Katherine I don't want to pick on your  
3 but I see you might have something to say.

4 KATHERINE: It is a success if he is  
5 having a good time because it is out of obligation  
6 for me and I have no expectations. I might not  
7 even want to have sex but if he wants sex then and  
8 I give it to him then, yes, I was a good wife  
9 today.

10 DR. EGGERS: Does that resonate with  
11 others?

12 We have one comment here and then we  
13 will go to the back.

14 MS. MODJOROS: As a sex therapist I deal  
15 with the idea of satisfaction a lot and  
16 satisfactory sex. I would say that the majority  
17 of my patients that is not the goal. They are not  
18 looking for satisfactory sex. But if you ask them  
19 specifically what it is that they would find  
20 satisfactory sometimes you get incredibly sad  
21 answers. Like a woman who says she doesn't want  
22 to cry after sex. A man who says I just want to

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

117

1 feel desired. And so looking for satisfactory  
2 sexual experience I think it is not the goal of  
3 the average adult. And I don't know that it  
4 should necessarily be the goal that we are looking  
5 for either. Probably satisfying, not satisfactory  
6 but satisfying sex and good sex and where emotions  
7 are pleasant afterwards would be a better goal at  
8 least for the patients I see.

9 DR. EGGERS: As a follow up I'm going to  
10 ask a show of hands. To follow up on this a show  
11 of hands if achieving a satisfactory sexual event  
12 is a meaningful aspect of your overall condition?

13 Okay. So it looks like for several of  
14 you that is true.

15 There were a couple of hands raised over  
16 here.

17 MS. WATSON: I'm Lauri Watson and I'm a  
18 sex therapist. I paid for my own travel.

19 I think that when women tell me, I've  
20 treated at this point hundreds and probably  
21 thousands of women with low sexual desire, and  
22 when they talk about what is satisfying it isn't

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

118

1 just necessarily an orgasm, although I think that  
2 is hard to understand if the goal is orgasm for  
3 perhaps a male partner, they'll say yes, I got  
4 aroused, I reached an orgasm. But what is  
5 missing for them and I'd like to split apart again  
6 desire and arousal. What is missing is they  
7 didn't necessarily want it. They didn't desire it  
8 in the first place. And that is subjective sense  
9 of desire is often very missing and feels  
10 difficult for them.

11 Thank you.

12 DR. EGGERS: One more over there.

13 KELLY: My name is Kelly. And I paid  
14 for my own travel. I agree with the two ladies  
15 here. It is -- there is no wanting to have sex.  
16 There is no -- and it is very difficult when you  
17 do have it it is out of obligation whether you  
18 want to admit to it or not. And it is difficult  
19 that it is. And I would say something that would  
20 end up being pleasurable would be the fact that  
21 when it ends your husband doesn't automatically  
22 think it was out of obligation. And it is

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

119

1 difficult, as the gentleman said, it is difficult  
2 for everybody. It doesn't just affect the female.  
3 It affects the male and their mental state which  
4 affects your relationship which affects how you  
5 deal with your kids and it affects how you deal  
6 with everybody else and how you think of yourself.  
7 It is an encompassing thing and to have to try to  
8 write it down every day is discouraging and  
9 depressing. So I think -- I know that kind of  
10 answered a bunch of different questions.

11 DR. EGGER: Karen and then we will go to  
12 Amanda and then I have a follow -- I have one wrap  
13 up question.

14 KAREN: Are any of you aware of the  
15 faked orgasm?

16 [Laughter]

17 DR. EGGERS: That was a rhetorical  
18 question.

19 KAREN: Well the laughter in the room  
20 sort of indicates that it is a phenomenon for all  
21 women to want to please their partner or think  
22 that their partner wants them to have this

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

120

1 orgasmic nirvana kind of feeling. It makes me  
2 wonder how many partners have actually talked to  
3 each other either at the beginning of a  
4 relationship or during their relationship about  
5 what pleasure they would like to have and how they  
6 can give it to each other. And for some people  
7 outer- course is much more pleasurable than  
8 intercourse and the discussion here has been  
9 focusing on intercourse and orgasm.

10 DR. EGGERS: Thank you.

11 KAREN: But how do you know what really  
12 pleases your partner most. It may not be that  
13 cultural stereotype, again as I've been commenting  
14 on that orgasm is not the necessary goal for all  
15 people.

16 DR. EGGERS: I will just reiterate that  
17 the Docket is -- it would be a great place to --  
18 we would like to hear across the spectrum about  
19 what your goals are in your sexuality, your sexual  
20 experience. So I'll encourage you to contribute a  
21 Docket comment and include that.

22 We'll go to Amanda and then I have one



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

121

1 question to wrap up.

2           AMANDA: I agree with what Karen was  
3 saying in that for me sex is not just about  
4 orgasm. I mean a successful or satisfying event  
5 for me is more about feeling connected to Ben and  
6 being close and feeling arousal. But it is also  
7 on the desire component of it is that I can have  
8 sex, it is not an issue being able to have sex  
9 because I can perform any time. The difference in  
10 desire is that comes from within and that makes me  
11 feel alive and like a woman and desirable and  
12 feminine and that is the aspect I think I bring to  
13 Ben when I'm feeling that which is not very often  
14 and so I think that is the difference between a  
15 satisfying sexual event that has desire  
16 accompanied with it because I feel like I am  
17 contributing.

18           DR. EGGERS: Great. And I see some head  
19 nodding.

20           We will go to the Web. Are there any  
21 final comments particularly ones that haven't  
22 touched upon something not addressed yet?

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

122

1 MS. GIAMBONE: We did hear a few  
2 participants comment on factors that they felt  
3 have led to their FSD including age, body image,  
4 boredom and then another participant commented on  
5 having more research on attitudes on sexual  
6 behavior specifically for residents in nursing or  
7 non nursing home settings. And finally we had one  
8 other comment on one participant commented that  
9 she has to pretend to enjoy it for her husband.

10 DR. EGGERS: Thank you.

11 It is very clear that coming up with  
12 questions to appropriately ask on such a  
13 challenging and personal and variable condition is  
14 difficult. So I am going to put a thing out for  
15 the Docket, too. If there -- if you are writing a  
16 Docket comment and you are like oh, I wish this  
17 questions would be asked or this is how you would  
18 have gotten really good thoughts about what is  
19 most significant to women's lives. Here is a  
20 question I'd ask. That would be very helpful. I  
21 think it would help FDA as we think about  
22 furthering moving forward and asking women

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

123

1 questions about this very personal tough subject.

2           So with that I'm going to say that we  
3 are finished with Topic 1 on the most significant  
4 symptoms. We are going to be into Topic 2.

5           Let's come back at 2:35. But before you  
6 -- can everyone in the audience give a round of  
7 applause to all of the women and men who shared  
8 their experiences.

9           [Applause.]

10           DR. EGGERS: Thank you so much. We'll  
11 be back at 2:35.

12           (WHEREUPON, a break was taken.)

13           DR. EGGERS: I am going to ask you to  
14 please make your way to your seats and the Topic 2  
15 participants if you could please make your way to  
16 the panel table.

17           Okay. All right. This is your last  
18 call to make it to your seats, please. We do want  
19 to make sure we have a rich discussion two.

20           And again as we get ready for discussion  
21 two I am going to ask the discussion two panel  
22 members to come up.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

124

1           Okay. Any of the other Panel 2  
2 discussants? Okay. Thank you.

3           As we work our way in I'll just recap  
4 the bridge between Topic 1 and Topic 2. We had a  
5 very rich discussion on the complexity of FSD in  
6 the previous topic and my colleagues have given me  
7 the head nod that we are getting very useful  
8 information on that complexity and on what matters  
9 to you and what's most significant to you both in  
10 your sexual experiences and as we've heard through  
11 your comments regarding the distress that you feel  
12 with this.

13           So as we move into Topic 2 we're going  
14 to focus on current approaches to treating FSD.  
15 Again with a particular focus on interest and  
16 arousal. We have touched upon some treatment  
17 issues already. It is unavoidable to have touched  
18 up on that in Topic 1 because they are  
19 intertwined, very difficult to untangle. We hope  
20 to do that now. And as we go through our comments  
21 it is going to be important that we can talk about  
22 symptoms on treatment versus off treatment,

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

125

1 whatever that treatment is that you are going to  
2 be talking about.

3           So we are looking at what you are  
4 currently doing to treat your conditions or  
5 symptoms? How well those are addressing the most  
6 significant symptoms of your condition. How your  
7 treatment regimen has changed over time? I think  
8 we've gotten a sense of that. Any downsides? And  
9 really importantly we'll save quite a bit of time  
10 for this is what would you look for in an ideal  
11 treatment for your condition? What symptoms would  
12 you most like to target? And what would you  
13 consider to be a meaningful improvement in the  
14 symptom.

15           And with that thinking about this  
16 question number six I know that we all know that  
17 specific treatments will be mentioned in the  
18 course of this discussion and that is appropriate.  
19 We will do so. It is unavoidable to do so.  
20 However as I mentioned in the ground rules up  
21 front we don't want to focus, this is not a  
22 discussion on any particular treatment, the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

126

1 virtues of it except to see what we can build upon  
2 to understand that common ground of drug  
3 development. What type of symptoms can treatments  
4 address? How meaningful that would be to you?  
5 And how you know those differences both in terms  
6 of frequency, how many more times you experience  
7 desire for example, as well as I'm going to call  
8 it the quality of that desire or that arousal; the  
9 strength of it or the intensity of it.

10           So as you think about your comments  
11 today try to build in those things. Please don't  
12 focus on specific treatments just for the sake of  
13 that treatment.

14           I'm also going to ask again when you are  
15 giving your first, when it is your first time  
16 speaking in this topic as well to always state  
17 your name and also disclose if you are associated  
18 with an organization that has an interest in FSD,  
19 if your travel has been sponsored, or if you have  
20 significant financial interest in drug development  
21 for FSD otherwise.

22           So we have four panelists up front.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

127

1 Again very similar to what we went through this  
2 morning. We are going to listen to these  
3 experiences shared. And then we will move into  
4 the facilitated discussion on this Topic.

5 So without further adieu we will ask  
6 Judith to begin. And you just push your little  
7 red microphone and bring that microphone pretty  
8 close so we can hear.

9 Thank you very much.

10 JUDITH: First of all I'd like again to  
11 thank Veritas for our travel arrangements. I'd  
12 like to thank Sara for telling me to change good  
13 afternoon to good -- I mean good morning to good  
14 afternoon in my introduction. And I'm not  
15 affiliated with any other pharmaceutical company  
16 or drug company.

17 So my name is Judith. I'm 66 years old  
18 and I've been dealing with FSD on and off for 17  
19 years. I would like to thank the FDA for their  
20 interest in the unmet needs of women. These are  
21 exclusively my own thoughts on the subject.

22 I believe I am entitled to and deserving

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

128

1 of a meaningful sexual relationship as are my  
2 daughter- in-laws and granddaughters. It is not  
3 solely the woman who is affected by this disorder,  
4 but her spouse, children, plus people in her  
5 social circles and workplace.

6 I'm a breast cancer survivor. I was on  
7 HRT when diagnosed in 1996, electively put myself  
8 back on HRT after a radiation treatment in '97.  
9 When the symptoms became a quality of life issue  
10 in 2009 I was diagnosed again with breast cancer a  
11 second time, taken off HRT before a double  
12 mastectomy in 2010. Within three months the great  
13 sex life I had previously enjoyed was gone.

14 I felt anger, cheated when it became  
15 apparent that it had disappeared. Symptoms I  
16 experiences which had the most negative impact on  
17 my life were fatigue, vaginal dryness and painful  
18 intercourse. These symptoms continuously awaken  
19 me which meant I averaged 45 minutes of sleep a  
20 night. I was exhausted. I did not have the  
21 energy for intercourse or for anything else. I  
22 became irritable. I didn't like living with



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

129

1 myself, never mind how difficult it was for my  
2 husband. Mood swings were crazy. I was short  
3 tempered, not pleasant to be around contrary to my  
4 normal behavior which was upbeat and positive. My  
5 libido was low. I knew I wanted to have sex but I  
6 had no desire. I refrained. However I love my  
7 husband and wanted the closeness, the feeling of  
8 well being that comes with the passionate  
9 satisfying sexual relationship. My self  
10 confidence plummeted. I felt I was less of a  
11 woman as I no longer had the sexual appetite that  
12 I had previously experienced and enjoyed. I had  
13 no desire. It had completely vanished. The  
14 vaginal dryness was uncomfortable, penetration was  
15 painful and stressful. Having sex was not at all  
16 appealing. The pain during intercourse was  
17 excruciating. Both my desire and interest were  
18 overshadowed by my fear of pain.

19           My husband introduced me to Dr.  
20 Goldstein who he had met at the VA. Diagnosis was  
21 made after an initial interview, a series of blood  
22 tests, questionnaires and a vaginal tour. I was

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

130

1 told that my clitoris was that of a six year old  
2 and that my hormone levels were almost non-  
3 existent.

4           Here was a doctor who believes in  
5 something other than verbal therapy, something  
6 tangible, a plan that hopefully would restore my  
7 lost sex life. Treatment has been an ongoing  
8 process for the last two and a half years.  
9 Initially changes in my symptoms would fluctuate  
10 from week to week, then month to month depending  
11 upon on regulation of my topical medications. I  
12 still record topical levels daily. Under Dr.  
13 Goldstein's strict monitoring blood tests were  
14 initially done every three to four weeks, now  
15 every eight to 12.

16           My fatigue is gone as well as the  
17 vaginal dryness. I produce sufficient  
18 lubrication, desire has increased and intercourse  
19 is no longer painful. I once again experience  
20 both vaginal, clitoral orgasms. However my desire  
21 is still not up to previous levels.

22           Getting the physical body in order was

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

131

1 paramount. Menopause and the aging process still  
2 manage to affect both my interest and desires, so  
3 therefore ongoing treatment is necessary.

4 I tried various medications until we  
5 found which worked best. Currently I am on DHEA,  
6 Progesterone, Estradiol and Testosterone  
7 Versabase, Estrogel and Testim.

8 I've had sessions with the sex and  
9 physical therapist. I did need to adjust the  
10 Testosterone dosage when acne worsened.  
11 Monitoring my blood test was followed by  
12 adjustments made to the Estrogel insuring my count  
13 stayed within the required range with someone with  
14 my history of breast cancer.

15 Downsides are the costs of the  
16 treatments not covered by insurance or Medicare,  
17 acne, some increasing facial and body hair. I  
18 believe treatments that deal specifically with  
19 women's low hormone levels and sexual dysfunction  
20 are crucial to our psychological and physical well  
21 being.

22 FDA approved medicines that can target

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

132

1 improve and enhance women's sexual function plus  
2 be cost effective would be awesome.

3 I personally as well as all other women  
4 need the FDA's help in finding a solution to FSD.  
5 Thank you.

6 DR. EGGERS: Thank you very much.

7 And now we will go to Katherine.

8 KATHERINE: Hi, I'm Katherine. I'm from  
9 Indianapolis, Indiana. I need to thank Veritas  
10 Meetings who was given grant by SPROUT among  
11 others for covering my basic travel expenses and  
12 making it possible for me to be here today.

13 I learned in high school sex Ed that a  
14 woman's sexual prime, so to speak, is in her 30s.  
15 Yet here I am age 30 and I have no sexual desire  
16 whatsoever. Things were very different in my 20s.  
17 I had an extremely healthy sexual appetite and a  
18 great relationship with my husband.

19 Immediately following the birth of my  
20 first son I noticed that I had not a lack of but  
21 no libido. Still I gave it time thinking well  
22 maybe it is just because you had a baby and you

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

133

1 are still healing. I actually waited a year and a  
2 half before finally booking an appointment with my  
3 family doctor at the request of my husband.

4 I told my doctor I need something for  
5 low libido. What do you have for me? His reply  
6 there isn't anything for women with sexual  
7 dysfunction but we can put you on an anti-  
8 depressant in hopes that being in a generally  
9 better mood will help with your libido.

10 [Huge sigh] so I left the office a bit  
11 confused. Why wasn't anything available to help  
12 me? Is it because I am the only woman in the world  
13 dealing with this problem. Surely I must be  
14 missing something. I began taking Celexa  
15 regularly and saw no improvement. My mood was  
16 happy, yes, but I was happily not wanting sex.

17 [Laughter.]

18 I went off of Celexa after three or four months of  
19 usage. I didn't have any negative side effects.  
20 But if I was only using it to help with my libido  
21 and it wasn't working I had no need for it  
22 anymore.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

134

1 I looked at other areas of my life.  
2 Could stress be an issue? Maybe my diet, my  
3 weight, depression; no because I eat organic  
4 fruits and vegetables, I maintain a healthy BMI, I  
5 exercise four to five days a week, I live a low  
6 stress lifestyle and I am not depressed. I am  
7 actually quite the opposite. The only thing to fix  
8 in my life is my low libido which is negatively  
9 impacting my marriage.

10 So I feel like my body has let me down.  
11 I feel like it is out of my control at this point.  
12 And I feel like I pulled a bait and switch with my  
13 poor husband who is undoubtedly wondering where  
14 the old me has run off to.

15 If there were a treatment available for  
16 my problem I highly doubt I would care about the  
17 side effect of the drug, the pros would far  
18 outweigh the cons in this situation.

19 The old me is what I'm after. I want to  
20 joke and laugh and flirt. I want to think about  
21 sex. I want to initiate sex. I want to have more  
22 of it. I want to be the woman my husband married

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

135

1 not too long ago.

2 Thank you.

3 DR. EGGERS: Thank you very much

4 Katherine.

5 And next we'll go to Barbara.

6 BARBARA: Okay. I also want to thank  
7 Veritas for supplying the grant so that I could be  
8 here to speak to all of you. Although I don't  
9 care how much it cost me, I'd be here to speak to  
10 all of you believe me.

11 Around 25 years ago I noticed that my  
12 sexual desire was decreasing. Within a year it  
13 was gone altogether. I felt dead inside. And  
14 although I had a wonderful marriage and love my  
15 husband very much I have no desire for sex. I  
16 felt shame and guilt. And had no idea what was  
17 happening. On the rare occasion that we did have  
18 sex it was done out of obligation rather than  
19 desire. I was embarrassed and reluctant to talk  
20 to anyone about it.

21 When I finally summoned the courage to  
22 talk to my gynecologist about it he listened but

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

136

1 said he has no solutions to offer. I researched  
2 this on my own and found that some people were  
3 using Testosterone cream. I was able to try  
4 Testosterone cream and after several months there  
5 was no change in desire. The only noticeable  
6 physical change was significant unwanted hair  
7 growth. So I discontinued the cream shortly  
8 thereafter.

9           In 2011 I answered an ad for women  
10 experiencing low sexual desire. After being  
11 evaluated I was diagnosed with HSDD and enrolled  
12 in a double blind study conducted by Dr. Irwin  
13 Goldstein for a drug Flibanserin. Initially I had  
14 no change whatsoever in desire. After a few  
15 months I was informed that I had been on the  
16 placebo and was asked if I would like to try the  
17 real thing. I said yes. I couldn't say it loud  
18 enough. And within a couple of weeks my feelings  
19 had changed dramatically. I had sexual feelings  
20 which I had not felt in many, many years. I was  
21 the one initiating sex much to the surprise of my  
22 husband and the experiences were very pleasurable.



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

137

1 I also had no negative side effects.

2           Shortly thereafter Dr. Goldstein  
3 informed me that the drug had been pulled and the  
4 trials discontinued. I was devastated to say the  
5 least.

6           After 25 years I had found something  
7 that worked and then it was taken away. Without  
8 Flibanserin as an option Dr. Goldstein tried a  
9 Testosterone pellet, off label, which was inserted  
10 via a minor surgical procedure. This caused the  
11 same unwanted hair growth and now weight gain but  
12 no change in desire to speak of. Had this worked  
13 I would have consented to undergo this minor  
14 surgery every six months or however long it took.  
15 But it did not work.

16           One benefit of this experience is that I  
17 am no longer afraid to talk about my condition  
18 with friends and family. It is amazing how many  
19 women of all ages I talk to that have some degree  
20 of HSDD and have been quietly seeking a solution.

21           My husband and I are closer than ever  
22 now that he understands what HSDD is and how its

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

138

1 affects have nothing to do with my feelings toward  
2 him.

3 I conclude, I'm a nurse, I teach at  
4 three local hospitals, I deal with many doctors.  
5 Since 2011 I have been talking about HSDD to the  
6 doctors taking my classes. So many have patients  
7 with HSDD and after hearing my experiences they  
8 are extremely interested in having a viable  
9 solution for them.

10 I would like to see the FDA approve a  
11 treatment so women like men can have a solution  
12 for their most common form of sexual dysfunction  
13 and not have to go off label or order who knows  
14 what from foreign countries.

15 This disorder is real. And we need a  
16 solution.

17 Thank you.

18 DR. EGGERS: Thank you very much.

19 And finally we have Susan.

20 SUSAN: Hi. I'm Susan. I am not  
21 affiliated with any organization who has paid for  
22 my trip here today. But I did contact the New

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

139

1 View Campaign this summer as a way to get my story  
2 out. And I heard about this meeting through the  
3 New View Campaign. And I don't think I would have  
4 heard about this meeting if I hadn't made that  
5 call.

6 I'm not currently engaged in the medical  
7 world around my condition. So I don't think I  
8 would have known about this meeting.

9 I stopped having desire for sex about  
10 two years into my now eleven year partnership with  
11 my husband. Although I was alarmed it wasn't  
12 until about four years later when I lost my orgasm  
13 that my attention was capture.

14 Up to this point I had a very narrow  
15 view of sexual desire focusing mainly on  
16 physicality. I really thought I had lost  
17 something. I was resigned to the idea that sex  
18 was going to be a drag for the rest of my life.  
19 As I began my process I went down some of the  
20 common paths of pathology, testing hormones,  
21 looking in the DSM, et cetera. My doctor told me  
22 that my Testosterone was on the low side of normal

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

140

1 and that I could try experimenting with hormones.  
2 I told her I was working on relationship and that  
3 I wanted to try that first and not confuse drug  
4 therapy with relationship work. She stated she  
5 thought that was best; that I could try hormones  
6 down the road if I wanted to.

7           Once I decided I didn't want to live a  
8 sexually repressed life I started finding  
9 information that would be helpful to me. I picked  
10 up an old book by David Schnarch called Passionate  
11 Marriage that I had laying around. The book  
12 helped me to expand on my curiosity and explore my  
13 orientation towards sex and desire and find better  
14 questions. What is desire? Maybe it is not about  
15 a physical feeling. Maybe it is about something  
16 entirely different that exists outside the  
17 physical realm.

18           My partner and I had done work on  
19 ourselves in a therapeutic setting challenging  
20 individual issues that worked against us in  
21 relationship. We exposed a war between us  
22 sexually that had to do with the stereotypical

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

141

1 ideas about men and women that we had personalized  
2 to each other. We would bring these ideas to the  
3 sexual relationship without verbalizing them thus  
4 creating distance and disconnection. We learned  
5 through our study of the work by David Schnarch  
6 that our sexual problems were a co-created problem  
7 in our relationship and that I wasn't the problem.  
8 Schnarch's approach helped changed our thinking  
9 from pathological to relational.

10           Once I was able to move out of feeling  
11 bad about my waning physical desire I relaxed and  
12 started a powerful process of learning more deeply  
13 about love. I didn't recover physically desirous  
14 feeling prior to sex. I had originally thought  
15 this was the goal. I was wrong. What I do have  
16 is a deep desire for a relationship and that is  
17 what drives my desire to be sexual with my  
18 husband.

19           The physical experience changed for both  
20 of us. Our kiss became connected and deep. My  
21 orgasm came back with a quality I hadn't  
22 experienced before. Most importantly we now know

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

142

1 sex is relationship and we enjoy the physical  
2 contact as a way to interact and be close and  
3 connected on a deep intimate level.

4 My partner and I differ in our physical  
5 experience of sex. But that is no longer  
6 threatening to either of us. Accepting our sexual  
7 differences has been part of the whole change.

8 Today when we have problems that arise  
9 sexually, instead of looking for something outside  
10 the relationship for help, we go to what is going  
11 on in our life right now that could be affecting  
12 us.

13 My therapist said that whatever is going  
14 on in the kitchen is going on in the bedroom.

15 When I think about the downsides to my  
16 journey we both were challenged along the way to  
17 stay with it. The material that arises is  
18 unpredictable and where you are headed is unknown.  
19 What kept me going was the immediate and projected  
20 and far reaching benefits.

21 It literally changed the way we live,  
22 share space, and relate together on a daily basis.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

143

1 What I would look for in an ideal treatment for my  
2 lack of desire is a broader definition of normal  
3 sexuality for both sexes. I would appreciate a  
4 movement away from a culturally driven definition  
5 of normal that creates distress and anxiety in  
6 people when they don't think they are living up to  
7 an ideal.

8 I think there are all kinds of reasons  
9 people don't relax sexually in their relationships  
10 and it is much more complex than physical  
11 diagnosis and physical treatments.

12 It is my personal opinion that  
13 treatments that allow for sexual difference  
14 account for the human waxing and waning of  
15 physical and sexual desire and arousal and focus  
16 on relationship work in general would be most  
17 helpful.

18 Where to go from there is more a  
19 question for each person than it is finding an  
20 answer for all. I feel grateful that there was no  
21 shortcut for me. I would never have evolved my  
22 consciousness to embrace this much more important

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

144

1 understanding of life and love in relationship.

2 And the work continues.

3 Thank you.

4 MS. EGGERS: Thank you very much.

5 I think I'll save clarifying questions  
6 until we get into the discussion given the time.

7 It goes without saying that we owe  
8 another round of applause to these women who have  
9 so eloquently shared their experiences.

10 [Applause.]

11 They have been -- they really set I think a good  
12 foundation for our discussion.

13 Again I am going to ask another show of  
14 hands. How many of you heard your experiences  
15 reflected in at least one of the panel comments,  
16 one of the panelists?

17 Okay.

18 Anyone whose experience differs  
19 completely from what you heard?

20 Okay. So it sounds like we've captured  
21 generally a sense of the range of experiences that  
22 we've had; both the successes and the failures



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

145

1 with treatments and the wide range of  
2 perspectives.

3           We are going to start with a polling  
4 question that will set the stage to understand  
5 what you here in the room and what you on the Web  
6 have tried or are currently doing. So I guess we  
7 are only focusing on what you are currently doing.

8           So what are you currently doing to treat  
9 your condition or its symptoms? And this is a  
10 long list, so I'll read it out for you. You can  
11 select all that apply. So if you've got your  
12 little clickers, please use them. Any  
13 prescription medications and for that let's  
14 include investigational therapies. Over- the-  
15 counter products. And by investigational if  
16 you've participated in a clinical trial for a  
17 therapy.

18           b) Over-the-counter products, c)  
19 physical therapy, massage or acupuncture, d)  
20 dietary supplement or dietary changes, e)  
21 lifestyle changes such as exercises, avoiding  
22 stressful situations, et cetera, behavioral

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

146

1 therapies or couple sex therapy, some other  
2 support group would be g). h) If you are doing  
3 something else that you don't think fits into one  
4 of these categories. Or i) if you are not doing  
5 or taking any therapies of any kind. And you  
6 can select all that apply.

7 Yes, it is unsurprising that we get a  
8 range of many different things. The most  
9 prevalent here in the room being the prescription  
10 medicines followed closely by the over-the-counter  
11 products. We will get into that a little bit. A  
12 quarter or you in the room say you are not doing  
13 or taking any therapies which is interesting. We  
14 might follow up on that a little bit and get your  
15 reasons why for that.

16 On the Web?

17 MS. GIAMBONE: On the Web we have about  
18 50 percent of the people not doing or taking any  
19 therapies. And --

20 DR. EGGERS: I'm sorry, 50 percent?

21 MS. GIAMBONE: Yes. Just about 50  
22 percent. And then we also have about 36 percent

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

147

1 incorporated lifestyle changes or are using over-  
2 the-counter products.

3 DR. EGGERS: Okay. Thank you. So we  
4 have a lot to cover. Again what we are looking  
5 for is really how these overall are changing in  
6 how you feel symptoms. And in how they are  
7 addressing your overall need for therapies of any  
8 kind.

9 MS. WHITTAKER: Excuse me, Sara, can we  
10 ask for clarification on the Web as to how many  
11 patients are taking prescription?

12 DR. EGGERS: Yeah, how many are taking  
13 prescription?

14 MS. GIAMBONE: We had 18 percent taking  
15 prescription medication.

16 DR. EGGERS: Okay. So we will begin  
17 with medical treatments, medical therapies. And  
18 we are actually going to start with  
19 investigational drugs. Barbara mentioned and  
20 investigational drug, Flibanserin. And we are  
21 wondering -- first of all how many of you here  
22 have taken an investigational drug, Flibanserin or

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

148

1 anything else that would like to share your  
2 experience with that?

3           Okay.    Here.

4           So what we are really interested in  
5 again is what noticeable changes are you feeling  
6 and what and how do you know that those -- how you  
7 know that those changed, what you perceived  
8 differently and how meaningful those are to you.

9           AMANDA: I was on the Flibanserin trial  
10 but -- I'm Amanda. I'm sorry. As you know the  
11 trial was stopped. I also had tried Testosterone  
12 before that off-label. Unfortunately I found that  
13 worked better in the gym for me than it did in the  
14 bedroom. But when I was on Flibanserin it did not  
15 take long, much like Barbara's experience. It  
16 took a few weeks before I noticed a dramatic  
17 difference. Going from no thoughts during the day  
18 and really no desire, no initiation to suddenly  
19 texting and earlier when we were talking about  
20 visual clues and written things I always say it  
21 was like I'd text him in the middle of the day and  
22 get a flutter and I did not mean in my heart, in

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

149

1 the middle of the day for no apparent reason and  
2 frequently we would opt to skip dessert at dinner  
3 and go home. So I noticed an initial change very  
4 early on. I would say I began initiating where I  
5 had not in a long time. And likewise virtually no  
6 side affects whatsoever. So I was also devastated  
7 when that trial ended.

8 DR. EGGER: Any other comments? We are  
9 going to talk about Testosterone and other hormone  
10 products in a little bit. Any other -- one other  
11 investigational drug, a trial that you were in to  
12 demonstrate how you saw changes in symptoms or did  
13 not?

14 Okay. We have one in the back. We'll  
15 get a microphone to you.

16 MS. GUESS: Hi, I'm Marsha Guess. I am  
17 actually a physician who treats sexual dysfunction  
18 in some women. If you could just expand on your  
19 response and how long you used the therapy and how  
20 long you responded to the therapy and whether or  
21 not your symptoms changed while you were taking  
22 that therapy?

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

150

1 DR. EGGERS: Thank you very much. As we  
2 go through I think those are great follow up  
3 questions as we go through any of these therapies  
4 to address.

5 So if there are no more comments. Let's  
6 move to Testosterone products because we heard two  
7 of you on the panel discuss those. And several of  
8 you had mentioned it this morning. There are  
9 different types of Testosterone products. So I'm  
10 going to ask for some help on a show of hands just  
11 to see what the different types that we have.

12 Christy can I put you on the -- a show  
13 of hands please for --

14 DR. CHANG: A topical Testosterone,  
15 cream, gel?

16 So let's start with FDA approved topical  
17 products.

18 DR. EGGERS: For men?

19 DR. CHANG: Yeah, for men?

20 DR. EGGERS: That are used off-label?

21 DR. CHANG: What about for a compounded  
22 Testosterone product?

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

151

1 DR. EGGERS: If you have used -- if you  
2 are using it now or have used it?

3 DR. CHANG: Injections, Testosterone  
4 injections?

5 Testosterone pellets?

6 DR. EGGERS: Okay. So we have the wide -  
7 - we run the gamut in terms of experience with the  
8 Testosterone products. We won't differentiate for  
9 the rest of our conversation but we will just take  
10 note that there is a wide variation.

11 Would anyone like to follow up? We  
12 heard I'm going to say more successful and less  
13 successful experience up here. Would anyone like  
14 to follow up first with who feels that they are  
15 finding success with their Testosterone product  
16 and do you want to explain that?

17 MS. ROBSON: I am Michelle King Robson,  
18 excuse me, and I have not been paid to be here  
19 today.

20 I suffered from a complete hysterectomy  
21 at the age of 42 and tanked. So my hormone levels  
22 were gone. And it took me a year and nine doctors

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

152

1 to figure out how to get well. And there were two  
2 things, one was estrogen, Estradiol and the other  
3 was Testosterone cream. With those two things it  
4 changed my life. And it actually caused me to  
5 start a company called EmpowHER.com which is  
6 women's health online because I almost didn't  
7 survive it.

8           One of the things, one of the side  
9 effects that I had along with suffering from  
10 sexual dysfunction was I had no brain function.  
11 My short term memory was gone, I had joint pain, I  
12 had sleeplessness, all the things that women have  
13 talked about today; hot flashes, night sweats, you  
14 name it.

15           This is so common on our sight. It is  
16 so disturbing to see what women are faced with  
17 every single day and we've got to make changes  
18 here. And I am so happy that we are doing this  
19 today.

20           DR. EGGERS: Anyone else over there.

21           CARMON: Hi, I talked a little bit  
22 earlier but I didn't tell you that I've been



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

153

1 married to my husband for 33 years and we have ten  
2 children together and yes we do know what causes  
3 that.

4 [Laughter.]

5 And I didn't enjoy it for about 30 years of our  
6 marriage. And I am so thankful that we went and  
7 had blood tests done and found -- I was grateful  
8 to find out that my Testosterone was in the  
9 basement. And I am using a product called Axiron  
10 which is topical and I put it on under my arm.  
11 And it has helped me tremendously. I had not been  
12 having orgasms for a long, long time. And I not  
13 only can have an orgasm now but I can have  
14 multiple orgasms during a sexual encounter with my  
15 husband which makes him really happy. It makes me  
16 happy.

17 So I am very thankful for that. And one  
18 thing my husband has said about using these  
19 products to help you when you are having problems  
20 with -- I was diagnosed with Hypoactive Sexual  
21 Disorder. And one thing that is a good way to  
22 think about it is that people have hearing aids,

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

154

1 they have eye glasses to help them when they are  
2 vision isn't good. And to treat this like it is  
3 some oddity; that it is something we shouldn't  
4 look at as another tool that we can have is wrong.  
5 It is just another tool in our toolbox and we can  
6 use therapy when we have problems. And yeah, I was  
7 a busy mom and needed to get more sleep. But the  
8 problem was actually physical with me. It wasn't a  
9 mental problem.

10           So let's give women another tool that  
11 they can use to help enhance their ability to have  
12 a better sexual life with their husband or their  
13 partner.

14           DR. EGGERS: Thank you.

15           Carmon, right?

16           CARMON: Yes.

17           DR. EGGERS: Can I ask a follow up  
18 question. When did you first notice changes after  
19 taking the Testosterone?

20           CARMON: It was within weeks.

21           DR. EGGERS: Okay.

22           CARMON: And it has been very steady and

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

155

1 it has been a lot better. It is very noticeable.

2 DR. EGGERS: Thank you.

3 Are there any on the other -- oh, go  
4 ahead.

5 BEVERLY: Hi, you probably know who I  
6 am. So --

7 DR. EGGERS: Beverly.

8 BEVERLY: My name is Beverly. I have  
9 experience with at least four or five of these  
10 medications. So I thought it might be beneficial  
11 to tell you I started with Testim, topical  
12 medication prescribed for men. Unfortunately I  
13 had to use so much of it that I smelled like a guy  
14 and my girlfriends were attracted to me which  
15 really wasn't appealing.

16 [Laughter.]

17 That one had to go because it didn't do anything  
18 to help my boyfriend be attracted to me; right.  
19 So we switched to Axiron under the arm, great  
20 medication. Felt the effects, major stomach  
21 upset, had to go off of that one.

22 Then I went to Testosterone injections

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

156

1 in my thighs and I learned to self inject.

2 Fascinating process, lots of bruising, lots of  
3 bleeding, lots of drama but it worked.

4 Unfortunately I have an idiosyncratic body that  
5 metabolizes medication very quickly, so I went  
6 from once a week, to twice a week, and I said this  
7 isn't working anymore.

8                   Finally I said all right fine, the  
9 pellet, we'll try that. It is a beautiful thing.  
10 It lasts a long time. It is minor in putting it  
11 in but that is the one I've stuck with.

12                   I just thought it might be beneficial to  
13 hear all of those different medications that are  
14 approved for men but not for women but that I've  
15 tried. And honestly because I process medication  
16 so quickly I could feel a difference within a very  
17 short period of time, like a week. So hopefully  
18 that helps.

19                   DR. EGGERS: Thank you very much.

20                   Okay. One more to see someone who has  
21 an opposite experience where it hasn't worked for  
22 them or that the side effects were such that or

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

157

1 the downsides were such that you choose to not  
2 take the product anymore? Oh right, there, yep.

3           KELLY: I'm Kelly and I have done  
4 compounded Testosterone and then Testim as well  
5 and I didn't see any effect whatsoever. And at  
6 that point in time and I didn't even see effect in  
7 the gym, like that other lady. I was at least  
8 hoping to get something out of it. But at that  
9 point in time stopped using that one and then I  
10 had also been prescribed Wellbutrin at the  
11 beginning to see if that would maybe help me at  
12 least enjoy life. And it probably made me kinder  
13 to my children but it still didn't give me any  
14 better desire. My children thought that I was a  
15 nicer mommy at that point in time. But no  
16 Testosterone treatment has worked for me as far as  
17 those were concerned. And like -- they smell and  
18 they are sticky and you think does it -- can it  
19 really make a difference and for me it didn't. So  
20 right now I am not doing anything. It has just  
21 kind of stayed the same.

22           DR. EGGERS: Okay. Yeah, go ahead.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

158

1 DR. KWEDER: A couple of the folks, I  
2 just want to ask you a specific question because a  
3 couple of folks who have described success with  
4 Testosterone commented on having had their  
5 Testosterone blood levels checked.

6 KELLY: Yes.

7 DR. KWEDER: Were you diagnosed with low  
8 Testosterone?

9 KELLY: Yes, I was.

10 DR. KWEDER: Thanks.

11 DR. EGGERS: I want to make sure that we  
12 keep moving on here. So I'm going to move to  
13 other hormonal products that aren't Testosterone.  
14 We heard some other mentions of those up here; if  
15 anyone would like to share your experiences with  
16 any of the other hormone products? Okay. In the  
17 back there.

18 MEG: Hi, my name is Meg and yes,  
19 Veritas paid for me to come here. I had a  
20 hysterectomy; did keep my ovaries. And have once  
21 the menopause symptoms started coming on I started  
22 taking HRT, a patch. And I can tell an amazing

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

159

1 difference in not only sexual responsiveness but  
2 in other areas of my life when I take it and you  
3 know the doctors are all like you can only take it  
4 for a few years. They are very interested in me  
5 weaning off of it for whatever the side effects  
6 are. And I am very concerned about what am I  
7 going to do when they say that those years are up  
8 because I mean that affects all areas of my life  
9 including my -- at work how well I can perform. I  
10 get the brain fog. I start crying, which I never  
11 cry at work. I mean because I have 50 employees  
12 and you know you can't cry in front of 50  
13 employees. So I am very very concerned that what  
14 is there, what is on the horizon, not just for  
15 sexual responsiveness but for the other areas in  
16 our lives because I mean I am a baby boomer. We  
17 are all working longer and longer. Women have  
18 these issues and there needs to be some kinds of  
19 solutions because we are productive way into our  
20 years that in the past you would have been  
21 retired. So that is definitely something that I'm  
22 interested in and needs to be addressed.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

160

1 DR. EGGERS: Thank you for sharing that  
2 prospective, thank you.

3 Let's move on, there was quite a few of  
4 you who talked about over-the-counter products.  
5 By the way if we are not getting to the products  
6 that you take, please submit those to the Docket  
7 or if we can - - maybe we will have some time at  
8 the end. But I want to make sure we touch upon  
9 some of these. Do you have a comment sir?

10 UNIDENTIFIED PERSON: Can you talk about  
11 PDE-5 inhibitors.

12 DR. EGGERS: Can we -- PDE-5 inhibitors?

13 Okay. Can we have a show of hands? How  
14 many have taken those off-label? Viagra.

15 Okay. Maybe you could clarify the  
16 question for me please.

17 DR. CHANG: PDE-5 inhibitors are  
18 medications like Viagra, Cialis, similar  
19 medications.

20 DR. EGGERS: Okay. Show of hands. So a  
21 number of you have.

22 Yeah.



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

161

1 KAREN: One of the physicians I was  
2 seeing recommended that I try Viagra. So I got a  
3 very tiny prescription and I tired one pill and  
4 the only thing that got swollen were my sinuses  
5 and that was it.

6 [Laughter.]

7 DR. EGGERS: Well we -- we will take one  
8 more.

9 DR. PARISH: Yes, Sharon Parish from  
10 ISSWSH. Just backing up I'd encourage you and urge  
11 you to separate the comments of naturally and  
12 surgically menopausal women about their treatments  
13 from those that are pre menopausal because their  
14 experience of hormonal treatments may be very  
15 different. And it will confuse the understanding  
16 of the patient experience if that is not separated  
17 more clearly as we go forward.

18 DR. EGGERS: Great. Okay.

19 So maybe as we do go forward if you feel  
20 comfortable saying at what side of the change you  
21 are on, that would be helpful for us. And then if  
22 you are writing in to expand on your experience in

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

162

1 the Docket if you could similarly let us know  
2 that.

3           As far as the over-the-counter products  
4 we don't want to spend too much time but I think  
5 it would be useful to understand what you're  
6 including in this. So would anyone like to just  
7 briefly mention what they included in b) when they  
8 indicated it?

9           LOUANNE: My name is Louanne, I spoke  
10 before.

11           Lubricants obviously, so liquid silk is  
12 our favorite but I think the use of a lubricant  
13 isn't necessarily a thing that is associated with  
14 sexual problems. Some people use it just to  
15 enhance pleasure as a starting point even when  
16 they are 20 and have plenty of their own natural  
17 lubrication to go around. Sexual toys and  
18 accessories I guess would perhaps fall into that  
19 category too.

20           DR. EGGERS: Anyone who did not include  
21 lubricant?

22           Okay. Right here.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

163

1            CHERYL:    Hi, my name is Cheryl and I  
2 have tried over-the-counter Provestra and Steel  
3 Libido. None have worked for me.

4            DR. EGGERS:    We will go to Amanda.

5            AMANDA:    I'm Amanda and likewise I did  
6 actually order something off the Internet one  
7 time. I don't even remember the name of it, that  
8 is how sad it is but promised increased libido.  
9 That did not work. And my comment about  
10 lubricants; they are great as far as physically  
11 helping the process but they do nothing for  
12 helping your desire.

13           DR. EGGERS:    Okay. I see some heads  
14 nodding to that.

15           Let's talk about I'm going to put  
16 lifestyle changes and behavioral therapies or  
17 couples sex therapies and support groups kind of  
18 together as things that work on relationships and  
19 other things. And we did hear Susan explain that  
20 and others have today.

21           Does anyone have an experience with that  
22 that is different than what we've already heard

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

164

1 that can expand upon this, like to talk about it?

2           If it has worked for you or hasn't  
3 worked for you?

4           Yes.

5           JENA: It is not like a support group.

6 Sorry my name is Jena Umbidwa (ph) and I don't  
7 have any financial interest or affiliations.

8           What I found useful was reading about my  
9 sexuality because I had the view that I have to  
10 have penetration and achieve orgasm through  
11 penetration. And it was very stressing for me  
12 because this was not the case. And then I started  
13 reading about my anatomy and about women's  
14 pleasure centers and I read Hite report from Shere  
15 Hite and she was pointing out that a lot of women  
16 participating in her research were not achieving  
17 orgasm through vagina orgasm through penetration.  
18 And then I started to problematize that real and  
19 also I watched Orgasm Inc. which you should  
20 definitely watch it is very informative. Then I  
21 started thinking about my sexuality and I found  
22 how I can achieve pleasure and this was not the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

165

1 way that I was learned before that we see in the  
2 movies or that is taught to us. So I had this  
3 increased knowledge which was reliable. It was a  
4 great knowledge and as Mary from the former  
5 interview stated it was knowledge from Internet or  
6 movies or I don't know other stuff. And I think it  
7 has changed my conceptualization of sexuality and  
8 my experiences a lot.

9 DR. EGGERS: Jena. Thank you.

10 We will have Sandy follow up.

11 DR. KWEDER: There actually is an FDA  
12 approved medical device name of which is escaping  
13 me at the moment. Yes, I want to know if anybody  
14 -- that isn't one of the choices up there and I'd  
15 like to know if folks have had experience with  
16 that.

17 DR. EGGERS: Sure. Can we have a show  
18 of hand if you have currently or have tried using  
19 that device? EROS.

20 DR. KWEDER: I believe it is for sexual  
21 arousal disorder and orgasmia. I believe that is  
22 the indication.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

166

1 CAROL: EROS is a device and it is a  
2 device to encourage arousal in the vulva and the  
3 clitoris and it used to be by prescription only.  
4 I don't know if it still is. And it used to cost  
5 around \$500. And if you look at their Website and  
6 you look at the shape of this device it is very  
7 much like a vibrator, different kind of vibrator.

8 DR. EGGERS: Any other follow up  
9 questions on medical treatments?

10 Oh, okay, we've --

11 MR. SHIELDS: Thank you. My name is  
12 Wayne Shields. I represent an association of  
13 health professionals, Association of Reproductive  
14 Health Professionals. The reason I'm commenting  
15 is not for a medical issue. It is reporting back  
16 what my folks tell me that they experience on the  
17 front line. My folks are basically the ones who  
18 work with clients. And what I hear back from them  
19 and I hear this a lot is that there isn't adequate  
20 response for this issue with their clients and  
21 that there is indeed a subgroup of clients who  
22 simply need help with desire, the desire side of

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

167

1 the equation. I agree with some of the folks  
2 earlier who mentioned that it is complicated and  
3 different for every individual and that is true.  
4 But there is definitely a reported group of folks  
5 who no matter what have trouble with the desire  
6 side of the equation. So I'd encourage us to pay  
7 attention to that group even if they are not the  
8 majority.

9 DR. EGGERS: Okay.

10 NATALIE: Hi, this is Natalie again. I  
11 wanted to make a comment about --

12 DR. EGGERS: Can you hold the microphone  
13 closer.

14 NATALLIE: -- about physical therapy,  
15 massage and acupuncture and so forth. I had a --  
16 like I mentioned before a great sex life with my  
17 partner. I didn't change anything. I had an IUD  
18 put in, took it out six weeks later. One month  
19 later he was on a trip, he got back and it was  
20 like a switch that went off. Everything was all  
21 of a sudden different. And I went to about ten  
22 doctors, hospitals, institutions and everyone said

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

168

1 it was in my head. I throughout that year tried -  
2 - we went to couples therapy. We went to sex  
3 therapy. I had physical therapy which was very  
4 invasive. Acupuncture. I even had a guy go in  
5 and do hysteroscopy and laparoscopy to see if he  
6 could see anything in the camera that was wrong  
7 with me. And it was perfectly normal. And I can  
8 talk about how it affected me and how depressed I  
9 was and how mal- functional and just horrible it  
10 was.

11 But I finally find, I was doing  
12 research, a book that got published two months  
13 earlier and that is how I found my doctor and he  
14 took the hormonal tests and found that I had only  
15 20 percent of what was normal for my age group of  
16 Testosterone. And literally a week or two after I  
17 was treated everything changed and I was fine  
18 again.

19 So I just wanted to reiterate that  
20 everything else I tried didn't work.

21 DR. EGGERS: Thank you very much.

22 Are there any Web comments on treatments



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

169

1 particularly those we haven't had a chance to  
2 discuss yet?

3 MS. GIAMBONE: We heard several  
4 treatment options that did not work for some of  
5 these participants including BioTE pellet therapy,  
6 Testim. In terms of lifestyle changes, meditation  
7 did not work. And another participant commented  
8 that she was prescribed an anti-depressant and  
9 that made her unable to reach orgasm.

10 DR. EGGERS: Thank you.

11 We talked earlier in the afternoon about  
12 tracking condition as it changes over time. And  
13 there was a lot of difficulty in answering that  
14 question because it depends if you are on  
15 treatment, if the treatment has natural cycles and  
16 everything. And so I think it is useful to follow  
17 up on that question again. I am going to pose a  
18 side experiment if you went to your doctor and he  
19 or she said I am going to start you on this new  
20 therapy, whatever therapy you are taking and I  
21 want you to track your symptoms given the  
22 therapies that you are currently taking are there

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

170

1 variability in those symptoms and please when you  
2 are answering the question state which therapy you  
3 are on or the combination. But are you noticing  
4 changes over time in those therapies as you are on  
5 treatment. And if so, if you were asked to  
6 identify those treatments over time what time  
7 period would you need to use: day, weeks, months,  
8 in order to kind of capture that variability as it  
9 changes. Hopefully that question made some sense.  
10 Any brave souls to try to first answer the  
11 question as I posed it?

12                   Okay. And then we will go --

13                   MS. ROBSON: Michelle King Robson. I go  
14 every three months for testing so I do blood work.  
15 And it does change so I've been on Hormone  
16 Replacement Therapy, the Climara Patch  
17 specifically and then I take Testosterone twice a  
18 day that is compounded, 1/8th of a teaspoon in the  
19 morning and afternoon to keep the consistency and  
20 flow the same because a lot of women go like this  
21 with their treatment therapies.

22                   We test every three months so we do it

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

171

1 by symptom and also by blood work. So she wants  
2 to know both because sometimes the blood work can  
3 be normal but you are still having some of the  
4 symptoms. If I gain a little bit of weight it can  
5 change. If I lose a little bit of weight it can  
6 change. It really isn't a one size fits all  
7 program unfortunately. It is more dependent upon  
8 each individual woman as to what they need and  
9 what they are going to end up taking.

10 So a lot of it -- it has changed over  
11 time, over the past 10, 11 years it is constantly  
12 changing and being tweaked. And that is how I  
13 stay well and healthy.

14 DR. EGGERS: And that longer time period  
15 that you are talking about you are talking three  
16 month time period that you revisit do you track in  
17 between those three months?

18 MS. ROBSON: I am always tracking.

19 DR. EGGERS: Okay.

20 MS. ROBSON: Yeah. You have to, I mean  
21 you really do.

22 DR. EGGERS: Anyone else. I'm sorry

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

172

1 hands went up and I -- we'll go to Sue.

2 MS. WHITTAKER: Can we just go a little  
3 bit farther. When you said you are always  
4 tracking, how often do you track? And what are  
5 you tracking?

6 MS. ROBSON: So I have to track on a  
7 daily basis because my medication changes up. One  
8 day I'll take one patch, the next day I'll take a  
9 different dosage. So it has to be tracked on a  
10 daily basis because of the differential in it;  
11 right, so and the same with the Testosterone Cream  
12 too. So everyday there is a tracking system on my  
13 phone actually and I always know when I've  
14 forgotten to take something because I will  
15 definitely have a side effect or a symptom from  
16 it. It is almost immediate. You get to know your  
17 body so well.

18 DR. EGGERS: And what type of effects  
19 are you tracking when you are -- are you writing  
20 down certain symptoms?

21 MS. ROBSON: Yes. I'll write down -- so  
22 for example I had heart palpitations and without

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

173

1 getting into great detail of it I went into --  
2 because having heart palpitations and being 55  
3 years old isn't really a good thing since heart  
4 disease is the number one killer of women as we  
5 know. I wasn't getting enough estrogen. So when  
6 I went into the physician, when I went into the  
7 cardiologist they wanted me to take less. They  
8 wanted me to go off the estrogen. And then when I  
9 went to my primary care physician who is taking  
10 care of me she said you need a little bit more.  
11 And it actually worked the heart palpitations were  
12 gone.

13 Same with joint pain. So joint pain  
14 traveled in my body. So if I didn't take the  
15 right -- if I wasn't taking the right amount I'd  
16 get joint pain.

17 Same with sexual function, libido and  
18 brain function. Those are all pretty typical.

19 DR. EGGERS: Thank you.

20 We had a comment over here.

21 SUE: So I'm on a different

22 Testosterone. I am on the pellet. Sue. And the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

174

1 pellet last approximately six months. But it is  
2 individual with each person whether you are a man,  
3 whether you are a woman. I mean I think we have a  
4 lot more similarities with men than people think  
5 about. The Testosterone for me takes four to six  
6 weeks to kick in and then the last three to four  
7 weeks of that six month period it is pretty much  
8 gone. So I can tell by my symptomatology I know  
9 that if I have symptoms right after the pellet is  
10 put in that they are going to go away. On the  
11 other end I don't recognize the symptoms until my  
12 HSDD has returned for a few weeks. So for me  
13 while I don't track it on a piece of paper it is  
14 about a three to four week recall at which point I  
15 realize oh, I need a new pellet. I would never --  
16 on a daily basis I don't think about it but I'll  
17 think back and go oh, I've been thinking a lot  
18 about sex lately, I guess the pellet has finally  
19 kicked in. It really takes a little longer for  
20 recall for myself personally.

21 DR. EGGERS: Okay.

22 We have Amanda.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

175

1           AMANDA: Amanda. When -- I agree with  
2 what she was saying. I still think it is not it  
3 for me. I was not a daily process. I don't need  
4 to think about it every day. I'm busy. I'm a  
5 wife. I'm a mother. I work full time. I can't  
6 take the time to think is my level low or I'm  
7 going to have to go have something replaced. When  
8 I was on the Flibanserin trial we had to fill out  
9 a daily diary which was almost comical because  
10 quite honestly like I said I'm a mother, I work  
11 full time, I don't think about sex 24/7; that is  
12 not what it is intended to do. But it is the lack  
13 of desire doesn't just go away one day and you  
14 take a pill and it returns. I personally don't  
15 believe this is a condition that is just going to  
16 get better and then you quit. I think it is  
17 something that we are going to live with; it is a  
18 long term process, it is not a daily tracking. It  
19 is more of a weeks and months and future and  
20 everything. So it is not like physically you can  
21 take it one day and it turns on and you don't have  
22 to take it the next day. It is either on or off.

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2014

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

176

1 DR. EGGERS: Thank you.

2 So I want to ask a question about --  
3 we've talked about symptoms and changing over time  
4 and there are two concepts. There is the number of  
5 times that you might think of something or that  
6 something might happen. And then there is the  
7 intensity of that or the strength of it or the  
8 quality of it, however you think of it. When you  
9 are on these treatments and you are talking about  
10 how they affect you, are you thinking about both  
11 of those or does one come to mind more the number  
12 of them or how do you conceptualize that  
13 difference when you are thinking about how well  
14 treatments work for you between the number of  
15 times, maybe a frequency, with which something  
16 returns or the intensity with which it returns?

17 So when you are thinking about how well  
18 treatments are working for you how do you  
19 conceptualize the difference between the number of  
20 times so that you think more often about something  
21 or you that you experience something with more  
22 intensity, maybe arousal with more intensity? Do



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

177

1 you conceptualize that differently?

2 BEVERLY: It is an interesting question.  
3 I heard Sue say her pellets last about six months.  
4 Sometimes mine last two months, sometimes they  
5 last four months. And I feel the effect right  
6 away. So my body just metabolizes it differently  
7 than hers. But about three weeks in to four weeks  
8 into the pellet I think my Testosterone level goes  
9 so high that I think about nothing but sex. I  
10 wake up every day thinking about sex. I go to bed  
11 every night thinking about sex. And like, okay,  
12 really I would like a therapy that worked better,  
13 that was more even for me because I end up  
14 becoming obsessed with this conversation.

15 [Laughter.]

16 Right. So I go from not being interested at all to  
17 not being able to think about anything but that.  
18 But then about three weeks later I'm not thinking  
19 about it at all and I am like what happened to me?  
20 So the rise and fall is definitely more profound  
21 for me. And no I don't keep a diary. I have a  
22 clear, very clear recollection of when it starts

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

178

1 and when it stops. But hopefully that helps.

2 DR. EGGERS: Karen? We will go with  
3 Karen here next.

4 KAREN: I observe that there's a lot of  
5 variation in this one particular product that is  
6 being used. It is my understanding that it is  
7 off-label for women; is that correct?

8 DR. EGGERS: You are talking  
9 Testosterone?

10 KAREN: Testosterone, whatever. It is  
11 off- label for women.

12 DR. KWEDER: Yes.

13 KAREN: I just observe how interesting  
14 it is that all these women have such a different  
15 experience with this product that is not FDA  
16 recommended for women, approved.

17 DR. EGGERS: Your point has been noted.

18 So we only have -- Oh, go ahead Hylton.

19 MR. JOFFE: I had one question. I was  
20 interested in hearing perspectives. It sounds  
21 like with treatment such as Testosterone you are  
22 talking about something that we take every day.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

179

1 And I was wondering what folks thought about  
2 intermittent treatments where you see this as a  
3 condition where you take something when you want  
4 to feel more desire as opposed to something you  
5 take every day? Does that make sense to anybody?  
6 I'd be interested in hearing thoughts on that.

7 DR. EGGERS: We'll go there first.

8 LOUANNE: My name is Louanne. It is  
9 funny you asked that because I was just having a  
10 thought does this comment fit anywhere in this  
11 discussion. I've been using Testim on my calves  
12 for 12 years. And I just put a little bit on and  
13 rub my calves together while I'm brushing my teeth  
14 every morning and that is sort of a two for one  
15 kind of thing; that is how I remember to do it  
16 every day. And then about this time a year ago my  
17 husband was diagnosed with tongue cancer and so  
18 here was a big change in our life and lots of  
19 surgeries and things changed. And so sex was not  
20 on our list of activities for a while. So I just  
21 backed off on my Testim which was under my control  
22 and I just let it ride until he was feeling back

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

180

1 to a bit of a more normal interest in sexual  
2 things. So that is what I think you are asking as  
3 life fluctuates can you adjust your treatments and  
4 I have. Is that what you are asking?

5 MR. JOFFE: And even one step further  
6 intimately using medications from one week to the  
7 next or one day to the next, using or not using.  
8 Interested if that resonates with anyone or makes  
9 sense to anybody?

10 LOUANNE: If I know we are going on  
11 vacation to Hawaii I'm usually gearing up the week  
12 before. Yeah.

13 [Laughter]

14 One year ago. So yeah in anticipation because  
15 Testosterone isn't sort of like you put it on this  
16 morning and tonight you feel like wow it is a  
17 kicking in thing. For many people it is like a  
18 two month process if they are particularly low.  
19 For people who kind of just want to ride the top  
20 of the wave for whom it works I think they can  
21 kind of pull back and forth on the throttle a  
22 little bit based on what their plans are and what

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

181

1 their life is like. But I think that what someone  
2 over here said. It was Karen I think. I think  
3 that there are two probable causes to sexual  
4 desire problems. Some of them have to do with  
5 Testosterone and some of them have to do with  
6 something else completely going on the brain that  
7 is different. When people don't get Testosterone  
8 to work I think it is a whole different diagnosis.

9           And frankly I was really upset when I  
10 saw DSM5 put arousal and interest in the same  
11 bullet. I was like what are they thinking about.  
12 This is crazy because they are two very different  
13 processes. So that was my take as a therapist and  
14 a patient. Did that answer your question?

15           DR. EGGERS: We will go with Katherine.  
16 Katherine do you have an answer for this question?

17           KATHERINE: I think so. What I was  
18 going to say was my sexual dysfunction isn't a  
19 physical issue. I have no trouble with orgasm. I  
20 have no trouble with any of the other signs. I  
21 haven't experienced the change, whatever you are  
22 talking about. But I don't even think about sex.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

182

1 So for me it is not like I'd want to just take a  
2 pill right before having sex with my husband. I  
3 want to feel it all the time. It can't -- it is  
4 not just like a physical thing, like I thought  
5 Viagra was just for erectile dysfunction where you  
6 take it if you know you are going to have sex.  
7 Maybe I'm thinking the wrong drug, I don't know.  
8 But this is something I want to experience all the  
9 time, 24/7. I want that part of my life back  
10 because just thinking about sex, not having it but  
11 even just thinking about it impacts the rest of me  
12 too. It makes me feel like a more sexual person.  
13 It makes me feel like a woman. So I would be  
14 interested in not just taking something before  
15 having intercourse or if I think I'm going to have  
16 intercourse but taking something everyday knowing  
17 that those effects are going to last me 24/7/365  
18 you know.

19 DR. EGGERS: Thank you very much.

20 Okay. I'm going to move on. We will  
21 have time for one caller -- oh we have no callers.  
22 Okay.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

183

1           Then we have more time to explore --  
2 okay. We have one more thought. Okay. We will go  
3 there first.

4           MS. ROBSON: To answer your question  
5 because I've had a complete hysterectomy and had  
6 my ovaries removed I couldn't do that. I wouldn't  
7 be able to decide when I want to take something  
8 right because I'd just be going like this. I'd be  
9 roller coasting all over the place. So I need the  
10 consistency. And I think to Katherine's point is  
11 that what happened with me is I had no desire.  
12 Zero. It was gone. It was gone for a long time.  
13 And then when I finally got well it came back.  
14 And when it came back it was like -- it was pretty  
15 remarkable because I had already made the decision  
16 that I was just going to live my life that way for  
17 the rest of my life at 42 years old. And that is  
18 what happens so many times. So I am so thankful  
19 that there are options. I just wish that they  
20 were FDA approved and they were paid for by  
21 insurance. And that is one of the things that we  
22 face as women.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

184

1 DR. EGGERS: So we will take two more  
2 comments. We will go to Amanda and then we will  
3 come to you.

4 Actually we will go to you first?

5 MS. MODJOROS: I wanted to echo what  
6 Katherine said. A lot of my patients don't look  
7 at this as a I feel like chicken tonight; I don't  
8 feel like chicken tonight. The benefit that  
9 Katherine wants, that a lot of my patients want,  
10 they want to feel the desire all the time. The  
11 converse is what they -- the distress that they  
12 feel. I have patients who will wake up and say  
13 okay it has been five days, it has been ten days,  
14 I have to give my husband sex tonight. They have  
15 anxiety all day long. They stress about it. They  
16 plan it out. They are like oh, my God I've got to  
17 do this and there is not going to be orgasm, there  
18 is not going to be arousal and I have to get the  
19 lubricant. All of this. And it is because it  
20 doesn't come naturally. When they were in their  
21 teenage years, when they were in their 20s it may  
22 have come naturally for them and that loss of



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

185

1 themselves and that constant preoccupation with  
2 what's wrong with me causes distress every day.  
3 So if they had an option to take a pill to relieve  
4 that distress or take a medication rather to  
5 relieve that distress that would be huge for them  
6 whereas I don't have many patients that would say  
7 I just want one day, I'll do something and you  
8 know see what happens. Most of them want all the  
9 time.

10 DR. EGGERS: Okay. We are going to go  
11 there and then we will come to you Amanda.

12 JENNY: I'm Jenny and I thank Veritas  
13 but I would have come anyway. I had accepted the  
14 invitation.

15 And I just don't see why we can't have  
16 both, the long term and the instant. You have  
17 Viagra and Cialis. So I think women should have  
18 the option as well of having it both ways.

19 DR. EGGERS: Thank you. And then right  
20 here. And then we have time for one more comment  
21 with Susan and then we are going to have to wrap  
22 up.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

186

1           AMANDA: So I think we are talking about  
2 three separate things and I want to address the  
3 question about the intermittent use. It is my  
4 understanding from experience and from all the  
5 commercials that Viagra works on the spot as a  
6 blood flow issue. And I think that for most of us  
7 that have lack of desire and are distressed by it,  
8 it is not a blood flow issue. I mean you can just  
9 send blood down there and I'm going to all of a  
10 sudden want to have sex. It is not an issue of  
11 not being able to have sex. So what I want is to  
12 want to want it all the time to her point over her  
13 and Katherine's; I want to always desire my  
14 husband and I don't want it to be situational.

15           The Testosterone comment I understand  
16 that for some women it works but I think she said  
17 it perfectly when it is designed for men and so it  
18 is going to vary between women to women and that  
19 is a very valid reason why on the packet insert  
20 there are strong labels about men using  
21 Testosterone staying away from their wife or their  
22 spouse for several hours because of the transfer

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

187

1 and the side effects that it can cause. I  
2 actually had some of the side effects.

3           The goal for me is to still to have  
4 desire for Ben all the time and for it to not  
5 cause distress and to just get that desire back  
6 and the measuring a satisfying event it goes back  
7 to what I said earlier, women don't forget a  
8 sexually satisfying event. So I don't need to  
9 record that in a diary. I am going to remember  
10 that for weeks to come.

11           DR. EGGERS: We are going to go with  
12 Karen and then we are going to have to wrap up our  
13 -- or Susan, I am sorry Susan. And then we are  
14 going to have to wrap up the discussion.

15           SUSAN: I just wanted to say that as I  
16 am sitting here listening to this I feel  
17 distressed. I feel distressed that we are looking  
18 for a drug to basically achieve a perfect sex  
19 life. You know when I hear 365 days a week I  
20 think that is a lofty goal and I was just thinking  
21 that we are talking about distress and I just had  
22 to say that I feel distressed that we are looking

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

188

1 for perfection when it comes to sex.

2 DR. EGGERS: Thank you very much Susan.

3 With that -- well, okay, we are going to  
4 go with two more comments and we are going to go  
5 with the woman in the orange who has had her hand  
6 up patiently. And then we will come to you.

7 UNIDENTIFIED PERSON: Hi. I think if you  
8 are talking about something a woman could take  
9 instantaneously then you are really saying she is  
10 only responsive sexual person versus having a  
11 subjective sexual desire. And I think that -- I  
12 am a sex therapist and I feel like I have had a  
13 lot of success treating women without medication  
14 but I am here today because I believe that it also  
15 gives women a choice. I think that yes, they can  
16 work up to it, they can have good erotic  
17 stimulation, they can have even a good experience  
18 but having the choice to have desire coming into  
19 that experience is really erotic and wonderful.

20 DR. EGGERS: Thank you.

21 Okay. So briefly your comment?

22 MARTA: My name is Marta and I'm here

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

189

1 representing an organization Red Hot Mamas which  
2 is an educational company for menopausal women.  
3 And one of the things I'd like to touch on is a  
4 lot of the women that write in on the forum talk  
5 about it takes years for them to develop to the  
6 point where they are actually able to view it as a  
7 problem and to actually seek help. And how many  
8 doctors they've gone to that have said there are  
9 no options for you. I can't help you. And they  
10 are worried about their relationships. They are  
11 having a hard time with menopause anyway but they  
12 have no libido and there is no outlet, nowhere for  
13 them to go. And it is not something you can talk  
14 about with your neighbor. So it is a very, very  
15 big problem and we need a lot of choices just like  
16 men have. And that way women can actually move  
17 their lives along. And it is a big deal for  
18 marriages and relationships. So I just wanted to  
19 point that out there are a lot of women talking  
20 about it.

21 DR. EGGERS: Thank you. This has been a  
22 very rich discussion filled with many topics that

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

190

1 we could spend days covering and you spend so much  
2 of your time thinking about.

3           So again I am going to reiterate we want  
4 to hear from you. We only had this amount of time  
5 today to do so. But the Docket is available. We  
6 do look at all the comments that come in. So  
7 please expand upon the thoughts or thing that you  
8 want to expand upon that you heard today, please  
9 do so.

10           This portion of our discussion is now  
11 closing. Again we thank you so much for sharing  
12 your very personal experiences and the courage it  
13 takes to come up here and do so. So another round  
14 of applause from everyone.

15           [Applause.]

16           DR. EGGERS: Another reminder for the  
17 evaluation forms they are at the registration  
18 table or will be floating around. So please fill  
19 those out.

20           And now I will turn it over to Pujita  
21 who is going to do the open public comment. So  
22 thank you very much.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

191

1 [Applause]

2 MS. VAIDYA: Hello everyone. I'd like to  
3 thank you all for coming here today. And we are  
4 now moving into the open public comments session.  
5 And for those of you who are not aware the purpose  
6 of this session is to allow an opportunity for  
7 those who have not had a chance to speak on issues  
8 that are not related to our two main discussion  
9 topics. This is an opportunity for folks who are  
10 not patients or patient representatives to  
11 comment.

12 Please keep in mind that we will not be  
13 responding to your comments but they will be  
14 transcribed and be part of the public record.

15 For the sake of transparency we request  
16 that you disclose if you are affiliated with an  
17 organization that has an interest in drug  
18 development, in FSD, or if your travel here today  
19 has been funded by an organization, or if you have  
20 significant financial interest in any  
21 pharmaceutical companies. If you do not have any  
22 such interest, you may state that for the record

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

192

1 as well.

2           So we have collected sign up before the  
3 meeting. We have 15 people signed up and about 30  
4 minutes for this session. So please be respectful  
5 to your other colleagues here and other patients  
6 and stick to the two minute limit that we have.  
7 We have a timer up front. I have it here. And  
8 when the light turns from green to red over here  
9 that means your time has ended and I will then ask  
10 the next speaker to come to the mic.

11           So I'll run through the order of the  
12 speakers and I apologize if I mispronounce your  
13 name.

14           So first we will have Leonore Tiefer,  
15 Alessandra Hirsch, Thea Cacchioni, Sidney Wolfe,  
16 Rebecca Holliman, Judy Segal, Ashland Gena,  
17 Kimberly, Sally Greenberg, Deborah Arrindell,  
18 Susan Scanlon, Beth, sorry. I'll get back to you,  
19 sorry, Sue Goldstein, Amanda, and then Michelle  
20 Robson.

21           So first could I have Leonore Tiefer to  
22 the mic please? So we have two mics set up, one



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

193

1 to the right and one to the left. So if Leonore  
2 could come to one of them and then I'll have  
3 Alessandra Hirsch at the other one ready for the  
4 next one.

5 DR. TIEFER: Hi. So I'm Leonore Tiefer.  
6 I am a New York Psychologist and the founder of  
7 the New View Campaign which is a campaign to  
8 challenge medicalization. I've thrown my remarks  
9 out 12 times. I feel like this has been a surreal  
10 meeting. It's -- we are talking at cross purposes  
11 with each other. And it was very distressing that  
12 we sort of start off this meeting by saying we are  
13 committed to developing a drug when, in fact, we  
14 can't even agree on what it is for. And we have  
15 an over representation of people who are taking  
16 drugs paid by drug companies to come and talk  
17 about them.

18 This is not the way to do science.  
19 There is nothing representative about what is  
20 going on here. We have a huge literature on  
21 psycho-educational, psycho-therapeutic, self  
22 learning, spiritual methods to understand

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

194

1 sexuality. And what I hear here today is there  
2 are people who believe deeply in normality. And  
3 they had it and they've lost it and they want to  
4 go back to it. And then there is the rest of us  
5 who believe that the whole thing is a process  
6 going forward. It is not a medical model. There  
7 is no normal that you lost and you are going back  
8 to. It is the wrong way to look at it.

9           We need move conversation. We don't need  
10 to move into drug trials.

11           [Applause.]

12           MS. VAIDYA: Thank you.

13           Next Alessandria and then could I get  
14 Thea to the mic, please. Thank you.

15           You have to turn it on.

16           MS. HIRSCH: Hello. My name is  
17 Alessandra Hirsch. I have a master's degree in  
18 physiology from Georgetown University Medical  
19 Center. And I currently work as the project  
20 manager for PharmedOut which is a program that  
21 educates health care professionals on  
22 pharmaceutical marketing practices and encourages

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

195

1 evidence based prescribing.

2 I speak to you today as a young woman  
3 who is concerned about the implications of  
4 treating female sexual dysfunction with  
5 Flibanserin and other drugs. And I speak only for  
6 myself.

7 When I mentioned to a male friend the  
8 idea that the FDA is sexist because it has not  
9 approved a female sexuality drug whereas it has  
10 approved a bevy of similar drugs for men he  
11 laughed at me and said if a good female sex drug  
12 had been invented and the FDA were truly sexist it  
13 would have been pushed faster than aspirin.  
14 Perhaps my friend has a point. What could be more  
15 keen to the male interest than a drug that  
16 encourages women to have more sex?

17 Let's take that implication a little bit  
18 further. I imagine myself in bed with my partner.  
19 He initiates a sexual encounter which I rebuff.  
20 Today because I have a kind and attentive partner  
21 my refusal would not equal rejection but merely a  
22 reflection on my mood that day. We would go to

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

196

1 sleep.

2                   Years from now with a drug that treats  
3 FSIAD on the market he might say to me it is okay  
4 that you are not in the mood, why don't you just  
5 take your pill for that? What if I still refuse?  
6 Do I lose the right to say no because there is a  
7 pill to fix me?

8                   The scenario that I described seems to  
9 me like a very possible outcome in addition to the  
10 already exhausting list of micro aggressions that  
11 affect women daily.

12                   Here are some things that have helped me  
13 with period of low libido. My boyfriend,  
14 switching boyfriends, chocolate, coffee, certain  
15 episodes of Grey's Anatomy, pornography, upgrading  
16 my vibrator, the phrase a little to the left, the  
17 phrase not so hard, the phrase I love you, reading  
18 Fifty Shades of Grey, removable shower head,  
19 having tips from my girlfriends, having backrubs,  
20 back scratches, a good night sleep and absence of  
21 judgment from my boyfriend and an absence of  
22 judgment from my friends, a defiance of judgment

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

197

1 from society and an acceptance of myself and the  
2 libido I came with.

3 MS. VAIDYA: Excuse me, Alessandria,  
4 your two minutes is up.

5 MS. HIRSCH: That is okay. Thank you.

6 [Applause.]

7 MS. VAIDYA: Can I please have Sidney  
8 Wolfe to the stand to the right please. Thank  
9 you.

10 DR. CACCHIONI: Hi. My name is Thea  
11 Cacchioni. I have a Ph.D. in the psychology of  
12 sexuality from the University of Warwick, U.K. and  
13 I'm a professor at the University of Victoria,  
14 British Columbia.

15 I would like to personally thank the FDA  
16 for at this point not approving a drug that is  
17 unsafe or ineffective. I think there have been  
18 enough drugs in the history of women's health as  
19 we heard from Karen's comments today that have  
20 been approved without enough research.

21 A subtext of the discussion today is  
22 that many women's sexual difficulties are the side

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

198

1 effects of drugs that have been approved for the  
2 treatment of other conditions. And yet we've also  
3 heard a lot about the off-label use of drugs which  
4 have not been approved for this reason and that  
5 concerns me very much as well as the various ways  
6 that they are being used out there in the world.

7 I'd like to just express disappointment  
8 to that. This is a patient centered hearing and  
9 yet it seems as though it has been mainly people  
10 who have been sponsored by industry who have been  
11 able to afford to attend. I don't think it is  
12 truly representative; not to take away from your  
13 experiences.

14 So just to conclude I would like to say  
15 it seems as though the line between industry and  
16 patient perspectives is very thin.

17 [Applause.]

18 MS. VAIDYA: Thank you.

19 Sidney Wolfe and then could I have  
20 Rebecca Holliman to the mic on the left please.  
21 Thank you.

22 MR. WOLFE: Sid Wolfe, the Health

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

199

1 Researchers Group. Don't have any financial  
2 conflicts of interest. Just one quick comment  
3 before the other three quick comments.

4           One, no drugs have been approved for man  
5 or women for this purpose. The FDA took a strong  
6 position at a hearing last month in September that  
7 use of Testosterone for a whole variety of things  
8 including pre-sexual desire there is no evidence  
9 for it. I got involved in these issues about ten  
10 years about when I testified along with Dr. Tiefer  
11 at a hearing where they were considering the  
12 approval of Testosterone patch for women. The  
13 physician who reviewed the drug said "the clinical  
14 significance of the increase with active treatment  
15 yielding on average of only five to six points  
16 more than placebo on a score of 100 for sexual  
17 desire is unknown".

18           More recently in 2010 another drug  
19 Flibanserin which has been mentioned several times  
20 was also turned down and one of the reasons it was  
21 turned down again was that the placebo response  
22 rate was really quite high. And in an interesting

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

200

1 article by someone who has been here and has  
2 spoken, Dr. Kingsberg, after this hearing and  
3 after the drug was turned down she commented on  
4 the placebo effect. They can be explained by  
5 other more psychological factors, for example,  
6 women enrolled in these trials that desire to  
7 improve their sex lives and take an active role in  
8 seeking help. Additionally expectancies for  
9 enhanced sexual desire would increase a woman's  
10 perception of having desire. Two frequent diary  
11 entries which she opposed and which some people  
12 today -- were the sum and substance of at least  
13 one of the reasons why the placebo worked.

14           And finally before the microphone gets  
15 turned off it is a very complicated issue.  
16 Everyone has agreed that it is and since we are  
17 only about 30 miles from Baltimore where H.L.  
18 Makin was. The quote with Makin "for every  
19 complicated problem there is a simple solution  
20 which is usually wrong".

21           Thank you.

22           [Applause.]



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

201

1 MS. VAIDYA: Thank you.

2 Next we have Rebecca. And then could I  
3 get Judy Segal to the mic as well for after.

4 Okay. Go ahead Rebecca.

5 MS. HOLLIMAN: Hi my name is Rebecca  
6 Holliman. I'm a graduate student at Georgetown  
7 University. And I work as volunteer staff for  
8 PharmedOut which is a Georgetown project that aims  
9 to encourage evidence based prescribing. I have  
10 no financial conflicts of interest.

11 I worry about the potential harm to  
12 women if we leave this issue solely in the hands  
13 of the medical community. Sex is complicated.  
14 Biological function cannot be isolated from  
15 physiological, psychological and social factors.  
16 It would be a disservice to women to take this  
17 approach.

18 The doctor's office can be an  
19 intimidating place for women to address concerns  
20 about their sexuality. Women are left vulnerable  
21 to messages designed to push a profit instead of  
22 to educate.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

202

1 Pills have a higher profit margin than  
2 education but opting for the quick fix may cause  
3 more harm than good.

4 In an article written by Grant Stoddard  
5 he described his experience with having sex on  
6 Viagra. In it he made the comment penises are  
7 often referred to as tools and that is exactly  
8 what mine felt like a wood-like dodonic (ph)  
9 prosthesis that was being ridden with little  
10 emotional or physical input from me. The  
11 experience was strangely feminizing. For the  
12 first time I was a passive partner during sex  
13 without necessarily being turned on or even having  
14 my head in the game.

15 Maybe we have already done men a  
16 disservice in focusing on medication to fix the  
17 machinery of sex at the same time spreading the  
18 message that the body is the only part of them  
19 that matters. The emphasis on a medical fix is  
20 likely to prove more damaging than helpful to  
21 women in the long run. Medical technology is too  
22 easily manipulated a device. I can imagine the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

203

1 commercials already. He made you dinner, he  
2 bought you roses, don't you want to be able to  
3 respond.

4 A pill or device in a market with  
5 inadequate infrastructure to educate women about  
6 the non-medical components of arousal is  
7 dangerously open to abuse. Once again women will  
8 become little more than the functions of their  
9 bodies.

10 Thank you.

11 [Applause.]

12 MS. VAIDYA: Thank you.

13 And next we have Judy. And then could I  
14 get Alska (ph) Ashley to the mic, please.

15 DR. SEGAL: Hi, my name is Judy Segal.

16 As I mentioned before I'm funded by the Social  
17 Science Humanities Research Counsel. I'm a  
18 professor at the University of British Columbia  
19 and my area of research is discourse language and  
20 persuasion in health and medicine.

21 And so I do want to make another comment  
22 about some of the language I've heard today.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

204

1           One of the words that has been missing  
2 has come up from time to time but it hasn't been  
3 at the center of anything in terms of goals of  
4 treatment end points is the word pleasure. It  
5 seems to me that a lot of what I've heard about is  
6 well interest, arousal, orgasm, husbands, guilt,  
7 anxiety, wanting to be free of those but I haven't  
8 heard a lot about pleasure. And it seems to me  
9 that if we don't talk about sexual pleasure in  
10 women as an end point of treatment if there is  
11 going to be some kind of treatment then that is  
12 say sexist, anti-feminist, in a way that I think  
13 not approving drugs that haven't been shown to be  
14 safe and effective isn't sexist and anti-  
15 feminist.

16           Thank you.

17           [Applause.]

18           MS. VAIDYA: Thank you Judy.

19           Next we have Ashland and can I also get  
20 Kimberly to the mic.

21           MS. JERVIS: Hi. My name is Coco Jervis.  
22 I will be speaking on behalf of Ashland. I'm the

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

205

1 program director at the National Women's Health  
2 Network. The Network talks to patients and other  
3 concerned about sexual problems and/or women's  
4 health voice information service. The Women's  
5 Health Information Service is supported by our  
6 members. We do not take any financial  
7 contributions from drug companies, medical device  
8 manufacturers, insurance companies or any other  
9 interest that have a financial stake in the  
10 women's health decision making.

11           The Women's Health Voice was launched in  
12 1978 and has operated continuously since then.  
13 Women routinely contact us with questions about  
14 sexual problems. And the questions that they ask  
15 us are is this normal? Are my sexual problems  
16 caused by something a medical professional did?  
17 Does the medical profession have anything to offer  
18 me? Does what is being offered work? And what  
19 are the risks and side effects of what is being  
20 offered? And are there alternatives?

21           What we have found when talking to women  
22 with concerns about sexual problems is that good

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

206

1 answers do not exist to any of the questions women  
2 ask us. And on behalf of hundreds of women who  
3 have brought these questions to us via the Women's  
4 Health

5           Voice we want the FDA to know the  
6 following: women want more information about what  
7 is normal but not just what is hetero-normative.  
8 They want to know about natural history studies of  
9 changes in sexuality including desire, arousal,  
10 and a response with age and reproductive events.  
11 Women want more information that is currently  
12 available about the effectiveness of medical  
13 treatments, procedures and medications on the  
14 desire and arousal and satisfaction.

15           Then of course some of them want to know  
16 what medical treatments are available. They want  
17 to know if treatments they've heard about are  
18 legitimate and stringently evaluated by the FDA.  
19 They want to know if medical treatments actually  
20 work and how well. They want information on about  
21 what exactly effective means.

22           Women who contact us with questions

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

207

1 about sexual problems want reliable information  
2 about the risks of side effects associated with  
3 medical treatments.

4 [Applause.]

5 MS. VAIDYA: Thank you.

6 Next we have Kimberly and can I get  
7 Sally on the mic as well. Okay.

8 KMBERLY: Hi. My name is Kim and I am  
9 just representing myself. I view myself as a  
10 potential patient as a pre-menopausal woman who  
11 has young children and as a doctoral student. I  
12 understand fatigue and I understand how that  
13 affects my own desire.

14 But I am most concerned that any  
15 medication that is on the market be both safe and  
16 effective for its intended use.

17 And I just wanted to mention how greatly  
18 I appreciate that the FDA is dedicated to both  
19 safety and true efficacy.

20 Thank you.

21 [Applause.]

22 MS. VAIDYA: Thank you.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

208

1           So next we have Sally. And then could I  
2 also get Deborah.

3           MS. GREENBERG: Good afternoon. My name  
4 is Sally Greenberg. I'm the Executive Director of  
5 the National Consumers League. We are the oldest  
6 consumer organization in the U.S. founded in 1899  
7 by pioneering women during the progressive era who  
8 focused much of their work on health care and work  
9 place protections for women and children. And  
10 they fought passionately for women's equality and  
11 fair treatment.

12           More recently NCL has been a champion  
13 for the safe use of medications and work closely  
14 with the FDA on better medication adherence  
15 through our Script Your Future Campaign.

16           I'm here today because when it comes to  
17 sexual dysfunction treatments and I am going to  
18 talk really fast it is clear that we have a gross  
19 gender imbalance in products approved for men  
20 versus women. With 26 new drugs either approved or  
21 marketed for different aspects of male sexual  
22 dysfunction including erectile dysfunction,



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

209

1 Peyronie's disease, loss of libido due to  
2 hypergonadism.

3           There is nothing so far for women in the  
4 most common form of sexual dysfunction, HSDD. And  
5 we have to ask the question why? Viagra was  
6 approved for erectile dysfunction 16 years ago.  
7 It was fast-tracked at the FDA and review in one  
8 six month cycle despite a long list of adverse  
9 reactions including very serious cardiovascular  
10 effects especially if it is co-administered with  
11 other commonly used drugs.

12           16 years later despite worthy efforts  
13 women still do not have an FDA approved safe and  
14 effective treatment for HSDD.

15           This is what women end up doing is they  
16 go to the Internet and they buy I have 51 examples  
17 here of stuff on the Internet that claims to  
18 provide increased libido for women. These  
19 treatments are proven neither safe nor effective  
20 and because the FDA has dragged its feet and  
21 failed to act and address this gender imbalance we  
22 have women going and getting products that could

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

210

1 hurt them and waste their money.

2           So if we sound angry; if I sound angry,  
3 I am and I think -- congratulate the FDA for doing  
4 this workshop here today but we need to move  
5 beyond this -- I'm cut off so thank you for your  
6 time, you get the picture.

7           [Applause.]

8           MS. VAIDYA: Thank you Sally.

9           We have Deborah ready to speak and then  
10 can I get Susan right after her.

11           MS. ARRINDELL: Good afternoon. I'm  
12 Deborah Arrindell with the American Sexual Health  
13 Association. Our organization was established in  
14 1914 when women were largely considered vixens,  
15 vectors or infections, and maybe vamps.

16           It is wonderful that we've come to the  
17 point where we can begin to talk about women  
18 having healthy sexual lives. Women have right  
19 perhaps to desire, arousal, even pleasure. So we  
20 really appreciate that the FDA has today given  
21 organizations like mine and people like me an  
22 opportunity to hear from patients which I have

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

211

1 things I have only read about. And what I've  
2 heard is despair, anxiety, loss of confidence,  
3 loss of self-worth, troubled relationships and  
4 families in crises. And sexual health, we  
5 believe, is a basic human right.

6           What we've heard is that women will try  
7 everything including "some things I don't even  
8 remember the names of". And indeed I do believe  
9 for some women chocolate, strawberries, and  
10 certain episodes of Grey's Anatomy can make a  
11 difference. But for many other women that is  
12 simply not the case.

13           We heard that for some woman a month in  
14 the Caribbean would not do the trick. Not being  
15 able to have sexual desire will only add to  
16 anxiety there.

17           So I believe that sexual health is a  
18 basic human right and those are the women for whom  
19 we ask the FDA to provide some options. We don't  
20 want a magic pill. We want an opportunity for  
21 those women and their providers to together figure  
22 out what is right for them and what might work.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

212

1 I believe that deeply buried in the  
2 Constitution there must be a basic right to  
3 healthy sexuality. I am going to go with the  
4 Pursuit of Happiness.

5 Thank you.

6 [Applause.]

7 MS. VAIDYA: Thank you very much.

8 Next we have Susan. And after that we  
9 will have Beth.

10 MS. SCANLAN: Hi. Thank you for letting  
11 me speak. I am Susan Scanlan. I am Chair  
12 Emeritus of the National Council of Women's  
13 Organizations, a coalition of 240 progressive  
14 women's groups representing 12 million American  
15 women. I am also Chair of Even the Score a  
16 coalition of patients, providers, advocates and  
17 practitioners who have come together to address  
18 the gender disparity in treatments for male versus  
19 female sexual dysfunction.

20 There are 26 drugs approved for men and  
21 zero for women. Up to one in ten women, American  
22 women, suffer from FSIAD. That represents as many

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

213

1 as 16 million women with no answer to this  
2 devastating condition.

3           How pervasive is the problem? 75  
4 percent of women patients here today are not from  
5 the Washington, D.C. area. They are from all over  
6 the country. And they need and deserve our help.

7           And let me salute the women who came  
8 here and husbands who spoke; so courageous.

9           We support medical treatment for FSIAD.  
10 We are tired of hearing that female sexual health  
11 is complex as if there would be no answer if we  
12 didn't study it. Make no mistake men are equally  
13 complex and there has been no shortage of  
14 medications to address their sexual dysfunction.

15           In 1960 the birth control pill  
16 precipitated a societal shift to recognize women's  
17 rights as reproductive beings.

18           In 2014 let's shift to recognize women's  
19 rights as sexual beings.

20           Thank you very much.

21           [Applause.]

22           MS. VAIDYA: Thank you.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

214

1           Next we have Beth and then Sue.

2           MS. BATTAGLINO: Hi. I'm Beth  
3 Battaglino. I'm CEO of HealthyWomen.org, the  
4 leading not for profit consumer women's health  
5 organization who represents more than five million  
6 women annually that visit our Website. And I want  
7 to share with you that the top three topics that  
8 trend the most women's sexual health continues to  
9 be in the top three. So we know that women are  
10 seeking information and want information and feel  
11 that they need to go to a lot of Websites to find  
12 that information because it is an embarrassing  
13 topic for so many.

14           I also want to share that we recently  
15 did a survey of over 1,000 women and 81 percent of  
16 the women that took the survey said that their  
17 sexual relationships or lack of sexual  
18 relationships is very distressful in their  
19 relationship and more than 53 percent of these  
20 women said that they've been living with this for  
21 more than a year.

22           So it is time that we do something. And

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

215

1 they have more options.

2 I also want to share that Healthy Women  
3 will continue to provide women with credible  
4 medically researched and vetted information and  
5 that is how we have remained in business for over  
6 26 years.

7 And I want to thank the FDA for  
8 commencing this panel. I think it is important  
9 but more importantly I really want to thank the  
10 real women and your real voices how powerful and  
11 so nice to have your spouses here. So thank you.

12 [Applause.]

13 MS. VAIDYA: Thank you Beth.

14 Next we have Sue and then Amanda.

15 MS. GOLDSTEIN: I am Sue Goldstein. I  
16 am a sexuality educator and a clinical researcher.  
17 And I'm here representing the everyday patient  
18 rather than the large societies. I've interviewed  
19 a great number of patients in my lifetime, first  
20 to write a book, and then working with them for  
21 clinical research.

22 And women are angry. And I'm here to

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

216

1 thank the FDA for bringing up this topic for us  
2 being to talk about it. As a sexuality educator  
3 one of the messages I would like to say is as long  
4 as we hide behind walls and we whisper about what  
5 we do; how can we expect everybody out in the  
6 community to be comfortable talking about sexual  
7 health.

8                   Women are afraid to talk to their  
9 physicians about their sexual health problems.  
10 And if they do, what they are told go get a glass  
11 of wine, go away for the weekend. And they know  
12 that is not the solution. Yes, you can say sex is  
13 complicated. The fact is sex is multi-factorial.  
14 It is multi-factorial for women. It is multi-  
15 factorial for men. And what we do is we do our  
16 best. And we have been able to come up with  
17 solutions for men and I'm hoping after this forum  
18 the FDA will work with companies so we have  
19 solutions for women.

20                   But there area women out there who are  
21 angry because there is nothing for them and they  
22 are being told you can't have a choice. All we are



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

217

1 asking is we're Americans, we have a choice  
2 whether we can choose abortion or not, we don't  
3 have to go to the back rooms and get coat hangers  
4 into our cervices to abort. We want a choice that  
5 if we want to have a biologic therapy in addition  
6 to or instead of physical therapy, sex therapy, we  
7 need a choice. All we are asking for is a choice.  
8 Nobody is telling anybody else they need to take a  
9 medication. We are just asking to make those  
10 options available.

11 Thank you.

12 [Applause.]

13 MS. VAIDYA: Thank you Sue.

14 Next we have Amanda and then finally  
15 Michelle Robson.

16 AMANDA: Thank you. I have a very  
17 healthy marriage and we have a very open line of  
18 communication. We are not here looking for  
19 perfection and Ben is not here to expect me to  
20 meet his demands. Instead we are looking for  
21 restoration of my sexual desire.

22 As we age we lose things. When we lose

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

218

1 the ability to sleep many of us take a sleep FDA  
2 approved medication. Some choose not to treat.  
3 When we lose the ability to handle stress some of  
4 choose an anxiety medicine that the FDA has  
5 approved. Others choose not to. So when we lose  
6 our desire to have sex with our husbands do we not  
7 have an FDA approved option to choose from. I  
8 recognize and respect that some choose not to do  
9 that and that is their choice. But as an educated  
10 professional woman who understands the risks and  
11 benefits associated with taking prescription  
12 medicine I would appreciate having the chance to  
13 have an FDA approved option to choose from and to  
14 allow me the opportunity to work with my physician  
15 in finding a solution to this problem.

16 I've heard it said a lot today that it  
17 is complex. It is really not. It is really not  
18 any more complicated than anything else that we  
19 lose.

20 BEN: And I just want to say that men  
21 have many options when it comes to sexual  
22 dysfunction. Women deserve to have some options

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

219

1 too.

2 Thank you.

3 [Applause.]

4 MS. VAIDYA: Thank you.

5 And finally we have Michelle Robson.

6 MS. ROBSON: Thank you for the

7 opportunity to speak today before the FDA. I have

8 no affiliation which I've already said and I have

9 no financial gain. My name is Michelle King

10 Robson. And I am the founder of EmpowHER.com. We

11 have over three and one half million women coming

12 to our site every single month. What do we see?

13 The top five is sexual health and relationships

14 every single day because we track this on a daily

15 basis.

16 I to suffered from sexual dysfunction.

17 It is one of the reasons why I started the

18 company. I see how women are silently suffering

19 because that is what women do. We don't have

20 options and choices. We need options and choices

21 today.

22 Without the option and choice that I had

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

220

1 to go to compounding and to have an FDA approved  
2 patch I would not be standing in this room. I  
3 would not have created this company. I would not  
4 be helping millions of women around the world who  
5 are dealing with health issues.

6           Women's health is underserved. It is  
7 very clear that it is very underserved. And it  
8 has got to change. We are no longer viewed as  
9 just vehicles. We are bearing children and we are  
10 contributing to society and paying taxes as well.

11           When I spoke to you in 2010 my story and  
12 the data was there and the data hasn't changed and  
13 it is now 2014.

14           Generations of women have suffered in  
15 silence for far too long, far too long. And it is  
16 time for the FDA to act. Please act.

17           Treatments and open doors for research  
18 and find more and better solutions and to no  
19 longer say no. We deserve no less. Just say  
20 yes.

21           [Applause.]

22           MS. VAIDYA: Thank you.

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

221

1           That brings our session to the end. And  
2 I would like to call Dr. Sandra Kweder to the  
3 stand for our closing.

4           DR. KWEDER: Well, good afternoon,  
5 everyone. And I recognize that we are ten minutes  
6 before you opportunity to stand up and stretch.  
7 So I'm going to try and summarize what we heard  
8 today. And I hope you can bear with me because I  
9 am looking at my little laptop screen.

10           But I did try to divide my comments into  
11 a couple of areas. One of which is separated  
12 first by the two panels and also acknowledging  
13 some of the general comments that were made.

14           First I want to thank you for all my  
15 colleagues here for being here and spending the  
16 day in a room that is sometimes a little dark and  
17 seats that are often a little uncomfortable. And  
18 in particular for expressing yourselves and a  
19 willingness to listen if you didn't express  
20 yourself to a discussion about a topic that is  
21 sometimes a little uncomfortable. And if you have  
22 any doubt about that I ask you to think back to

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

222

1 the first panel that got up when Sara got up and  
2 tried to generate some discussion. I could see  
3 people shifting in their seats. There was a  
4 little silence and people are thinking oh my gosh  
5 how are we going to fill this afternoon. But  
6 quickly you arose to the occasion and I am really  
7 glad that you did.

8 I found it very informative and I think  
9 I speak for my colleagues in that manner as well.

10 We are not here to solve all the world's  
11 problems. That is way beyond any of our pay  
12 grades. But we are here to listen and try and  
13 respond professionally and thoughtfully to  
14 concerns raised by patients who have conditions or  
15 concerns that you think that we need to hear  
16 about. And you certainly outdid yourselves today  
17 in expressing that.

18 I do want to acknowledge and we heard  
19 this throughout the comments peppered during the  
20 day and at the end in the open public hearing that  
21 -- I want to acknowledge that there is a breadth  
22 of perspective on the issues that we discussed

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

223

1 today. I would be gravely disappointed if there  
2 were not a breadth of perspective. And any time  
3 we at the agency tackle something that is  
4 difficult there is a wide breadth of perspective  
5 and people feel very passionately along that full  
6 spectrum. That is just fine.

7           So I will acknowledge that there remains  
8 some who are concerned that we need more attention  
9 to the etiologies and I use plural and physiology  
10 of female sexual disorder conditions that have  
11 been the focus of today's discussion particularly  
12 they expressed concern about the need to consider  
13 the natural variation in sexual desire from one  
14 person to the next or over the course of any  
15 individual's lifetime and life experiences.

16           Another concern that was expressed was  
17 that we always take care not to allow undue  
18 influence from the pharmaceutical industry in any  
19 discussions of any particular medical condition.

20           And other speakers expressed concern  
21 that not enough attention has been paid to  
22 addressing treatments for women who are

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

224

1 experiencing this condition that we discussed  
2 today and there is actually probably a spectrum of  
3 conditions based on the kinds of things people  
4 raised their hands about in describing their own  
5 circumstances.

6           But acknowledging all that I'd like to  
7 try and summarize what we heard from Panel 1 that  
8 was so eloquently expressed by the panel members.  
9 What was most striking to me was how similar the  
10 experiences described by the four panelists seemed  
11 to be to those who subsequently expressed  
12 themselves in the discussion portion following  
13 that panel. I would just recount that 75 percent  
14 of you who voted cited no or reduced excitement or  
15 pleasure during sexual activity. 75 percent  
16 expressed no or reduced non genital sensation  
17 during sexual activity. And a large number of you  
18 as well particularly made a point to express that  
19 your major issue of concern is a lack of any  
20 desire to even contemplate sexual activity in the  
21 first place.

22           And I would say that was one of the most



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

225

1 important messages for us today was that this  
2 complete lack of interest in sexual activity seems  
3 to be a really predominant feature that many of  
4 you shared often to the point of working hard in  
5 your life to avoid any experience in life or  
6 circumstance in your day-to-day existence that  
7 might result in pressure to engage in sexual  
8 activity.

9           There was an expression by many of  
10 having great difficulty in becoming sexually  
11 aroused at all with some noting that they can't  
12 reach orgasm; although most expressed the  
13 difficulty in becoming aroused at all as more  
14 important than any orgasmia.

15           Many of you expressed a point in time in  
16 your life when you recognized that suddenly  
17 something changed. For some people it was the  
18 birth of a child, for some people it was surgical  
19 intervention. There were a variety of things  
20 expressed. But you referred to what was -- had  
21 always been for most of your life normal very  
22 suddenly became different. Although others of you

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

226

1 expressed that the onset of this was different.  
2 And some who spoke expressed the importance of  
3 factoring in age, the variation in that according  
4 to a particular age or period of physiologic  
5 differences in a woman's life.

6           One of the things that I heard was that  
7 interest is different from arousal. Interest is  
8 different from the physiologic process of arousal  
9 itself. And arousal may often be generated by  
10 interest or physical stimulation but many women  
11 experience difficulty in both of those spheres.  
12 There is like a Venn diagram where they overlap  
13 but they are different.

14           With regard to signs and symptoms it was  
15 interesting when Sara brought up the issue with  
16 regard to signs and symptoms this discussion of  
17 what constitutes a satisfying sexual experience.  
18 And some of you expressed that a satisfying sexual  
19 experience is not something that is easy to  
20 measure. It means different things to different  
21 people. But you all raised your hands to indicate  
22 that having satisfying sex is different but it is

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

227

1 highly different depending on the individual.

2 Overall I think there seemed to be a  
3 convergence on satisfaction being related to some  
4 sense of emotional positivity and sense of self  
5 worth. To me this is an important component. I  
6 think we are going to hear more about that  
7 tomorrow when we talk about the aspect of being  
8 able to measure sexual satisfaction in clinical  
9 studies of new drugs. It is something that is  
10 often prominent in the scoring system used. So  
11 understanding what is behind those is really,  
12 really important.

13 In terms of the effect of the disorder  
14 or variations in the disorder on people's lives  
15 and functionings all who spoke and this was quite  
16 striking indicated what a profound affect this has  
17 had on your lives beginning with stressing the  
18 effect on your sense of self worth but in  
19 particular your relationships. Not and most  
20 prominently your relationship with your spouse or  
21 significant other or sexual partner but also how  
22 that affect impacted you beyond just that one-on-

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

228

1 one relationship. It affected oftentimes your  
2 family lives, your relationships with your family,  
3 how you felt about yourself in your ability to do  
4 other things in your life.

5           Some described a cycle of anxiety and  
6 disappointment associated with coping with the  
7 condition. And it was noted and duly noted on our  
8 part that having some input as we think about  
9 measures to assess this condition getting input  
10 from partners of women with this disorder may be  
11 important in our understanding its impact on  
12 people's lives.

13           So to move on to Panel 2 and trying to  
14 grasp current approaches to treatment, current  
15 treatments and how well they worked I did note  
16 among the four panelists there was one panelist  
17 who focused most particularly on the facilitated  
18 work on relationships and developing a sense of  
19 really understanding intimacy itself as part of  
20 addressing this disorder. And interestingly it was  
21 about one in four and also about 25 percent of the  
22 people in the room who had done some sort of work

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

229

1 like that in seeking to address this disorder. So  
2 it seems like the panel was quite representative  
3 of the people in the room.

4           The types of things that were mentioned  
5 included Estrogen treatments, various forms of  
6 Testosterone, a lot of emphasis and discussion on  
7 Testosterone. And you really reflected a gamut of  
8 experience from topical, injected or pellets. And  
9 what was also striking was there was a great  
10 variation in people's experiences and success in  
11 treatment with Testosterone which does suggest  
12 that there may be different underlying etiologies  
13 of this condition that may respond differently to  
14 different hormonal interventions.

15           Estrogens I think we can say that the  
16 responses were similarly varied. Several of you  
17 mentioned systemic use, noticing improvement in  
18 symptoms including more widespread affects that go  
19 beyond just sexual function but to other aspects  
20 of functioning in day-to-day life particularly  
21 those women who had experienced surgical menopause  
22 or menopause again going back to the spectrum of

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

230

1 affects, impacts that different stages in life can  
2 have on sexual functioning.

3           Interesting that PDE5 inhibitors, the  
4 Viagras, the Sildenafil, Cialis and the other  
5 things, some have tried them. Those who mentioned  
6 them seemed to be not particularly enamored with  
7 their effectiveness.

8           And several of you mentioned trying a  
9 variety of over-the-counter products to try and  
10 address your concerns.

11           Several in the room have participated in  
12 clinical trials for Flibanserin and those who did  
13 mentioned that they had participated indicated  
14 that they had had positive effects from that drug  
15 on sexual desire.

16           The side effects that were mentioned  
17 were not surprising, in particular I would say the  
18 most prominent one was undesired hair growth with  
19 Testosterone was the one that was mentioned most  
20 often and a variety of other things but didn't  
21 seem to have any patterns.

22           As far as an ideal treatment I thought

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

231

1 that discussion was interesting. Overall a  
2 subjective -- what most people seemed to desire  
3 most was something that would bring them back to  
4 what they saw as having a healthy sexual life and  
5 desire to engage in sexual activity. It seems to  
6 be the most elusive aspect of successful treatment  
7 from what I heard today and probably one that  
8 needs the most focus in developing therapies.

9 Favor was expressed by some for  
10 treatments that can be managed on an as needed  
11 basis. But it was also important to some of you  
12 that this isn't something that comes and goes,  
13 this sense of self worth that one has from being  
14 able to have a sense of being a sexual being isn't  
15 something that comes and goes, it is kind of a  
16 continuum or a continuous desire to feel what one  
17 perceives as normal.

18 So I'm not sure there is one ideal. I  
19 don't think I came away with a sense that there is  
20 one ideal but that there is probably breadth in  
21 perspective on this issue. And I think as we  
22 proceed and encourage companies to proceed with

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

232

1 considering therapies in this area and using  
2 measure and considering clinical trials for any  
3 products that are developed in this field; those  
4 are factors that we all collectively in here at  
5 FDA and academia where people, and in clinical  
6 medicine and in the pharmaceutical industry are  
7 going to have to probe these issue a little bit  
8 further.

9           So I couldn't capture absolutely  
10 everything that you expressed. I would have been  
11 up here all afternoon because that is how long it  
12 took to express these things. But I do hope that  
13 I've touched on some of the major themes.

14           I think -- I hope that most of you are  
15 planning on being here tomorrow because the  
16 discussion will be expanded from this to taking  
17 what was said today to thinking about how to  
18 measure these things; how to take them into  
19 consideration in clinical studies; how to develop  
20 a study end point and measures of this of these  
21 factors that are so important to you as patients  
22 so that in any clinical trial we can do you



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

233

1 justice and really assess therapies and whether  
2 they really do achieve the things that you find  
3 most important in meeting your needs.

4           So again thank you for your attention.  
5 Thank you for your serious consideration of the  
6 plethora of issues that we have before us.

7           And I hope many of you will be joining  
8 us tomorrow.

9           Thanks very much.

10           [Applause.]

11           (WHEREUPON, the public meeting  
12 concluded.)

13

14

15

16

17

18

19

20

21

22

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

234

1 CERTIFICATE OF NOTARY PUBLIC

2 I, MICHAEL FARKAS, the officer before whom the  
3 foregoing deposition was taken, do hereby certify  
4 that the witness whose testimony appears in the  
5 foregoing deposition was duly sworn by me; that  
6 the testimony of said witness was recorded by me  
7 and thereafter reduced to typewriting under my  
8 direction; that said deposition is a true record  
9 of the testimony given by said witness; that I am  
10 neither counsel for, related to, nor employed by  
11 any of the parties to the action in which this  
12 deposition was taken; and, further, that I am not  
13 a relative or employee of any counsel or attorney  
14 employed by the parties hereto, nor financially or  
15 otherwise interested in the outcome of this  
16 action.

17 

18  
19 MICHAEL FARKAS  
20 Notary Public in and  
for the State of Maryland

21 My commission expires: 6/27/2018

22 Notary Registration No.: 256324

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

235

1 CERTIFICATE OF TRANSCRIPTION

2 I, CHERYL LaSELLE, hereby certify that I am not  
3 the Court Reporter who reported the following  
4 proceeding and that I have typed the transcript of  
5 this proceeding using the Court Reporter's notes  
6 and recordings. The foregoing/attached transcript  
7 is a true, correct, and complete transcription of  
8 said proceeding.

9

10

11



12

13

\_\_\_\_\_  
CHERYL LaSELLE  
Transcriptionist

14

15

16

17

18

19

20

21

22

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p style="text-align: center;"><u>          </u> \$</p> <p><b>\$35,000</b> 52:5</p> <p><b>\$500</b> 166:5</p> <p style="text-align: center;"><u>          </u> 1</p> <p><b>1</b> 3:10,11 32:9 46:8 123:3 124:4,18 224:7</p> <p><b>1,000</b> 214:15</p> <p><b>1/8th</b> 170:18</p> <p><b>10</b> 171:11</p> <p><b>100</b> 60:22 77:16 199:16</p> <p><b>10903</b> 1:15</p> <p><b>11</b> 171:11</p> <p><b>12</b> 23:14,18 61:2,9 130:15 179:12 193:9 212:14</p> <p><b>124</b> 3:13</p> <p><b>127</b> 3:14</p> <p><b>13</b> 17:21 103:16,17</p> <p><b>14</b> 3:6 17:21</p> <p><b>15</b> 53:18 192:3</p> <p><b>16</b> 17:10 209:6,12 213:1</p> <p><b>17</b> 17:16 127:18</p> <p><b>1700</b> 22:14</p> <p><b>18</b> 22:5 147:14</p> <p><b>1899</b> 208:6</p> <p><b>191</b> 3:15</p> <p><b>1914</b> 210:14</p> <p><b>1960</b> 213:15</p> <p><b>1960s</b> 60:18</p> <p><b>1971</b> 60:12</p> <p><b>1978</b> 205:12</p>	<p><b>1980s</b> 62:10</p> <p><b>1995</b> 22:5</p> <p><b>1996</b> 128:7</p> <p style="text-align: center;"><u>          </u> 2</p> <p><b>2</b> 3:13,14 66:2 123:4,14 124:1,4,13 228:13</p> <p><b>2:35</b> 123:5,11</p> <p><b>20</b> 3:7 16:11 45:15,16 162:16 168:15</p> <p><b>2008</b> 23:13</p> <p><b>2009</b> 12:19 128:10</p> <p><b>2010</b> 128:12 199:18 220:11</p> <p><b>2011</b> 136:9 138:5</p> <p><b>2012</b> 15:16 16:10 17:5</p> <p><b>2014</b> 1:11 213:18 220:13</p> <p><b>2015</b> 18:5</p> <p><b>2016</b> 17:16</p> <p><b>20993</b> 1:17</p> <p><b>20s</b> 132:16 184:21</p> <p><b>221</b> 3:16</p> <p><b>23</b> 60:12</p> <p><b>24/7</b> 175:11 182:9</p> <p><b>24/7/365</b> 182:17</p> <p><b>240</b> 212:13</p> <p><b>25</b> 135:11 137:6 228:21</p> <p><b>256324</b> 234:22</p> <p><b>26</b> 208:20 212:20 215:6</p> <p><b>27</b> 1:11</p>	<p style="text-align: center;"><u>          </u> 3</p> <p><b>3</b> 44:19</p> <p><b>30</b> 3:9 44:6,21 52:3 78:11 83:2 132:15 153:5 192:3 200:17</p> <p><b>30s</b> 132:14</p> <p><b>31</b> 1:16 44:21</p> <p><b>33</b> 153:1</p> <p><b>35</b> 61:2</p> <p><b>36</b> 146:22</p> <p><b>365</b> 187:19</p> <p><b>39</b> 47:13 50:21</p> <p style="text-align: center;"><u>          </u> 4</p> <p><b>4,500</b> 17:8</p> <p><b>40</b> 17:7 44:21 69:16 82:21 90:19</p> <p><b>42</b> 151:21 183:17</p> <p><b>43</b> 22:13 23:18</p> <p><b>45</b> 60:16 128:19</p> <p><b>47</b> 3:10</p> <p style="text-align: center;"><u>          </u> 5</p> <p><b>50</b> 45:22 54:7 82:19 96:4 112:17 146:18,20,21 159:11,12</p> <p><b>50s</b> 59:6</p> <p><b>51</b> 44:22 90:19,21 209:16</p> <p><b>53</b> 214:19</p> <p><b>55</b> 44:16 173:2</p> <p><b>59</b> 22:6</p> <p><b>5th</b> 17:17</p>	<p style="text-align: center;"><u>          </u> 6</p> <p><b>6/27/2018</b> 234:21</p> <p><b>60</b> 44:22</p> <p><b>60s</b> 79:13</p> <p><b>66</b> 3:11 127:17</p> <p><b>67</b> 63:17</p> <p style="text-align: center;"><u>          </u> 7</p> <p><b>75</b> 25:21 58:4 213:3 224:13,15</p> <p style="text-align: center;"><u>          </u> 8</p> <p><b>8</b> 3:3</p> <p><b>80</b> 58:4</p> <p><b>81</b> 214:15</p> <p><b>8th</b> 17:14</p> <p style="text-align: center;"><u>          </u> 9</p> <p><b>97</b> 128:8</p> <p style="text-align: center;"><u>          </u> A</p> <p><b>ability</b> 12:8 15:9 16:4 53:6,15 59:9 62:12 98:19 154:11 218:1,3 228:3</p> <p><b>able</b> 19:8 30:16 36:7,15 39:8,14 54:2 56:1 59:18 60:2 62:19,21 73:18 74:19 78:20 87:10 88:7,8 107:3 121:8 136:3 141:10 177:17 183:7 186:11 189:6 198:11 203:2 211:15 216:16 227:8 231:14</p>
---	--	--	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>abort</b> 217:4</p> <p><b>abortion</b> 217:2</p> <p><b>absence</b> 24:7 71:21 102:12 196:20,21</p> <p><b>absent</b> 25:10,12 43:10,11 44:17 82:3 102:10</p> <p><b>absolutely</b> 89:4 232:9</p> <p><b>abuse</b> 203:7</p> <p><b>academia</b> 10:10 232:5</p> <p><b>accept</b> 60:6 64:7 87:9</p> <p><b>acceptable</b> 109:3</p> <p><b>acceptance</b> 197:1</p> <p><b>accepted</b> 185:13</p> <p><b>Accepting</b> 142:6</p> <p><b>access</b> 64:2</p> <p><b>accessories</b> 162:18</p> <p><b>accommodate</b> 38:9</p> <p><b>accompanied</b> 121:16</p> <p><b>accompany</b> 95:20</p> <p><b>accomplish</b> 87:10</p> <p><b>according</b> 226:3</p> <p><b>Accordingly</b> 29:2</p> <p><b>account</b> 11:9 23:16 97:20 143:14</p> <p><b>accurately</b> 108:4,6</p> <p><b>achieve</b> 22:9 53:7 64:12 87:10 164:10,22 187:18 233:2</p> <p><b>achieving</b> 117:11 164:16</p>	<p><b>acknowledge</b> 222:18,21 223:7</p> <p><b>acknowledged</b> 42:3</p> <p><b>acknowledging</b> 221:12 224:6</p> <p><b>acne</b> 131:10,17</p> <p><b>acronyms</b> 45:13</p> <p><b>across</b> 9:3 112:21 120:18</p> <p><b>act</b> 98:1 209:21 220:16</p> <p><b>action</b> 234:11,16</p> <p><b>active</b> 19:6 58:7 199:14 200:7</p> <p><b>activities</b> 73:2,3 179:20</p> <p><b>activity</b> 24:7,9 43:11,13 44:18 72:5,7,8 77:9 82:8,12,16,21 84:16 89:6,13 114:21 224:15,17,20 225:2,8 231:5</p> <p><b>actual</b> 91:14 97:17 98:1 112:18</p> <p><b>actually</b> 4:6 28:12 69:4 77:9 78:16 85:11 86:16 89:20 94:4 96:1 97:22 105:13 108:22 110:21 112:15 120:2 133:1 134:7 147:18 149:17 152:4 154:8 163:6 165:11 172:13 173:11 184:4 187:2 189:6,7,16 206:19 224:2</p> <p><b>acupuncture</b> 145:19</p>	<p>167:15 168:4</p> <p><b>ad</b> 136:9</p> <p><b>add</b> 96:6 211:15</p> <p><b>added</b> 63:8 93:5</p> <p><b>addition</b> 28:13 103:8 196:9 217:5</p> <p><b>additional</b> 63:16</p> <p><b>Additionally</b> 27:2 200:8</p> <p><b>address</b> 11:21 39:8 40:3 84:20 126:4 150:4 186:2 201:19 209:21 212:17 213:14 229:1 230:10</p> <p><b>addressed</b> 32:3 41:6 67:8 121:22 159:22</p> <p><b>addressing</b> 40:18 41:11 66:1 125:5 147:7 223:22 228:20</p> <p><b>adequate</b> 166:19</p> <p><b>adherence</b> 208:14</p> <p><b>adieu</b> 127:5</p> <p><b>adjust</b> 131:9 180:3</p> <p><b>adjustments</b> 131:12</p> <p><b>administer</b> 106:9</p> <p><b>ADMINISTRATIO N</b> 1:2</p> <p><b>admit</b> 118:18</p> <p><b>adopted</b> 53:16</p> <p><b>adult</b> 23:14 71:10 117:3</p> <p><b>advance</b> 17:1 32:21</p> <p><b>advances</b> 66:13</p> <p><b>advantage</b> 18:16</p>	<p><b>adverse</b> 209:8</p> <p><b>advertising</b> 60:21</p> <p><b>advise</b> 12:16 16:17</p> <p><b>advocate</b> 38:12 53:10</p> <p><b>advocates</b> 8:13 38:5 212:16</p> <p><b>Affairs</b> 37:5,13 39:21</p> <p><b>affect</b> 13:13 23:5 31:15 58:5 97:2 109:3 119:2 131:2 176:10 196:11 227:16,22</p> <p><b>affected</b> 16:6 95:21 96:14 128:3 168:8 228:1</p> <p><b>affecting</b> 54:14 109:4 142:11</p> <p><b>affects</b> 9:2 21:21 54:15 71:22 82:5 97:11 105:8,9,10,11,13 119:3,4,5 138:1 149:6 159:8 207:13 229:18 230:1</p> <p><b>affiliated</b> 7:16 34:2 68:7 127:15 138:21 191:16</p> <p><b>affiliation</b> 219:8</p> <p><b>affiliations</b> 164:7</p> <p><b>afford</b> 56:1 198:11</p> <p><b>afraid</b> 96:9 137:17 216:8</p> <p><b>afternoon</b> 4:4,10 8:3 20:17 51:9 57:11 67:12 113:9 127:13,14 169:11</p>
---	---	---	--

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 3

<p>170:19 208:3                  210:11 221:4                  222:5 232:11</p> <p><b>afterwards</b> 117:7</p> <p><b>against</b> 140:20</p> <p><b>age</b> 44:3,8,20                  60:12,16 61:2                  63:17 64:6,8 86:4                  89:2 90:16 122:3                  132:15 151:21                  168:15 206:10                  217:22 226:3,4</p> <p><b>agency</b> 223:3</p> <p><b>agency's</b> 4:16</p> <p><b>agenda</b> 3:2 5:3                  46:9,12</p> <p><b>agent</b> 58:16</p> <p><b>ages</b> 22:5 44:4,21                  89:15 137:19</p> <p><b>aggressions</b> 196:10</p> <p><b>aging</b> 63:15,19                  131:1</p> <p><b>ago</b> 47:16 51:20                  103:17 135:1,11                  179:16 180:14                  209:6</p> <p><b>agreed</b> 104:11                  200:16</p> <p><b>Ah</b> 17:1</p> <p><b>ahead</b> 65:10 75:15                  76:14 77:15 85:4                  104:5 155:4                  157:22 178:18                  201:4</p> <p><b>aid</b> 35:19</p> <p><b>aids</b> 18:18 153:22</p> <p><b>aims</b> 201:8</p> <p><b>akin</b> 91:13</p>	<p><b>alarmed</b> 139:11</p> <p><b>Alessandra</b> 192:15                  193:3 194:17</p> <p><b>Alessandria</b> 194:13                  197:3</p> <p><b>alike</b> 17:2</p> <p><b>alive</b> 121:11</p> <p><b>allergic</b> 51:22</p> <p><b>allow</b> 143:13 191:6                  218:14 223:17</p> <p><b>allowed</b> 15:19</p> <p><b>alone</b> 73:22 87:6                  103:18</p> <p><b>already</b> 17:1,22                  28:22 48:18                  124:17 163:22                  183:15 196:10                  202:15 203:1                  219:8</p> <p><b>Alaska</b> 203:14</p> <p><b>alter</b> 78:3</p> <p><b>altered</b> 61:4</p> <p><b>alternative</b> 11:10</p> <p><b>alternatives</b> 205:20</p> <p><b>altogether</b> 135:13</p> <p><b>am</b> 20:20 35:11                  45:10 50:22 52:4                  55:14 63:11                  64:14,18                  65:18,19,22 66:8                  68:5,9 69:16 74:19                  78:8 79:6,7 80:2                  85:5,6 87:2 88:1,8                  95:6 101:3,5                  103:15 108:1,17                  113:1,3,7 121:16                  122:14 123:13,21                  127:22 131:5                  132:15 133:12</p>	<p>134:6 137:17                  138:20 144:13                  149:16 151:17                  152:18 153:6,9,17                  155:6 157:20                  159:6,13,16                  169:17,19 171:18                  173:22 177:19                  183:18                  187:9,13,16                  188:12,14 190:3                  193:6 207:8,14                  208:17 210:3                  212:3,11,15                  215:15,16 219:10                  221:9 222:6                  234:9,12 235:2</p> <p><b>Amanda</b> 80:11                  108:17 109:13                  119:12 120:22                  121:2 148:9,10                  163:4,5 174:22                  175:1 184:2                  185:11 186:1                  192:19 215:14                  217:14,16</p> <p><b>amazing</b> 137:18                  158:22</p> <p><b>American</b> 24:2                  210:12 212:14,21</p> <p><b>Americans</b> 217:1</p> <p><b>among</b> 132:10                  228:16</p> <p><b>amount</b> 57:1,17                  59:21 80:22                  107:11 109:21                  173:15 190:4</p> <p><b>analogy</b> 58:15</p> <p><b>analysis</b> 22:14</p> <p><b>anatomy</b> 164:13                  196:15 211:10</p>	<p><b>and/or</b> 64:17 205:3</p> <p><b>Andrea</b> 15:5 18:6</p> <p><b>anger</b> 128:14</p> <p><b>angry</b> 53:22 56:6                  210:2 215:22                  216:21</p> <p><b>annually</b> 214:6</p> <p><b>answer</b> 35:10,17                  43:16 57:18 72:12                  77:11,13 78:1 84:9                  108:10,11,12                  143:20 170:10                  181:14,16 183:4                  213:1,11</p> <p><b>answered</b> 39:16                  90:20 119:10                  136:9</p> <p><b>answering</b> 46:6                  169:13 170:2</p> <p><b>answers</b> 39:19                  48:7,12,17 54:17                  92:6,22 97:16                  116:21 206:1</p> <p><b>anti</b> 52:14 133:7                  204:14</p> <p><b>anticipation</b> 180:14</p> <p><b>anti-depressant</b>                  98:18 169:8</p> <p><b>anti-feminist</b> 204:12</p> <p><b>anxiety</b> 22:9 26:11                  73:17                  98:5,6,7,11,17                  102:2 113:17                  143:5 184:15                  204:7 211:2,16                  218:4 228:5</p> <p><b>anxious</b> 73:19 87:8</p> <p><b>anybody</b> 52:16                  97:14 165:13</p>
---	--	--	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>179:5 180:9 217:8</p> <p><b>anymore</b> 77:20 88:12 133:22 156:7 157:2</p> <p><b>anyone</b> 6:6 36:10 67:4 73:13 74:4,5,15 76:9,12 85:17 87:12 94:17 96:22 102:9,12,14,22 105:22 106:17 108:12 135:20 144:18 151:11,13 152:20 158:15 162:6,20 163:21 171:22 180:8</p> <p><b>anything</b> 73:14 77:7 113:10 128:21 133:6,11 148:1 155:17 157:20 167:17 168:6 177:17 204:3 205:17 218:18</p> <p><b>anyway</b> 185:13 189:11</p> <p><b>anywhere</b> 106:12 179:10</p> <p><b>apart</b> 43:20 45:19 118:5</p> <p><b>apologize</b> 192:12</p> <p><b>apparent</b> 128:15 149:1</p> <p><b>appeal</b> 55:20,22</p> <p><b>appealed</b> 55:17</p> <p><b>appealing</b> 129:16 155:15</p> <p><b>appear</b> 22:3</p> <p><b>appears</b> 23:9 73:6 234:4</p> <p><b>appetite</b> 129:11</p>	<p>132:17</p> <p><b>applause</b> 4:18 65:2,3 123:7,9 144:8,10 190:14,15 191:1 194:11 197:6 198:17 200:22 203:11 204:17 207:4,21 210:7 212:6 213:21 215:12 217:12 219:3 220:21 233:10</p> <p><b>application</b> 11:6 16:20</p> <p><b>applications</b> 10:6 12:2 21:5</p> <p><b>apply</b> 12:4 43:15 107:22 145:11 146:6</p> <p><b>appointment</b> 133:2</p> <p><b>appreciate</b> 21:6 42:10 51:13 65:5 84:21 143:3 207:18 210:20 218:12</p> <p><b>approach</b> 15:2 16:13 97:12 141:8 201:17</p> <p><b>approached</b> 88:4</p> <p><b>approaches</b> 5:18 31:18 40:7 124:14 228:14</p> <p><b>approaching</b> 68:19,22</p> <p><b>appropriate</b> 29:9 41:2 100:4 104:13 125:18</p> <p><b>appropriately</b> 122:12</p> <p><b>approval</b> 54:5 56:17</p>	<p>199:12</p> <p><b>approve</b> 61:20,22 138:10</p> <p><b>approved</b> 10:14 27:14 28:12 54:4 113:5 131:22 150:16 156:14 165:12 178:16 183:20 195:9,10 197:20 198:1,4 199:4 208:19,20 209:6,13 212:20 218:2,5,7,13 220:1</p> <p><b>approves</b> 28:14</p> <p><b>approving</b> 197:16 204:13</p> <p><b>approximately</b> 174:1</p> <p><b>archived</b> 7:10</p> <p><b>area</b> 3:7 43:1 98:2 203:19 213:5 216:20 232:1</p> <p><b>areas</b> 16:12 18:7 134:1 159:2,8,15 221:11</p> <p><b>aren't</b> 100:11 158:13</p> <p><b>arise</b> 39:10 142:8</p> <p><b>arises</b> 142:17</p> <p><b>arm</b> 153:10 155:19</p> <p><b>arose</b> 222:6</p> <p><b>arousal</b> 4:15 5:20 6:16 9:6 21:16 24:10,14,17 25:12 26:10 27:19 28:21 29:10 35:16 38:2 43:13 45:3,5,12 55:3 59:11 62:6 66:9 67:19 68:17 69:1,7,9,12,13 76:7 82:3,4,9,22</p>	<p>83:7,17,19 84:6 86:13,21 87:19 89:22 91:19 92:3 93:22 94:7,22 95:9,21 96:2,5 97:2 98:13 100:6,9,13 110:10 118:6 121:6 124:16 126:8 143:15 165:21 166:2 176:22 181:10 184:18 203:6 204:6 206:9,14 210:19 226:7,8,9</p> <p><b>aroused</b> 22:8 53:6 55:14 58:19 69:10 75:17 76:1 97:17 118:4 225:11,13</p> <p><b>arranged</b> 51:10</p> <p><b>arrangements</b> 106:6 127:11</p> <p><b>array</b> 48:10</p> <p><b>Arrindell</b> 192:17 210:11,12</p> <p><b>arrive</b> 25:6</p> <p><b>article</b> 200:1 202:4</p> <p><b>asexual</b> 59:17</p> <p><b>Ashland</b> 192:16 204:19,22</p> <p><b>Ashley</b> 2:9 203:14</p> <p><b>asleep</b> 49:6</p> <p><b>aspect</b> 117:12 121:12 227:7 231:6</p> <p><b>aspects</b> 13:3,21 18:9 31:11 32:2 58:9 86:12 94:19 95:1 99:22 100:5 102:15 105:17</p>
---	--	---	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 5

107:22 110:14 208:21 229:19 <b>aspirin</b> 195:13 <b>assess</b> 12:14 15:9 228:9 233:1 <b>assessed</b> 11:2 <b>assessing</b> 29:18 <b>assessment</b> 11:8 30:6 <b>assist</b> 57:14 <b>associated</b> 11:13 28:11,16 43:14 64:9 126:17 162:13 207:2 218:11 228:6 <b>association</b> 24:2 166:12,13 210:13 <b>assume</b> 90:8 <b>assure</b> 11:19 <b>astray</b> 98:4 <b>attain</b> 24:11,13 <b>attempt</b> 59:3 72:8 <b>attempted</b> 58:21 <b>attend</b> 32:21 36:15 198:11 <b>attended</b> 31:4 <b>attention</b> 14:12 109:22 110:1,11,13 139:13 167:7 223:8,21 233:4 <b>attentional</b> 110:4 <b>attentive</b> 195:20 <b>attitudes</b> 122:5 <b>attorney</b> 234:13 <b>attracted</b> 155:14,18 <b>audience</b> 6:1 8:14	34:17 36:10 39:9 123:6 <b>Audrey</b> 2:5 3:3 5:2 7:21 8:5 31:4 40:12 <b>authentic</b> 20:2 <b>author</b> 68:11 <b>authorization</b> 11:7 <b>automatically</b> 118:21 <b>available</b> 15:5 18:12,22 133:11 134:15 190:5 206:12,16 217:10 <b>Avenue</b> 1:15 <b>average</b> 117:3 199:15 <b>averaged</b> 128:19 <b>avoid</b> 42:6 73:20,22 75:4 225:5 <b>avoiding</b> 49:3,8 145:21 <b>awaken</b> 128:18 <b>aware</b> 7:15 11:15 28:4 55:11 119:14 191:5 <b>away</b> 6:18 110:14 112:4 137:7 143:4 174:10 175:13 177:6 186:21 198:12 216:11 231:19 <b>awesome</b> 132:2 <b>Axiron</b> 153:9 155:19 <hr/> B <hr/> <b>baby</b> 132:22 159:16 <b>backed</b> 179:21	<b>background</b> 3:7 5:9 9:8 10:13 14:16,21 30:21 <b>backing</b> 161:10 <b>backrubs</b> 196:19 <b>bad</b> 141:11 <b>bait</b> 134:12 <b>Baltimore</b> 200:17 <b>Barbara</b> 135:5,6 147:19 <b>Barbara's</b> 148:15 <b>barely</b> 49:15 <b>based</b> 10:17 11:4 12:3 30:5 57:22 89:2 101:22 180:22 195:1 201:9 224:3 <b>basement</b> 153:9 <b>basic</b> 6:20 132:11 211:5,18 212:2 <b>basically</b> 52:2 88:2 166:17 187:18 <b>basis</b> 109:1 142:22 172:7,10 174:16 219:15 231:11 <b>Battaglini</b> 214:2,3 <b>battling</b> 43:18 <b>bear</b> 221:8 <b>bearing</b> 220:9 <b>beautiful</b> 49:17 64:10 156:9 <b>became</b> 47:15 48:2 56:9 59:3,7,12,15 63:18 108:22 109:2,11 128:9,14,22 141:20 225:22 <b>become</b> 58:18 62:14	87:2,3 107:13 203:8 <b>becomes</b> 66:13 <b>becoming</b> 22:8 98:20 177:14 225:10,13 <b>bed</b> 49:5,6 68:21,22 75:20 177:10 195:18 <b>bedroom</b> 79:6 142:14 148:14 <b>begin</b> 4:9 127:6 147:16 210:17 <b>beginning</b> 107:7 114:12 120:3 157:11 227:17 <b>behalf</b> 204:22 206:2 <b>behavior</b> 122:6 129:4 <b>behavioral</b> 28:2 145:22 163:16 <b>behind</b> 54:6 216:4 227:11 <b>beings</b> 213:17,19 <b>Beitz</b> 2:3 <b>believe</b> 6:8 39:3 54:11 85:11 105:19 127:22 131:18 135:10 165:20,21 175:15 188:14 194:2,5 211:5,8,17 212:1 <b>believes</b> 130:4 <b>beltway</b> 43:5 <b>Ben</b> 104:21 121:5,13 187:4 217:19 218:20 <b>beneficial</b> 155:10
--	--	--	---



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

Page 6

<p>156:12</p> <p><b>benefit</b> 11:8,12 15:12 16:15 19:10 20:12 29:12,17 30:2 137:16 184:8</p> <p><b>benefits</b> 11:3 15:9 142:20 218:11</p> <p><b>besides</b> 26:17 87:8</p> <p><b>best</b> 62:21 79:13 87:3 131:5 140:5 216:16</p> <p><b>Beth</b> 192:18 212:9 214:1,2 215:13</p> <p><b>betrays</b> 79:17</p> <p><b>better</b> 13:21 14:1 15:2 16:16 29:14 57:2 63:10 99:21 103:15 112:6,7,12 117:7 133:9 140:13 148:13 154:12 155:1 157:14 175:16 177:12 208:14 220:18</p> <p><b>Beverly</b> 51:9,10 57:8,9 65:12,18 66:5,8 74:17,18 75:16 76:6 78:7 79:22 97:3,5 98:15 155:5,7,8 177:2</p> <p><b>Beverly's</b> 76:10,15</p> <p><b>bevy</b> 195:10</p> <p><b>beyond</b> 20:4 93:22 101:17 210:5 222:11 227:22 229:19</p> <p><b>biggest</b> 31:21 55:22 69:8 73:17</p> <p><b>biologic</b> 217:5</p>	<p><b>Biological</b> 201:14</p> <p><b>biology</b> 104:9</p> <p><b>BioTE</b> 112:14 169:5</p> <p><b>birth</b> 47:16 60:13,14,18 132:19 213:15 225:18</p> <p><b>bit</b> 10:13 31:9 43:20 45:19 66:2,7 67:13 72:19 83:14,15 88:21,22 89:3 91:12 92:9 93:2,9 95:4,18 96:3 97:9 98:4 101:5 107:14 125:9 133:10 146:11,14 149:10 152:21 171:4,5 172:3 173:10 179:12 180:1,22 195:17 232:7</p> <p><b>Blakely</b> 37:14</p> <p><b>Bldg</b> 1:16</p> <p><b>bleeding</b> 156:3</p> <p><b>blended</b> 93:17</p> <p><b>blessing</b> 78:15</p> <p><b>blind</b> 136:12</p> <p><b>blood</b> 48:10 54:18 80:4 106:11 129:21 130:13 131:11 153:7 158:5 170:14 171:1,2 186:6,8,9</p> <p><b>blowing</b> 64:12</p> <p><b>BMI</b> 134:4</p> <p><b>Board</b> 68:14</p> <p><b>boasted</b> 60:22</p> <p><b>bodies</b> 80:6 203:9</p> <p><b>bodily</b> 62:4 68:21</p>	<p>69:7,12</p> <p><b>body</b> 49:18 58:13,15 61:1 69:2,4,10 77:7 79:5,16 80:2 85:10 110:2 122:3 130:22 131:17 134:10 156:4 172:17 173:14 177:6 202:18</p> <p><b>Bone</b> 8:6 20:21</p> <p><b>book</b> 103:10 140:10,11 168:12 215:20</p> <p><b>booking</b> 133:2</p> <p><b>boomer</b> 159:16</p> <p><b>boomers</b> 63:20</p> <p><b>boredom</b> 122:4</p> <p><b>bother</b> 22:18</p> <p><b>bothered</b> 43:9</p> <p><b>bothers</b> 5:16</p> <p><b>bought</b> 203:2</p> <p><b>boyfriend</b> 155:18 196:13,21</p> <p><b>boyfriends</b> 81:14 196:14</p> <p><b>brain</b> 152:10 159:10 173:18 181:6</p> <p><b>brand</b> 60:19</p> <p><b>brave</b> 84:17 170:10</p> <p><b>breach</b> 61:11</p> <p><b>breadth</b> 222:21 223:2,4 231:20</p> <p><b>break</b> 3:12 31:17 91:2 123:12</p> <p><b>breast</b> 128:6,10 131:14</p> <p><b>bridge</b> 124:4</p>	<p><b>brief</b> 9:8 23:21 31:1 58:3 94:6</p> <p><b>briefed</b> 56:7</p> <p><b>briefly</b> 112:8 162:7 188:21</p> <p><b>bring</b> 32:11 33:13 121:12 127:7 141:2 231:3</p> <p><b>bringing</b> 98:2 216:1</p> <p><b>brings</b> 221:1</p> <p><b>British</b> 197:14 203:18</p> <p><b>broad</b> 16:5 38:21</p> <p><b>broader</b> 40:18 41:5 105:11,12 108:21 143:2</p> <p><b>broadly</b> 14:11 31:14</p> <p><b>brochure</b> 60:21</p> <p><b>brought</b> 114:9 206:3 226:15</p> <p><b>bruising</b> 156:2</p> <p><b>brushing</b> 179:13</p> <p><b>budget</b> 101:1</p> <p><b>build</b> 33:4,7 34:20 36:3 67:13 76:12 126:1,11</p> <p><b>building</b> 61:17 91:13,16 113:17</p> <p><b>builds</b> 95:9</p> <p><b>bullet</b> 181:11</p> <p><b>bum</b> 80:20</p> <p><b>bunch</b> 119:10</p> <p><b>burden</b> 80:17 81:5</p> <p><b>buried</b> 212:1</p> <p><b>busier</b> 47:20</p> <p><b>business</b> 53:12</p>
--	--	--	---

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2014

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 7

215:5 <b>busy</b> 154:7 175:4 <b>button</b> 37:3 <b>buy</b> 209:16 <hr/> <p style="text-align: center;">C</p> <hr/> <b>Cacchioni</b> 192:15 197:10,11 <b>Cadillac</b> 60:20 <b>caller</b> 182:21 <b>callers</b> 182:21 <b>calves</b> 179:11,13 <b>camera</b> 168:6 <b>campaign</b> 139:1,3 193:7 208:15 <b>campus</b> 1:14 21:7 <b>Canada</b> 99:4 <b>cancer</b> 128:6,10 131:14 179:17 <b>candidates</b> 17:15 <b>capacities</b> 63:6 <b>capacity</b> 6:9 62:20 <b>Capital</b> 1:22 <b>capture</b> 19:22 139:13 170:8 232:9 <b>captured</b> 144:20 <b>card</b> 32:12 <b>cardiologist</b> 173:7 <b>cardiovascular</b> 209:9 <b>care</b> 37:17 38:13 41:8 45:5 47:10 64:2,4 134:16 135:9 173:9,10 194:21 208:8	223:17 <b>career</b> 62:14 <b>careful</b> 60:13 <b>carefully</b> 13:8 42:12 64:19 <b>Caribbean</b> 211:14 <b>Carla</b> 73:16 74:3 95:4,5,17 96:16 <b>Carmon</b> 78:6 152:21 154:15,16,20,22 <b>Carol</b> 57:9,11 60:10 65:12,21 107:5,6 166:1 <b>case</b> 53:1 58:7 61:17,21 104:9 164:12 211:12 <b>categories</b> 94:4 146:4 <b>categorize</b> 85:16 <b>categorizing</b> 27:5 <b>category</b> 97:19 162:19 <b>cause</b> 26:2 63:12 92:5 96:11 187:1,5 202:2 <b>caused</b> 61:7 137:10 152:4 205:16 <b>causes</b> 153:2 181:3 185:2 <b>CDER</b> 1:3 4:11 20:22 37:12 <b>Celexa</b> 133:14,18 <b>center</b> 1:3 4:11 14:20 194:19 204:3 <b>centered</b> 198:8 <b>centers</b> 164:14	<b>central</b> 99:10 <b>CEO</b> 214:3 <b>certain</b> 109:18,21 172:20 196:14 211:10 <b>certainly</b> 66:8 69:18 105:10 222:16 <b>CERTIFICATE</b> 234:1 235:1 <b>certify</b> 234:3 235:2 <b>cervices</b> 217:4 <b>cetera</b> 26:18 63:7 108:14 139:21 145:22 <b>Chair</b> 212:11,15 <b>challenge</b> 63:15 114:13 193:8 <b>challenged</b> 142:16 <b>challenges</b> 12:11,13 63:5 64:8 94:22 114:11 <b>challenging</b> 30:13 122:13 140:19 <b>champion</b> 208:12 <b>chance</b> 6:6 34:11 35:10 169:1 191:7 218:12 <b>Chang</b> 2:6 3:7 9:7 20:16,20 86:15 150:14,19,21 151:3 160:17 <b>change</b> 31:16 60:6,7 92:4 103:9,13,20 112:15 113:12 115:6 127:12 136:5,6,14 137:12 142:7 149:3 161:20 167:17 170:15 171:5,6	179:18 181:21 220:8 <b>changed</b> 52:2 71:2 103:19,22 104:2 115:19 125:7 136:19 141:8,19 142:21 148:7 149:21 152:4 165:7 168:17 171:10 179:19 220:12 225:17 <b>changes</b> 23:5 28:16 29:17 59:9 68:21 69:7 89:11 130:9 145:20,21 147:1 148:5 149:12 152:17 154:18 163:16 169:6,12 170:4,9 172:7 206:9 <b>changing</b> 69:4 105:17 114:6,10 147:5 171:12 176:3 <b>characterized</b> 24:6,10,12 <b>cheated</b> 128:14 <b>checked</b> 158:5 <b>Cheryl</b> 163:1 235:2,13 <b>chicken</b> 184:7,8 <b>child</b> 47:17 60:15 104:1 225:18 <b>children</b> 73:22 79:15 128:4 153:2 157:13,14 207:11 208:9 220:9 <b>chime</b> 34:18 <b>chocolate</b> 196:14 211:9
--	--	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

Page 8

<p><b>choice</b> 72:22 97:15 188:15,18 216:22 217:1,4,7 218:9 219:22</p> <p><b>choices</b> 57:4 98:5 165:14 189:15 219:20</p> <p><b>choose</b> 72:2 82:7 157:1 217:2 218:2,4,5,7,8,13</p> <p><b>choreographed</b> 76:21</p> <p><b>Christina</b> 2:6 3:7 9:7 20:20 40:13</p> <p><b>Christy</b> 86:14 150:12</p> <p><b>Cialis</b> 160:18 185:17 230:4</p> <p><b>circle</b> 98:20</p> <p><b>circles</b> 128:5</p> <p><b>circumstance</b> 225:6</p> <p><b>circumstances</b> 224:5</p> <p><b>cited</b> 22:5 224:14</p> <p><b>claiming</b> 62:11</p> <p><b>claims</b> 11:15 209:17</p> <p><b>clarification</b> 93:20 147:10</p> <p><b>clarify</b> 86:18 160:15</p> <p><b>clarifying</b> 33:2 65:6 90:14 144:5</p> <p><b>clarity</b> 58:9</p> <p><b>classes</b> 101:18 138:6</p> <p><b>classification</b> 27:8</p> <p><b>classified</b> 24:4 27:4</p> <p><b>clear</b> 66:14 108:8 122:11 177:22 208:18 220:7</p>	<p><b>clearly</b> 108:7 161:17</p> <p><b>click</b> 37:3</p> <p><b>clicker</b> 35:17 42:15,16 91:3</p> <p><b>clickers</b> 35:13,14 42:20 145:12</p> <p><b>clients</b> 166:18,20,21</p> <p><b>Climara</b> 170:16</p> <p><b>climax</b> 60:2 91:17</p> <p><b>climaxing</b> 58:21</p> <p><b>clinical</b> 10:1 13:5 20:21 21:4 25:2 29:16,21 30:10 68:12 145:16 199:13 215:16,21 227:8 230:12 232:2,5,19,22</p> <p><b>clinically</b> 26:4</p> <p><b>clitoral</b> 130:20</p> <p><b>clitoris</b> 69:6 130:1 166:3</p> <p><b>close</b> 74:8 121:6 127:8 142:2</p> <p><b>closely</b> 10:7 146:10 208:13</p> <p><b>closeness</b> 129:7</p> <p><b>closer</b> 87:18 137:21 167:13</p> <p><b>closing</b> 3:16 6:13 56:4 190:11 221:3</p> <p><b>clues</b> 148:20</p> <p><b>co</b> 89:7</p> <p><b>co-administered</b> 209:10</p> <p><b>coalition</b> 212:13,16</p> <p><b>coasting</b> 183:9</p> <p><b>coat</b> 217:3</p>	<p><b>Coco</b> 204:21</p> <p><b>co-created</b> 141:6</p> <p><b>coffee</b> 196:14</p> <p><b>cofounder</b> 63:18</p> <p><b>coital</b> 95:8</p> <p><b>colleagues</b> 30:20 65:6 86:11 92:14 124:6 192:5 221:15 222:9</p> <p><b>collect</b> 15:3,18</p> <p><b>collected</b> 192:2</p> <p><b>collection</b> 24:3</p> <p><b>collectively</b> 232:4</p> <p><b>Columbia</b> 197:14 203:18</p> <p><b>combination</b> 170:3</p> <p><b>combined</b> 24:18</p> <p><b>comes</b> 11:17 28:22 66:18 112:21 121:10 129:8 188:1 208:16 218:21 231:12,15</p> <p><b>comfortable</b> 41:20 71:3 90:5 161:20 216:6</p> <p><b>comical</b> 175:9</p> <p><b>coming</b> 32:21 42:22 63:21 94:2,10 113:3 122:11 158:21 188:18 191:3 219:11</p> <p><b>commencing</b> 215:8</p> <p><b>comment</b> 3:15 6:5,7,10 17:8,17 36:12,14 37:1,3 38:15 42:5 70:1 73:1 74:4 83:8 85:1,18 88:22 89:3</p>	<p>96:6,20 99:1 116:12 120:21 122:2,8,16 160:9 163:9 167:11 173:20 179:10 185:20 186:15 188:21 190:21 191:11 199:2 202:6 203:21</p> <p><b>commented</b> 114:11 122:4,8 158:4 169:7 200:3</p> <p><b>commenting</b> 120:13 166:14</p> <p><b>comments</b> 3:10,13 17:8 32:17,18 33:1 35:4 36:21 38:10 48:5 67:1 94:7 96:18 105:20 114:4 121:21 124:11,20 126:10 144:15 149:8 150:5 161:11 168:22 184:2 188:4 190:6 191:4,13 197:19 199:3 221:10,13 222:19</p> <p><b>commercials</b> 186:5 203:1</p> <p><b>commission</b> 234:21</p> <p><b>commitments</b> 16:10</p> <p><b>committed</b> 9:13 16:11 193:13</p> <p><b>committing</b> 40:21</p> <p><b>common</b> 9:5 14:7 22:4 126:2 138:12 139:20 152:15 209:4</p> <p><b>commonly</b> 209:11</p>
---	--	---	---

(866) 448 - DEPO

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

Page 9

<p><b>communicate</b> 20:7</p> <p><b>communicated</b> 76:20</p> <p><b>communicating</b> 17:6</p> <p><b>communication</b> 217:18</p> <p><b>communications</b> 101:22</p> <p><b>communities</b> 10:4</p> <p><b>community</b> 16:6 29:6 53:15 64:4 201:13 216:6</p> <p><b>companies</b> 10:3,7 11:6 191:21 193:16 205:7,8 216:18 231:22</p> <p><b>company</b> 1:22 55:18 127:15,16 152:5 189:2 219:18 220:3</p> <p><b>complain</b> 24:15</p> <p><b>complained</b> 22:2</p> <p><b>complaints</b> 22:6,7,17</p> <p><b>complete</b> 151:20 183:5 225:2 235:7</p> <p><b>completely</b> 7:19 60:3 70:4 71:6 110:3 129:13 144:19 181:6</p> <p><b>complex</b> 9:1 23:2 143:10 213:11,13 218:17</p> <p><b>complexity</b> 21:13 124:5,8</p> <p><b>complicated</b> 12:7,16 29:2,4 167:2 200:15,19 201:13</p>	<p>216:13 218:18</p> <p><b>component</b> 121:7 227:5</p> <p><b>components</b> 23:5 203:6</p> <p><b>compounded</b> 150:21 157:4 170:18</p> <p><b>compounding</b> 220:1</p> <p><b>computer</b> 74:9</p> <p><b>concept</b> 92:21</p> <p><b>concepts</b> 176:4</p> <p><b>conceptualization</b> 165:7</p> <p><b>conceptualizations</b> 70:5</p> <p><b>conceptualize</b> 67:21 70:2 73:9 176:12,19 177:1</p> <p><b>conceptualizes</b> 91:11 92:10</p> <p><b>conceptualizing</b> 84:18</p> <p><b>concern</b> 59:17 223:12,16,20 224:19</p> <p><b>concerned</b> 157:17 159:6,13 195:3 205:3 207:14 223:8</p> <p><b>concerns</b> 198:5 201:19 205:22 222:14,15 230:10</p> <p><b>concierge</b> 52:7</p> <p><b>conclude</b> 138:3 198:14</p> <p><b>concluded</b> 233:12</p> <p><b>condition</b> 5:15 8:12 9:11 13:17 15:5</p>	<p>18:13 21:19 27:5,6,9 31:12,20 32:2 51:18 53:2 54:21 56:19 58:9 59:1 60:1 100:16 102:16 104:12,16 106:1 117:12 122:13 125:6,11 137:17 139:7 145:9 169:12 175:15 179:3 213:2 223:19 224:1 228:7,9 229:13</p> <p><b>conditions</b> 11:22 12:10,18 24:4,5 27:11,16 29:3,8 30:4,15 89:9 99:8 125:4 198:2 222:14 223:10 224:3</p> <p><b>conduct</b> 10:1,5</p> <p><b>conducted</b> 136:12</p> <p><b>confidence</b> 97:12 129:10 211:2</p> <p><b>confident</b> 64:14</p> <p><b>confirmed</b> 54:20</p> <p><b>conflict</b> 16:1</p> <p><b>conflicts</b> 199:2 201:10</p> <p><b>confounding</b> 103:2</p> <p><b>confuse</b> 140:3 161:15</p> <p><b>confused</b> 93:1 133:11</p> <p><b>congratulate</b> 210:3</p> <p><b>connected</b> 121:5 141:20 142:3</p> <p><b>cons</b> 134:18</p>	<p><b>consciousness</b> 143:22</p> <p><b>consented</b> 137:13</p> <p><b>consequence</b> 63:13</p> <p><b>consequently</b> 25:2</p> <p><b>consider</b> 12:19 71:22 82:5 115:18 125:13 223:12</p> <p><b>consideration</b> 232:19 233:5</p> <p><b>considerations</b> 46:19</p> <p><b>considered</b> 26:13,21 210:14</p> <p><b>considering</b> 199:11 232:1,2</p> <p><b>consistency</b> 170:19 183:10</p> <p><b>Consortium</b> 63:19</p> <p><b>constant</b> 101:6 102:13 103:4,6 185:1</p> <p><b>constantly</b> 171:11</p> <p><b>Constituent</b> 37:5 39:21</p> <p><b>constitutes</b> 22:20 226:17</p> <p><b>Constitution</b> 212:2</p> <p><b>consulted</b> 57:19</p> <p><b>consumer</b> 208:6 214:4</p> <p><b>Consumers</b> 208:5</p> <p><b>contact</b> 39:20 138:22 142:2 205:13 206:22</p> <p><b>containing</b> 28:13</p> <p><b>contemplate</b> 224:20</p>
---	--	---	--

(866) 448 - DEPO

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>context</b> 5:7 71:16 89:14</p> <p><b>continue</b> 215:3</p> <p><b>continues</b> 144:2 214:8</p> <p><b>continuous</b> 231:16</p> <p><b>continuously</b> 128:18 205:12</p> <p><b>continuum</b> 231:16</p> <p><b>contraception</b> 60:21</p> <p><b>contrary</b> 129:3</p> <p><b>contribute</b> 35:9 36:12 38:4 113:11 120:20</p> <p><b>contributing</b> 121:17 220:10</p> <p><b>contributions</b> 205:7</p> <p><b>contributors</b> 26:7</p> <p><b>control</b> 60:14,18 134:11 179:21 213:15</p> <p><b>convening</b> 28:18</p> <p><b>convergence</b> 227:3</p> <p><b>conversation</b> 34:13 69:21 70:10 110:8 151:9 177:14 194:9</p> <p><b>conversations</b> 42:7</p> <p><b>converse</b> 184:11</p> <p><b>conversely</b> 109:5</p> <p><b>convey</b> 20:3</p> <p><b>cope</b> 18:12</p> <p><b>coping</b> 59:13 228:6</p> <p><b>correct</b> 60:1 178:7 235:7</p> <p><b>correctly</b> 29:2</p>	<p><b>correlation</b> 55:16</p> <p><b>cost</b> 132:2 135:9 166:4</p> <p><b>costs</b> 73:21 131:15</p> <p><b>cougar</b> 64:18</p> <p><b>Council</b> 99:3 212:12</p> <p><b>counsel</b> 203:17 234:10,13</p> <p><b>count</b> 80:6 131:12</p> <p><b>counter</b> 145:15</p> <p><b>countries</b> 138:14</p> <p><b>country</b> 23:20 213:6</p> <p><b>couple</b> 47:17 54:3 70:20 71:14 77:1 91:21 92:10,11 105:2 117:15 136:18 146:1 158:1,3 221:11</p> <p><b>couples</b> 28:3 163:17 168:2</p> <p><b>coupling</b> 64:17</p> <p><b>courage</b> 60:6 135:21 190:12</p> <p><b>courageous</b> 213:8</p> <p><b>course</b> 15:21 16:18 88:18 91:16 101:22 120:7 125:18 206:15 223:14</p> <p><b>Court</b> 235:3,5</p> <p><b>cover</b> 13:4 48:20 100:1 147:4</p> <p><b>covered</b> 54:4 56:3 97:8 131:16</p> <p><b>covering</b> 17:20 31:8 132:11 190:1</p> <p><b>covers</b> 18:7 24:3</p>	<p><b>crazy</b> 129:2 181:12</p> <p><b>cream</b> 136:3,4,7 150:15 152:3 172:11</p> <p><b>create</b> 75:5</p> <p><b>created</b> 220:3</p> <p><b>creates</b> 143:5</p> <p><b>creating</b> 141:4</p> <p><b>credible</b> 215:3</p> <p><b>crises</b> 211:4</p> <p><b>criteria</b> 13:5 99:16</p> <p><b>critical</b> 9:21 15:8,14 86:8 109:9</p> <p><b>critics</b> 22:15</p> <p><b>cross</b> 193:10</p> <p><b>crucial</b> 93:15,16 131:20</p> <p><b>cry</b> 80:16 116:22 159:11,12</p> <p><b>crying</b> 59:4 159:10</p> <p><b>cues</b> 82:10 83:1,8 86:19,20 91:20</p> <p><b>cultural</b> 64:10 120:13</p> <p><b>culturally</b> 143:4</p> <p><b>culture</b> 64:14 81:19</p> <p><b>cumulative</b> 61:7</p> <p><b>cure</b> 18:20 19:1</p> <p><b>curiosity</b> 140:12</p> <p><b>current</b> 5:18 124:14 228:14</p> <p><b>currently</b> 13:16 31:19 57:15 65:13,19 101:3 108:17 125:4 131:5 139:6 145:6,7,8 165:18</p>	<p>169:22 194:19 206:11</p> <p><b>cut</b> 210:5</p> <p><b>cycle</b> 209:8 228:5</p> <p><b>cycles</b> 169:15</p> <hr/> <p style="text-align: center;">D</p> <hr/> <p><b>D.C</b> 43:1 213:5</p> <p><b>daily</b> 5:14 13:14 31:14 72:1 82:6 97:8 103:5,19 105:21 108:14,19 109:1,10 130:12 142:22 172:7,10 174:16 175:3,9,18 196:11 219:14</p> <p><b>Dalkon</b> 60:19 61:6,10,19</p> <p><b>damage</b> 61:7</p> <p><b>damages</b> 61:15</p> <p><b>damaging</b> 202:20</p> <p><b>danger</b> 112:20</p> <p><b>dangerously</b> 203:7</p> <p><b>dark</b> 221:16</p> <p><b>data</b> 21:4 220:12</p> <p><b>daughter</b> 53:16 128:2</p> <p><b>daughters</b> 56:22</p> <p><b>David</b> 140:10 141:5</p> <p><b>day</b> 4:21 39:8 53:13 64:14 65:22 81:7 101:8 103:22 105:22 106:8 107:3,8 111:4,8 119:8 148:17,21 149:1 152:17 170:7,18 172:8 175:4,13,21,22 177:10 178:22</p>
---	---	--	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>179:5,16 180:7 184:15 185:2,7 195:22 219:14 221:16 222:20</p> <p><b>days</b> 9:4,15 134:5 184:13 187:19 190:1</p> <p><b>day-to-day</b> 225:6 229:20</p> <p><b>DBRUP</b> 8:8</p> <p><b>dead</b> 135:13</p> <p><b>deal</b> 64:5 79:21 110:10 116:14 119:5 131:18 138:4 189:17</p> <p><b>dealing</b> 63:11 71:15 127:18 133:13 220:5</p> <p><b>dealt</b> 101:16</p> <p><b>dear</b> 63:11</p> <p><b>death</b> 63:11</p> <p><b>deaths</b> 63:7</p> <p><b>debacle</b> 61:10</p> <p><b>debate</b> 23:9</p> <p><b>Deborah</b> 192:17 208:2 210:9,12</p> <p><b>December</b> 17:17</p> <p><b>decide</b> 75:21 183:7</p> <p><b>decided</b> 140:7</p> <p><b>decision</b> 15:15 20:13 60:13 183:15 205:10</p> <p><b>decisions</b> 10:17 12:5 62:17</p> <p><b>declined</b> 55:18</p> <p><b>decrease</b> 47:18 96:2</p> <p><b>decreasing</b> 135:12</p>	<p><b>dedicated</b> 207:18</p> <p><b>deep</b> 141:16,20 142:3</p> <p><b>deeply</b> 141:12 194:2 212:1</p> <p><b>defective</b> 61:18</p> <p><b>defiance</b> 196:22</p> <p><b>define</b> 22:19</p> <p><b>defined</b> 11:1 24:1 26:5 30:8</p> <p><b>defining</b> 49:10</p> <p><b>definitely</b> 21:22 49:21 73:20 81:2 96:15 105:8 159:21 164:20 167:4 172:15 177:20</p> <p><b>definition</b> 23:7 143:2,4</p> <p><b>degree</b> 137:19 194:17</p> <p><b>delighted</b> 57:4</p> <p><b>delightful</b> 56:10</p> <p><b>deliverable</b> 19:17</p> <p><b>delivery</b> 58:1</p> <p><b>delve</b> 43:19</p> <p><b>demand</b> 64:2</p> <p><b>demands</b> 217:20</p> <p><b>demonstrate</b> 10:19 149:12</p> <p><b>demonstrated</b> 11:12</p> <p><b>demonstrating</b> 41:22</p> <p><b>dense</b> 92:7 93:6</p> <p><b>dependent</b> 108:8 171:7</p> <p><b>depending</b> 44:9</p>	<p>130:10 227:1</p> <p><b>depends</b> 23:1 76:6 115:14 169:14</p> <p><b>deposition</b> 234:3,5,8,12</p> <p><b>depressant</b> 133:8</p> <p><b>depressants</b> 52:15</p> <p><b>depressed</b> 98:17 134:6 168:8</p> <p><b>depressing</b> 108:22 119:9</p> <p><b>depression</b> 26:11 53:4 113:6 134:3</p> <p><b>depth</b> 33:9 39:13 83:15 102:5</p> <p><b>Deputy</b> 8:6</p> <p><b>derive</b> 22:11</p> <p><b>describe</b> 8:21 27:3 73:13 84:5</p> <p><b>described</b> 40:5 98:7 158:3 196:8 202:5 224:10 228:5</p> <p><b>describing</b> 224:4</p> <p><b>deserve</b> 51:4 213:6 218:22 220:19</p> <p><b>deserving</b> 127:22</p> <p><b>design</b> 13:6</p> <p><b>designed</b> 14:4 16:8 186:17 201:21</p> <p><b>designing</b> 12:13</p> <p><b>desirable</b> 121:11</p> <p><b>desire</b> 22:7 23:6 24:6,17 25:10 26:9 28:21 29:10 43:10 44:18 45:4 47:18 48:2 49:20 50:9 51:5 62:6 68:17,19 69:3,10 80:21</p>	<p>87:20 88:2,6,10 96:5 98:12,19 100:9,13 102:18 103:12 104:7 117:21 118:6,7,9 121:7,10,15 126:7,8 129:6,13,17 130:18,20 132:15 135:12,15,19 136:5,10,14 137:12 139:9,15 140:13,14 141:11,16,17 143:2,15 148:18 157:14 163:12 166:22 167:5 175:13 179:4 181:4 183:11 184:10 186:7,13 187:4,5 188:11,18 199:8,17 200:6,9,10 206:9,14 207:13 210:19 211:15 217:21 218:6 223:13 224:20 230:15 231:2,5,16</p> <p><b>desired</b> 117:1</p> <p><b>desires</b> 131:2</p> <p><b>desirous</b> 141:13</p> <p><b>despair</b> 211:2</p> <p><b>despite</b> 24:13 209:8,12</p> <p><b>dessert</b> 149:2</p> <p><b>detail</b> 8:21 31:10 36:9 72:19 173:1</p> <p><b>detailed</b> 33:5</p> <p><b>details</b> 5:4</p> <p><b>determination</b> 11:4 59:21 115:5,8</p>
---	--	---	--

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 12

<p><b>determine</b> 10:15 115:10</p> <p><b>determined</b> 55:20 115:9</p> <p><b>determining</b> 11:2</p> <p><b>deterrent</b> 113:18,19</p> <p><b>devastated</b> 62:2 137:4 149:6</p> <p><b>devastating</b> 49:21 213:2</p> <p><b>develop</b> 10:1 13:21 14:1 189:5 232:19</p> <p><b>developed</b> 30:9 232:3</p> <p><b>developing</b> 9:17 29:2,11 30:14 193:13 228:18 231:8</p> <p><b>development</b> 1:7 3:5 4:16 5:8 6:4,15 8:5,20 9:14,15,22 10:8 12:6,19,21 13:4 14:8,17 16:18 20:12,18 30:10 34:6 39:13 40:22 126:3,20 191:18</p> <p><b>device</b> 165:12,19 166:1,2,6 202:22 203:4 205:7</p> <p><b>devices</b> 61:20,22</p> <p><b>devoted</b> 57:17</p> <p><b>DHEA</b> 131:5</p> <p><b>diabetes</b> 89:8</p> <p><b>diagnose</b> 12:8</p> <p><b>diagnosed</b> 23:11 48:22 103:17 128:7,10 136:11 153:20 158:7 179:17</p>	<p><b>diagnosis</b> 23:16 24:19 25:1,4,6,14 26:8,13 27:1 29:1 30:5 45:2 86:9 129:20 143:11 181:8</p> <p><b>diagnostic</b> 13:5 24:19 25:8</p> <p><b>diagram</b> 226:12</p> <p><b>dialogue</b> 31:7 38:4,15,17</p> <p><b>diary</b> 105:21,22 106:3 107:7 110:22 175:9 177:21 187:9 200:10</p> <p><b>Diego</b> 48:15,22</p> <p><b>diet</b> 134:2</p> <p><b>dietary</b> 145:20</p> <p><b>differ</b> 75:10 142:4</p> <p><b>difference</b> 60:8 67:20 78:19 81:1 88:5 91:2 121:9,14 143:13 148:17 156:16 157:19 159:1 176:13,19 211:11</p> <p><b>differences</b> 70:10 89:11 126:5 142:7 226:5</p> <p><b>different</b> 12:4 16:12 24:5 31:2 44:9 48:7 54:18 67:9 70:4 71:1,6 75:13,17 83:19 84:5,11 86:6 91:22 109:14 110:3 119:10 132:16 140:16 146:8 150:9,11 156:13 161:15 163:22</p>	<p>166:7 167:3,21 172:9 173:21 178:14 181:7,8,12 208:21 225:22 226:1,7,8,13,20,22 227:1 229:12,14 230:1</p> <p><b>differential</b> 172:10</p> <p><b>differentiate</b> 83:15 151:8</p> <p><b>differentiating</b> 68:16</p> <p><b>differentiation</b> 86:7</p> <p><b>differently</b> 67:22 91:12 92:9,10 110:12 148:8 177:1,6 229:13</p> <p><b>differing</b> 44:7</p> <p><b>differs</b> 144:18</p> <p><b>difficult</b> 50:9 72:14 77:22 84:9 85:3 110:8 118:10,16,18 119:1 122:14 124:19 129:1 223:4</p> <p><b>difficulties</b> 11:18 22:3 67:18,19 197:22</p> <p><b>difficulty</b> 22:8 24:13 59:13 86:21 169:13 225:10,13 226:11</p> <p><b>dinner</b> 149:2 203:1</p> <p><b>direct</b> 14:19 30:1 42:5 55:15</p> <p><b>directed</b> 114:22</p> <p><b>direction</b> 91:5 234:8</p> <p><b>directly</b> 40:3</p>	<p><b>director</b> 8:6 205:1 208:4</p> <p><b>disappeared</b> 59:10 128:15</p> <p><b>disappointed</b> 53:22 56:15 223:1</p> <p><b>disappointment</b> 198:7 228:6</p> <p><b>disclose</b> 34:2,7 68:6 83:22 91:9 126:17 191:16</p> <p><b>disclosure</b> 104:20</p> <p><b>disclosures</b> 68:3</p> <p><b>disconnection</b> 141:4</p> <p><b>discontinued</b> 136:7 137:4</p> <p><b>discouraging</b> 119:8</p> <p><b>discourse</b> 203:19</p> <p><b>discrepancy</b> 59:14</p> <p><b>discretion</b> 7:19</p> <p><b>discuss</b> 9:15 30:13 39:12 58:10 150:7 169:2</p> <p><b>discussants</b> 33:5 34:1 124:2</p> <p><b>discussed</b> 222:22 224:1</p> <p><b>discussing</b> 22:22</p> <p><b>discussion</b> 3:8,11,14 5:11,21 6:14 13:2 14:5 15:22 29:13 30:22 32:8,18 33:3 35:19 36:3 37:20 40:5,15 41:1,3,14 46:5,8,11,15,22 70:16 71:19 72:3 80:12 99:22 102:6 113:10 120:8 123:19,20,21</p>
--	---	---	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 13

124:5 125:18,22 127:4 144:6,12 179:11 187:14 189:22 190:10 191:8 197:21 221:20 222:2 223:11 224:12 226:16 229:6 231:1 232:16 <b>discussions</b> 22:19 223:19 <b>disease</b> 3:7 5:14 15:11 16:7,12 18:9 61:8 99:13 173:4 209:1 <b>diseases</b> 17:7,14,19 89:7 <b>dishes</b> 74:8 76:3 <b>disinterest</b> 114:8 <b>dismayed</b> 56:9 <b>disorder</b> 9:2,6 20:19 21:16 24:6,10,12,14,17,1 8 26:11 27:19 28:11 45:3,4,5 128:3 138:15 153:21 165:21 223:10 227:13,14 228:10,20 229:1 <b>disorders</b> 24:20 <b>disparity</b> 212:18 <b>display</b> 61:17 <b>disputed</b> 23:10 <b>dissatisfaction</b> 59:2 <b>disservice</b> 104:14 201:16 202:16 <b>distance</b> 141:4 <b>distinction</b> 88:11 <b>distinctions</b> 92:16	<b>distinctly</b> 71:1 <b>distress</b> 23:13,17 26:2,5 46:21 92:5 124:11 143:5 184:11 185:2,4,5 187:5,21 <b>distressed</b> 186:7 187:17,22 <b>distressful</b> 214:18 <b>distressing</b> 104:17 108:22 193:11 <b>distribution</b> 86:2 89:15 <b>disturbances</b> 21:22 <b>disturbing</b> 152:16 <b>diverse</b> 16:5 70:8 <b>divide</b> 221:10 <b>division</b> 8:6 11:19 18:15 20:21 21:1 <b>Docket</b> 19:10 36:6,19 38:11,15 92:15 96:18 120:17,21 122:15,16 160:6 162:1 190:5 <b>doctor</b> 52:7 54:1 60:19 61:12 107:17 112:16 130:4 133:3,4 139:21 168:13 169:18 <b>doctoral</b> 207:11 <b>doctors</b> 52:3 54:12 56:18 62:10 138:4,6 151:22 159:3 167:22 189:8 <b>doctor's</b> 201:18 <b>document</b> 20:8	<b>documenting</b> 25:18 <b>dodonic</b> 202:8 <b>domino</b> 96:15 <b>done</b> 17:22 41:4 48:10 106:11 110:3,11 112:15 130:14 135:18 140:18 153:7 157:3 202:15 228:22 <b>doors</b> 220:17 <b>dosage</b> 58:1 60:1 107:12 131:10 172:9 <b>dose</b> 107:21 <b>double</b> 128:11 136:12 <b>doubt</b> 134:16 221:22 <b>downsides</b> 31:21 125:8 131:15 142:15 157:1 <b>Dr</b> 4:3 5:2 8:2 14:18 20:16 23:13 30:18,19 40:20 45:1 46:3 47:6 48:16 51:7 54:16 57:8 60:10 64:22 65:9,10,11 66:1,20 68:7 70:12 74:3,10,15 75:7 76:5,9,22 77:12,21 78:21 80:7 81:9,22 83:5,13 84:8 85:17,20 86:11,15,22 87:12,17 88:14,16,18,19 89:4,18 90:3 91:6 92:11 93:3,19 94:12,15 95:17 96:16 98:3,21	99:21 100:17,20 101:9 102:4,22 104:4,18 105:15 106:11,15 107:5,18 109:12 110:17 111:11,16,20 112:2,7,11 113:7,14,21 114:1,19 116:10 117:9 118:12 119:11,17 120:10,16 121:18 122:10 123:10,13 129:19 130:12 132:6 135:3 136:12 137:2,8 138:18 146:20 147:3,12,16 149:8 150:1,14,18,19,20, 21 151:1,3,6 152:20 154:14,17,21 155:2,7 156:19 157:22 158:1,7,10,11 160:1,12,17,20 161:7,9,18 162:20 163:4,13 165:9,11,17,20 166:8 167:9,12 168:21 169:10 171:14,19,22 172:18 173:19 174:21 176:1 178:2,8,12,17 179:7 181:15 182:19 184:1 185:10,19 187:11 188:2,20 189:21 190:16 193:5 197:10 199:10 200:2 203:15 221:2,4
--	--	--	---



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>drag</b> 139:18</p> <p><b>dragged</b> 209:20</p> <p><b>drama</b> 156:3</p> <p><b>dramatic</b> 81:1 148:16</p> <p><b>dramatically</b> 136:19</p> <p><b>drawer</b> 52:18</p> <p><b>driven</b> 143:4</p> <p><b>drives</b> 141:17</p> <p><b>drug</b> 1:2,3,7 3:4 4:11,16 5:8 6:4,15 8:5,19 9:14,15,21 10:3,7,8,14,19 11:2,4,5,6 12:6,14 13:4,10 14:8,12,17 15:13 16:9,17 20:12,18 28:2,20 29:11,16,19 30:10,14 34:5 39:12 40:17,22 54:3 58:5 126:2,20 127:16 134:17 136:13 137:3 140:3 147:20,22 149:11 182:7 187:18 191:17 193:13,16 194:10 195:9,11,15 196:2 197:16 199:13,18 200:3 205:7 230:14</p> <p><b>drugs</b> 8:8 9:20 10:1,6 14:20 15:22 21:1 27:13 29:3 54:5,13 61:22 113:5 147:19 193:16 195:5,10 197:18 198:1,3 199:4 204:13 208:20 209:11 212:20 227:9</p>	<p><b>dryness</b> 113:15 128:17 129:14 130:17</p> <p><b>DSM</b> 99:16 139:21</p> <p><b>DSM5</b> 25:5 181:10</p> <p><b>due</b> 12:7 28:16 55:13 104:6 107:20 112:18 209:1</p> <p><b>duly</b> 228:7 234:5</p> <p><b>duration</b> 25:16</p> <p><b>during</b> 16:17 22:10 24:15 28:15 43:13 61:6 74:20 82:8,11,16,21 84:16 89:6,12 120:4 129:16 148:17 153:14 202:12 208:7 222:19 224:15,17</p> <p><b>duty</b> 78:16 79:11</p> <p><b>dynamic</b> 111:8</p> <p><b>dynamics</b> 23:4 26:18</p> <p><b>dysfunction</b> 1:6 4:14 5:9,19 8:4,11 9:1 11:17 12:7,9,11,18 14:9 18:4 21:2,14,18,20 22:20,22 23:8,11,22 26:7 27:19 29:9 38:1 50:12 131:19 133:7 138:12 149:17 152:10 181:18 182:5 195:4 208:17,22 209:4,6 212:19 213:14 218:22 219:16</p> <p><b>dysfunctional</b> 57:15</p>	<p>59:16</p> <hr/> <p>E</p> <hr/> <p><b>ear</b> 92:2</p> <p><b>earlier</b> 98:10 148:19 152:22 167:2 168:13 169:11 187:7</p> <p><b>early</b> 59:6 73:22 149:4</p> <p><b>easily</b> 45:10 93:14 202:22</p> <p><b>easy</b> 42:19 73:2 81:20 115:22 226:19</p> <p><b>eat</b> 134:3</p> <p><b>ebb</b> 63:4,8</p> <p><b>echo</b> 184:5</p> <p><b>ecstasy</b> 64:13</p> <p><b>Ed</b> 132:13</p> <p><b>Edition</b> 24:19</p> <p><b>educate</b> 62:15 201:22 203:5</p> <p><b>educated</b> 56:18 218:9</p> <p><b>educates</b> 194:21</p> <p><b>education</b> 202:2</p> <p><b>educational</b> 189:2</p> <p><b>educator</b> 62:15 68:11 87:1 101:15 215:16 216:2</p> <p><b>effect</b> 62:9 96:15 134:17 157:5,6 172:15 177:5 200:4 227:13,18</p> <p><b>effective</b> 10:16 27:20 29:11 132:2 204:14 206:21</p>	<p>207:16 209:14,19</p> <p><b>effectiveness</b> 206:12 230:7</p> <p><b>effects</b> 61:1 133:19 137:1 152:9 155:20 156:22 159:5 172:18 182:17 187:1,2 198:1 205:19 207:2 209:10 230:14,16</p> <p><b>efficacy</b> 9:20 10:20 12:14 207:19</p> <p><b>efforts</b> 14:17 20:9 209:12</p> <p><b>EGGER</b> 119:11 149:8</p> <p><b>Eggers</b> 3:9 4:3,10 14:3 30:18,19 45:1 46:3 47:6 51:7 57:8 60:10 64:22 65:10 66:1,20 68:7 69:20 70:12 74:3,10,15 75:7 76:5,9,22 77:12,21 78:21 80:7 81:9,22 83:5,13 84:8 85:17 86:11,22 87:12,17 88:14,18 89:18 90:3 92:11 93:3,19 94:12,15 95:17 96:16 98:3,21 99:21 100:17 101:9 102:4,22 104:4,18 105:15 106:15 107:5,18 109:12 110:17 111:11,16,20 112:2,7,11 113:7,14,21 114:1,19 115:16 116:10 117:9 118:12 119:17</p>
--	--	---	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 15

<p>120:10,16 121:18                  122:10 123:10,13                  132:6 135:3                  138:18 144:4                  146:20                  147:3,12,16                  150:1,18,20                  151:1,6 152:20                  154:14,17,21                  155:2,7 156:19                  157:22 158:11                  160:1,12,20                  161:7,18 162:20                  163:4,13 165:9,17                  166:8 167:9,12                  168:21 169:10                  171:14,19,22                  172:18 173:19                  174:21 176:1                  178:2,8,17 179:7                  181:15 182:19                  184:1 185:10,19                  187:11 188:2,20                  189:21 190:16</p> <p><b>ego</b> 105:10</p> <p><b>egregious</b> 61:11</p> <p><b>eight</b> 106:14 130:15</p> <p><b>either</b> 26:9 28:21                  40:3 45:12 77:8                  84:5 86:17 87:6                  117:5 120:3 142:6                  175:22 208:20</p> <p><b>elaborate</b> 26:14</p> <p><b>electively</b> 128:7</p> <p><b>elevated</b> 81:3</p> <p><b>eleven</b> 139:10</p> <p><b>eloquently</b> 144:9                  224:8</p> <p><b>else</b> 48:14 68:5                  74:4,5,15 78:22                  85:18 87:12 95:2</p>	<p>96:22 119:6                  128:21 146:3                  148:1 152:20                  168:20 171:22                  181:6 217:8                  218:18</p> <p><b>elusive</b> 231:6</p> <p><b>embarrassed</b> 135:19</p> <p><b>embarrassing</b> 81:18                  214:12</p> <p><b>embrace</b> 143:22</p> <p><b>emerge</b> 70:11</p> <p><b>emerged</b> 22:13</p> <p><b>Emeritus</b> 212:12</p> <p><b>emotional</b> 23:3                  202:10 227:4</p> <p><b>emotionally</b> 75:12                  77:8</p> <p><b>emotions</b> 117:6</p> <p><b>emphasis</b> 202:19                  229:6</p> <p><b>emphatic</b> 106:12</p> <p><b>employed</b> 234:10,14</p> <p><b>employee</b> 234:13</p> <p><b>employees</b>                  159:11,13</p> <p><b>EmpowHER.com</b>                  152:5 219:10</p> <p><b>enable</b> 36:3 37:19</p> <p><b>enables</b> 31:6</p> <p><b>enamored</b> 230:6</p> <p><b>encased</b> 58:13</p> <p><b>encompassing</b> 119:7</p> <p><b>encounter</b> 153:14                  195:19</p> <p><b>encounters</b> 25:22</p>	<p><b>encourage</b> 6:20 14:4                  36:16 38:3,14                  72:11 92:13                  120:20 161:10                  166:2 167:6 201:9                  231:22</p> <p><b>encourages</b> 31:6                  194:22 195:16</p> <p><b>endocrinologists</b>                  52:10</p> <p><b>endured</b> 52:13</p> <p><b>energy</b> 57:18 128:21</p> <p><b>engage</b> 5:22 37:17                  225:7 231:5</p> <p><b>engaged</b> 139:6</p> <p><b>Engagement</b> 37:13</p> <p><b>engaging</b> 114:21</p> <p><b>engorged</b> 69:6</p> <p><b>enhance</b> 63:2 132:1                  154:11 162:15</p> <p><b>enhanced</b> 200:9</p> <p><b>enjoy</b> 49:13 122:9                  142:1 153:5                  157:12</p> <p><b>enjoyed</b> 128:13                  129:12</p> <p><b>enlarge</b> 101:16</p> <p><b>enlarged</b> 69:7</p> <p><b>enormously</b> 70:7</p> <p><b>enrolled</b> 136:11                  200:6</p> <p><b>ensued</b> 22:19</p> <p><b>enter</b> 64:3</p> <p><b>entire</b> 44:7 58:13                  105:14</p> <p><b>entirely</b> 140:16</p> <p><b>entitled</b> 127:22</p>	<p><b>entrepreneur</b> 53:13</p> <p><b>entries</b> 200:11</p> <p><b>environments</b> 27:10</p> <p><b>episodes</b> 196:15                  211:10</p> <p><b>equal</b> 72:15 195:21</p> <p><b>equality</b> 208:10</p> <p><b>equally</b> 213:12</p> <p><b>equation</b> 167:1,6</p> <p><b>equipped</b> 64:5</p> <p><b>era</b> 208:7</p> <p><b>erect</b> 69:6</p> <p><b>erectile</b> 182:5                  208:22 209:6</p> <p><b>EROS</b> 165:19 166:1</p> <p><b>erotic</b> 62:3 72:5,16                  188:16,19</p> <p><b>erotica</b> 87:4</p> <p><b>error</b> 59:22</p> <p><b>escaping</b> 165:12</p> <p><b>especially</b> 109:8                  209:10</p> <p><b>essential</b> 18:7 30:7</p> <p><b>Essentially</b> 79:11</p> <p><b>established</b> 210:13</p> <p><b>esteem</b> 53:9</p> <p><b>estimated</b> 23:14</p> <p><b>Estradiol</b> 131:6                  152:2</p> <p><b>estrogel</b> 106:7</p> <p><b>Estrogel</b> 131:7,12</p> <p><b>estrogen</b> 28:13                  152:2 173:5,8                  229:5</p> <p><b>Estrogens</b> 229:15</p>
---	---	---	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>et</b> 26:18 63:7 108:14 139:21 145:22</p> <p><b>ethical</b> 61:13</p> <p><b>etiologies</b> 223:9 229:12</p> <p><b>evaluate</b> 12:2</p> <p><b>evaluated</b> 30:9 136:11 206:18</p> <p><b>evaluating</b> 9:17,20 13:10</p> <p><b>evaluation</b> 1:3 4:11 6:15 10:14 14:8 39:22 40:17 190:17</p> <p><b>evaluations</b> 42:11</p> <p><b>evening</b> 107:3</p> <p><b>event</b> 94:2 115:3,9,19 116:1 117:11 121:4,15 187:6,8</p> <p><b>events</b> 206:10</p> <p><b>eventual</b> 62:13</p> <p><b>everybody</b> 80:15 119:2,6 216:5</p> <p><b>everyday</b> 43:5 172:12 182:16 215:17</p> <p><b>everyone</b> 4:6 20:17 33:15 34:7 38:9 41:18 42:1,15 46:9 70:18 84:4 92:14 123:6 167:22 190:14 191:2 200:16 221:5</p> <p><b>everything</b> 99:19 100:1 103:22 104:1 167:20 168:17,20 169:16 175:20 211:7</p>	<p>232:10</p> <p><b>evidence</b> 10:20 12:3 55:13 102:21 195:1 199:8 201:9</p> <p><b>evolved</b> 143:21</p> <p><b>exactly</b> 22:20 26:5 91:1 202:7 206:21</p> <p><b>example</b> 12:16 18:18 27:17 49:5 126:7 172:22 200:5</p> <p><b>examples</b> 209:16</p> <p><b>excellent</b> 59:22</p> <p><b>except</b> 126:1</p> <p><b>exchange</b> 75:20</p> <p><b>excited</b> 58:19 78:9</p> <p><b>excitement</b> 7:14 24:11 43:12 82:8,14,21 83:16,19 84:6,15 85:9 89:22 91:13 224:14</p> <p><b>exclusion</b> 27:1</p> <p><b>exclusively</b> 127:21</p> <p><b>excruciating</b> 129:17</p> <p><b>excuse</b> 147:9 151:18 197:3</p> <p><b>Executive</b> 208:4</p> <p><b>exercise</b> 36:1 134:5</p> <p><b>exercises</b> 145:21</p> <p><b>exhausted</b> 128:20</p> <p><b>exhausting</b> 196:10</p> <p><b>exist</b> 206:1</p> <p><b>existence</b> 225:6</p> <p><b>existent</b> 130:3</p> <p><b>existing</b> 27:15</p> <p><b>exists</b> 140:16</p>	<p><b>expand</b> 88:21 92:17 95:3 140:12 149:18 161:22 164:1 190:7,8</p> <p><b>expanded</b> 232:16</p> <p><b>expect</b> 42:1 56:11 76:17 89:1 216:5 217:19</p> <p><b>expectancies</b> 200:8</p> <p><b>expectation</b> 64:9</p> <p><b>expectations</b> 56:13 89:1 115:15,16,17,18,2 2 116:6</p> <p><b>expected</b> 43:2</p> <p><b>expenses</b> 47:10 132:11</p> <p><b>experience</b> 8:11 15:11,13 25:2 27:7 31:13 32:19 38:1 41:17,18 43:22 47:14 49:4 57:13,16 59:18 67:4 71:5,21 73:8 75:10,11,13,14,17 76:2,16 78:4 81:17 82:3 94:21 95:9,20 97:21 98:10 99:16 101:10,21 102:10,14 103:1 105:4 109:6 114:12,15 117:2 120:20 126:6 130:19 137:16 141:19 142:5 144:18 148:2,15 151:7,13 155:9 156:21 161:14,16,22 163:21 165:15 166:16 176:21 178:15 182:8</p>	<p>186:4 188:17,19 202:5,11 225:5 226:11,17,19 229:8</p> <p><b>experienced</b> 47:18 53:3 58:2 59:2 67:17 71:3 95:11 105:7 129:12 141:22 181:21 229:21</p> <p><b>experiences</b> 13:14 18:8 31:15 33:10 34:19 35:22 36:17 38:7,20,21 40:7 41:19,21 43:22 44:1,9 45:18 50:1 63:3 66:22 67:11 70:22 71:1 84:22 92:9 102:1 109:14 123:8 124:10 127:3 128:16 136:22 138:7 144:9,14,21 158:15 165:8 190:12 198:13 223:15 224:10 229:10</p> <p><b>experiencing</b> 20:1,5 99:20 136:10 224:1</p> <p><b>experiment</b> 107:7 169:18</p> <p><b>experimented</b> 57:20</p> <p><b>experimenting</b> 140:1</p> <p><b>expires</b> 234:21</p> <p><b>explain</b> 14:3 84:17 106:2 151:16 163:19</p> <p><b>explained</b> 26:10 200:4</p>
--	---	---	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 17

<p><b>explicitly</b> 11:1</p> <p><b>explore</b> 14:11 72:18 140:12 183:1</p> <p><b>exploring</b> 13:3 69:20 72:14</p> <p><b>exposed</b> 140:21</p> <p><b>expound</b> 66:7,9</p> <p><b>express</b> 56:4 198:7 221:19 224:18 232:12</p> <p><b>expressed</b> 41:13 223:12,16,20 224:8,11,16 225:12,15,20 226:1,2,18 231:9 232:10</p> <p><b>expresses</b> 38:16</p> <p><b>expressing</b> 41:21 221:18 222:17</p> <p><b>expression</b> 64:16 225:9</p> <p><b>extend</b> 65:1</p> <p><b>external</b> 11:15</p> <p><b>extremely</b> 132:17 138:8</p> <p><b>eye</b> 154:1</p> <hr/> <p style="text-align: center;">F</p> <hr/> <p><b>face</b> 52:19 54:15 70:22 183:22</p> <p><b>faced</b> 152:16</p> <p><b>faces</b> 41:18</p> <p><b>facial</b> 131:17</p> <p><b>facilitate</b> 12:15</p> <p><b>facilitated</b> 3:11,14 32:7 33:3 46:22 127:4 228:17</p>	<p><b>facilitator</b> 5:12</p> <p><b>facilities</b> 64:3</p> <p><b>facing</b> 41:18</p> <p><b>fact</b> 95:13 99:17 118:20 193:13 216:13</p> <p><b>factor</b> 26:20 93:15,16</p> <p><b>factorial</b> 216:15</p> <p><b>factoring</b> 226:3</p> <p><b>factors</b> 11:9 12:8 23:2 26:12 114:15,16 115:12 122:2 200:5 201:15 232:4,21</p> <p><b>facts</b> 103:3</p> <p><b>failed</b> 95:5 209:21</p> <p><b>failure</b> 22:11 87:11 114:17</p> <p><b>failures</b> 144:22</p> <p><b>fair</b> 37:20 102:18 208:11</p> <p><b>fairly</b> 56:9</p> <p><b>faked</b> 119:15</p> <p><b>fall</b> 162:18 177:20</p> <p><b>fallen</b> 80:18</p> <p><b>falls</b> 80:21 81:6</p> <p><b>families</b> 211:4</p> <p><b>family</b> 21:22 53:8 105:14 133:3 137:18 228:2</p> <p><b>fantasies</b> 43:11 44:19 72:6,17</p> <p><b>Farkas</b> 1:21 234:2,19</p> <p><b>farther</b> 172:3</p>	<p><b>Fascinating</b> 156:2</p> <p><b>fast</b> 208:18 209:7</p> <p><b>faster</b> 195:13</p> <p><b>fatigue</b> 128:17 130:16 207:12</p> <p><b>fault</b> 50:3</p> <p><b>Favor</b> 231:9</p> <p><b>favorite</b> 162:12</p> <p><b>favors</b> 11:16</p> <p><b>FDA</b> 1:2,14 2:2 5:6 7:16 8:8 9:13 10:6,15 11:3,16,19 12:15 20:19 27:14 28:12 29:5,21 30:20,21 37:18 39:6 40:21 51:13 54:4 56:8 61:20,21 86:11 100:6 122:21 127:19 131:22 138:10 150:16 165:11 178:15 183:20 195:8,12 197:15 199:5 206:5,18 207:18 208:14 209:7,13,20 210:3,20 211:19 215:7 216:1,18 218:1,4,7,13 219:7 220:1,16 232:5</p> <p><b>FDA's</b> 3:4 8:19 9:18 10:13 11:8 14:16 37:5 40:11 132:4</p> <p><b>fear</b> 129:18</p> <p><b>feature</b> 225:3</p> <p><b>features</b> 25:6</p> <p><b>Federal</b> 17:5,13 32:16 46:10</p> <p><b>fee</b> 16:9</p>	<p><b>feeble</b> 62:22</p> <p><b>feedback</b> 42:10</p> <p><b>feel</b> 28:9 37:18 40:1 41:20 43:21 49:19 50:5,19 51:3,4 56:16 71:2 73:17 78:2,4,18 79:8 85:2,13,14 90:5 97:13 100:15 105:10 106:10 113:11 117:1 121:11,16 124:11 134:10,11,12 143:20 147:6 156:16 161:19 177:5 179:4 180:16 182:3,12,13 184:7,8,10,12 187:16,17,22 188:12 193:9 214:10 223:5 231:16</p> <p><b>feeling</b> 75:17,18 85:10,11,15 87:11 106:22 114:16 120:1 121:5,6,13 129:7 140:15 141:10,14 148:5 179:22</p> <p><b>feelings</b> 51:3 111:5 136:18,19 138:1</p> <p><b>feels</b> 30:3 50:15,17 74:21 118:9 151:14</p> <p><b>feet</b> 209:20</p> <p><b>fell</b> 49:5</p> <p><b>felt</b> 48:21 58:13 59:15 77:17 85:14 111:6 114:17 122:2 128:14 129:10 135:13,16</p>
---	---	--	--

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 18

<p>136:20 155:20                  202:8 228:3</p> <p><b>female</b> 1:6 4:14                  5:9,19 8:4 9:1,5                  12:6,18 14:9 18:3                  20:18 21:2,13,15                  22:20 23:20,22                  24:9,17 27:18 38:1                  45:2,4 119:2                  195:4,9,11 212:19                  213:10 223:10</p> <p><b>feminine</b> 121:12</p> <p><b>feminist</b> 204:15</p> <p><b>feminizing</b> 202:11</p> <p><b>fertility</b> 62:3</p> <p><b>fewer</b> 47:18</p> <p><b>field</b> 13:1 232:3</p> <p><b>fifth</b> 24:19 25:9</p> <p><b>Fifty</b> 196:18</p> <p><b>figuratively</b> 64:1</p> <p><b>figure</b> 16:14 22:13                  47:19 76:4 152:1                  211:21</p> <p><b>fill</b> 40:1 175:8                  190:18 222:5</p> <p><b>filled</b> 6:9 189:22</p> <p><b>final</b> 17:15 19:15                  25:11 35:6 76:12                  121:21</p> <p><b>finally</b> 26:20 46:20                  60:2,11 122:7                  133:2 135:21                  138:19 156:8                  168:11 174:18                  183:13 200:14                  217:14 219:5</p> <p><b>financial</b> 34:5 91:8                  126:20 164:7                  191:20 199:1</p>	<p>201:10 205:6,9                  219:9</p> <p><b>financially</b> 234:14</p> <p><b>finding</b> 87:2 107:20                  110:7 132:4 140:8                  143:19 151:15                  218:15</p> <p><b>fine</b> 33:20 156:8                  168:17 223:6</p> <p><b>finish</b> 74:8</p> <p><b>finished</b> 123:3</p> <p><b>first</b> 5:6 10:18                  17:11,20 18:4                  19:17 22:22 24:5                  25:9 26:8 32:5                  33:19,20,22 34:8                  37:22 40:6 47:9                  48:18 58:11                  60:14,17 67:17                  78:13 83:10,21                  100:18,19 108:1                  114:4 118:8                  126:15 127:10                  132:20 140:3                  147:21 151:14                  154:18 170:10                  179:7 183:3 184:4                  192:14,21 202:12                  215:19 221:12,14                  222:1 224:21</p> <p><b>fiscal</b> 17:21 18:5</p> <p><b>fit</b> 46:13 76:21 78:4                  179:10</p> <p><b>fits</b> 146:3 171:6</p> <p><b>five</b> 16:12 45:15                  46:2 47:16 134:5                  155:9 184:13                  199:15 214:5                  219:13</p> <p><b>fix</b> 57:2 112:4 113:3                  134:7 196:7</p>	<p>202:2,16,19</p> <p><b>flashes</b> 152:13</p> <p><b>flew</b> 48:22</p> <p><b>Flibanserin</b> 113:4                  136:13 137:8                  147:20,22                  148:9,14 175:8                  195:5 199:19                  230:12</p> <p><b>flip</b> 111:3</p> <p><b>flirt</b> 134:20</p> <p><b>floating</b> 33:11,13                  35:14 190:18</p> <p><b>floor</b> 54:8</p> <p><b>flow</b> 63:4,8 170:20                  186:6,8</p> <p><b>flown</b> 78:8</p> <p><b>fluctuate</b> 130:9</p> <p><b>fluctuates</b> 180:3</p> <p><b>flutter</b> 148:22</p> <p><b>flying</b> 101:2</p> <p><b>focus</b> 9:4 14:11                  21:14 38:6                  40:11,15 45:11                  46:11 110:4,15                  124:14,15 125:21                  126:12 143:15                  223:11 231:8</p> <p><b>focused</b> 4:16 5:8 6:4                  8:5 14:17 20:18                  34:10 40:6 79:7                  97:22 208:8                  228:17</p> <p><b>focuses</b> 37:6 82:2</p> <p><b>focusing</b> 17:10                  120:9 139:15                  145:7 202:16</p> <p><b>fog</b> 159:10</p>	<p><b>folks</b> 94:5 158:1,3                  165:15 166:16,17                  167:1,4 179:1                  191:9</p> <p><b>follow-up</b> 77:11</p> <p><b>food</b> 1:2 6:20</p> <p><b>forces</b> 103:7</p> <p><b>forego</b> 18:21</p> <p><b>foregoing</b> 234:3,5</p> <p><b>foregoing/attached</b>                  235:6</p> <p><b>foreign</b> 138:14</p> <p><b>foremost</b> 10:19                  37:22 40:6</p> <p><b>foreplay</b> 76:19,20                  88:3</p> <p><b>forever</b> 50:22 61:4                  64:10 88:4</p> <p><b>forget</b> 55:9 109:8                  187:7</p> <p><b>forgot</b> 83:22</p> <p><b>forgotten</b> 172:14</p> <p><b>form</b> 9:5 64:15                  65:16 138:12                  209:4</p> <p><b>formal</b> 6:21</p> <p><b>format</b> 3:8 5:11 14:4                  31:3,6 32:4</p> <p><b>former</b> 61:18 165:4</p> <p><b>forms</b> 39:22 190:17                  229:5</p> <p><b>forth</b> 167:15 180:21</p> <p><b>Fortunately</b> 54:11</p> <p><b>forum</b> 189:4 216:17</p> <p><b>forward</b> 8:10                  29:5,10 34:13 39:8                  42:13 89:21 100:2</p>
--	---	---	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>122:22 161:17,19 194:6 <b>fought</b> 208:10 <b>foundation</b> 32:7 144:12 <b>founded</b> 208:6 <b>founder</b> 193:6 219:10 <b>fourth</b> 47:17 104:1 <b>frankly</b> 181:9 <b>free</b> 37:18 40:2 78:2,4 85:2 204:7 <b>frequency</b> 25:18 82:14 126:6 176:15 <b>frequent</b> 200:10 <b>frequently</b> 22:4 149:2 <b>fresher</b> 80:2 <b>friend</b> 195:7,14 <b>friends</b> 48:5 53:8 81:13 137:18 196:22 <b>front</b> 32:10 61:17 65:8 125:21 126:22 159:12 166:17 192:7 <b>fruits</b> 134:4 <b>frustrated</b> 50:20 59:3 <b>frustrating</b> 58:11 <b>FSAD</b> 24:18 27:15 29:1 30:4 45:5 <b>FSAID</b> 38:3 <b>FSD</b> 6:16 9:14,18 13:4,10,20,22 21:2 24:2,4 34:3,5 35:16 40:10,20,22</p>	<p>43:15 45:10,11,14 94:19 95:1 122:3 124:5,14 126:18,21 127:18 132:4 191:18 <b>FSIAD</b> 9:6,9 21:15 24:22 25:7 26:22 27:3,14 29:1 30:4 31:18 45:3 196:3 212:22 213:9 <b>fulfilling</b> 48:3 55:1 76:2 113:20 <b>full</b> 4:21 20:11 36:14 38:10 48:10 52:18 55:19 175:5,11 223:5 <b>fully</b> 62:21 <b>fun</b> 81:15 95:16 96:11 <b>function</b> 23:1 50:9 62:10 132:1 152:10 173:17,18 201:14 229:19 <b>functional</b> 168:9 <b>functioning</b> 58:4 63:16 229:20 230:2 <b>functionings</b> 227:15 <b>functions</b> 30:3 203:8 <b>funded</b> 78:7 80:13 95:6 191:19 203:16 <b>funding</b> 81:12 <b>funny</b> 179:9 <b>furthering</b> 122:22 <b>Furthermore</b> 26:1 <b>future</b> 20:7,12 51:1 55:21 57:16 175:19 208:15</p>	<p style="text-align: center;"><u>                    </u> G <u>                    </u></p> <p><b>gain</b> 137:11 171:4 219:9 <b>game</b> 202:14 <b>gamut</b> 151:7 229:7 <b>Garbled</b> 112:1 <b>Gassman</b> 2:5 3:3 5:2 8:2,5 40:20 <b>gearing</b> 180:11 <b>gel</b> 65:22 103:5 150:15 <b>Gena</b> 192:16 <b>gender</b> 208:19 209:21 212:18 <b>general</b> 52:7 61:1 100:13 102:7 143:16 221:13 <b>generalized</b> 27:11 <b>generally</b> 34:18 41:6 133:8 144:21 <b>generate</b> 222:2 <b>generated</b> 226:9 <b>Generations</b> 220:14 <b>genital</b> 82:11,15 83:2,3 89:5,6,10,12 224:16 <b>gentleman</b> 119:1 <b>geographic</b> 43:3 <b>Georgetown</b> 194:18 201:6,8 <b>gets</b> 16:20 39:16 106:9 200:14 <b>getting</b> 50:16 52:11,21 60:5 68:20 69:4,5,6 80:3 88:13 92:13</p>	<p>101:20 103:16 124:7 130:22 160:5 173:1,5 209:22 228:9 <b>GIAMBONE</b> 44:16 45:22 82:19 94:9,14 114:7 122:1 146:17,21 147:14 169:3 <b>GIAMGONE</b> 83:12 <b>girlfriends</b> 155:14 196:19 <b>given</b> 16:6 21:12 51:14 52:14 84:11 124:6 132:10 144:6 169:21 210:20 234:9 <b>gives</b> 19:11 188:15 <b>giving</b> 5:7,8 6:11 126:15 <b>glad</b> 10:8 222:7 <b>glass</b> 216:10 <b>glasses</b> 154:1 <b>glove</b> 58:14 <b>goal</b> 14:10 31:5 37:19 109:3 116:17 117:2,4,7 118:2 120:14 141:15 187:3,20 <b>goals</b> 11:11 120:19 204:3 <b>God</b> 184:16 <b>Goldstein</b> 48:16 54:16 68:4,9 100:20 106:11 129:20 136:13 137:2,8 192:19 215:15 <b>Goldstein's</b> 130:13</p>
---	---	---	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>gone</b> 44:10 46:14 49:20 128:13 130:16 135:13 151:22 152:11 173:12 174:8 183:12 189:8</p> <p><b>gosh</b> 222:4</p> <p><b>gotten</b> 4:8 15:12 56:3 122:18 125:8</p> <p><b>government</b> 10:11</p> <p><b>grab</b> 65:8</p> <p><b>grades</b> 222:12</p> <p><b>grading</b> 27:4</p> <p><b>gradual</b> 59:7</p> <p><b>graduate</b> 201:6</p> <p><b>granddaughters</b> 128:2</p> <p><b>grant</b> 132:10 135:7 202:4</p> <p><b>grants</b> 47:10</p> <p><b>grasp</b> 228:14</p> <p><b>grateful</b> 21:9 143:20 153:7</p> <p><b>gratified</b> 19:13</p> <p><b>gravely</b> 223:1</p> <p><b>great</b> 1:16 7:7 55:4 67:3 79:12 98:21 112:13 120:17 121:18 128:12 132:18 150:2 155:19 161:18 163:10 165:4 167:16 173:1 215:19 225:10 229:9</p> <p><b>greatly</b> 9:11 207:17</p> <p><b>green</b> 192:8</p> <p><b>Greenberg</b> 192:17</p>	<p>208:3,4</p> <p><b>Grey</b> 196:18</p> <p><b>Grey's</b> 196:15 211:10</p> <p><b>grit</b> 88:8</p> <p><b>gross</b> 208:18</p> <p><b>ground</b> 33:16 37:21 125:20 126:2</p> <p><b>group</b> 146:2 164:5 167:4,7 168:15 199:1</p> <p><b>groups</b> 163:17 212:14</p> <p><b>growing</b> 81:13</p> <p><b>grown</b> 79:15</p> <p><b>growth</b> 136:7 137:11 230:18</p> <p><b>guess</b> 95:15 101:14 145:6 149:16 162:18 174:18</p> <p><b>guidance</b> 12:19</p> <p><b>guilt</b> 135:16 204:6</p> <p><b>guilty</b> 50:19 114:16</p> <p><b>guy</b> 155:13 168:4</p> <p><b>guys</b> 81:7</p> <p><b>gym</b> 148:13 157:7</p> <p><b>gynecologist</b> 52:6 112:16 135:22</p> <hr/> <p style="text-align: center;">H</p> <hr/> <p><b>H.L</b> 200:17</p> <p><b>hair</b> 131:17 136:6 137:11 230:18</p> <p><b>half</b> 6:5 130:8 133:2 219:11</p> <p><b>hall</b> 6:19</p>	<p><b>Hampshire</b> 1:15</p> <p><b>hand</b> 6:8 33:15 34:11 37:15 68:1 71:3 78:5 90:5,9,12 104:20 108:15 109:15 110:18 165:18 188:5</p> <p><b>handle</b> 218:3</p> <p><b>handled</b> 106:5</p> <p><b>hands</b> 34:17 48:6 66:21 70:19 71:8 75:14 77:1 90:2 93:18 94:20 101:9 115:17,21 117:10,11,15 144:14 150:10,13 160:13,20 172:1 201:12 224:4 226:21</p> <p><b>hangers</b> 217:3</p> <p><b>happen</b> 56:14,17 66:18 79:9 88:5 93:5 95:12 99:18 176:6</p> <p><b>happened</b> 77:10 87:22 103:14 115:20 177:19 183:11</p> <p><b>happens</b> 27:9 73:13,14 75:9 77:8 98:12,14 183:18 185:8</p> <p><b>happily</b> 133:16</p> <p><b>Happiness</b> 212:4</p> <p><b>happy</b> 7:13 19:13 39:1 65:18 66:9 133:16 152:18 153:15,16</p> <p><b>hard</b> 50:7 77:10,12</p>	<p>79:21 115:5 118:2 189:11 196:17 225:4</p> <p><b>harm</b> 201:11 202:3</p> <p><b>haven't</b> 39:18 67:8 94:9 121:21 169:1 181:21 204:7,13</p> <p><b>having</b> 18:5,16 22:2 26:9 30:12 35:16 51:19 58:15 68:18,21 79:9 102:2 105:6 113:19 116:5 122:5 129:15 138:8 139:9 153:12,19 158:4 171:3 173:2 179:9 182:2,10,15 185:18 188:10,18 189:11 196:19 200:10 202:5,13 210:18 218:12 225:10 226:22 228:8 231:4</p> <p><b>Hawaii</b> 180:11</p> <p><b>head</b> 54:20 74:11,19 84:14 88:20 111:3 121:18 124:7 168:1 196:18 202:14</p> <p><b>headaches</b> 95:2,8,18,19 96:10</p> <p><b>headed</b> 142:18</p> <p><b>heads</b> 163:13</p> <p><b>healing</b> 133:1</p> <p><b>health</b> 9:19 37:5,17 38:13 39:21 45:5 64:4 68:15 85:22 99:8 152:6 166:13,14 194:21 197:18 198:22</p>
---	---	---	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>203:20 205:1,4,5,10,11 206:4 208:8 210:12 211:4,17 213:10 214:4,8 216:7,9 219:13 220:5,6 <b>healthy</b> 7:6 48:4 80:17 132:17 134:4 171:13 210:18 212:3 215:2 217:17 231:4 <b>HealthyWomen.org</b> 214:3 <b>hear</b> 13:12,18 16:3,5 18:17 19:2,7 25:3 26:19 35:2 36:4 38:17 64:19,20 67:11 96:20 98:10 102:11 112:10 120:18 122:1 127:8 156:13 163:19 166:18,19 187:19 190:4 194:1 210:22 222:15 227:6 <b>heard</b> 19:22 20:4 33:4,8 39:19 66:22 91:22 94:9,10 98:11 105:18 114:7,15 124:10 139:2,4 144:14,19 150:6 151:12 158:14 163:22 169:3 177:3 190:8 197:19 198:3 203:22 204:5,8 206:17 211:2,6,13 218:16 221:7 222:18 224:7 226:6 231:7 <b>hearing</b> 8:10 13:10</p>	<p>28:6 51:16 107:19 138:7 153:22 178:20 179:6 198:8 199:6,11 200:2 213:10 222:20 <b>hears</b> 91:22 92:1 <b>heart</b> 70:13,16 148:22 172:22 173:2,3,11 <b>heartbeat</b> 52:19 <b>heaven</b> 101:18 <b>heavy</b> 92:6 <b>hell</b> 87:22 <b>Hello</b> 47:8 91:6 191:2 194:16 <b>help</b> 9:18 12:15 13:16,18,20 28:8,20 29:10,20 34:13 39:7 42:19 51:18,19 52:9,11,22 53:11 86:20 122:21 132:4 133:9,11,20 142:10 150:10 153:19 154:1,11 155:18 157:11 166:22 189:7,9 200:8 213:6 <b>helped</b> 17:9 28:9 78:12 96:4 101:4 140:12 141:8 153:11 196:12 <b>helpful</b> 65:17 71:16 92:8,17 122:20 140:9 143:17 161:21 202:20 <b>helping</b> 38:6 86:20 163:11,12 220:4 <b>helps</b> 16:16 35:19</p>	<p>41:4 42:14 156:18 178:1 <b>hereby</b> 234:3 235:2 <b>hereto</b> 234:14 <b>hers</b> 177:7 <b>heterogeneous</b> 24:3 <b>hetero-normative</b> 206:7 <b>hey</b> 74:7 113:7 <b>hi</b> 14:18 68:4 77:2 78:6 80:11 81:11 87:14 99:2 111:18,19 132:8 138:20 149:16 152:21 155:5 158:18 163:1 167:10 188:7 193:5 197:10 201:5 203:15 204:21 207:8 212:10 214:2 <b>hide</b> 216:4 <b>high</b> 53:14 56:13 132:13 177:9 199:22 <b>higher</b> 75:21 202:1 <b>highly</b> 62:3 134:16 227:1 <b>Hirsch</b> 192:15 193:3 194:16,17 197:5 <b>history</b> 59:1 61:11 131:14 197:18 206:8 <b>hit</b> 53:17 <b>Hite</b> 164:14,15 <b>HIV</b> 18:18 <b>hold</b> 39:15 64:8 112:3 167:12</p>	<p><b>Holliman</b> 192:16 198:20 201:5,6 <b>Hollywood</b> 81:20 <b>home</b> 122:7 149:3 <b>honestly</b> 56:5,9 74:21 156:15 175:10 <b>honeymoon</b> 58:3 <b>hope</b> 30:15 41:4 51:2 57:13 62:15 124:19 221:8 232:12,14 233:7 <b>hopefully</b> 29:6 130:6 156:17 170:9 178:1 <b>hopes</b> 133:8 <b>hoping</b> 17:16 25:2 51:16 157:8 216:17 <b>horizon</b> 159:14 <b>hormonal</b> 27:21 158:13 161:14 168:14 229:14 <b>hormone</b> 48:11 130:2 131:19 149:9 151:21 158:16 170:15 <b>hormones</b> 48:20 139:20 140:1,5 <b>horrible</b> 168:9 <b>hospitals</b> 52:9 138:4 167:22 <b>hot</b> 69:14,15,17 152:13 189:1 <b>hour</b> 6:5 <b>hours</b> 54:7 186:22 <b>house</b> 74:1 <b>housekeeping</b> 6:17</p>
---	---	---	--



Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 22

<p><b>HRT</b> 128:7,8,11 158:22</p> <p><b>HSDD</b> 24:17 27:14 29:1 30:4 45:4 47:15 49:1 50:6 136:11 137:20,22 138:5,7 174:12 209:4,14</p> <p><b>huge</b> 74:22 105:4 133:10 185:5 193:20</p> <p><b>hugs</b> 49:9</p> <p><b>human</b> 102:19 143:14 211:5,18</p> <p><b>Humanities</b> 99:3 203:17</p> <p><b>hundreds</b> 117:20 206:2</p> <p><b>hurdle</b> 107:16</p> <p><b>hurt</b> 96:10 210:1</p> <p><b>husband</b> 48:3 49:5,11 50:2,5 62:4 63:12 69:15,16 77:3 78:10,14 79:3,11 80:3,19 92:2 96:8 113:19 118:21 122:9 129:2,7,19 132:18 133:3 134:13,22 135:15 136:22 137:21 139:11 141:18 153:1,15,18 154:12 179:17 182:2 184:14 186:14</p> <p><b>husbands</b> 96:7,19 204:6 213:8 218:6</p> <p><b>Hylton</b> 2:4 178:18</p> <p><b>hypergonadism</b></p>	<p>209:2</p> <p><b>hypertension</b> 89:9</p> <p><b>Hypoactive</b> 24:6,16 45:4 153:20</p> <p><b>hysterectomy</b> 61:5 62:1,12 63:9 151:20 158:20 183:5</p> <p><b>hysteroscopy</b> 168:5</p> <hr/> <p style="text-align: center;">I</p> <hr/> <p><b>I'd</b> 4:13 37:20 54:5 71:17 118:5 122:20 127:10,11 135:9 148:21 161:10 165:14 167:6 173:15 179:6 182:1 183:8 189:3 191:2 198:7 224:6</p> <p><b>idea</b> 99:12 110:22 116:15 135:16 139:17 195:8</p> <p><b>ideal</b> 31:22 125:10 143:1,7 230:22 231:18,20</p> <p><b>ideas</b> 114:5 141:1,2</p> <p><b>identifiable</b> 27:12</p> <p><b>identified</b> 32:14,19</p> <p><b>identify</b> 29:20 35:15 84:10 170:6</p> <p><b>identifying</b> 9:16 12:11 29:8 30:2</p> <p><b>idiosyncratic</b> 76:16 156:4</p> <p><b>ignorance</b> 64:6</p> <p><b>ill</b> 64:4</p> <p><b>I'll</b> 5:10 14:15 15:1 20:14 31:1,9</p>	<p>53:2,19 55:9 73:21 74:7 88:4 90:8 92:13 98:3 100:1,3 110:18 120:20 124:3 144:5 145:10 172:8,21 174:16 185:7 192:11,18 193:2</p> <p><b>illnesses</b> 26:21 63:7</p> <p><b>illustrate</b> 103:1</p> <p><b>I'm</b> 4:11 5:1 7:21 8:5 17:2 34:16 47:13 50:21 51:12,16 53:12 55:2 60:2 65:7,21 66:12,20 67:16 68:4,10,12,13 72:19 73:16,18,19 74:13 75:22 76:1,2 77:2 78:20 79:3,10,12 80:11 85:5,21 86:17 91:7 94:4 95:5 97:7,20 99:4 102:19 104:7,8,22 106:5 107:3,22 108:1,9 110:7 111:9 117:9,17 121:13 123:2 126:7,14 127:14,17 128:6 132:8 134:19 138:3,20 139:6 146:20 148:10 149:16 150:9 151:12 157:3 158:12 159:21 163:5,15 166:14 171:22 173:21 175:4,5,6,10 177:18 179:13 180:11 182:7,15,20 185:12 186:9 188:22 193:5</p>	<p>197:13 201:6 203:16,17 204:22 208:4,16 210:5,11 214:2,3 215:17,22 216:17 221:7 231:18</p> <p><b>image</b> 122:3</p> <p><b>imagine</b> 107:21 195:18 202:22</p> <p><b>imbalance</b> 208:19 209:21</p> <p><b>immediate</b> 142:19 172:16</p> <p><b>Immediately</b> 132:19</p> <p><b>immensely</b> 113:18</p> <p><b>impact</b> 9:11 21:20 31:12 72:1 74:20 82:6 97:8 105:2,5 128:16 228:11</p> <p><b>impacted</b> 76:7 227:22</p> <p><b>impacting</b> 134:9</p> <p><b>impacts</b> 5:14 53:9 55:9 94:10,13 182:11 230:1</p> <p><b>implanted</b> 65:19</p> <p><b>implication</b> 105:12 195:17</p> <p><b>implications</b> 195:3</p> <p><b>importance</b> 42:1 226:2</p> <p><b>important</b> 8:9 10:13 13:3,22 14:7 29:15,18 35:1 39:4 40:8,9 48:21 50:5 72:9 73:7 84:11 86:3 88:11 89:20 105:1 106:21 108:20 109:10</p>
--	---	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>124:21 143:22 215:8 225:1,14 227:5,12 228:11 231:11 232:21 233:3</p> <p><b>importantly</b> 26:6 31:22 36:5 125:9 141:22 215:9</p> <p><b>impossible</b> 52:16</p> <p><b>improve</b> 132:1 200:7</p> <p><b>improvement</b> 125:13 133:15 229:17</p> <p><b>impulses</b> 85:12</p> <p><b>inability</b> 22:8 24:11 53:4,7</p> <p><b>inadequate</b> 59:16 203:5</p> <p><b>Inc</b> 164:19</p> <p><b>include</b> 13:5 16:11 22:7 28:2 53:3 84:19 90:1,4 92:21 120:21 145:14 162:20</p> <p><b>included</b> 16:8 62:13 90:8 91:15 93:6 94:16 162:7 229:5</p> <p><b>includes</b> 34:1 40:16</p> <p><b>including</b> 11:9 12:18 23:3 61:5 72:3 122:3 159:9 162:6 169:5 199:8 206:9 208:22 209:9 211:7 229:18</p> <p><b>incorporated</b> 63:1 147:1</p> <p><b>incorporating</b> 35:6</p> <p><b>increase</b> 107:14 199:14 200:9</p>	<p><b>increased</b> 113:18 130:18 163:8 165:3 209:18</p> <p><b>increasing</b> 131:17</p> <p><b>incredibly</b> 84:4 116:20</p> <p><b>indeed</b> 166:21 211:8</p> <p><b>Indiana</b> 132:9</p> <p><b>Indianapolis</b> 132:9</p> <p><b>indicate</b> 104:19 226:21</p> <p><b>indicated</b> 70:21 90:17 162:8 227:16 230:13</p> <p><b>indicates</b> 44:8 119:20</p> <p><b>indication</b> 11:10 165:22</p> <p><b>indications</b> 11:17</p> <p><b>indirectly</b> 40:4</p> <p><b>individual</b> 42:6 140:20 167:3 171:8 174:2 227:1</p> <p><b>individually</b> 12:3</p> <p><b>individual's</b> 223:15</p> <p><b>industry</b> 10:10 29:5 39:2 198:10,15 223:18 232:6</p> <p><b>ineffective</b> 197:17</p> <p><b>infections</b> 210:15</p> <p><b>inflammatory</b> 61:8</p> <p><b>influence</b> 223:18</p> <p><b>inform</b> 20:8</p> <p><b>information</b> 6:11 11:5 15:3,18 19:11,21 36:19 37:7,11 39:20</p>	<p>40:12 112:19,21 113:1 124:8 140:9 205:4,5 206:6,11,20 207:1 214:10,12 215:4</p> <p><b>informative</b> 164:20 222:8</p> <p><b>informed</b> 62:17 112:22 136:15 137:3</p> <p><b>informing</b> 15:15</p> <p><b>infrastructure</b> 203:5</p> <p><b>inhibitors</b> 160:11,12,17 230:3</p> <p><b>inhibits</b> 98:19</p> <p><b>initial</b> 129:21 149:3</p> <p><b>initially</b> 51:20 130:9,14 136:13</p> <p><b>initiate</b> 49:8 55:14 72:8 75:9,19 76:18 77:5,9,19 78:14 81:14 96:9 134:21</p> <p><b>initiated</b> 73:3 75:11</p> <p><b>initiates</b> 79:3 195:19</p> <p><b>initiating</b> 48:1 66:12 73:15 80:16 81:2 136:21 149:4</p> <p><b>initiation</b> 24:9 72:6,20 73:7,10 75:8 98:13 148:18</p> <p><b>initiative</b> 3:5 4:17 5:8 8:21 15:16</p> <p><b>inject</b> 156:1</p> <p><b>injected</b> 58:15 229:8</p> <p><b>injections</b> 52:13 57:21 151:3,4 155:22</p>	<p><b>in-laws</b> 128:2</p> <p><b>input</b> 13:20 16:4 30:6 38:17 39:3 202:10 228:8,9</p> <p><b>insert</b> 186:19</p> <p><b>inserted</b> 66:14 137:9</p> <p><b>inside</b> 42:22 49:19 135:13</p> <p><b>insight</b> 16:19</p> <p><b>instance</b> 103:5</p> <p><b>instant</b> 185:16</p> <p><b>instantaneously</b> 188:9</p> <p><b>instantly</b> 92:4</p> <p><b>instead</b> 142:9 201:21 217:6,20</p> <p><b>Institute</b> 47:12</p> <p><b>institutions</b> 167:22</p> <p><b>instruments</b> 30:9</p> <p><b>insurance</b> 48:19 54:4 55:17 131:16 183:21 205:8</p> <p><b>insure</b> 37:20 40:9</p> <p><b>insuring</b> 131:12</p> <p><b>intend</b> 12:17</p> <p><b>intended</b> 10:16,20 21:1 29:19 175:12 207:16</p> <p><b>intense</b> 114:9</p> <p><b>intensely</b> 58:20</p> <p><b>intensity</b> 126:9 176:7,16,22</p> <p><b>intent</b> 31:5</p> <p><b>interact</b> 53:14 142:2</p> <p><b>interacting</b> 23:2</p> <p><b>intercourse</b> 22:11</p>
---	---	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>24:15 28:15 59:4 97:18 120:8,9 128:18,21 129:16 130:18 182:15,16</p> <p><b>interest</b> 4:15 5:20 6:16 7:8,14 9:5 10:9 16:1 21:16 24:7 34:3,5 35:16 38:2 43:10 44:14,18 45:3,12 53:5 55:3 62:20 66:10 67:19 68:8 69:2,13 71:21 72:4 76:8 86:13 91:8 93:22 94:7,22 95:21 97:2 100:5 103:12 124:15 126:18,20 127:20 129:17 131:2 164:7 180:1 181:10 191:17,20,22 195:15 199:2 201:10 204:6 205:9 225:2 226:7,10</p> <p><b>interest/arousal</b> 20:19</p> <p><b>interested</b> 13:15 28:6 29:22 32:17 55:14 66:12,13 67:22 68:17 75:18 76:1 80:2 87:2 97:17 105:6 138:8 148:4 159:4,22 177:16 178:20 179:6 180:8 182:14 234:15</p> <p><b>interesting</b> 74:18 81:7 91:10 99:10 146:13 177:2 178:13 199:22 226:15 230:3</p>	<p>231:1</p> <p><b>interestingly</b> 228:20</p> <p><b>intermittent</b> 179:2 186:3</p> <p><b>internal</b> 48:11</p> <p><b>International</b> 68:14 85:21</p> <p><b>Internet</b> 113:2 163:6 165:5 209:16,17</p> <p><b>interplay</b> 58:7 69:18</p> <p><b>interrupt</b> 112:2 113:8</p> <p><b>intertwined</b> 124:19</p> <p><b>intervention</b> 109:20 110:16 225:19</p> <p><b>interventions</b> 109:19,21 110:9,12 229:14</p> <p><b>interview</b> 7:19 129:21 165:5</p> <p><b>interviewed</b> 68:11 103:9 215:18</p> <p><b>intimacy</b> 81:3 228:19</p> <p><b>intimate</b> 142:3</p> <p><b>intimately</b> 180:6</p> <p><b>intimidating</b> 201:19</p> <p><b>introduced</b> 129:19</p> <p><b>introduction</b> 127:14</p> <p><b>intrusive</b> 54:10</p> <p><b>invaluable</b> 13:11</p> <p><b>invasive</b> 168:4</p> <p><b>invented</b> 195:12</p> <p><b>inventor</b> 61:12</p> <p><b>investigational</b> 145:14,15</p>	<p>147:19,20,22 149:11</p> <p><b>investigators</b> 11:21 22:6</p> <p><b>invitation</b> 32:15 185:14</p> <p><b>invite</b> 96:20</p> <p><b>invited</b> 32:16</p> <p><b>involve</b> 15:20 109:21</p> <p><b>involved</b> 15:21 18:22 199:9</p> <p><b>ironically</b> 52:15</p> <p><b>irritable</b> 128:22</p> <p><b>Irwin</b> 136:12</p> <p><b>isn't</b> 69:10 103:18 117:22 133:6 154:2 156:7 162:13 165:14 166:19 171:6 173:3 180:15 181:18 204:14 231:12,14</p> <p><b>isolated</b> 59:17 201:14</p> <p><b>issue</b> 43:2 51:19 52:5 54:21 55:6 63:16 66:9 69:9 75:6 76:7,8 79:21 96:5 105:1 113:5,16 121:8 128:9 134:2 166:15,20 181:19 186:6,8,10 200:15 201:12 224:19 226:15 231:21 232:7</p> <p><b>issues</b> 6:15,17 12:22 14:7,11 27:17,22 30:14 36:6</p>	<p>39:12,13 40:8,9,16 41:5 55:3 66:16 72:15 83:14 113:9 124:17 140:20 159:18 191:7 199:9 220:5 222:22 233:6</p> <p><b>ISSWSH</b> 161:10</p> <p><b>item</b> 3:2 89:5</p> <p><b>items</b> 5:4</p> <p><b>it's</b> 27:7 61:19 85:13 95:15 109:16 193:10</p> <p><b>IUD</b> 60:19 61:19 167:17</p> <p><b>I've</b> 51:17 52:17 56:3 68:11 75:1 79:19 91:22 95:11 99:9 117:19 120:13 127:18 131:8 152:22 156:11,14 170:15 172:13 174:17 179:11 183:5 184:16 193:8 203:22 204:5 211:1 215:18 218:16 219:8 232:13</p> <hr/> <p style="text-align: center;"><b>J</b></p> <hr/> <p><b>Jena</b> 164:5,6 165:9</p> <p><b>Jenny</b> 185:12</p> <p><b>Jervis</b> 204:21</p> <p><b>job</b> 15:2 63:6 72:13</p> <p><b>Joffe</b> 2:4 100:7 178:19 180:5</p> <p><b>join</b> 30:16</p> <p><b>joining</b> 8:15 21:8 233:7</p>
---	---	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>joint</b> 152:11 173:13,16</p> <p><b>joke</b> 134:20</p> <p><b>joked</b> 49:15</p> <p><b>journey</b> 142:16</p> <p><b>judgment</b> 196:21,22</p> <p><b>Judith</b> 106:5,20 127:6,10,17</p> <p><b>Judy</b> 99:2 192:16 201:3 203:13,15 204:18</p> <p><b>Julie</b> 2:3</p> <p><b>jumping</b> 49:6</p> <p><b>justice</b> 233:1</p> <hr/> <p style="text-align: center;"><b>K</b></p> <hr/> <p><b>Karen</b> 60:11,12 64:22 83:21,22 84:13 85:3 86:22 87:1 101:13,14,19 115:13,14 119:11,14,19 120:11 121:2 161:1 178:2,3,4,10,13 181:2 187:12</p> <p><b>Karen's</b> 197:19</p> <p><b>Katherine</b> 77:2,13 110:21 111:12 116:2,4 132:7,8 135:4 181:15,16,17 184:6,9</p> <p><b>Katherine's</b> 183:10 186:13</p> <p><b>keen</b> 195:15</p> <p><b>Kelly</b> 118:13 157:3 158:6,9</p> <p><b>key</b> 17:1</p>	<p><b>kick</b> 47:1 174:6</p> <p><b>kicked</b> 174:19</p> <p><b>kicking</b> 180:17</p> <p><b>kids</b> 26:17 49:12 119:5</p> <p><b>killer</b> 173:4</p> <p><b>killers</b> 52:17</p> <p><b>Kim</b> 207:8</p> <p><b>Kimberly</b> 192:17 204:20 207:6</p> <p><b>kinder</b> 157:12</p> <p><b>kinds</b> 13:9 79:16 87:6 103:21 109:18 143:8 159:18 224:3</p> <p><b>king</b> 77:18 151:17 170:13 219:9</p> <p><b>Kingsberg</b> 104:6,7 200:2</p> <p><b>Kiosk</b> 6:20</p> <p><b>kiss</b> 141:20</p> <p><b>kisses</b> 49:9</p> <p><b>kitchen</b> 142:14</p> <p><b>kitten</b> 64:18</p> <p><b>KMBERLY</b> 207:8</p> <p><b>knew</b> 16:4 48:13 98:4 129:5</p> <p><b>knowledge</b> 165:3,4,5</p> <p><b>known</b> 8:7 9:6 139:8</p> <p><b>Kweder</b> 2:10 3:16 65:9,11 88:16,19 158:1,7,10 165:11,20 178:12 221:2,4</p> <hr/> <p style="text-align: center;"><b>L</b></p> <hr/> <p><b>label</b> 137:9 138:13</p>	<p>178:11</p> <p><b>labels</b> 186:20</p> <p><b>lack</b> 22:7 80:21 132:20 143:2 175:12 186:7 214:17 224:19 225:2</p> <p><b>lacking</b> 75:3</p> <p><b>ladies</b> 86:18 118:14</p> <p><b>lady</b> 157:7</p> <p><b>language</b> 42:6 99:6,7,10,19 203:19,22</p> <p><b>laparoscopy</b> 168:5</p> <p><b>lapses</b> 61:13</p> <p><b>laptop</b> 221:9</p> <p><b>large</b> 28:4 64:4 107:20 215:18 224:17</p> <p><b>Large-Group</b> 3:11,14</p> <p><b>largely</b> 210:14</p> <p><b>larger</b> 29:6</p> <p><b>LaSELLE</b> 235:2,13</p> <p><b>last</b> 24:14,16 33:19 46:12 49:3 50:18 112:17 115:3 123:17 130:8 174:1,6 177:3,4,5 182:17 199:6</p> <p><b>lasts</b> 156:10</p> <p><b>late</b> 73:21</p> <p><b>lately</b> 174:18</p> <p><b>later</b> 9:7 61:2 80:3 139:12 167:18,19 177:18 209:12</p> <p><b>laugh</b> 134:20</p>	<p><b>laughed</b> 195:11</p> <p><b>laughter</b> 63:22 101:18 119:16,19 133:17 153:4 155:16 161:6 177:15 180:13</p> <p><b>launched</b> 205:11</p> <p><b>Lauri</b> 117:17</p> <p><b>law</b> 10:21</p> <p><b>laying</b> 140:11</p> <p><b>lead</b> 9:7</p> <p><b>leader</b> 9:8 20:21</p> <p><b>leading</b> 214:4</p> <p><b>League</b> 208:5</p> <p><b>Leah</b> 81:22</p> <p><b>learn</b> 19:5 42:13 87:9</p> <p><b>learned</b> 61:6 63:1 81:13 132:13 141:4 156:1 165:1</p> <p><b>learning</b> 60:5 141:12 193:22</p> <p><b>least</b> 16:11 25:14,15,21 53:19 67:1 75:21 117:8 137:5 144:15 155:9 157:7,12 200:12</p> <p><b>leave</b> 201:12</p> <p><b>leaving</b> 93:10</p> <p><b>led</b> 122:3</p> <p><b>legal</b> 10:18</p> <p><b>legitimate</b> 206:18</p> <p><b>Leonore</b> 70:7,15 76:15 109:16 192:14,21 193:1,5</p> <p><b>Leonore's</b> 70:16</p>
---	--	---	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>less</b> 23:9 45:15 72:16 85:13 90:19 129:10 151:12 173:7 220:19</p> <p><b>let's</b> 42:9 65:12 72:18 75:8 82:2 83:14 90:19 93:21 94:15 111:16 112:4 114:3 123:5 145:13 150:5,16 154:10 160:3 163:15 195:17 213:18</p> <p><b>letting</b> 212:10</p> <p><b>level</b> 7:13 81:3 142:3 175:6 177:8</p> <p><b>levels</b> 53:14 130:2,12,21 131:19 151:21 158:5</p> <p><b>libido</b> 78:11 95:13 129:5 132:21 133:5,9,20 134:8 163:3,8 173:17 189:12 196:13 197:2 209:1,18</p> <p><b>Lidocaine</b> 58:16</p> <p><b>life</b> 9:12 13:14 21:18,21 22:1 31:14 48:4 52:1,18 54:14 55:1,9 60:17 61:3 63:5,8,14 66:11,17 71:10 72:2 79:14 82:6 87:21 97:8 128:9,13,17 130:7 134:1,8 139:18 140:8 142:11 144:1 152:4 154:12 157:12 159:2,8 167:16 179:18 180:3</p>	<p>181:1 182:9 183:16,17 187:19 223:15 225:5,16,21 226:5 228:4 229:20 230:1 231:4</p> <p><b>lifestyle</b> 134:6 145:21 147:1 163:16 169:6</p> <p><b>lifetime</b> 215:19 223:15</p> <p><b>light</b> 103:11 192:8</p> <p><b>likelihood</b> 75:19</p> <p><b>likely</b> 56:13 202:20</p> <p><b>likewise</b> 80:11 149:5 163:5</p> <p><b>limit</b> 192:6</p> <p><b>limited</b> 21:12 25:1 34:14 53:4</p> <p><b>limits</b> 16:3 87:9</p> <p><b>line</b> 44:17 166:17 198:15 217:17</p> <p><b>link</b> 37:2</p> <p><b>liquid</b> 162:11</p> <p><b>list</b> 17:9,10,14 145:10 179:20 196:10 209:8</p> <p><b>listen</b> 37:22 38:14 39:6 64:19 127:2 221:19 222:12</p> <p><b>listened</b> 135:22</p> <p><b>listening</b> 13:8 39:5 187:16</p> <p><b>literally</b> 64:1 142:21 168:16</p> <p><b>literature</b> 193:20</p> <p><b>little</b> 35:13 45:19 66:2,7 67:13 72:19</p>	<p>83:14,15 87:17 88:21 89:3 91:11 92:9 93:1 95:4,18 96:3 97:9 98:4 101:5 107:14 110:8 127:6 145:12 146:11,14 149:10 152:21 171:4,5 172:2 173:10 174:19 179:12 180:22 195:17 196:16 202:9 203:8 221:9,16,17,21 222:4 232:7</p> <p><b>live</b> 7:9 42:21 61:3 101:3 134:5 140:7 142:21 175:17 183:16</p> <p><b>lives</b> 47:20 71:15 122:19 159:16 189:17 200:7 210:18 227:14,17 228:2,12</p> <p><b>living</b> 47:14 71:11 128:22 143:6 214:20</p> <p><b>local</b> 138:4</p> <p><b>localized</b> 65:22</p> <p><b>located</b> 6:18</p> <p><b>lockstep</b> 101:19</p> <p><b>lofty</b> 187:20</p> <p><b>log</b> 105:21 110:22</p> <p><b>long</b> 28:1 45:14 64:2 71:9 77:5 78:13 109:3 135:1 137:14 145:10 148:15 149:5,19,20 153:12 156:10 175:18 183:12</p>	<p>184:15 185:16 202:21 209:8 216:3 220:15 232:11</p> <p><b>longer</b> 20:11 59:12 76:19 81:17 105:6 108:21 129:11 130:19 137:17 142:5 159:17 171:14 174:19 220:8,19</p> <p><b>lose</b> 171:5 196:6 217:22 218:3,5,19</p> <p><b>losing</b> 63:14</p> <p><b>loss</b> 52:20 53:5 58:12 62:2,6,8,11 63:6,12 88:10 184:22 209:1 211:2,3</p> <p><b>lost</b> 53:15,18 55:6 103:12 130:7 139:12,16 194:3,7</p> <p><b>lot</b> 4:22 16:1 22:18 43:18 68:11,13 72:14 74:1 81:21 97:20,21 101:21 103:3,10 107:1,11 116:15 147:4 155:1 164:15 165:8 166:19 169:13 170:20 171:10 174:4,17 178:4 184:6,9 188:13 189:4,15,19 198:3 204:5,8 214:11 218:16 229:6</p> <p><b>lots</b> 156:2,3 179:18</p> <p><b>Louanne</b> 85:5 162:9 179:8 180:10</p> <p><b>loud</b> 136:17</p>
--	---	---	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 27

<p><b>love</b> 49:18 50:19                  63:14 79:10 96:6                  129:6 135:14                  141:13 144:1                  196:17</p> <p><b>lover</b> 87:3,9 105:5</p> <p><b>loves</b> 50:7</p> <p><b>low</b> 26:9 28:21 53:6                  78:11 95:13                  117:21 129:5                  131:19 133:5                  134:5,8 136:10                  139:22 158:7                  175:6 180:18                  196:13</p> <p><b>lubricant</b> 162:12,21                  184:19</p> <p><b>lubricants</b> 162:11                  163:10</p> <p><b>lubricated</b> 58:19</p> <p><b>lubrication</b> 130:18                  162:17</p> <p><b>lucky</b> 79:12</p> <hr/> <p style="text-align: center;">M</p> <hr/> <p><b>M.D</b> 2:5,6,10                  3:3,7,16</p> <p><b>M.P.H</b> 2:6 3:7</p> <p><b>machinery</b> 202:17</p> <p><b>magic</b> 211:20</p> <p><b>magnifying</b> 110:15</p> <p><b>magnitude</b> 11:11</p> <p><b>main</b> 5:21 46:14                  191:8</p> <p><b>mainly</b> 139:15 198:9</p> <p><b>maintain</b> 24:11                  53:5,7 134:4</p> <p><b>major</b> 21:22 52:8,19</p>	<p>55:6 63:12 155:20                  224:19 232:13</p> <p><b>majority</b> 90:13                  116:16 167:8</p> <p><b>Makin</b> 200:18</p> <p><b>mal</b> 168:9</p> <p><b>male</b> 118:3 119:3                  195:7,15 208:21                  212:18</p> <p><b>Mamas</b> 189:1</p> <p><b>man</b> 49:18 50:12,18                  54:1 56:2                  105:3,8,9,12                  116:22 174:2                  199:4</p> <p><b>manage</b> 9:18 131:2</p> <p><b>managed</b> 231:10</p> <p><b>manager</b> 194:20</p> <p><b>mandates</b> 25:18</p> <p><b>manhood</b> 96:14</p> <p><b>manipulated</b> 202:22</p> <p><b>manner</b> 222:9</p> <p><b>manual</b> 24:20                  25:8,13,17 26:6,14                  27:2 54:7</p> <p><b>manufacturers</b>                  205:8</p> <p><b>Marcea</b> 2:7 66:3                  89:18</p> <p><b>margin</b> 202:1</p> <p><b>Maria</b>                  111:15,18,19,21                  112:2,5,9,13                  113:7,13,15,22</p> <p><b>market</b> 196:3 203:4                  207:15</p> <p><b>marketed</b> 60:20</p>	<p>208:21</p> <p><b>marketing</b> 10:15                  11:7 194:22</p> <p><b>marriage</b> 51:2 96:12                  134:9 135:14                  140:11 153:6                  217:17</p> <p><b>marriages</b> 189:18</p> <p><b>married</b> 50:20 69:16                  74:1 134:22 153:1</p> <p><b>Marsha</b> 149:16</p> <p><b>Marta</b> 188:22</p> <p><b>Mary</b> 165:4</p> <p><b>Maryland</b> 1:17                  234:20</p> <p><b>massage</b> 145:19                  167:15</p> <p><b>mastectomy</b> 128:12</p> <p><b>master's</b> 194:17</p> <p><b>mate</b> 105:5</p> <p><b>material</b> 142:17</p> <p><b>math</b> 90:18</p> <p><b>matter</b> 5:14 13:13                  14:10 31:10 58:20                  88:3 167:5</p> <p><b>matters</b> 124:8                  202:19</p> <p><b>may</b> 12:10 18:11,15                  20:9 23:15 24:16                  26:15 27:22 31:4                  33:2 35:3 37:18                  41:1 48:17 49:4                  64:3 69:2,9,13                  86:20 89:11                  92:3,4,5 120:12                  161:14 184:21                  191:22 202:2                  226:9 228:10</p>	<p>229:12,13</p> <p><b>maybe</b> 69:5,12,15                  70:20 73:2 90:1                  98:3 100:11                  132:22 134:2                  140:14,15 157:11                  160:7,15 161:19                  176:15,22 182:7                  202:15 210:15</p> <p><b>mean</b> 45:11 51:1                  69:19 83:17 84:7                  96:13 102:17                  113:5 121:4                  127:13 148:22                  159:8,11,16                  171:20 174:3                  186:8</p> <p><b>meaning</b> 10:22                  27:11</p> <p><b>meaningful</b> 12:12                  29:20 41:11                  117:12 125:13                  126:4 128:1 148:8</p> <p><b>means</b> 26:5 192:9                  206:21 226:20</p> <p><b>meant</b> 128:19</p> <p><b>measurable</b> 12:13</p> <p><b>measure</b> 13:21                  29:15,17 226:20                  227:8 232:2,18</p> <p><b>measures</b> 13:6 30:2                  228:9 232:20</p> <p><b>measuring</b> 13:9                  187:6</p> <p><b>media</b> 7:11</p> <p><b>medical</b> 9:7 12:9                  26:21 40:20 51:17                  54:21 55:19 56:19                  57:1 61:12 99:8                  104:11 109:18</p>
---	---	--	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 28

<p>110:9 139:6                  147:17 165:12                  166:9,15 194:6,18                  201:13 202:19,21                  205:7,16,17                  206:12,16,19                  207:3 213:9                  223:19</p> <p><b>medicalization</b>                  193:8</p> <p><b>medically</b> 55:21                  215:4</p> <p><b>Medicare</b> 131:16</p> <p><b>medication</b> 52:1                  58:1 60:1 65:16                  107:12 147:15                  155:12,20                  156:5,15 172:7                  185:4 188:13                  202:16 207:15                  208:14 217:9                  218:2</p> <p><b>medications</b> 26:21                  57:21 130:11                  131:4 145:13                  155:10 156:13                  160:18,19 180:6                  206:13 208:13                  213:14</p> <p><b>medicine</b> 10:17                  47:12 203:20                  218:4,12 232:6</p> <p><b>medicines</b> 131:22                  146:10</p> <p><b>meditation</b> 169:6</p> <p><b>meet</b> 217:20</p> <p><b>meeting</b> 1:8 4:14                  6:6,22 7:4,8,14                  8:4,9,17,18 9:4                  10:10 13:7 14:3,21                  16:15 18:3,4,18</p>	<p>20:18 21:17 28:19                  31:2 36:11,13,16                  39:11,22 42:10                  44:15 57:12                  104:10 139:2,4,8                  192:3 193:10,12                  233:3,11</p> <p><b>meetings</b> 4:8 6:4                  8:20 15:1 16:12,16                  18:7 19:4,18,19                  31:3 42:12,14                  132:10</p> <p><b>Meg</b> 158:18</p> <p><b>Melanie</b> 91:6</p> <p><b>members</b> 32:14                  123:22 205:6                  224:8</p> <p><b>member's</b> 67:1</p> <p><b>memory</b> 152:11</p> <p><b>men</b> 11:16,22 22:2                  57:5 80:18 81:8,15                  88:6 91:17 96:21                  123:7 138:11                  141:1 150:18,19                  155:12 156:14                  174:4 186:17,20                  189:16 195:10                  202:15 208:19                  212:20 213:12                  216:15,17 218:20</p> <p><b>menopausal</b>                  161:12,13 189:2</p> <p><b>menopause</b> 28:17                  44:11 89:10 131:1                  158:21 189:11                  229:21,22</p> <p><b>men's</b> 74:22</p> <p><b>mental</b> 74:16 119:3                  154:9</p> <p><b>mentally</b> 73:15</p>	<p>75:12 77:6,8</p> <p><b>mention</b> 95:6 105:18                  162:7 207:17</p> <p><b>mentioned</b> 14:7 15:6                  28:22 31:4,9 37:8                  40:13 66:6                  105:2,19,21 111:1                  114:8 125:17,20                  147:19 150:8                  167:2,16 195:7                  199:19 203:16                  229:4,17                  230:5,8,13,16,19</p> <p><b>mentions</b> 158:14</p> <p><b>merely</b> 35:19 195:21</p> <p><b>mess</b> 91:3</p> <p><b>message</b> 202:18</p> <p><b>messages</b> 201:21                  216:3 225:1</p> <p><b>met</b> 129:20</p> <p><b>metabolizes</b> 156:5                  177:6</p> <p><b>methods</b> 193:22</p> <p><b>metro</b> 43:1</p> <p><b>Mexico</b> 49:11</p> <p><b>mic</b> 33:13 87:18                  192:10,22 194:14                  198:20 201:3                  203:14 204:20                  207:7</p> <p><b>Michael</b> 1:21                  234:2,19</p> <p><b>Michelle</b> 151:17                  170:13 192:19                  217:15 219:5,9</p> <p><b>micro</b> 196:10</p> <p><b>microphone</b> 42:4                  57:10 65:8 68:2                  127:7 149:15</p>	<p>167:12 200:14</p> <p><b>microphones</b> 33:12</p> <p><b>mics</b> 92:13 192:22</p> <p><b>middle</b> 148:21 149:1</p> <p><b>migraine</b> 95:10,11</p> <p><b>mild</b> 27:4</p> <p><b>miles</b> 200:17</p> <p><b>million</b> 212:14 213:1                  214:5 219:11</p> <p><b>millions</b> 220:4</p> <p><b>mind</b> 55:8 64:12                  129:1 176:11                  191:12</p> <p><b>mindfulness</b> 79:20</p> <p><b>minds</b> 73:12 80:6</p> <p><b>mindset</b> 85:9</p> <p><b>mine</b> 177:4 202:8                  210:21</p> <p><b>minimum</b> 42:7</p> <p><b>minor</b> 137:10,13                  156:10</p> <p><b>minute</b> 4:3,5 14:21                  16:22 33:17 34:14                  44:12 192:6</p> <p><b>minutes</b> 8:22 10:12                  54:3 93:10 114:3                  128:19 192:4                  197:4 221:5</p> <p><b>misconduct</b> 61:12</p> <p><b>mispronounce</b>                  192:12</p> <p><b>missing</b> 118:5,6,9                  133:14 204:1</p> <p><b>mission</b> 9:18</p> <p><b>mistake</b> 213:12</p> <p><b>mix</b> 45:7,17</p>
--	--	--	--

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014

<b>mode</b> 39:5	<b>mother-in-law</b> 60:15	<hr/> <b>N</b> <hr/>	<b>nice</b> 45:17 215:11
<b>model</b> 194:6	<b>mothers</b> 56:21	<b>namely</b> 25:17	<b>nicer</b> 157:15
<b>moderate</b> 27:4	<b>move</b> 23:21 29:10	<b>narrow</b> 40:11	<b>night</b> 128:20 152:13
<b>Modjoros</b> 91:6,7	33:3 34:13 42:9	139:14	177:11 196:20
116:14 184:5	46:7 82:2 89:21	<b>Natalie</b> 87:14,19	<b>nine</b> 53:17 151:22
<b>mom</b> 48:15,21 49:15	92:12,19 93:21	167:10	<b>nipples</b> 69:5
154:7	124:13 127:3	<b>NATALLIE</b> 167:14	<b>nirvana</b> 64:13 120:1
<b>moment</b> 49:10	141:10 150:6	<b>National</b> 205:1	<b>Nobody</b> 217:8
79:4,18 112:5,9	158:12 160:3	208:5 212:12	<b>nod</b> 124:7
165:13	182:20 189:16	<b>natural</b> 63:13	<b>nodding</b> 84:14
<b>mommy</b> 157:15	194:9,10 210:4	106:17 162:16	121:19 163:14
<b>Monday</b> 1:11	228:13	169:15 206:8	<b>non</b> 28:2 82:11,15
<b>money</b> 48:19 210:1	<b>moved</b> 52:6	223:13	83:3 89:6,12 122:7
<b>monitoring</b> 110:7	<b>movement</b> 143:4	<b>naturally</b> 161:11	130:2 224:16
130:13 131:11	<b>movie</b> 93:9,10	184:20,22	<b>none</b> 43:15 56:21
<b>month</b> 130:10	<b>movies</b> 81:20 93:12	<b>nature</b> 11:12 13:3	163:3
167:18 171:16	165:2,6	<b>naughty</b> 92:2	<b>nonexistent</b> 48:2
174:7 180:18	<b>moving</b> 42:13 100:2	<b>NCL</b> 208:12	59:12
199:6 209:8	122:22 158:12	<b>necessarily</b> 41:8	<b>non-medical</b> 109:19
211:13 219:12	191:4	79:4 91:14 117:4	203:6
<b>monthly</b> 108:14	<b>Mullin</b> 2:8 3:6 8:20	118:1,7 162:13	<b>non-participation</b>
<b>months</b> 25:15 59:7	14:15,18 20:16	202:13	7:17
88:13 128:12	<b>multi</b> 216:14	<b>necessary</b> 55:21	<b>nor</b> 209:19
133:18 136:4,15	<b>multi-faceted</b> 9:2	120:14 131:3	234:10,14
137:14 168:12	<b>multi-factorial</b>	<b>negative</b> 42:6 128:16	<b>norm</b> 109:2,11
170:7,14,22	216:13,14	133:19 137:1	<b>normal</b> 22:22 23:1
171:17 174:1	<b>multiple</b> 97:15	<b>negatively</b> 134:8	48:2,13 70:21
175:19 177:3,4,5	153:14	<b>neglected</b> 44:12	71:1,5,9,11
<b>mood</b> 129:2	<b>Muscle</b> 52:17	<b>neighbor</b> 189:14	81:5,19 87:21
133:9,15 195:22	<b>muted</b> 85:13	<b>neither</b> 43:14 209:19	102:19 129:4
196:4	<b>myriad</b> 97:10	234:10	139:22 143:2,5
<b>moods</b> 110:2	<b>myself</b> 49:3,8 50:21	<b>nerve</b> 52:13	168:7,15 171:3
<b>morbid</b> 89:8	58:21 64:18 79:19	<b>nervous</b> 85:12	180:1 194:7
<b>morning</b> 4:4 49:6	81:12 97:13 106:9	<b>Network</b> 205:2	205:15 206:7
127:2,13 150:8	108:18 128:7	<b>neurologic</b> 89:9	225:21 231:17
170:19 179:14	129:1 174:20	<b>newer</b> 80:2	<b>normalcy</b> 104:7
180:16	195:6,18 197:1		<b>normality</b> 194:2
<b>mother</b> 175:5,10	207:9		<b>northern</b> 91:8



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>Notary</b> 234:1,19,22  <b>note</b> 50:11 151:10  228:15  <b>noted</b> 178:17 228:7  <b>notes</b> 4:20 19:21  39:7 235:5  <b>nothing</b> 49:19 56:13  67:4 77:7 79:9  111:8 138:1  163:11 177:9  193:19 209:3  216:21  <b>notice</b> 17:5,13 25:19  32:16 46:10  154:18  <b>noticeable</b> 47:16  136:5 148:5 155:1  <b>noticed</b> 7:12 132:20  135:11 148:16  149:3  <b>noticing</b> 170:3  229:17  <b>noting</b> 225:11  <b>Novocain</b> 58:17  <b>nowhere</b> 189:12  <b>numbing</b> 58:16  <b>numbness</b> 58:13  <b>numerous</b> 57:19  <b>nurse</b> 138:3  <b>nursing</b> 122:6,7</p> <hr/> <p style="text-align: center;">O</p> <hr/> <p><b>Oak</b> 1:14  <b>OB</b> 112:16  <b>obligation</b> 50:2  116:5 118:17,22  135:18</p>	<p><b>Obligatory</b> 80:15  <b>obsessed</b> 177:14  <b>obsessional</b> 110:15  <b>obsessionally</b> 110:6  <b>obvious</b> 88:6  <b>obviously</b> 23:19  90:22 162:11  <b>occasion</b> 135:17  222:6  <b>occasionally</b> 35:7  <b>occasions</b> 43:7  <b>occur</b> 49:4 69:14  <b>occurred</b> 74:13  <b>occurrence</b> 109:11  <b>occurrences</b> 47:19  109:9  <b>occurring</b> 25:21  <b>occurs</b> 74:13 79:2  87:20  <b>October</b> 1:11 17:13  <b>oddity</b> 154:3  <b>offer</b> 136:1 205:17  <b>offered</b> 97:16 101:2  205:18,20  <b>offering</b> 17:15  <b>office</b> 4:12 8:8 14:19  37:5,12 39:20  133:10 201:18  <b>officer</b> 234:2  <b>offices</b> 86:10  <b>off-label</b> 148:12  150:20 160:14  178:7 198:3  <b>oftentimes</b> 228:1  <b>oh</b> 5:5 17:3 47:6  80:8 85:13 88:18</p>	<p>106:4 122:16  155:3 157:2  166:10 174:15,17  178:18 182:21  184:16 222:4  <b>okay</b> 5:5 7:20 17:1  35:13 42:8 43:18  45:1,7,17 46:3  47:8 66:20 67:7  68:9 70:3 71:7,12  72:13 73:5  74:13,15 75:15  76:5,9,11 79:10  81:10 82:13  83:5,13 85:17  86:22 88:16  90:6,13,21,22  92:11 93:3,19  94:12,18 98:3,9,21  101:12 102:4,16  106:22 107:2,18  108:7 109:12,14  110:17 111:16  112:5,13  113:14,21,22  114:2 115:13,21  117:13 123:17  124:1,2 135:6  144:17,20  147:3,16 148:3  149:14 151:6  154:21 156:20  157:22 158:16  160:13,15,20  161:18 162:22  163:13 166:10  167:9 170:12  171:19 174:21  177:11 182:20,22  183:2 184:13  185:10 188:3,21  196:3 197:5 201:4  207:7  <b>old</b> 47:13 50:22</p>	<p>53:17,18 63:17  64:6,11 127:17  130:1 134:14,19  140:10 173:3  183:17  <b>older</b> 60:5 86:7 89:8  90:19 103:9,16  <b>oldest</b> 208:5  <b>one-on</b> 227:22  <b>ones</b> 10:4  15:10,11,13  17:21,22 37:7  121:21 166:17  <b>one's</b> 110:2  <b>ongoing</b> 130:7 131:3  <b>online</b> 152:6  <b>onset</b> 54:22 59:5  71:14 226:1  <b>open</b> 3:15 6:5,10  37:20 74:14 99:17  190:21 191:4  203:7 217:17  220:17 222:20  <b>Opening</b> 3:3 4:2  <b>openly</b> 50:6  <b>operated</b> 205:12  <b>operator</b> 111:14,18  112:12  <b>opinion</b> 84:3 143:12  <b>opinions</b> 41:13,14  <b>opportunities</b> 39:17  <b>opportunity</b> 18:19  19:3 29:5 35:9  36:9 51:13 57:6,12  96:17 191:6,9  210:22 211:20  218:14 219:7  221:6</p>
---	--	--	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 31

<p><b>opposed</b> 179:4 200:11</p> <p><b>opposite</b> 134:7 156:21</p> <p><b>opt</b> 149:2</p> <p><b>optimize</b> 16:14</p> <p><b>opting</b> 202:2</p> <p><b>option</b> 93:13 137:8 185:3,18 218:7,13 219:22</p> <p><b>options</b> 5:10 50:13 169:4 183:19 189:9 211:19 215:1 217:10 218:21,22 219:20</p> <p><b>orange</b> 188:5</p> <p><b>order</b> 29:20 108:5 130:22 138:13 163:6 170:8 192:11</p> <p><b>organic</b> 89:7 134:3</p> <p><b>organization</b> 34:3 37:16 126:18 138:21 189:1 191:17,19 208:6 210:13 214:5</p> <p><b>organizations</b> 38:12 39:3 68:8 210:21 212:13</p> <p><b>organs</b> 62:9,16</p> <p><b>orgasm</b> 22:9,10 24:13 52:16 53:7 55:3 58:18 62:7,22 74:20 79:7 81:17 84:19 90:1,4 91:14,17 92:21 93:8,13 95:1 98:20 101:20 114:14 118:1,2,4 119:15 120:9,14 121:4</p>	<p>139:12 141:21 153:13 164:10,17,19 169:9 181:19 184:17 204:6 225:12</p> <p><b>orgasmia</b> 165:21 225:14</p> <p><b>orgasmic</b> 24:12 64:13 120:1</p> <p><b>orgasms</b> 130:20 153:12,14</p> <p><b>orientation</b> 140:13</p> <p><b>originally</b> 141:14</p> <p><b>Ospemifene</b> 28:14</p> <p><b>others</b> 8:15 37:17 77:12 94:3 108:16 116:11 132:11 163:20 218:5 225:22</p> <p><b>otherwise</b> 95:7 126:21 234:15</p> <p><b>ourselves</b> 140:19</p> <p><b>outcome</b> 13:6 20:10 115:15 196:9 234:15</p> <p><b>outcomes</b> 12:11,20 14:2 29:22 30:1</p> <p><b>outdid</b> 222:16</p> <p><b>outer</b> 101:21 120:7</p> <p><b>outlet</b> 189:12</p> <p><b>outlets</b> 7:12</p> <p><b>outlined</b> 25:5</p> <p><b>outlines</b> 27:2</p> <p><b>outside</b> 43:1 140:16 142:9</p> <p><b>outweigh</b> 11:3 134:18</p>	<p><b>ovaries</b> 61:5 158:20 183:6</p> <p><b>overall</b> 14:16 21:14 117:12 147:5,7 227:2 231:1</p> <p><b>overlap</b> 226:12</p> <p><b>overshadowed</b> 129:18</p> <p><b>over-the-counter</b> 145:18 146:10 160:4 162:3 163:2 230:9</p> <p><b>overview</b> 3:4,8 5:7,11 23:22</p> <p><b>owe</b> 144:7</p> <hr/> <p style="text-align: center;">P</p> <hr/> <p><b>packet</b> 186:19</p> <p><b>page</b> 3:2 29:7 42:2 46:12</p> <p><b>paid</b> 68:5 85:6 99:4 117:18 118:13 138:21 151:18 158:19 183:20 193:16 223:21</p> <p><b>pain</b> 22:10 24:14,15 28:10,11,15 52:17 53:4 95:1,14 96:12 114:9 129:16,18 152:11 173:13,16</p> <p><b>painful</b> 95:15 128:17 129:15 130:19</p> <p><b>palpitations</b> 172:22 173:2,11</p> <p><b>panel</b> 2:2 3:10,13 32:5,14 33:5,8 34:1 48:10 67:1 123:16,21 124:1 144:15 150:7</p>	<p>215:8 222:1 224:7,8,13 228:13 229:2</p> <p><b>panelist</b> 228:16</p> <p><b>panelists</b> 65:7,11 70:20 126:22 144:16 224:10 228:16</p> <p><b>panels</b> 54:18 221:12</p> <p><b>paper</b> 174:13</p> <p><b>paralyzed</b> 60:16</p> <p><b>parameters</b> 29:18</p> <p><b>paramount</b> 42:1 131:1</p> <p><b>parents</b> 63:7</p> <p><b>Parish</b> 85:20,21 89:4 161:9</p> <p><b>participant</b> 114:10 122:4,8 169:7</p> <p><b>participants</b> 38:3 39:1 122:2 123:15 169:5</p> <p><b>participate</b> 7:18 18:22 19:9 39:14 57:12</p> <p><b>participated</b> 145:16 230:11,13</p> <p><b>participating</b> 6:1 21:7 36:10 43:8 44:6 164:16</p> <p><b>participation</b> 7:6,17 14:13 19:7 35:1 37:21 38:6 56:8</p> <p><b>particular</b> 15:22 16:20 27:10 31:11 34:19 35:16 40:16,17 45:11 99:7,9 102:9 115:8 124:15 125:22</p>
---	--	--	--

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 32

<p>178:5 221:18                  223:19 226:4                  227:19 230:17</p> <p><b>particularly</b> 4:14                  5:19 6:16 37:16                  38:1 54:13 80:18                  97:1 113:12 114:5                  121:21 169:1                  180:18 223:11                  224:18 228:17                  229:20 230:6</p> <p><b>parties</b> 234:11,14</p> <p><b>partner</b> 26:17 27:10                  66:6 68:19 69:11                  73:4,15 75:11                  76:20 87:6 102:1                  114:17 118:3                  119:21,22 120:12                  140:18 142:4                  154:13 167:17                  195:18,20 202:12                  227:21</p> <p><b>partnered</b> 64:17</p> <p><b>partners</b> 10:11 38:4                  72:20 78:18                  96:7,19 120:2                  228:10</p> <p><b>partner's</b> 24:8 72:8                  73:7</p> <p><b>partnership</b> 139:10</p> <p><b>party</b> 55:19</p> <p><b>passed</b> 51:21</p> <p><b>passionate</b> 51:12                  56:5 129:8 140:10</p> <p><b>passionately</b> 208:10                  223:5</p> <p><b>passive</b> 202:12</p> <p><b>past</b> 24:4 49:14 59:2                  64:8 159:20                  171:11</p>	<p><b>patch</b> 158:22 170:16                  172:8 199:12                  220:2</p> <p><b>pathological</b> 141:9</p> <p><b>pathology</b> 139:20</p> <p><b>paths</b> 139:20</p> <p><b>patience</b> 59:21</p> <p><b>patient</b> 4:16 5:7,22                  6:4 8:4,19 10:4                  12:20 14:17 15:19                  19:19 20:17                  25:14,19 26:3 27:6                  29:22 30:3 36:11                  37:8 48:16                  68:10,16 85:5                  161:16 181:14                  191:10 198:8,16                  207:10 215:17</p> <p><b>Patient-Focused</b> 1:7                  3:4 8:19</p> <p><b>patiently</b> 188:6</p> <p><b>patient-reported</b>                  14:1 20:10 29:22</p> <p><b>patients</b> 5:15,22                  8:13 9:18 12:12                  13:8,12,15,19,22                  15:4,20 18:8,19                  19:2,8 21:9 25:20                  28:7 29:9,14 30:7                  31:7 32:6 37:6                  41:12 68:12,13                  86:9 91:12 92:1                  103:21 116:17                  117:8 138:6                  147:11 184:6,9,12                  185:6 191:10                  192:5 205:2                  210:22 212:16                  213:4 215:19                  222:14 232:21</p> <p><b>patient's</b> 15:7</p>	<p><b>Patients</b> 15:10</p> <p><b>patterns</b> 107:10                  230:21</p> <p><b>pay</b> 55:18 104:22                  110:13 167:6                  222:11</p> <p><b>paying</b> 109:22                  110:1,10 220:10</p> <p><b>PDE5</b> 230:3</p> <p><b>PDE-5</b> 160:11,12,17</p> <p><b>pellet</b> 66:14 80:1,5                  100:21 103:7                  137:9 156:9 169:5                  173:22                  174:1,9,15,18                  177:8</p> <p><b>pellets</b> 65:20 112:15                  151:5 177:3 229:8</p> <p><b>pelvic</b> 54:8 61:8,15                  62:9</p> <p><b>penetration</b> 129:14                  164:10,11,17</p> <p><b>penises</b> 202:6</p> <p><b>people</b> 19:14 32:16                  36:15                  44:5,17,20,22                  45:22 53:14 56:18                  76:17 82:20 87:3,4                  90:17 93:12 97:14                  100:8 101:10                  105:2,20 109:12                  111:2 120:6,15                  128:4 136:2                  143:6,9 146:18                  153:22 162:14                  174:4 180:17,19                  181:7 192:3                  193:15 194:2                  198:9 200:11                  210:21 222:3,4                  223:5 224:3</p>	<p>225:17,18 226:21                  228:22 229:3                  231:2 232:5</p> <p><b>people's</b> 227:14                  228:12 229:10</p> <p><b>peppered</b> 222:19</p> <p><b>per</b> 103:20</p> <p><b>perceived</b> 148:7</p> <p><b>perceives</b> 231:17</p> <p><b>percent</b> 22:13                  23:14,18 25:21                  44:17,21 45:22                  58:4 60:22 77:16                  82:19,22 83:2,3                  96:4 146:18,20,22                  147:14 168:15                  213:4 214:15,19                  224:13,15 228:21</p> <p><b>perception</b> 200:10</p> <p><b>perfect</b> 187:18</p> <p><b>perfection</b> 188:1                  217:19</p> <p><b>perfectly</b> 168:7                  186:17</p> <p><b>perform</b> 121:9 159:9</p> <p><b>performance</b> 22:9</p> <p><b>perhaps</b> 69:11 118:3                  162:18 195:14                  210:19</p> <p><b>period</b> 54:13 58:2                  59:7 100:22                  108:13 156:17                  170:7 171:14,16                  174:7 196:13                  226:4</p> <p><b>periods</b> 58:3</p> <p><b>permits</b> 35:9</p> <p><b>person</b> 74:7,12                  92:20 93:4 114:1</p>
--	---	---	--

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 33

<p>143:19 160:10                  174:2 182:12                  188:7,10 223:14</p> <p><b>personal</b> 21:10                  23:12,17                  41:14,17,19 51:16                  52:6 54:9 65:4                  70:10,17 101:21                  105:4 122:13                  123:1 143:12                  190:12</p> <p><b>personalized</b> 141:1</p> <p><b>personally</b> 43:9                  132:3 174:20                  175:14 197:15</p> <p><b>perspective</b> 15:4,8                  18:20 26:19 38:19                  101:17 222:22                  223:2,4 231:21</p> <p><b>perspectives</b> 5:18                  13:11 32:20 33:10                  35:21 38:7,22                  41:22 96:21 145:2                  178:20 198:16</p> <p><b>persuasion</b> 203:20</p> <p><b>pervades</b> 64:6</p> <p><b>pervasive</b> 213:3</p> <p><b>Peyronie's</b> 209:1</p> <p><b>ph</b> 23:13 37:14                  106:5 164:6 202:8                  203:14</p> <p><b>Ph.D</b> 2:8 3:6,9                  197:11</p> <p><b>pharmaceutical</b>                  127:15 191:21                  194:22 223:18                  232:6</p> <p><b>Pharmaceuticals</b>                  47:11</p> <p><b>PharmedOut</b></p>	<p>194:20 201:8</p> <p><b>phenomenon</b> 64:5                  119:20</p> <p><b>phone</b> 47:3 102:8,9                  111:17 112:3                  114:2 172:13</p> <p><b>phones</b> 7:2 35:8</p> <p><b>phrase</b> 196:16,17</p> <p><b>physical</b> 54:8                  58:8,14,16 59:9                  74:16 84:6 97:6                  98:11 130:22                  131:9,20 136:6                  140:15,17                  141:11,19 142:1,4                  143:10,11,15                  145:19 154:8                  167:14 168:3                  181:19 182:4                  202:10 217:6                  226:10</p> <p><b>physicality</b> 139:16</p> <p><b>physically</b> 73:14                  75:12 77:6 141:13                  163:10 175:20</p> <p><b>physician</b> 59:22                  91:7 98:16 107:10                  111:22 149:17                  173:6,9 199:13                  218:14</p> <p><b>physicians</b> 57:19                  112:16 161:1                  216:9</p> <p><b>physiologic</b> 226:4,8</p> <p><b>physiological</b> 23:3                  54:21 57:3 201:15</p> <p><b>physiology</b> 102:19                  194:18 223:9</p> <p><b>pick</b> 72:9,22 84:7                  116:2</p>	<p><b>picked</b> 140:9</p> <p><b>picture</b> 108:21 210:6</p> <p><b>piece</b> 75:3 174:13</p> <p><b>pill</b> 60:18 161:3                  175:14 182:2                  185:3 196:5,7                  203:4 211:20                  213:15</p> <p><b>pills</b> 57:20 202:1</p> <p><b>pilot</b> 16:13</p> <p><b>piloting</b> 15:1</p> <p><b>pinnacle</b> 91:16</p> <p><b>pioneering</b> 208:7</p> <p><b>placebo</b> 136:16                  199:16,21                  200:4,13</p> <p><b>plan</b> 130:6 184:16</p> <p><b>planning</b> 232:15</p> <p><b>plans</b> 180:22</p> <p><b>play</b> 9:21 66:18</p> <p><b>pleasant</b> 117:7                  129:3</p> <p><b>please</b> 7:1 32:10                  33:18 34:13                  35:12,22 38:11                  39:19 42:3,5,7                  61:16 66:3 73:1                  78:2 90:4,12                  104:20 114:18                  115:13 119:21                  123:14,15,18                  126:11 145:12                  150:13 160:6,16                  170:1 190:7,8,18                  191:12 192:4,22                  194:14 197:7,8                  198:20 203:14                  220:16</p> <p><b>pleased</b> 8:13</p>	<p><b>pleases</b> 120:12</p> <p><b>pleasurable</b> 85:16                  118:20 120:7                  136:22</p> <p><b>pleasure</b> 22:11                  43:12 59:19                  82:8,15,21 83:16                  84:16 89:22 91:15                  92:22 95:15 120:5                  162:15 164:14,22                  204:4,8,9 210:19                  224:15</p> <p><b>plenty</b> 162:16</p> <p><b>plethora</b> 233:6</p> <p><b>plug</b> 30:11</p> <p><b>plummeted</b> 129:10</p> <p><b>plural</b> 223:9</p> <p><b>plus</b> 128:4 132:1</p> <p><b>point</b> 14:6 17:22                  28:10 42:18 46:14                  48:4 52:5 70:13,16                  76:10 96:8 113:8                  117:20 134:11                  139:14 157:6,9,15                  162:15 174:14                  178:17 183:10                  186:12 189:6,19                  195:14 197:16                  204:10 210:17                  224:18 225:4,15                  232:20</p> <p><b>pointed</b> 22:15</p> <p><b>pointing</b> 164:15</p> <p><b>points</b> 13:21 29:21                  102:21 199:15                  204:4</p> <p><b>polling</b> 35:10,11                  36:4 42:16 44:13                  46:4 67:14,17                  71:17 72:22 145:3</p>
---	--	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>poor</b> 134:13  <b>popular</b> 64:14  <b>population</b> 23:20  <b>porn</b> 81:19  <b>pornography</b>  196:15  <b>portion</b> 46:22  190:10 224:12  <b>pose</b> 169:17  <b>posed</b> 38:8 46:10  170:11  <b>position</b> 99:14 199:6  <b>positive</b> 63:1 129:4  230:14  <b>positivity</b> 227:4  <b>possible</b> 16:6 22:21  31:1 55:4,22 108:4  132:12 196:9  <b>potential</b> 9:17 27:22  201:11 207:10  <b>powerful</b> 141:12  215:10  <b>practice</b> 42:20 54:20  <b>practices</b> 194:22  <b>practitioner</b> 52:7  113:1  <b>practitioners</b> 112:22  212:17  <b>pre</b> 161:13  <b>precious</b> 62:3  <b>precipitated</b> 213:16  <b>precisely</b> 61:21  <b>predominant</b> 225:3  <b>prefer</b> 83:18  <b>pregnant</b> 49:16  62:12</p>	<p><b>pre-menopausal</b>  207:10  <b>premise</b> 104:10  <b>preoccupation</b>  185:1  <b>preoccupied</b> 110:7  <b>prepare</b> 56:6  <b>prepared</b> 4:7  <b>prescribed</b> 155:12  157:10 169:8  <b>prescribing</b> 195:1  201:9  <b>prescription</b> 16:9  54:2 145:13 146:9  147:11,13,15  161:3 166:3  218:11  <b>prescriptions</b> 52:21  <b>presence</b> 7:15 11:9  12:9 23:16  <b>present</b> 7:12 63:11  <b>presented</b> 63:5  67:12  <b>presenting</b> 32:18  <b>presents</b> 29:4 63:15  <b>pre-sexual</b> 199:8  <b>President</b> 85:21  <b>pressure</b> 102:2  225:7  <b>pressures</b> 64:10  <b>pretend</b> 122:9  <b>pretty</b> 101:6 127:7  173:18 174:7  183:14  <b>prevalent</b> 146:9  <b>previous</b> 26:1 44:13  124:6 130:21</p>	<p><b>previously</b> 128:13  129:12  <b>Price</b> 73:16 95:5  96:1  <b>primarily</b> 21:15  105:9  <b>primary</b> 5:13 37:19  59:17 173:9  <b>prime</b> 132:14  <b>printed</b> 46:11 47:4  <b>prior</b> 54:22 141:14  <b>PRO</b> 30:8  <b>probable</b> 181:3  <b>probably</b> 7:12 32:12  54:7 80:5 117:5,20  155:5 157:12  224:2 231:7,20  <b>probe</b> 88:16 232:7  <b>problem</b> 26:9 50:12  52:20 54:9 95:8  98:15 107:15  110:5,15 113:3  133:13 134:16  141:6,7 154:8,9  189:7,15 200:19  213:3 218:15  <b>problematic</b> 18:9  <b>problematize</b>  164:18  <b>problems</b> 22:3 23:15  28:8 50:8 69:8  79:2 141:6 142:8  153:19 154:6  162:14 181:4  205:3,14,15,22  207:1 216:9  222:11  <b>procedure</b> 137:10  <b>procedures</b> 206:13</p>	<p><b>proceed</b> 231:22  <b>proceeding</b>  235:4,5,8  <b>process</b> 9:16,22 10:8  12:16 13:4 14:4  15:20 16:18 17:4  59:7 81:8 130:8  131:1 139:19  141:12 156:2,15  163:11 175:3,18  180:18 194:5  226:8  <b>processes</b> 181:13  <b>produce</b> 19:16  130:17  <b>producing</b> 18:1  <b>product</b> 11:13 19:18  40:17 150:22  151:15 153:9  157:2 178:5,15  <b>productive</b> 159:19  <b>products</b> 8:7 20:22  27:15,16,21  28:12,13 61:18  66:2 145:15,18  146:11 147:2  149:10 150:6,9,17  151:8 153:19  158:13,16 160:4,5  162:3 208:19  209:22 230:9  232:3  <b>profession</b> 63:18  205:17  <b>professional</b> 37:13  205:16 218:10  <b>professionally</b>  222:13  <b>professionals</b>  166:13,14 194:21</p>
---	--	---	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 35

<p><b>professor</b> 104:8 197:13 203:18</p> <p><b>profit</b> 201:21 202:1 214:4</p> <p><b>profound</b> 56:10 62:9 177:20 227:16</p> <p><b>Progesterone</b> 131:6</p> <p><b>program</b> 15:19 16:2,8,11 17:16 30:12 37:9 171:7 194:20 205:1</p> <p><b>Programs</b> 4:12 14:19</p> <p><b>progression</b> 104:3</p> <p><b>progressive</b> 208:7 212:13</p> <p><b>progressively</b> 59:8</p> <p><b>project</b> 97:13 194:19 201:8</p> <p><b>projected</b> 142:19</p> <p><b>prominent</b> 227:10 230:18</p> <p><b>prominently</b> 227:20</p> <p><b>promise</b> 100:2</p> <p><b>promised</b> 163:8</p> <p><b>promote</b> 9:19</p> <p><b>pronounced</b> 59:8</p> <p><b>proper</b> 5:2</p> <p><b>proposed</b> 11:11</p> <p><b>pros</b> 14:2 30:1 134:17</p> <p><b>prospective</b> 160:2</p> <p><b>prosthesis</b> 202:9</p> <p><b>protect</b> 9:19</p> <p><b>protections</b> 208:9</p> <p><b>prove</b> 202:20</p>	<p><b>proven</b> 209:19</p> <p><b>Provestra</b> 163:2</p> <p><b>provide</b> 9:8 14:16 19:3 32:7 209:18 211:19 215:3</p> <p><b>provided</b> 11:5</p> <p><b>provider</b> 37:17 45:6</p> <p><b>providers</b> 38:13 211:21 212:16</p> <p><b>provides</b> 12:20 36:14</p> <p><b>providing</b> 10:12 30:20 37:6</p> <p><b>psychiatric</b> 24:2 26:10</p> <p><b>psychic</b> 62:5</p> <p><b>psychically</b> 62:2</p> <p><b>psycho</b> 109:19 110:12</p> <p><b>psycho-educational</b> 109:20 193:21</p> <p><b>psychological</b> 58:8 84:6 131:20 200:5 201:15</p> <p><b>psychologist</b> 104:8 193:6</p> <p><b>psychology</b> 197:11</p> <p><b>psycho-therapeutic</b> 193:21</p> <p><b>PTSD</b> 63:9</p> <p><b>public</b> 1:8 3:15 6:5,10 9:19 17:7,17 31:3 35:5 36:5,19,22 190:21 191:4,14 222:20 233:11 234:1,19</p> <p><b>published</b> 17:5,14 168:12</p>	<p><b>pudendal</b> 52:13</p> <p><b>Pujita</b> 6:10 190:20</p> <p><b>pull</b> 81:7 180:21</p> <p><b>pulled</b> 134:12 137:3</p> <p><b>purpose</b> 29:19 33:7 39:11 99:22 191:5 199:5</p> <p><b>purposes</b> 193:10</p> <p><b>purr</b> 64:20</p> <p><b>Pursuit</b> 212:4</p> <p><b>push</b> 47:7 127:6 201:21</p> <p><b>pushed</b> 195:13</p> <p><b>putting</b> 156:10</p> <hr/> <p style="text-align: center;"><b>Q</b></p> <hr/> <p><b>Q&amp;A</b> 39:16</p> <p><b>qualify</b> 25:13</p> <p><b>qualitative</b> 30:5</p> <p><b>quality</b> 9:12 21:21 112:4 126:8 128:9 141:21 176:8</p> <p><b>quantifiable</b> 23:9</p> <p><b>quantitative</b> 30:6</p> <p><b>quarter</b> 146:12</p> <p><b>quest</b> 57:18</p> <p><b>question</b> 33:14 34:9,10 39:14 40:19 43:16 44:14,19 62:7 65:9 66:4,10 67:14 71:17 72:12 73:2,11 77:11,13,18 78:2 80:14 82:2 83:11 84:3 86:15 87:5 88:2 89:19,21 90:16 91:11 92:21</p>	<p>93:1,7 97:7 100:7 103:3 105:16 107:22 108:2,10,12 111:14,21 115:6 119:13,18 121:1 122:20 125:16 143:19 145:4 154:18 158:2 160:16 169:14,17 170:2,9,11 176:2 177:2 178:19 181:14,16 183:4 186:3 209:5</p> <p><b>questionnaires</b> 129:22</p> <p><b>questions</b> 18:14 33:2,6 35:10,11,17 37:10 38:8 39:7,9,17 40:2 42:16 46:4,9,18 65:7 67:15,18 77:22 78:3 84:9 110:19 111:13 114:20,22 119:10 122:12,17 123:1 140:14 144:5 150:3 166:9 205:13,14 206:1,3,22</p> <p><b>quick</b> 199:2,3 202:2</p> <p><b>quickest</b> 4:7</p> <p><b>quickly</b> 17:4 51:21 56:14,17 156:5,16 222:6</p> <p><b>quietly</b> 137:20</p> <p><b>quit</b> 175:16</p> <p><b>quite</b> 6:7 15:8,14 31:2 51:12 56:6 110:11 125:9 134:7 160:3 175:10 199:22</p>
--	--	--	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 36

227:15 229:2 <b>quote</b> 200:18 <hr/> <p style="text-align: center;">R</p> <hr/> <b>radiation</b> 128:8 <b>raise</b> 33:14 68:1 90:5,9,11 <b>raised</b> 37:15 117:15 222:14 224:4 226:21 <b>raising</b> 71:3 93:18 <b>range</b> 32:19,20 33:9 38:21 44:4,7,8 61:15 67:10,11 86:4 89:2 90:16 108:21 131:13 144:21 145:1 146:8 <b>rap</b> 80:20 <b>rapid</b> 52:19 <b>rapidly</b> 22:10 49:2 <b>rare</b> 43:7 135:17 <b>rate</b> 46:19 115:2 199:22 <b>rather</b> 110:16 135:18 185:4 215:18 <b>rationale</b> 28:18 <b>reach</b> 37:18 169:9 225:12 <b>reached</b> 118:4 <b>reaching</b> 22:10 114:13 142:20 <b>reaction</b> 52:1 <b>reactions</b> 209:9 <b>reading</b> 97:7 164:8,13 196:17 <b>ready</b> 11:20 123:20	193:3 210:9 <b>real</b> 95:16 136:17 138:15 164:18 215:10 <b>reality</b> 59:14 64:7 <b>realize</b> 21:19 115:5 174:15 <b>realized</b> 47:21 111:5 <b>really</b> 15:17 16:4 20:2 26:5,22 29:9,12 30:7 31:5,6 33:4,8 34:13,20 35:1 36:2 37:6 41:7 42:10,14 44:5 53:9,10 66:10,17 74:2 77:3,7 78:8 79:21 92:16 96:13 97:16 103:21 104:17 109:2,5 110:4 120:11 122:18 125:9 139:16 144:11 147:5 148:4,18 153:15 155:15 157:19 171:6,21 173:3 174:19 177:12 181:9 188:9,19 199:22 208:18 210:20 215:9 218:17 222:6 225:3 227:11,12 228:19 229:7 233:1,2 <b>realm</b> 140:17 <b>reason</b> 21:17 107:9 149:1 166:14 186:19 198:4 <b>reasons</b> 143:8 146:15 199:20 200:13 219:17	<b>reassuring</b> 67:10 <b>reauthorized</b> 16:9 <b>Rebecca</b> 192:16 198:20 201:2,4,5 <b>rebuff</b> 195:19 <b>recall</b> 174:14,20 <b>recap</b> 112:8 124:3 <b>receive</b> 17:17 <b>received</b> 45:2 54:16 60:22 84:1 87:15 <b>recently</b> 28:14 50:1 55:17 112:14 199:18 208:12 214:14 <b>receptive</b> 24:8 68:18 <b>recognition</b> 28:19 <b>recognize</b> 9:10 21:19 174:11 213:16,18 218:8 221:5 <b>recognized</b> 225:16 <b>recollection</b> 177:22 <b>recommend</b> 39:15 <b>recommendations</b> 12:21 <b>recommended</b> 60:19 161:2 178:16 <b>record</b> 20:3 35:5 106:8 108:14 109:7 130:12 187:9 191:14,22 234:8 <b>recorded</b> 234:6 <b>recording</b> 7:3 <b>recordings</b> 235:6 <b>recount</b> 224:13 <b>recover</b> 141:13	<b>recovered</b> 62:21 <b>recovery</b> 61:6 62:13 <b>red</b> 127:7 189:1 192:8 <b>reduce</b> 86:21 102:1 110:10 <b>reduced</b> 24:7 25:10,12 43:10,11 44:18 71:21 72:4,5,6 82:4,7,9,10,14,15, 20,22 83:2 89:5 224:14,16 234:7 <b>Reed-Hoff</b> 106:4,5 <b>reference</b> 20:8 111:22 <b>referred</b> 202:7 225:20 <b>referring</b> 9:16 89:5 <b>reflect</b> 38:21 <b>reflected</b> 66:22 144:15 229:7 <b>reflection</b> 195:22 <b>reflective</b> 32:20 <b>reflects</b> 38:18,19 40:11 <b>refocus</b> 79:19 <b>refrained</b> 129:6 <b>reframed</b> 110:4 <b>refusal</b> 195:21 <b>refuse</b> 196:5 <b>regain</b> 53:19 <b>regard</b> 11:16 226:14,16 <b>regarding</b> 70:22 124:11 <b>regardless</b> 51:12
--	---	---	--

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 37

<p><b>regenerate</b> 62:19</p> <p><b>regimen</b> 125:7</p> <p><b>Register</b> 17:5,13 32:16 46:10</p> <p><b>registered</b> 38:14</p> <p><b>registration</b> 6:8 7:7 190:17 234:22</p> <p><b>regular</b> 80:17</p> <p><b>regularly</b> 34:16 133:15</p> <p><b>regulation</b> 130:11</p> <p><b>regulations</b> 11:1</p> <p><b>Regulations.gov</b> 37:1</p> <p><b>regulatory</b> 10:16,18 12:4 39:12</p> <p><b>reiterate</b> 14:6 120:16 168:19 190:3</p> <p><b>rejected</b> 50:17</p> <p><b>rejection</b> 195:21</p> <p><b>relate</b> 25:10 50:10 77:17 97:1 142:22</p> <p><b>related</b> 4:15 6:7,15 11:17 12:17 58:17 81:4 89:10 107:11 191:8 227:3 234:10</p> <p><b>relates</b> 5:20 38:2</p> <p><b>relating</b> 29:8 99:7</p> <p><b>relational</b> 141:9</p> <p><b>relationship</b> 23:3 26:12,15,18 50:14 55:6 62:4 66:16 74:21 75:2 80:18 96:12 105:3,11,14 110:1 119:4 120:4 128:1 129:9</p>	<p>132:18 140:2,4,21 141:3,7,16 142:1,10 143:16 144:1 214:19 227:20 228:1</p> <p><b>relationships</b> 53:5,8 78:19 143:9 163:18 189:10,18 211:3 214:17,18 219:13 227:19 228:2,18</p> <p><b>relative</b> 234:13</p> <p><b>relatively</b> 24:21,22 93:14 103:6</p> <p><b>relax</b> 49:13 143:9</p> <p><b>relaxed</b> 141:11</p> <p><b>relaxers</b> 52:17</p> <p><b>reliable</b> 30:8 165:3 207:1</p> <p><b>reliably</b> 12:14</p> <p><b>relieve</b> 185:3,5</p> <p><b>religiously</b> 107:8</p> <p><b>reluctant</b> 48:18 135:19</p> <p><b>remain</b> 24:21</p> <p><b>remained</b> 215:5</p> <p><b>remains</b> 223:7</p> <p><b>remarkable</b> 183:15</p> <p><b>remarks</b> 3:3,16 4:2 6:13 7:22 193:8</p> <p><b>remedies</b> 28:7</p> <p><b>remember</b> 71:10 105:18 108:6 163:7 179:15 187:9 211:8</p> <p><b>reminder</b> 190:16</p> <p><b>remotely</b> 8:15</p>	<p><b>removable</b> 196:18</p> <p><b>removal</b> 61:5</p> <p><b>removed</b> 183:6</p> <p><b>remuneration</b> 84:1</p> <p><b>replaced</b> 175:7</p> <p><b>Replacement</b> 170:16</p> <p><b>reply</b> 133:5</p> <p><b>report</b> 19:16 20:6 25:20 108:5 164:14</p> <p><b>reported</b> 1:21 12:20 22:6 30:1 167:4 235:3</p> <p><b>Reporter</b> 235:3</p> <p><b>Reporter's</b> 235:5</p> <p><b>reporting</b> 1:22 61:13 166:15</p> <p><b>reports</b> 18:1 35:6</p> <p><b>repository</b> 36:20</p> <p><b>represent</b> 30:1 39:2 166:12</p> <p><b>representation</b> 10:9 43:3 193:15</p> <p><b>representative</b> 11:18 15:19 36:12 37:9 193:19 198:12 229:2</p> <p><b>representatives</b> 6:1 191:10</p> <p><b>represented</b> 44:4</p> <p><b>representing</b> 189:1 207:9 212:14 215:17</p> <p><b>represents</b> 212:22 214:5</p> <p><b>repressed</b> 140:8</p> <p><b>reproductive</b> 8:7</p>	<p>20:22 61:3 104:8 166:13 206:10 213:17</p> <p><b>repulsion</b> 114:8</p> <p><b>request</b> 11:7 33:22 133:3 191:15</p> <p><b>required</b> 131:13</p> <p><b>requirement</b> 10:21</p> <p><b>research</b> 1:3 4:12 18:20 39:2 52:8 61:14 99:3,6 122:5 164:16 168:12 197:20 203:17,19 215:21 220:17</p> <p><b>researched</b> 136:1 215:4</p> <p><b>researcher</b> 68:12 99:5 102:20 215:16</p> <p><b>researchers</b> 10:4 199:1</p> <p><b>Reserve</b> 104:9</p> <p><b>residents</b> 122:6</p> <p><b>resigned</b> 139:17</p> <p><b>resolved</b> 13:1</p> <p><b>resolves</b> 107:15</p> <p><b>resonate</b> 70:1 76:10 83:20 109:13 116:10</p> <p><b>resonates</b> 180:8</p> <p><b>resources</b> 37:4</p> <p><b>respect</b> 29:7 38:8 41:22 42:2 104:6 218:8</p> <p><b>respectful</b> 104:16 192:4</p> <p><b>respond</b> 73:18 76:18 79:17 84:18 203:3</p>
---	--	--	--



Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 38

<p>222:13 229:13  <b>responded</b> 149:20  <b>responding</b> 79:5      191:13  <b>responds</b> 79:18  <b>response</b> 23:1,6      59:11 72:20 77:5      80:14 82:9 83:1,7      86:16 87:5 91:19      149:19 166:20      199:21 206:10  <b>responses</b> 22:14      34:10,14 74:17      82:18 83:10 86:3,8      88:17 89:2,14 91:3      229:16  <b>responsible</b> 12:10      21:3  <b>responsive</b> 72:7      73:13 188:10  <b>responsiveness</b>      73:10 159:1,15  <b>rest</b> 60:16 90:8      139:18 151:9      182:11 183:17      194:4  <b>restoration</b> 217:21  <b>restore</b> 130:6  <b>restored</b> 60:4  <b>restrooms</b> 6:18 7:1  <b>result</b> 21:22 89:11      92:3 225:7  <b>results</b> 44:13 61:14  <b>retired</b> 159:21  <b>retooling</b> 62:13  <b>return</b> 64:15 95:22  <b>returned</b> 81:5      174:12</p>	<p><b>returns</b> 175:14      176:16  <b>review</b> 18:15 42:11      209:7  <b>reviewed</b> 35:4      199:13  <b>reviewers</b> 20:3  <b>reviewing</b> 16:20      21:4  <b>reviews</b> 21:1  <b>revisit</b> 171:16  <b>revisiting</b> 102:5  <b>revolutionary</b> 60:18  <b>rhetorical</b> 119:17  <b>Ria</b> 37:14,18 39:20  <b>rich</b> 14:5 19:11      123:19 124:5      189:22  <b>ridden</b> 202:9  <b>ride</b> 179:22 180:19  <b>rights</b> 213:17,19  <b>ripe</b> 63:17  <b>rise</b> 177:20  <b>risk</b> 11:8  <b>risks</b> 11:3,13      15:10,14 205:19      207:2 218:10  <b>road</b> 140:6  <b>roar</b> 64:19  <b>Robson</b> 151:17      170:13 171:18,20      172:6,21 183:4      192:20 217:15      219:5,6,10  <b>robust</b> 55:1 66:11  <b>rocky</b> 96:13</p>	<p><b>role</b> 9:21 10:13      15:14 73:6 101:15      200:7  <b>roles</b> 11:14  <b>roller</b> 183:9  <b>room</b> 1:16 10:11      19:9 35:20 42:18      49:15 86:5 89:16      97:21 111:2      119:19 145:5      146:9,12 220:2      221:16 228:22      229:3 230:11  <b>rooms</b> 217:3  <b>root</b> 52:20  <b>roses</b> 203:2  <b>round</b> 65:1 123:6      144:8 190:13  <b>routinely</b> 43:6      205:13  <b>rub</b> 179:13  <b>rubber</b> 58:14  <b>ruled</b> 26:7  <b>rules</b> 33:16 37:21      125:20  <b>run</b> 37:8 53:12      134:14 151:7      192:11 202:21  <b>Russia</b> 53:16  <hr style="width: 50%; margin: 10px auto;"/> <p style="text-align: center;">S</p> <hr style="width: 50%; margin: 10px auto;"/> <b>sad</b> 116:20 163:8  <b>safe</b> 10:15,22 29:11      60:22 204:14      207:15 208:13      209:13,19  <b>safety</b> 9:20 11:2      12:14 27:22</p>	<p>207:19  <b>sake</b> 33:21 34:6 58:9      126:12 191:15  <b>Sally</b> 192:17 207:7      208:1,4 210:8  <b>salute</b> 213:7  <b>San</b> 48:15,22  <b>sanctity</b> 62:16  <b>Sandra</b> 2:10 3:16      221:2  <b>Sandy</b> 88:15 165:10  <b>Sara</b> 3:9 4:10 8:2      14:3 30:18 56:8      65:9 89:20 127:12      147:9 222:1      226:15  <b>sat</b> 70:9  <b>satisfaction</b> 23:6      116:15 206:14      227:3,8  <b>satisfactory</b>      115:3,4,11,19      116:1,16,18,20      117:1,5,11  <b>satisfied</b> 50:2  <b>satisfy</b> 114:18  <b>satisfying</b> 64:15      117:5,6,22      121:4,15 129:9      187:6,8      226:17,18,22  <b>saturates</b> 64:13  <b>save</b> 125:9 144:5  <b>saw</b> 52:3,7 73:11      133:15 149:12      181:10 231:4  <b>scale</b> 28:4  <b>Scanlan</b> 212:10,11</p>
---	---	---	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>Scanlon</b> 192:18</p> <p><b>scares</b> 56:1</p> <p><b>scenario</b> 196:8</p> <p><b>Schnarch</b> 140:10 141:5</p> <p><b>Schnarch's</b> 141:8</p> <p><b>school</b> 132:13</p> <p><b>science</b> 10:17 193:18 203:17</p> <p><b>Sciences</b> 99:3</p> <p><b>scientific</b> 6:14 12:22 30:12 35:18 36:1</p> <p><b>score</b> 47:11 199:16 212:15</p> <p><b>scoring</b> 227:10</p> <p><b>scratches</b> 196:20</p> <p><b>screen</b> 221:9</p> <p><b>screening</b> 16:1</p> <p><b>Script</b> 208:15</p> <p><b>se</b> 103:20</p> <p><b>sealing</b> 58:14</p> <p><b>seats</b> 4:6 123:14,18 221:17 222:3</p> <p><b>second</b> 4:19 24:9 26:12 58:17 112:3 128:11</p> <p><b>seeing</b> 161:2</p> <p><b>seek</b> 189:7</p> <p><b>seeking</b> 137:20 200:8 214:10 229:1</p> <p><b>seem</b> 230:21</p> <p><b>seemed</b> 81:20 224:10 227:2 230:6 231:2</p> <p><b>seems</b> 26:16 90:13</p>	<p>96:5 196:8 198:9,15 204:5,8 225:2 229:2 231:5</p> <p><b>seen</b> 75:1</p> <p><b>Segal</b> 192:16 201:3 203:15</p> <p><b>segment</b> 23:19</p> <p><b>segue</b> 20:9</p> <p><b>select</b> 145:11 146:6</p> <p><b>self</b> 53:9 74:22 97:12 110:7,15 129:9 156:1 193:21 227:4,18 231:13</p> <p><b>self-confidence</b> 53:6</p> <p><b>self-esteem</b> 96:14</p> <p><b>self-love</b> 64:16</p> <p><b>self-worth</b> 211:3</p> <p><b>send</b> 83:8 186:9</p> <p><b>sending</b> 36:22</p> <p><b>sensation</b> 58:14 82:11,16 83:3,16 85:10 89:6,12 90:17 224:16</p> <p><b>sensations</b> 84:19</p> <p><b>sense</b> 29:14 33:8 42:17 82:17 100:12 107:1 118:8 125:8 144:21 170:9 179:5 180:9 227:4,18 228:18 231:13,14,19</p> <p><b>sensitive</b> 21:11 41:15</p> <p><b>sensitivity</b> 58:12 60:3</p> <p><b>sensuality</b> 63:2 101:22</p>	<p><b>sent</b> 105:20</p> <p><b>separate</b> 69:17 89:17 100:12 161:11 186:2</p> <p><b>separated</b> 161:16 221:11</p> <p><b>separately</b> 58:10</p> <p><b>September</b> 199:6</p> <p><b>series</b> 8:18 15:1 129:21</p> <p><b>serious</b> 209:9 233:5</p> <p><b>seriously</b> 11:14</p> <p><b>service</b> 22:1 205:4,5</p> <p><b>serving</b> 5:12</p> <p><b>session</b> 191:4,6 192:4 221:1</p> <p><b>sessions</b> 39:16 131:8</p> <p><b>setting</b> 6:22 91:21 140:19</p> <p><b>settings</b> 122:7</p> <p><b>several</b> 28:12,13 42:12 59:20 98:9 117:13 136:4 150:7 169:3 186:22 199:19 229:16 230:8,11</p> <p><b>severe</b> 22:17 23:12 26:15 27:4 56:19 62:5</p> <p><b>severity</b> 9:3 27:3</p> <p><b>sex</b> 22:12 28:3,11 48:1,4 49:8,20 54:19 55:1 63:8 68:18 75:4,9,19,21,22 78:14,16 79:4,9,11,12,13 80:15 81:14,16 87:5,21 88:8 91:7</p>	<p>96:9 98:1 102:20 105:6 110:4,5 113:17,19,20 115:10 116:7,14,16,18,22 117:6,18 118:15 121:3,8 128:13 129:5,15 130:7 131:8 132:13 133:16 134:21 135:15,18 136:21 139:9,17 140:13 141:14 142:1,5 146:1 163:17 167:16 168:2 174:18 175:11 177:9,10,11 179:19 181:22 182:2,6,10 184:14 186:10,11 187:18 188:1,12 195:11,16 200:7 201:13 202:5,12,17 216:12,13 217:6 218:6 226:22</p> <p><b>sexes</b> 143:3</p> <p><b>sexist</b> 195:8,12 204:12,14</p> <p><b>sexual</b> 1:6 4:14 5:9,19 8:4,11 9:1,5 11:17,18 12:6,18 13:14 14:9 18:3 20:18 21:2,13,15,18 22:2,7,9,10,20,22 23:1,6,7,15,22 24:6,7,9,10,11,15, 16,17 25:10,22 26:7 27:7,19 28:8,11,21 31:13,15 38:1 41:18 43:10,11,12,13</p>
--	--	--	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014

<p>44:18,19 45:3,4,5                  47:12,19 49:4                  50:1,8,12 51:5                  58:20 59:2,4,11,18                  61:3                  62:6,8,9,16,20                  63:3,16 64:2,15                  66:11 68:15 70:22                  71:4,21                  72:5,7,8,16                  73:1,3,8 75:11                  77:9 78:18 80:17                  82:4,8,9,11,14,16,                  20,21,22 84:15,16                  85:9,22 89:6,12                  91:12,15,19 92:22                  94:1 95:20 109:6                  114:12,21                  115:3,9,19 116:1                  117:2,11,21                  120:19 121:15                  122:5 124:10                  128:1 129:9,11                  131:19                  132:1,14,15,17                  133:6 135:12                  136:10,19 138:12                  139:15 141:3,6,17                  142:6 143:13,15                  149:17 152:10                  153:14,20 154:12                  159:1,15                  162:14,17 165:20                  173:17 180:1                  181:3,18 182:12                  188:10,11                  195:4,19 197:22                  199:16 200:9                  204:9                  205:3,14,15,22                  207:1 208:17,21                  209:4 210:12,18                  211:4,15,17                  212:19                  213:10,14,19</p>	<p>214:8,17 216:6,9                  217:21 218:21                  219:13,16                  223:10,13                  224:15,17,20                  225:2,7 226:17,18                  227:8,21 229:19                  230:2,15                  231:4,5,14</p> <p><b>sexuality</b> 62:14                  63:2,13,18,19                  68:10 87:1 101:15                  120:19 143:3                  164:9,21 165:7                  194:1 195:9                  197:12 201:20                  206:9 212:3                  215:16 216:2</p> <p><b>sexually</b> 57:15                  58:3,19 59:16                  140:8,22 142:9                  143:9 187:8                  225:10</p> <p><b>sexy</b> 64:11 92:2</p> <p><b>Shades</b> 196:18</p> <p><b>shame</b> 81:21 135:16</p> <p><b>shape</b> 166:6</p> <p><b>share</b> 21:10 32:6                  34:19 35:21 36:16                  53:2 65:18 67:20                  74:16 94:17                  101:10 142:22                  148:1 158:15                  214:7,14 215:2</p> <p><b>shared</b> 123:7 127:3                  144:9 225:4</p> <p><b>sharing</b> 57:13 67:22                  160:1 190:11</p> <p><b>Sharon</b> 85:20 161:9</p> <p><b>shell</b> 49:18</p>	<p><b>Shere</b> 164:14</p> <p><b>Sheryl</b> 104:7</p> <p><b>shield</b> 60:19                  61:7,10,19</p> <p><b>Shields</b> 166:11,12</p> <p><b>Shifren</b> 23:13</p> <p><b>shift</b> 213:16,18</p> <p><b>shifting</b> 222:3</p> <p><b>shock</b> 62:2</p> <p><b>shoes</b> 81:6</p> <p><b>short</b> 21:2 80:22                  100:22 129:2                  152:11 156:17</p> <p><b>shortage</b> 213:13</p> <p><b>shortcut</b> 143:21</p> <p><b>shortly</b> 136:7 137:2</p> <p><b>shout</b> 7:5 94:5</p> <p><b>shower</b> 196:18</p> <p><b>shown</b> 27:20 204:13</p> <p><b>shows</b> 17:19 23:14                  74:2</p> <p><b>shut</b> 50:16 57:10</p> <p><b>Sid</b> 198:22</p> <p><b>sides</b> 47:4</p> <p><b>Sidney</b> 192:15 197:7                  198:19</p> <p><b>sigh</b> 77:6 133:10</p> <p><b>sight</b> 152:15</p> <p><b>sign</b> 192:2</p> <p><b>signed</b> 80:12 192:3</p> <p><b>significance</b> 199:14</p> <p><b>significant</b> 23:4,19                  26:2,4 31:12 34:5                  55:5,11 57:17                  59:20 72:1 82:6</p>	<p>97:7 122:19 123:3                  124:9 125:6                  126:20 136:6                  191:20 227:21</p> <p><b>significantly</b> 21:20                  43:9 47:15</p> <p><b>signs</b> 181:20                  226:14,16</p> <p><b>Sildenafil</b> 27:17                  230:4</p> <p><b>silence</b> 7:1 56:20                  220:15 222:4</p> <p><b>silent</b> 4:8</p> <p><b>silently</b> 219:18</p> <p><b>silk</b> 162:11</p> <p><b>Silver</b> 1:17</p> <p><b>similar</b> 83:10,13,18                  127:1 160:18                  195:10 224:9</p> <p><b>similarities</b> 174:4</p> <p><b>similarly</b> 162:1                  229:16</p> <p><b>simple</b> 49:9 200:19</p> <p><b>simply</b> 166:22                  211:12</p> <p><b>single</b> 24:18 111:8                  152:17 219:12,14</p> <p><b>sinuses</b> 161:4</p> <p><b>sir</b> 160:9</p> <p><b>sisters</b> 56:22</p> <p><b>site</b> 7:10 219:12</p> <p><b>sitting</b> 77:4 187:16</p> <p><b>situation</b> 76:21                  134:18</p> <p><b>situational</b> 27:9                  186:14</p> <p><b>situations</b> 49:4 67:9</p>
---	--	---	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>145:22</p> <p><b>six</b> 25:7,15,17,21 88:13 106:13 125:16 130:1 137:14 167:18 174:1,5,7 177:3 199:15 209:8</p> <p><b>size</b> 171:6</p> <p><b>skin</b> 58:12 60:3</p> <p><b>skip</b> 149:2</p> <p><b>Slagle</b> 2:9</p> <p><b>sleep</b> 128:19 154:7 196:1,20 218:1</p> <p><b>sleeplessness</b> 152:12</p> <p><b>slide</b> 17:12,19 19:15 26:2 46:14</p> <p><b>slides</b> 17:2</p> <p><b>slight</b> 47:18</p> <p><b>slow</b> 103:20</p> <p><b>slower</b> 104:2</p> <p><b>slowly</b> 59:10 103:14</p> <p><b>small</b> 53:12 59:9</p> <p><b>smell</b> 157:17</p> <p><b>smelled</b> 155:13</p> <p><b>social</b> 99:3 128:5 201:15 203:16</p> <p><b>societal</b> 213:16</p> <p><b>societies</b> 215:18</p> <p><b>society</b> 64:4 68:14 85:22 88:20 197:1 220:10</p> <p><b>solely</b> 128:3 201:12</p> <p><b>solo</b> 91:20</p> <p><b>solution</b> 51:4 57:18 132:4 137:20 138:9,11,16 200:19 216:12</p>	<p>218:15</p> <p><b>solutions</b> 136:1 159:19 216:17,19 220:18</p> <p><b>solve</b> 222:10</p> <p><b>someday</b> 56:1</p> <p><b>somehow</b> 85:2</p> <p><b>someone</b> 67:20 84:16 93:4 98:7 111:1 131:13 156:20 181:1 200:1</p> <p><b>sometime</b> 106:22</p> <p><b>son</b> 132:20</p> <p><b>sorry</b> 17:2 49:7 102:15,17 146:20 148:10 164:6 171:22 187:13 192:18,19</p> <p><b>sort</b> 16:13 17:9 19:17 71:10,13 79:19 80:19 81:13 94:1 107:22 109:1 115:10 119:20 179:14 180:15 193:12 228:22</p> <p><b>sought</b> 48:7 52:9</p> <p><b>soul</b> 105:5</p> <p><b>souls</b> 170:10</p> <p><b>sound</b> 112:4 210:2</p> <p><b>sounded</b> 70:9</p> <p><b>sounds</b> 54:10 83:6 100:4 144:20 178:20</p> <p><b>source</b> 19:11 23:12</p> <p><b>sources</b> 11:15</p> <p><b>space</b> 74:9 142:22</p> <p><b>spanning</b> 48:10</p>	<p><b>speak</b> 33:16,22 34:8,11 38:9 42:4 56:10 105:3 132:14 135:8,9 137:12 191:7 195:2,5 210:9 212:11 219:7 222:9</p> <p><b>speaker</b> 20:15 30:21 192:10</p> <p><b>speakers</b> 73:20 192:12 223:20</p> <p><b>speaking</b> 33:21 42:4 97:9 126:16 204:22</p> <p><b>specialists</b> 48:8 52:8 57:20</p> <p><b>specialties</b> 52:4,11</p> <p><b>specific</b> 6:14 14:12 27:10 32:1 34:10 40:12,16 41:1,10 42:6 97:16 125:17 126:12 158:2</p> <p><b>specifically</b> 13:12 21:3 22:16 25:16 27:14 31:13,14 110:9 116:19 122:6 131:18 170:17</p> <p><b>specifies</b> 25:13</p> <p><b>spectrum</b> 9:3 89:13 120:18 223:6 224:2 229:22</p> <p><b>spend</b> 10:12 88:4 162:4 190:1</p> <p><b>spending</b> 221:15</p> <p><b>spent</b> 48:18 54:7</p> <p><b>spheres</b> 226:11</p> <p><b>spiritual</b> 193:22</p>	<p><b>split</b> 118:5</p> <p><b>spoke</b> 162:9 213:8 220:11 226:2 227:15</p> <p><b>spoken</b> 200:2</p> <p><b>sponsored</b> 34:4 126:19 198:10</p> <p><b>sponsors</b> 11:21 12:17 16:17</p> <p><b>spot</b> 186:5</p> <p><b>spouse</b> 128:4 186:22 227:20</p> <p><b>spouses</b> 215:11</p> <p><b>spread</b> 91:1</p> <p><b>spreading</b> 202:17</p> <p><b>Spring</b> 1:17</p> <p><b>Sprout</b> 47:11 86:1 132:10</p> <p><b>stabilized</b> 60:2</p> <p><b>staff</b> 20:7 33:11,13 39:6 201:7</p> <p><b>stage</b> 145:4</p> <p><b>stages</b> 230:1</p> <p><b>stairway</b> 101:18</p> <p><b>stake</b> 205:9</p> <p><b>Stakeholder</b> 37:13</p> <p><b>stand</b> 197:8 221:3,6</p> <p><b>standards</b> 10:18 12:4,5</p> <p><b>standing</b> 69:14 220:2</p> <p><b>standpoint</b> 112:1</p> <p><b>stands</b> 30:22</p> <p><b>start</b> 5:6 18:14 32:18 42:19 47:5,6 66:21 69:3 71:18 72:19</p>
--	--	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>145:3 147:18 150:16 152:5 159:10 169:19 193:12</p> <p><b>started</b> 4:5 17:4 47:22 51:19,22 52:5 56:6 58:6 101:6 106:13 140:8 141:12 155:11 158:21 164:12,18,21 219:17</p> <p><b>starter</b> 72:3</p> <p><b>starting</b> 47:13 69:2 99:15 162:15</p> <p><b>starts</b> 69:11 79:11 177:22</p> <p><b>state</b> 33:19 68:2 100:15 102:19 104:19 119:3 126:16 170:2 191:22 234:20</p> <p><b>stated</b> 40:21 140:4 165:5</p> <p><b>Statistical</b> 24:20</p> <p><b>statutes</b> 11:1</p> <p><b>stay</b> 39:5 73:21 79:4,6,18 142:17 171:13</p> <p><b>stayed</b> 49:17 131:13 157:21</p> <p><b>staying</b> 186:21</p> <p><b>steady</b> 100:15 154:22</p> <p><b>Steel</b> 163:2</p> <p><b>step</b> 180:5</p> <p><b>stereotype</b> 81:15 120:13</p> <p><b>stereotypes</b> 64:6</p>	<p><b>stereotypical</b> 140:22</p> <p><b>stick</b> 192:6</p> <p><b>sticky</b> 157:18</p> <p><b>stimulated</b> 59:10</p> <p><b>stimulating</b> 69:11</p> <p><b>stimulation</b> 58:20 188:17 226:10</p> <p><b>stipend</b> 87:15</p> <p><b>Stoddard</b> 202:4</p> <p><b>stomach</b> 155:20</p> <p><b>stop</b> 52:12 56:20 93:11 99:18</p> <p><b>stopped</b> 48:1 81:4 139:9 148:11 157:9</p> <p><b>stops</b> 79:5 178:1</p> <p><b>stories</b> 21:10 32:6 36:17</p> <p><b>story</b> 36:14 47:14 51:15,17 56:7 57:7,13 66:5 139:1 220:11</p> <p><b>strain</b> 49:22 50:14</p> <p><b>strangely</b> 202:11</p> <p><b>Strategic</b> 4:12 14:19</p> <p><b>strawberries</b> 211:9</p> <p><b>strength</b> 126:9 176:7</p> <p><b>stress</b> 134:2,6 184:15 218:3</p> <p><b>stresses</b> 63:9 74:2</p> <p><b>stressful</b> 129:15 145:22</p> <p><b>stressing</b> 164:11 227:17</p> <p><b>stressor</b> 63:13</p> <p><b>stressors</b> 26:15,17</p>	<p>63:5 66:16 79:16</p> <p><b>stretch</b> 221:6</p> <p><b>strict</b> 130:13</p> <p><b>striking</b> 224:9 227:16 229:9</p> <p><b>stringently</b> 206:18</p> <p><b>stroke</b> 60:15</p> <p><b>strong</b> 34:22 186:20 199:5</p> <p><b>strongly</b> 56:16</p> <p><b>stuck</b> 156:11</p> <p><b>student</b> 201:6 207:11</p> <p><b>studied</b> 27:15,18 99:9</p> <p><b>studies</b> 22:1 28:4 206:8 227:9 232:19</p> <p><b>stuff</b> 165:6 209:17</p> <p><b>stupid</b> 50:15</p> <p><b>style</b> 31:3</p> <p><b>subgroup</b> 166:21</p> <p><b>subject</b> 23:8 51:12 84:20 123:1 127:21</p> <p><b>subjective</b> 118:8 188:11 231:2</p> <p><b>submit</b> 10:5 32:17 38:15 96:19 160:6</p> <p><b>submitted</b> 12:3 16:21 21:4 112:19</p> <p><b>subsequent</b> 20:9</p> <p><b>subsequently</b> 22:18 224:11</p> <p><b>substance</b> 26:22 200:12</p>	<p><b>substantial</b> 10:19</p> <p><b>subtext</b> 197:21</p> <p><b>subtle</b> 59:9</p> <p><b>succeeded</b> 58:22</p> <p><b>success</b> 116:4 151:15 158:3 188:13 229:10</p> <p><b>successes</b> 144:22</p> <p><b>successful</b> 75:20 121:4 151:12,13 231:6</p> <p><b>successfully</b> 88:1</p> <p><b>sudden</b> 167:21 186:10</p> <p><b>suddenly</b> 148:18 225:16,22</p> <p><b>Sue</b> 68:4 79:1 80:7 103:2 172:1 173:21,22 177:3 192:19 214:1 215:14,15 217:13</p> <p><b>Sue's</b> 69:22</p> <p><b>suffer</b> 212:22</p> <p><b>suffered</b> 51:17 61:15 78:10 151:20 219:16 220:14</p> <p><b>suffering</b> 56:20 152:9 219:18</p> <p><b>sufficient</b> 24:13 130:17</p> <p><b>suggest</b> 229:11</p> <p><b>suggested</b> 22:1</p> <p><b>suggests</b> 99:13</p> <p><b>sum</b> 200:12</p> <p><b>summarize</b> 35:3 221:7 224:7</p> <p><b>summary</b> 19:21</p>
---	---	--	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 43

<p>46:13 94:6  <b>summer</b> 139:1  <b>summoned</b> 135:21  <b>supplement</b> 145:20  <b>supplying</b> 135:7  <b>support</b> 21:5 28:4              40:10 57:14 59:22              146:2 163:17              164:5 213:9  <b>supported</b> 86:1              205:5  <b>supporting</b> 9:13              40:21  <b>supportive</b> 55:5  <b>suppose</b> 68:6  <b>supposed</b> 49:12  <b>sure</b> 38:20 45:16              55:15 65:18 82:19              85:4 89:4 90:3              94:14 97:21              123:19 158:11              160:8 165:17              231:18  <b>Surely</b> 133:13  <b>surgeries</b> 179:19  <b>surgery</b> 137:14  <b>surgical</b> 137:10              225:18 229:21  <b>surgically</b> 161:12  <b>surprise</b> 136:21  <b>surprised</b> 56:15  <b>surprising</b> 230:17  <b>surreal</b> 193:9  <b>survey</b> 35:18              214:15,16  <b>survive</b> 152:7</p>	<p><b>survivor</b> 128:6  <b>Susan</b> 138:19,20              163:19 185:21              187:13,15 188:2              192:18 210:10              212:8,11  <b>sweats</b> 152:13  <b>swelling</b> 52:19 54:15  <b>swings</b> 129:2  <b>switch</b> 103:11 111:3              134:12 167:20  <b>switched</b> 155:19  <b>switching</b> 196:14  <b>swollen</b> 161:4  <b>sworn</b> 234:5  <b>symptom</b> 12:17 25:9              43:14 58:11,17              102:14 104:13              125:14 171:1              172:15  <b>symptomatic</b> 107:14  <b>symptomatology</b>              174:8  <b>symptoms</b> 5:14 9:3              13:13 23:11              25:7,11,15,16,19,2              0 26:1 29:15              31:10,11,15,20              32:20 40:6 41:5              45:14 46:1,17,19              47:15 49:2,17 53:3              55:12 57:22 58:8              59:5 62:5 63:10              89:10 92:19 93:21              94:6,10,16 97:1              99:11,12,19 101:6              102:11 104:16              105:17              106:16,19,20              107:8,11,19</p>	<p>108:4,6,19 110:13              111:1 113:11              114:8 123:4              124:22 125:5,6,11              126:3 128:9,15,18              130:9 145:9 147:6              149:12,21 158:21              169:21 170:1              171:4 172:20              174:9,11 176:3              226:14,16 229:18  <b>system</b> 58:1 172:12              227:10  <b>systematically</b>              15:3,17  <b>systemic</b> 229:17</p> <hr/> <p style="text-align: center;">T</p> <hr/> <p><b>table</b> 35:12 123:16              190:18  <b>tackle</b> 223:3  <b>tactile</b> 86:20  <b>tags</b> 32:11  <b>tailor</b> 18:15  <b>taking</b> 47:9 59:11              65:21 103:5              133:14 138:6              146:5,13,18              147:11,12,14              149:21 154:19              158:22 169:20,22              171:9 173:9,15              182:14,16 193:15              218:11 232:16  <b>talk</b> 18:19 19:1              22:21 31:18 36:7,8              46:21 50:6 51:14              57:1 58:21 65:4              75:8 87:17 94:15              96:22 99:19              104:15 110:9</p>	<p>117:22 124:21              135:19,22              137:17,19 149:9              160:10 163:15              164:1 168:8              189:4,13 193:16              204:9 208:18              210:17 216:2,8              227:7  <b>talked</b> 54:19 68:13              73:9 83:6 114:21              120:2 152:13,21              160:4 169:11              176:3  <b>talking</b> 5:6 41:20              57:3 67:5 86:13              99:15 109:16,17              113:9 114:6 125:2              138:5 148:19              171:15 176:9              178:8,22 181:22              186:1 187:21              188:8 189:19              193:10 205:21              216:6  <b>talks</b> 205:2  <b>tangible</b> 130:6  <b>tanked</b> 151:21  <b>target</b> 125:12 131:22  <b>taught</b> 79:19  <b>taxes</b> 220:10  <b>teach</b> 138:3  <b>tached</b> 165:2  <b>teacher</b> 62:14  <b>teaching</b> 52:8  <b>team</b> 9:8 20:21 21:3  <b>tears</b> 114:9  <b>tease</b> 43:20 45:19              94:18</p>
--	--	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>teased</b> 93:7</p> <p><b>teasing</b> 92:7</p> <p><b>teaspoon</b> 170:18</p> <p><b>technical</b> 13:3</p> <p><b>techniques</b> 63:2</p> <p><b>technology</b> 91:4 202:21</p> <p><b>tee</b> 102:8</p> <p><b>teenage</b> 184:21</p> <p><b>teeth</b> 179:13</p> <p><b>teleconference</b> 86:5</p> <p><b>tempered</b> 129:3</p> <p><b>ten</b> 45:15 46:2 83:3 93:10 153:1 167:21 184:13 199:9 212:21 221:5</p> <p><b>tend</b> 75:4 83:17</p> <p><b>Tens</b> 61:14</p> <p><b>tense</b> 73:19</p> <p><b>tent</b> 32:12</p> <p><b>term</b> 20:11 24:3 28:1 64:2 83:18,19,20 90:7 99:22 100:2,3,4 109:3 152:11 175:18 185:16</p> <p><b>terminologies</b> 29:7</p> <p><b>terminology</b> 67:16</p> <p><b>terms</b> 15:15 42:2 59:14 82:13 83:16 84:12 88:9 90:4 112:20 113:16 114:10 126:5 151:7 169:6 204:3 227:13</p> <p><b>test</b> 48:20 80:4 106:11 131:11</p>	<p>170:22</p> <p><b>testified</b> 199:10</p> <p><b>Testim</b> 106:7 131:7 155:11 157:4 169:6 179:11,21</p> <p><b>testimony</b> 234:4,6,9</p> <p><b>testing</b> 48:11,19 54:19 139:20 170:14</p> <p><b>testosterone</b> 65:20,21 80:1 100:21 103:5,18 131:6,10 136:3,4 137:9 139:22 148:11 149:9 150:6,9,14,22 151:3,5,8,15 152:3 153:8 154:19 155:22 157:4,16 158:4,5,8,13 168:16 170:17 172:11 173:22 174:5 177:8 178:9,10,21 180:15 181:5,7 186:15,21 199:7,12 229:6,7,11 230:19</p> <p><b>tests</b> 48:10,13 129:22 130:13 153:7 168:14</p> <p><b>text</b> 148:21</p> <p><b>texting</b> 148:19</p> <p><b>thank</b> 4:19 8:1,2,15 14:13 20:16 30:17,19 32:21 43:4 45:1 46:5 51:6,7 57:6,8 60:9,10 64:21,22 66:5 67:3 74:3 75:7 76:22 78:21 80:7 81:9,22 82:1</p>	<p>85:17 87:18 88:14 93:19 96:16 102:4 104:4,21 105:15 106:6 110:19 111:11 113:14,21 114:19 118:11 120:10 122:10 123:10 124:2 127:9,11,12,19 132:5,6,9 135:2,3,6 138:17,18 144:3,4 147:3 150:1 154:14 155:2 156:19 160:1,2 165:9 166:11 168:21 169:10 173:19 176:1 182:19 185:12,19 188:2,20 189:21 190:11,22 191:3 194:12,14 197:5,8,15 198:18,21 200:21 201:1 203:10,12 204:16,18 207:5,20,22 210:5,8 212:5,7,10 213:20,22 215:7,9,11,13 216:1 217:11,13,16 219:2,4,6 220:22 221:14 233:4,5</p> <p><b>thankful</b> 153:6,17 183:18</p> <p><b>thanks</b> 90:13 111:20 158:10 233:9</p> <p><b>Thea</b> 81:11 102:17 192:15 194:14 197:10</p> <p><b>the-counter</b> 147:2</p> <p><b>themes</b> 232:13</p>	<p><b>themselves</b> 13:16 35:15 185:1 224:12</p> <p><b>therapeutic</b> 5:10 109:20 110:12 140:19</p> <p><b>therapies</b> 9:14,17 11:10,16 27:22 28:2,3,20 29:11 30:14 40:22 103:4 145:14 146:1,5,13,19 147:7,17 150:3 163:16,17 169:22 170:4,21 231:8 232:1 233:1</p> <p><b>therapist</b> 54:19 85:6,8 91:7 116:14 117:18 131:9 142:13 181:13 188:12</p> <p><b>therapy</b> 11:11 14:12 15:10 19:1 28:3 54:8 57:1 65:16 110:5 130:5 140:4 145:17,19 146:1 149:19,20,22 154:6 167:14 168:2,3 169:5,20 170:2,16 177:12 217:5,6</p> <p><b>thereafter</b> 136:8 137:2 234:7</p> <p><b>therefore</b> 10:8 14:9 41:22 131:3</p> <p><b>there's</b> 178:4</p> <p><b>Theresa</b> 2:8 3:6 8:20 14:15,18 37:8</p> <p><b>they'll</b> 118:3</p> <p><b>they've</b> 28:9 80:19 189:8 194:3</p>
--	--	--	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>206:17 214:20 <b>thighs</b> 156:1 <b>thin</b> 198:16 <b>third</b> 24:12 26:20 27:8 44:20 55:19 <b>thoughtfully</b> 222:13 <b>thoughts</b> 25:3 72:16 81:8 84:21 122:18 127:21 148:17 179:6 190:7 <b>thousands</b> 61:14 117:21 <b>threatening</b> 21:19 52:18 54:14 142:6 <b>throttle</b> 180:21 <b>throughout</b> 10:7 69:21 114:14 168:1 222:19 <b>thrown</b> 193:8 <b>thus</b> 15:9 141:3 <b>Tiefer</b> 192:14,21 193:5 199:10 <b>timer</b> 192:7 <b>tingly</b> 68:20 <b>tiny</b> 161:3 <b>tips</b> 196:19 <b>tired</b> 161:3 213:10 <b>today</b> 4:21 5:12,22 6:2,13 13:18 14:5,10,14 18:10,17 19:14 20:4 28:19 29:13 31:2 35:2,4 36:7,16 37:19 38:14,15,17 39:1,5,9 40:5,11,15 41:13 43:3,8 44:6</p>	<p>51:11,14 56:11 61:17 67:1 79:7 87:15 116:9 126:11 132:12 138:22 142:8 151:19 152:13,19 163:20 188:14 190:5,8 191:3,18 194:1 195:2,20 197:19,21 200:12 203:22 208:16 210:4,20 213:4 218:16 219:7,21 221:8 222:16 223:1 224:2 225:1 231:7 232:17 <b>today's</b> 4:13 8:3,18 10:10 13:7 18:3 21:14,17 39:22 46:11 223:11 <b>tomorrow</b> 4:22 6:13 13:1 14:10 30:13,16 39:15 45:13 227:7 232:15 233:8 <b>tomorrow's</b> 30:11 39:11 <b>tongue</b> 179:17 <b>tongue-tied</b> 45:9 <b>tonight</b> 180:16 184:7,8,14 <b>tool</b> 154:4,5,10 <b>toolbox</b> 154:5 <b>tools</b> 14:1 20:10 202:7 <b>top</b> 52:9 82:13 98:8 102:3 180:19 214:7,9 219:13 <b>topic</b> 3:10,11,13,14 5:17 21:11 32:9 34:11 46:8 55:8</p>	<p>66:2 123:3,4,14 124:4,6,13,18 126:16 127:4 214:13 216:1 221:20 <b>topical</b> 57:21 106:4,7 130:11,12 150:14,16 153:10 155:11 229:8 <b>topics</b> 5:13,21 6:8 13:5 31:8 32:5 34:12 41:15 46:5 189:22 191:9 214:7 <b>total</b> 61:4 62:6 <b>totality</b> 11:5 <b>totally</b> 104:1 <b>touch</b> 41:1,15 160:8 189:3 <b>touched</b> 59:10 121:22 124:16,17 232:13 <b>tough</b> 84:20 123:1 <b>tour</b> 129:22 <b>toward</b> 138:1 <b>towards</b> 140:13 <b>toys</b> 87:5 162:17 <b>track</b> 106:17,19,20 108:3,18 109:10 169:21 171:16 172:4,6 174:13 219:14 <b>tracked</b> 172:9 209:7 <b>tracking</b> 106:16 107:19 169:12 171:18 172:4,5,12,19 175:18 <b>transcribed</b> 191:14</p>	<p><b>transcript</b> 7:3 19:20 235:4,6 <b>transcription</b> 235:1,7 <b>Transcriptionist</b> 235:13 <b>transfer</b> 186:22 <b>transmission</b> 85:12 <b>transparency</b> 33:21 34:6 191:15 <b>traumatized</b> 62:1 <b>travel</b> 34:4 47:10 51:10 68:5 80:13 85:6 86:1 87:15 105:1 106:6 117:18 118:14 126:19 127:11 132:11 191:18 <b>traveled</b> 173:14 <b>traversed</b> 43:5 <b>treat</b> 12:17 13:16 14:9 18:10 21:2 27:14 29:3 31:19 35:22 125:4 145:8 154:2 218:2 <b>treated</b> 55:2 65:13,19 80:22 88:1,13 96:3 107:6,17 109:6 112:14 117:20 168:17 <b>treating</b> 5:18 31:18 124:14 188:13 195:4 <b>treatment</b> 3:7 27:18 28:15 30:2 32:1 40:7,10,20 41:7,8,10 50:13 52:4 54:17 55:13 56:3 57:19 65:15</p>
--	---	--	---



Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>66:7,18 75:4 78:12 100:8,11,12,19 101:3,4 102:10,13 103:15,16 107:21 108:9,11,18 109:17 111:10,22 112:18 124:16,22 125:1,7,11,22 126:13 128:8 130:7 131:3 134:15 138:11 143:1 157:16 169:4,15 170:5,21 178:21 198:2 199:14 204:4,10,11 208:11 209:14 213:9 228:14 229:11 230:22 231:6</p> <p><b>treatments</b> 8:12 13:19 15:5 18:11,21 28:5 41:1,3,4 55:19 56:2 102:6 104:13 109:18 125:17 126:3,12 131:16,18 143:11,13 145:1 147:17 161:12,14 166:9 168:22 170:6 176:9,14,18 179:2 180:3 206:13,16,17,19 207:3 208:17 209:19 212:18 220:17 223:22 228:15 229:5 231:10</p> <p><b>treats</b> 149:17 196:2</p> <p><b>tremendous</b> 10:9</p> <p><b>tremendously</b> 78:12 153:11</p>	<p><b>trend</b> 214:8</p> <p><b>trial</b> 13:6 18:22 59:21 145:16 148:9,11 149:7,11 175:8 232:22</p> <p><b>trials</b> 10:2,5 12:13 29:16,21 30:10 137:4 194:10 200:6 230:12 232:2</p> <p><b>trick</b> 211:14</p> <p><b>tried</b> 58:21 131:4 137:8 145:6 148:11 156:15 163:2 165:18 168:1,20 222:2 230:5</p> <p><b>tries</b> 50:7 110:14</p> <p><b>triggers</b> 27:12</p> <p><b>trip</b> 49:22 78:7 99:4 138:22 167:19</p> <p><b>trouble</b> 167:5 181:19,20</p> <p><b>troubled</b> 211:3</p> <p><b>trough</b> 88:8</p> <p><b>true</b> 117:14 167:3 207:19 234:8 235:7</p> <p><b>truly</b> 195:12 198:12</p> <p><b>try</b> 18:12 19:3,20,22 20:3,9 31:1 33:15 34:9,14 38:9 40:2 43:19,21 45:19 49:7 73:20 79:10 91:2 100:1,3 119:7 126:11 136:3,16 140:1,3,5 156:9 161:2 170:10 211:6 221:7,10 222:12 224:7</p>	<p>230:9</p> <p><b>trying</b> 15:3 88:4 100:12 228:13 230:8</p> <p><b>turn</b> 5:1 7:21 14:15 20:14 30:18 92:3 110:18 190:20 194:15</p> <p><b>turned</b> 52:2 63:17 69:3 103:11 199:20,21 200:3,15 202:13</p> <p><b>turns</b> 79:12 175:21 192:8</p> <p><b>tweaked</b> 171:12</p> <p><b>twice</b> 17:2 156:6 170:17</p> <p><b>type</b> 58:1 59:1 60:13 71:4 83:8 84:1 126:3 172:18</p> <p><b>typed</b> 235:4</p> <p><b>types</b> 150:9,11 229:4</p> <p><b>typewriting</b> 234:7</p> <p><b>typical</b> 173:18</p> <p><b>typically</b> 73:3</p> <hr/> <p style="text-align: center;">U</p> <hr/> <p><b>U.K</b> 197:12</p> <p><b>U.S</b> 11:7 22:4 23:14 208:6</p> <p><b>ultimate</b> 101:20</p> <p><b>ultrasounds</b> 48:12</p> <p><b>Umbidwa</b> 164:6</p> <p><b>unable</b> 169:9</p> <p><b>unattractive</b> 59:16</p> <p><b>unavoidable</b> 124:17 125:19</p>	<p><b>unbelievable</b> 95:10</p> <p><b>unchanged</b> 24:21</p> <p><b>uncomfortable</b> 129:14 221:17,21</p> <p><b>undergo</b> 137:13</p> <p><b>underlying</b> 12:9 99:13 229:12</p> <p><b>underserved</b> 220:6,7</p> <p><b>understand</b> 7:6,11 8:14 13:19,20 15:7 16:17 35:20 38:7 40:8 41:5 50:7 51:18 56:14,19 86:4 118:2 126:2 145:4 162:5 186:15 193:22 207:12</p> <p><b>understanding</b> 13:15 15:8 38:16,18 86:8,9 89:15 144:1 161:15 178:6 186:4 227:11 228:11,19</p> <p><b>understands</b> 137:22 218:10</p> <p><b>undesired</b> 230:18</p> <p><b>undiagnosed</b> 61:8</p> <p><b>undoubtedly</b> 134:13</p> <p><b>undue</b> 223:17</p> <p><b>unfamiliar</b> 53:1</p> <p><b>unfold</b> 46:5</p> <p><b>unfortunate</b> 36:20</p> <p><b>unfortunately</b> 49:16 55:5,20 56:12 80:20 81:5 108:19 148:12 155:12 156:4 171:7</p> <p><b>UNIDENTIFIED</b></p>
--	---	---	---

Capital Reporting Company  
 Patient-Focused Drug Development Public Meeting 10-27-2014  
 Page 47

<p>74:7,12 92:20 93:4                  160:10 188:7  <b>unique</b> 15:15 19:3                  76:16  <b>University</b> 194:18                  197:12,13 201:7                  203:18  <b>unknown</b> 142:18                  199:17  <b>unless</b> 65:6 88:12  <b>unmet</b> 57:1 104:10                  127:20  <b>unpredictable</b>                  142:18  <b>unrealistic</b> 64:9  <b>unsafe</b> 197:17  <b>unsurprising</b> 146:7  <b>untangle</b> 124:19  <b>untreated</b> 61:9  <b>unwanted</b> 136:6                  137:11  <b>upbeat</b> 129:4  <b>upgrading</b> 196:15  <b>upon</b> 41:1 67:13                  76:12 92:17 95:3                  121:22 124:16                  126:1 130:11                  160:8 164:1 171:7                  190:7,8  <b>upset</b> 155:21 181:9  <b>upside</b> 52:2  <b>urge</b> 161:10  <b>urogynecologists</b>                  52:10  <b>Urologic</b> 8:7 20:22  <b>usage</b> 133:19  <b>useful</b> 41:9 89:16</p>	<p>102:11 107:16                  110:16 124:7                  162:5 164:8                  169:16  <b>user</b> 16:9  <b>usual</b> 17:6  <b>usually</b> 91:15                  106:10 180:11                  200:20  <hr style="width: 20%; margin: 10px auto;"/> <p style="text-align: center;">V</p> <hr style="width: 20%; margin: 10px auto;"/> <b>VA</b> 129:20  <b>vacation</b> 49:11                  180:11  <b>vacations</b> 49:14  <b>vagina</b> 164:17  <b>vaginal</b> 28:16                  113:15 128:17                  129:14,22                  130:17,20  <b>VAIDYA</b> 191:2                  194:12 197:3,7                  198:18 201:1                  203:12 204:18                  207:5,22 210:8                  212:7 213:22                  215:13 217:13                  219:4 220:22  <b>valid</b> 186:19  <b>validated</b> 30:9  <b>valuable</b> 16:3  <b>value</b> 13:19  <b>vamps</b> 210:15  <b>vanished</b> 129:13  <b>variability</b> 170:1,8  <b>variable</b> 70:17                  122:13  <b>variation</b> 151:10</p>	<p>178:5 223:13                  226:3 229:10  <b>variations</b> 227:14  <b>varied</b> 84:4 87:7                  229:16  <b>varies</b> 114:14  <b>variety</b> 52:3 99:16                  199:7 225:19                  230:9,20  <b>various</b> 57:20 131:4                  198:5 229:5  <b>vary</b> 186:18  <b>vastly</b> 75:16  <b>vectors</b> 210:15  <b>vegetables</b> 134:4  <b>vehicle</b> 36:21  <b>vehicles</b> 220:9  <b>Venn</b> 226:12  <b>verbal</b> 82:10 83:1,7                  86:19 91:20 130:5  <b>verbalizing</b> 141:3  <b>verbatim</b> 25:8  <b>Veritas</b> 47:9 51:10                  78:7 80:14 85:7                  87:16 95:6 104:22                  106:5 127:11                  132:9 135:7                  158:19 185:12  <b>Versabase</b> 131:7  <b>version</b> 79:20  <b>versus</b> 86:6 124:22                  188:10 208:20                  212:18  <b>vestibular</b> 89:11  <b>vetted</b> 215:4  <b>via</b> 21:8 137:10                  206:3</p>	<p><b>viable</b> 138:8  <b>Viagra</b> 27:18                  160:14,18 161:2                  182:5 185:17                  186:5 202:6 209:5  <b>Viagras</b> 230:4  <b>vibrator</b> 166:7                  196:16  <b>Vicki</b> 100:17 103:22  <b>Victoria</b> 47:5,8 51:8                  77:15,16 100:19                  101:11 197:13  <b>view</b> 34:19                  139:1,3,15 164:9                  189:6 193:7 207:9  <b>viewed</b> 220:8  <b>views</b> 96:7  <b>Viki</b> 47:9  <b>violence</b> 26:17  <b>Virginia</b> 91:8  <b>virtually</b> 149:5  <b>virtues</b> 126:1  <b>vision</b> 154:2  <b>visit</b> 214:6  <b>visual</b> 82:10 83:1,7                  86:19 91:20                  148:20  <b>Vitro</b> 113:3  <b>vixens</b> 210:14  <b>voice</b> 19:18 205:4,11                  206:5  <b>voices</b> 215:10  <b>volume</b> 106:8  <b>volunteer</b> 201:7  <b>voted</b> 44:17 224:14  <b>votes</b> 86:17</p>
--	--	---	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p><b>vulnerable</b> 201:20</p> <p><b>vulva</b> 166:2</p> <p><b>vulvar</b> 28:16 89:10</p> <hr/> <p style="text-align: center;">W</p> <hr/> <p><b>wait</b> 42:3 94:12</p> <p><b>waited</b> 133:1</p> <p><b>waiting</b> 95:14</p> <p><b>wake</b> 177:10 184:12</p> <p><b>walls</b> 216:4</p> <p><b>wane</b> 46:17 55:12 100:10 101:7</p> <p><b>waned</b> 57:22</p> <p><b>wanes</b> 102:18</p> <p><b>waning</b> 100:14 102:10,13,15 103:7,19 105:7 111:9 141:11 143:14</p> <p><b>war</b> 140:21</p> <p><b>warning</b> 63:20</p> <p><b>Warwick</b> 197:12</p> <p><b>Washington</b> 42:22 213:5</p> <p><b>wasn't</b> 52:11,12 81:16 101:1,2 133:11,21 139:11 141:7 154:8 155:15 173:5,15</p> <p><b>waste</b> 79:8 210:1</p> <p><b>watch</b> 164:20</p> <p><b>watched</b> 164:19</p> <p><b>Watson</b> 117:17</p> <p><b>wave</b> 60:17 180:20</p> <p><b>wax</b> 46:17 55:12 100:9 101:7</p>	<p><b>waxed</b> 57:22</p> <p><b>waxes</b> 102:18</p> <p><b>waxing</b> 100:14 102:10,13,15 103:7,19 105:7 111:9 143:14</p> <p><b>Wayne</b> 166:12</p> <p><b>ways</b> 20:11 27:3 87:2,7 185:18 198:5</p> <p><b>weaning</b> 159:5</p> <p><b>wear</b> 58:5</p> <p><b>wearing</b> 66:15 75:4</p> <p><b>web</b> 6:2 7:10 8:15 10:11 21:8 23:2 34:22 35:2,8 37:2 42:18 44:13 45:21 46:1 72:11 82:17,20 83:5,9 94:5,8 114:4 121:20 145:5 146:16,17 147:10 168:22</p> <p><b>Webcast</b> 7:4,5,7,8 19:9 34:18</p> <p><b>Website</b> 36:18,22 166:5 214:6</p> <p><b>Websites</b> 214:11</p> <p><b>we'd</b> 29:13 46:20 71:20</p> <p><b>week</b> 49:11 130:10 134:5 156:6,17 168:16 174:14 180:6,11 187:19</p> <p><b>weekend</b> 216:11</p> <p><b>weekly</b> 108:14</p> <p><b>weeks</b> 106:13,14 130:14 136:18 148:16 154:20</p>	<p>167:18 170:7 174:6,7,12 175:19 177:7,18 187:10</p> <p><b>weight</b> 52:19 134:3 137:11 171:4,5</p> <p><b>welcome</b> 4:13 5:2 7:22 8:3 20:17 21:11 38:5 57:11</p> <p><b>we'll</b> 4:9 31:17 34:7 43:17 46:20 67:9 68:1 86:22 91:2 94:12 97:3 120:22 123:10 125:9 135:5 149:14 156:9 172:1 179:7</p> <p><b>Wellbutrin</b> 157:10</p> <p><b>we're</b> 5:5 8:12 17:16 32:5 33:15 99:20 109:16 124:13 217:1</p> <p><b>Western</b> 104:9</p> <p><b>wet</b> 68:20 69:5</p> <p><b>wetness</b> 69:1</p> <p><b>we've</b> 4:8 17:22 28:14 30:21 31:9 46:14 86:12 94:10 104:11 105:6 108:8 109:17 114:5,21 124:10 125:8 144:20,22 152:17 163:22 166:10 176:3 198:2 210:16 211:6</p> <p><b>whack</b> 106:10</p> <p><b>whatever</b> 125:1 142:13 159:5 169:20 178:10 181:21</p> <p><b>whatsoever</b> 132:16</p>	<p>136:14 149:6 157:5</p> <p><b>wheels</b> 75:1</p> <p><b>whereas</b> 103:6,13 104:2 185:6 195:9</p> <p><b>WHEREUPON</b> 123:12 233:11</p> <p><b>wherever</b> 75:20</p> <p><b>whether</b> 11:3,22 22:17 27:6,8,11 28:9 29:19 36:11 40:19 43:4 44:10 64:16 108:10 115:2,8,11,22 118:17 149:20 174:2,3 217:2 233:1</p> <p><b>whisper</b> 216:4</p> <p><b>Whitaker</b> 2:7</p> <p><b>White</b> 1:14</p> <p><b>WHITTAKER</b> 66:4 89:19 147:9 172:2</p> <p><b>whole</b> 52:1 81:3 87:21 97:10,20 98:2 104:10 142:7 181:8 194:5 199:7</p> <p><b>whom</b> 180:20 211:18 234:2</p> <p><b>whose</b> 144:18 234:4</p> <p><b>wide</b> 9:3 43:3 61:15 145:1 151:6,10 223:4</p> <p><b>wider</b> 16:4</p> <p><b>widespread</b> 229:18</p> <p><b>wife</b> 104:22 116:8 175:5 186:21</p> <p><b>willing</b> 11:20 18:21 21:10 79:3,10</p>
---	---	---	---

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014

<p>94:17 <b>willingness</b> 221:19 <b>winds</b> 93:8 <b>wine</b> 216:11 <b>wink</b> 64:16 <b>wisdom</b> 60:7 <b>wish</b> 36:8 122:16 183:19 <b>witness</b> 234:4,6,9 <b>Wolfe</b> 192:15 197:8 198:19,22 <b>woman</b> 23:10 41:9 50:20 62:18 86:7 88:19 91:11,22 92:1,8,10 93:8 105:9,13 116:21 121:11 128:3 129:11 133:12 134:22 171:8 174:3 182:13 188:5,8 195:2 207:10 211:13 218:10 <b>woman's</b> 21:21 23:6 132:14 200:9 226:5 <b>women</b> 8:10 9:2 11:22 22:1,4,5,14,15 23:1,8,15 24:15 28:20 32:19 35:2,15 37:22 38:18 40:10 41:17,20 51:3,18 56:20 57:14 61:14 62:15 64:11 65:2 67:5 79:15 80:20 81:20 86:4 89:8,16 91:17 97:21 100:22 103:10,11 104:14 117:19,21</p>	<p>119:21 122:22 123:7 127:20 132:3 133:6 136:9 137:19 138:11 141:1 144:8 149:18 152:12,16 154:10 156:14 159:17 161:12 164:15 170:20 173:4 178:7,11,14,16 183:22 185:17 186:16,18 187:7 188:13,15 189:2,4,16,19 195:16 196:11 199:5,12 200:6 201:12,16,19,20 202:21 203:5,7 204:10 205:13,21 206:1,2,6,11,22 208:7,9,20 209:3,13,15,18,22 210:14,17,18 211:6,9,11,18,21 212:15,21,22 213:1,4,7 214:6,9,15,16,20 215:2,3,10,22 216:8,14,19,20 218:22 219:11,18,19 220:4,14 223:22 226:10 228:10 229:21 <b>women's</b> 38:7 68:15 85:22 122:19 131:19 132:1 152:6 164:13 197:18,22 205:1,3,4,10,11 206:3 208:10 212:12,14 213:16,18 214:4,8</p>	<p>220:6 <b>wonder</b> 90:15 99:18 120:2 <b>wondered</b> 81:18 <b>wonderful</b> 44:5 78:15 135:14 188:19 210:16 <b>wondering</b> 86:18 100:10 134:13 147:21 179:1 <b>wood-like</b> 202:8 <b>work</b> 4:22 10:6 11:20 26:18 31:20 38:19 48:11 52:14 79:21 85:2 100:21 124:3 137:15 140:4,18 141:5 143:16 144:2 159:9,11 163:9,18 166:18 168:20 169:4,7 170:14 171:1,2 175:5,10 176:14 181:8 188:16 194:19 201:7 205:18 206:20 208:8,13 211:22 216:18 218:14 228:18,22 <b>worked</b> 131:5 137:7,12 140:20 148:13 156:3,21 157:16 163:3 164:2,3 173:11 177:12 200:13 228:15 <b>working</b> 10:3 18:1 41:7,10 88:7 104:12 133:21 140:2 156:7 159:17 176:18 215:20 225:4</p>	<p><b>workplace</b> 128:5 <b>works</b> 29:19 97:22 180:20 186:5,16 <b>workshop</b> 21:7,15 29:4 30:12 210:4 <b>world</b> 75:22 97:12 133:12 139:7 198:6 220:4 <b>world's</b> 222:10 <b>worried</b> 189:10 <b>worries</b> 46:21 <b>worry</b> 201:11 <b>worse</b> 63:10 95:10 <b>worsened</b> 49:2 131:10 <b>worth</b> 74:22 227:5,18 231:13 <b>worthy</b> 209:12 <b>wow</b> 180:16 <b>wrap</b> 6:12 119:12 121:1 185:21 187:12,14 <b>write</b> 19:21 40:2 54:2 92:15 107:1 111:7 119:8 172:21 189:4 215:20 <b>writing</b> 122:15 161:22 172:19 <b>written</b> 82:10 83:1,7 86:19 91:20 148:20 202:4 <b>wrong</b> 78:3 141:15 154:4 168:6 182:7 185:2 194:8 200:20 <b>wrote</b> 103:10</p>
---	---	--	--

Capital Reporting Company  
Patient-Focused Drug Development Public Meeting 10-27-2014  
Page 50

<hr/> <p style="text-align: center;">Y</p> <hr/> <p><b>yep</b> 157:2</p> <p><b>yet</b> 28:20 121:22 132:15 169:2 198:2,9</p> <p><b>yielding</b> 199:15</p> <p><b>York</b> 193:6</p> <p><b>young</b> 62:17 64:10,11 195:2 207:11</p> <p><b>younger</b> 44:6 86:6 90:21</p> <p><b>yours</b> 95:3</p> <p><b>yourself</b> 53:10 85:16 105:11 119:6 221:20 228:3</p> <p><b>yourselves</b> 221:18 222:16</p> <p><b>you've</b> 28:7 71:10 72:13 115:9,10 145:11,16</p> <hr/> <p style="text-align: center;">Z</p> <hr/> <p><b>zero</b> 183:12 212:21</p>			
---	--	--	--